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Abstract 
 
In 2004, the polyketide natural product, chamuvarinin (72) was isolated by Laurens et al. 
from the roots of Uvaria chamae, a member of the Annonaceae plant family. This unique 
tetrahydropyran containing acetogenin displayed potent levels of cytotoxic activity against 
the KB 3-1 cell line with an ED50 value of 0.8 nM. Upon initial isolation the relative and 
absolute stereochemical assignment of chamuvarinin (72) was unable to be readily 
achieved through 1H and 13C NMR analysis. The initial synthetic route described herein 
has enabled the relative and absolute stereochemical deterimination of chamuvarinin (72) 
through the first total synthesis completed in 20 longest linear steps in 1.5% overall yield. 
A revised synthetic strategy towards chamuvarinin (72) was completed in 17 longest linear 
steps in 2.2% overall yield. The revised route facilitated the assembly of non-natural 
chamuvarinin-like analogues and their trypanocidal and cytotoxic activities have been 
assessed. The synthesis of these analogues has formed the basis of a more focussed study 
through the design and synthesis of simplified triazole (295), isoxazole (325) and 
butenolide triazole (305) analogues as potential Trypanosoma brucei (causative agent in 
African Sleeping sickness) inhibitors.  
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 vii 
Compound Numbering 
  
All compounds intended toward the structure elucidation and total synthesis of 
chamuvarinin will be numbered according to the carbon chain of the natural product. This 
numbering is given on the structure and is used in 1H NMR assignments.  
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The naming of the compounds in the experimental chapter use IUPAC conventions. 
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Chapter 1 
Introduction 
 
1.1 Natural products  
 
For thousands of years nature has provided a diverse array of active secondary metabolites 
from various sources such as endogenous plants, marine organisms and increasingly 
associated microorganisms.1 Natural products are widely used in traditional medicinal 
practices for the treatment of a range of ailments such as parasitic infections, inflammation 
and colds. They have also proven to be amongst the most potent antibiotic, cytotoxic and 
antifungal agents known. Natural product research still remains a prevailing source for the 
discovery of novel drugs and new lead compounds, for instance an estimated 60% of 
anticancer drugs are of natural origin.2 However, the difficulty in isolation and structural 
determination of natural products has often necessitated the total synthesis to provide 
efficient access to the desired target and enable the design and synthesis of potent 
analogues.  
 
An area that has dominated the synthetic world is the development of drugs for the fight 
against cancer. The Annonaceae plant family is an example of nature providing novel 
bioactive components. The North American pawpaw tree (Asimina triloba, Figure 1.1) 
contains polyketide natural products, which have displayed potent cytotoxic activities. The 
edible fruits, seeds and twigs of the pawpaw tree have been part of the staple diet for 
various wildlife and indigenous people for many years.3 
 
     
Figure 1.1: Pawpaw tree4 and the dietary supplement Paw Paw-Cell-Reg5. 
 
In 2003, an FDA approved dietary supplement known as Paw Paw Cell-Reg containing 
standardized pawpaw extracts was introduced to the commercial market (Figure 1.1). Paw 
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Paw Cell-Reg has been clinically tested against stage IV cancer patients with prostate, 
lung, breast and lymphatic cancers in the state of Nevada.6,7 The results were promising, 
with decrease in tumour sizes and metastases observed, as well as the reduction of antigens 
in the bloodstream. Based on these studies, further exploration of the extracts of the 
pawpaw tree as a potential source for cancer chemotherapies is underway.      
 
1.2 Annonaceous acetogenins  
 
The Annonaceae (custard apple) form a large family of woody trees, shrubs and lianas 
found in tropical and subtropical locations, mainly in West Africa and South America, 
comprising of 130 genera and more than 2300 species (Figure 1.2).8,9 The leaves, fruit and 
roots of the Annonaceae are used in traditional medicinal practices. 
 
     
 
Figure 1.2: Representation of the Annonaceae plant family.10 
 
Annonaceae plants are the source of a unique class of polyketide derived natural products, 
termed the annonaceous acetogenins. The first acetogenin to be discovered was uvaricin 
(1), isolated in 1982 by Jolad and co-workers from the roots of Uvaria acuminate (Figure 
1.3).11 Uvaricin (1) was found to display potent anti-leukemic activity, which sparked a 
great deal of interest in this family of secondary metabolites.  
 
O O
O
OOAc OH
1
1524
uvaricin
1  
Figure 1.3: Uvaricin (1). 
 
Since the original isolation of 1, over fifty Annonaceae species have been the source of 
more than 400 acetogenins, many of which have displayed a variety of biological activities 
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including pesticidal, immunosuppressive, parasitic and cytotoxic properties.9 In 2001, 
McLaughlin and co-workers reported the development of a shampoo for head lice removal, 
which has been commercialized in the United States.12 The shampoo was based on a 
combination of extracts from thymol, tea tree oil and pawpaw (Asimina triloba), of which 
the annonaceous acetogenins are the bioactive components. 
 
The annonaceous acetogenins are polyketide derivatives, which generally consist of a C32 
or C34 carbon backbone appended to an α,β- unsaturated γ-lactone moiety. Their structural 
framework typically consists of one or two tetrahydrofuran (THF) ring systems with 
flanking hydroxyl groups situated midway along the hydrocarbon backbone. The diversity 
in the acetogenin family arises from the location, connectivity and stereochemistry of the 
polyether core structure. The acetogenins are primarily classified into two main groups, 
which are based according to the number and connectivity of the ether motifs (Figure 
1.4).9,13 Classical acetogenins consist of mono-THF (2), adjacent bis-THF (3), non-
adjacent bis-THF (4) and tris-THF (5). Also isolated from the Annonaceae plants are non-
THF linear acetogenins, which are also representatives of classical acetogenins and can be 
unsaturated (6), saturated epoxides (7) or polyhydroxylated (8) species. Non-classical 
acetogenins are comprised of adjacent tetrahydropyran (THP)-THF (9), non-adjacent THP-
THF (10) and mono-THP (11). The acetogenins can be further sub-grouped according to 
the γ-lactone moiety such as 12, 13 and 14.   
 
O
R OH
O O
R OH
O O O
OHR
O O
OHOH
O
O
OH
OH
O
O
OH
OH
O
OH
O OO O
11
2 3 4
9 10
5
O O
O
6
OH
OH
8
7
12 13
O O
14
O
γ-lactone  
Figure 1.4: Classification of annonaceous acetogenins. 
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1.3 Biosynthesis of acetogenins 
 
The acetogenins are polyketide derived natural products and construction of the THF/THP 
ring systems is proposed to occur via the biosynthetic pathway, outlined in Scheme 1.1.8d 
The THF-ring formation is presumed to arise from an unsaturated Z-alkene precursor 15, 
which undergoes stereoselective poly-epoxidation, cyclization reactions to afford 
acetogenins of type 16 with the trans-threo-trans motif. Evidence to support this 
biosynthetic pathway has been the isolation of linear acetogenins of type 6 and 7 (Figure 
1.4). 
 
O O
O
O O
OHOH
H2O
15
16  
Scheme 1.1: Proposed biosynthetic pathway for formation of polyether core of acetogenins. 
 
1.4 Structural determination and elucidation 
 
Plant extracts of the annonaceae are difficult to purify due to the complex mixtures of 
acetogenins present, hence separation of these natural products has relied on the use of 
high performance liquid chromatographic (HPLC) methods. Following isolation, structural 
elucidation of the acetogenins is required and is reliant upon mass spectrometry 
techniques, which enables the molecular mass to be determined. Also a combination of 
electron impact-mass spectrometry (EI-MS) and fast atom bombardment mass 
spectrometry (FAB-MS) facilitates in the determination of the presence of functional 
groups along the carbon backbone chain. 8d,14  
 
The absolute stereochemical assignment of the acetogenins upon isolation has proven to be 
problematic as the compounds are typically gums or waxes, which precludes the use of X-
ray crystallography. The relative stereochemistry of the ether core and flanking hydroxyl 
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groups can be tentatively assigned based on detailed analysis of both 1H and 13C NMR data 
and by comparison with acetogenin structures that have been confirmed by total synthesis.  
 
The important biological properties exhibited by these natural products often warrants 
further exploration, hence total synthesis can facilitate in the absolute stereochemical 
elucidation and provide access to the acetogenin compounds in reasonable quantities, 
enabling further biological evaluation.  
 
1.5 Biology and mechanism of action  
 
The annonaceous acetogenins have attracted a lot of attention due to their potent anti-
cancer, pesticidal and anti-malarial properties. Their potency is primarily attributed to the 
inhibition of the mitochondrial NADH-ubiquinone oxidoreductase (Complex I).15,16 
The mitochondrial Complex I is a large iron-sulfur protein comprised of 45 subunits 
(combined mass of ~980 kDa) in humans and is an essential component in the 
mitochondrial electron transport chain.17 Complex I is responsible for the transfer of two 
electrons from NADH to ubiquinone 17 (coenzyme Q) and the resulting redox reaction 
provides NAD+ and ubiquinol 18 (Scheme 1.2). This results in an electrochemical proton 
gradient across the mitochondrial membrane, which initiates the synthesis of adenosine 
triphosphate (ATP), required for cell function. 
 
O
O
MeO
MeO H
10
OH
OH
MeO
MeO H
10
NADH NAD+
Complex I
ubiquinone (CoQ10)
17
ubiquinol (CoQ10H2)
18  
Scheme 1.2: Redox reaction of CoQ10 and NADH to CoQ10H2 and NAD+ by Complex I. 
 
Recently in 2013, Sazanov and co-workers reported the entire crystal structure of Complex 
I from the bacteria T. thermophilus (Figure 1.5).18 Complex I is constructed by a 
hydrophilic and membrane domain and adopts an L-shape conformation. The ubiquinone 
binding site (Q) is located just above the ND1 subunit of Complex I, which forms part of 
the proton channel to the membrane. Figure 1.5 illustrates that the quinone moiety of 
CoQ10 binds in a long narrow cavity at the Q site and the remaining one to three isoprenoid 
units extend out of the cavity into the lipid bilayer. Reduction of ubiquinone (17) to 
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ubiquinol (18) results in subtle conformational changes, which drives the protons through 
the channel and across the mitochondrial membrane.  
 
 
 
Figure 1.5: Entire crystal structure of Complex I from T. thermophilus with ubiquinone bound in the Q 
channel. Figures prepared by Dr Lindsay Tulloch, Florence Group. 
 
Complex I is an attractive target for cancer chemotherapy, as inhibition of the electron 
transport chain shuts down the NADH-ubiquinone oxidoreductase, which leads to ATP 
depletion and ultimately results in apoptosis (cell death). Tumour cells have a much higher 
energy demand for ATP than normal cells and depletion of ATP, which is a key building 
block for the survival of cancer cells enabling cell division and growth, provides an 
opportunity for cancer treatment. However, concerns regarding the non-selective 
cytotoxicity of ATP inhibition on normal cells have been raised by pharmaceutical 
industries. Several in vivo studies with acetogenins have shown this not to be the case and 
that ATP inhibition appears to be detrimental only to cancer cells and not to normal cells.19 
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In 1993, McLaughlin and co-workers reported on bullatacin’s (19) cytotoxic activity 
(Figure 1.6).20 Bullatacin (19) was tested against athymic mice implanted with a human 
ovarian carcinoma (A-2780) cell line and exhibited 67% tumour growth inhibition (TGI) at 
50 µg/kg/day in comparison to cisplatin 20 (anti-cancer drug) which caused 78% TGI after 
10 days at 5000 µg/kg.3 A clear indication of these in vivo studies has shown that if 
treatment of the mice with the acetogenins were affecting the ability of normal cells to 
produce ATP, then death of the mice would be evident.  
  
Cl
Pt
Cl
NH3
NH3
cisplatin
20
O O
O
O
OH OH
bullatacin
19
15
OH
 
Figure 1.6: Acetogenin bullatacin (19) and cisplatin (20). 
 
1.5.1 Complex I inhibitors  
 
Classical Complex I inhibitors, shown in Figure 1.7, include the pesticide rotenone 21 
(isolated from the Fabaceae plant species) and antibiotic piericidin A 22 (isolated from 
Streptomyces mobaraensis), which exhibits structural similarities to ubiquinone (17). The 
acetogenins are the most potent inhibitors to date of Complex I.16,21  
 
O
O O
CH2
Me
O
MeO
OMe
H
H
H
rotenone 
21
NH
OMe
MeO
Me
O Me
Me Me
OH
Me
piericidin A
22  
Figure 1.7: Representative examples of mitochondrial Complex I inhibitors. 
 
It was initially postulated that the Complex I inhibitors bound competitively to the 
ubiquinone site. In an effort to gain a better understanding of the specific site of inhibition 
(Figure 1.8), several groups have performed photoaffinity labelling studies on Complex I.22 
Inhibitors such as fenpyroximate 23 (labelled fenpyroximate derivatives 24 and 25) and 
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acetogenins (DANA 26), were found not to bind to the Q site (ubiquinone recognition site) 
but rather bind in the PSST, 49 kDa and ND1 subunit domain, which taken together is 
proposed to construct the Complex I inhibitor/CoQ10 binding pocket (site distinct from 
ubiquinone).23 
 
O
O
O
NN
N
Me
Me
O
fenpyroximate 
23
O
O
O
NN
N
Me
Me
O
R
R3
R1
R2
APF 24: R = N3, R1, R3 = H, R2 = 125I
AIF 25: R = H, R1 = N3, R2 = H, R3 = 125I
O OO
O
OH
13
O125I
N N
DANA
 26  
Figure 1.8: Labelled derivatives of Complex I inhibitors. 
 
In 2011, Miyoshi and co-workers proposed the following model for the mechanism of 
action of the acetogenins (Figure 1.9) indicating the adjacent bis-THF acetogenin binds to 
the matrix side of Complex I on the ND1 subunit.24 With the ether core anchoring the 
acetogenin to the membrane, this enables the butenolide appendage to insert itself between 
the fourth and fifth regions of the transmembrane helices, binding competitively to the 
ubiquinone site. The binding of the acetogenin is proposed to disrupt the conformation of 
the ND1 and 49 kDa subunit, this in turn impacts on ATP synthesis as the NADH-
ubiquinone oxidoreductase is shut down. Miyoshi and co-workers illustrated that both the 
ether core and the butenolide appendage are essential for potent inhibition as they act in a 
co-operative manner when binding to Complex I.  
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Figure 1.9: Model of the binding site for the acetogenins.24 
 
 
1.6 Selected total syntheses of acetogenin natural products  
 
The structural elucidation of these polyketide natural products upon isolation has proven 
difficult. Pioneering work in this field by Hoye utilized advanced Mosher ester analysis for 
the absolute stereochemical determination of the carbinol stereocentres flanking the THF 
motifs and along the hydrocarbon chain for isolated mono and bis-THF acetogenins.25 This 
technique is not a straightforward task due to the local pseudo-C2 symmetry present in 
many acetogenins and requires the synthesis of complex model compounds as well as 
detailed NMR and mass spectrometry analysis, hence, total synthesis of these natural 
products is necessary. The majority of synthetic efforts have focussed on the assembly of 
the mono-THF and adjacent bis-THF acetogenins, detailed in Scheme 1.3.26 The 
stereoselective construction of the ether core motifs has resulted in the development of 
numerous methodology approaches, but are predominantly installed by intramolecular 
Williamson-type etherification reactions.  
 
OH OR O
Mono-THF Bis-THF
OH OR OR OH
O O
OR OH OH OR
base
base
30: R = Ms, Ts
32: R = Ms, Ts
inside-out
33: R = Ms, Ts
outside-in
OH
O
O
OH
acid
31
anti-threo-anti
 relationship
27
28
29
 
Scheme 1.3:  Types of Williamson etherification reactions in acetogenin synthesis. 
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Mono-THF motifs 27 and 28 can be constructed from either 1,4-epoxyalcohols 29 or 
activated 1,4-hydroxy sulfonate species 30.27 The stereoselective construction of the anti-
threo-anti relationship of the adjacent bis-THF core 31 have relied on the synthetic utility 
of pre-constructed pseudo-C2 symmetric precursors of types 32 and 33.28 With the correct 
stereochemical configurations installed in the precursors, application of a two directional 
inside-out or outside-in cascade cyclization sequence gives rise to the structural motifs of 
type 31. The anti-threo-anti array formed in 31 is a prevalent stereochemical motif found 
in many adjacently linked bis-THF acetogenins.  
 
1.6.1 Sinha and Keinan’s synthesis of goniocin  
 
In 1994, McLaughlin and co-workers isolated goniocin (34, Figure 1.10) from the bark of 
Goniothalamus giganteus and is the only known adjacent tris-THF in the acetogenin 
family.29 Goniocin (34) displayed potent cytotoxic activities against A-549, MCF-7 and 
HT-29 human solid tumour cell lines with ED50 values of 1.5 µM, 78.1 and 25.9 nM, 
respectively. The absolute stereochemistry proposed for the adjacent tris-THF core of 
goniocin (34) was the anti-threo-anti-threo-anti-threo relationship, this was later 
confirmed by the total synthesis from Sinha and co-workers.30 
 
O O O
O
O
OH
C12H25
OH goniocin
34
1
1022
 
Figure 1.10: Adjacent tris-THF acetogenin goniocin (34). 
 
The initial synthetic study towards goniocin 34 (Scheme 1.4) reported by Sinha and co-
workers31 relied on a rhenium oxide based triple oxidative cyclization32 reaction of 
advanced alcohol 35 to install the ether core of goniocin in one step. The cyclization 
reaction furnished a tris-THF core and upon analysis of the 1H and 13C NMR data indicated 
that the stereochemistry did not match the natural material. In fact the cyclization gave an 
unexpected stereochemical outcome resulting in the anti-threo-syn-threo-syn-threo product 
36 rather than the anti-threo-anti-threo-anti-threo polyether core. 
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C12H25 OTBDPS
OH
O O O
C12H25
OH
10
22
OTBDPS
36
Re2O7, TFAA, CH2Cl2, 
0 °C to RT, 48%
35
anti-threo-syn-threo-syn-threo  
Scheme 1.4: Attempted first synthesis of goniocin tris-THF core 36 by Sinha et.al.   
 
Sinha and co-workers reported the first total synthesis of goniocin (34), by first 
constructing the C10-C13 THF ring system (Scheme 1.5).30 Once the C10-C13 THF ring 
system was in place a two-directional outside-in Williamson etherification was employed 
to install the remaining two THF ring systems. The synthesis of 37 began with the 
Sharpless asymmetric epoxidation of advanced allylic alcohol 38 to give epoxy alcohol 39, 
followed by C9 reduction with Red-Al and subsequent primary silyl protection to give 
alcohol 40. Construction of the C10-C13 THF ring system was achieved by application of 
an oxidative cyclization reaction of 40 in the presence of a rhenium oxide agent to install 
the desired THF ring and subsequent silyl protection of the resultant alcohol gave anti-
THF product 37 in 55% yield.    
 
C12H25
HO
OO
C12H25
OO OHO
C12H25
OTBDPS
OO HO
C12H25
OO
OTBS O
OTBDPS
Ti-(i-OPr)4, (-)-DET, 
TBHP, mol sieves, 
CH2Cl2, RT, 88%
1) Red-Al, THF, 0 °C
2) TBDPSCl, Hunig's base, 
CH2Cl2, RT, 95% over 2 steps
38 39
4037
1) CF3CO2ReO3, 
2,6-lut, CH2Cl2, RT
2) TBSCl, ImH,
DMF, RT
55% over 2 steps
10
10
1010
21
21 21
21
 
Scheme 1.5: Synthesis of C10-C13 THF alkene 37. 
 
Having constructed the anti C10-C13 THF ring system, attention turned to the installation 
of the remaining two adjacently linked THF ring systems (Scheme 1.6). This was 
accomplished in three further steps from anti-THF 37 by Sharpless asymmetric 
dihydroxylation of the C17-C18 olefin to give an intermediate 1,2-diol, followed by 
activation as the double mesylate 41. The two-directional Williamson etherification 
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precursor 41 was treated under acid mediated conditions to initiate both the acetonide 
cleavage and C8/C14 silyl deprotection, subsequent refluxing in pyridine resulted in 
concomitant outside-in cyclization to furnish the desired threo-anti-threo-anti-threo-anti 
tris-THF diol 42. Diol 42 was transformed in a further four steps to the phosphonium salt 
43. Treatment of phosphonium salt 43 with n-BuLi and addition of aldehyde 44 installed 
the C7-C8 olefin to afford 45 in 70% yield. The first total synthesis of goniocin (34) was 
achieved in two further steps involving hydrogenation of 45 and global deprotection.  
 
C12H25
OO
OTBS
O
OTBDPS
OMs
OMs
O O O
C12H25
OH
1022
HO
C12H25
OO
OTBS O
OTBDPS
37
1) AD-mix α, 
t-BuOH, H2O, 0 °C
2) MsCl, Et3N, 
CH2Cl2, 0 °C
87% over 2 steps
41
TsOH, H2O, MeOH
then pyridine,
reflux, 60%
O O O
C12H25
OMOM
1022
PPh3I 4 steps
4243
O
O
O
H
TBDPSO
44
O O O
O
O
TBDPSO
C12H25
OMOM
1
1022
n-BuLi, THF,
0 °C, 70%
45
2 steps
goniocin
34
10 10
21 21
1
 
Scheme 1.6: Synthesis of goniocin (34). 
 
1.6.2 Jacobsen’s synthesis of muconin 
 
In 1996, McLaughlin and co-workers isolated muconin (46, Figure 1.11), an adjacent 
THF-THP acetogenin from the leaves of Rollinia mucosa and is one of only eight THP 
containing acetogenins to have been reported.33 Muconin (46) displayed potent levels of 
cytotoxic activity against several cancer cell lines including renal carcinoma A-498 and 
pancreas carcinoma PACA-2 with ED50 values of 0.29 µM and 0.87 nM, respectively.  
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Figure 1.11: Acetogenin muconin (46). 
 
In 1998, Jacobsen and co-workers reported the total synthesis of muconin (46) by 
application of a highly convergent and efficient assembly of chiral building blocks 
(Scheme 1.7).34 The synthesis of muconin (46) began with the preparation of the 
dihydropyran 47 building block, installed by application of a hetero-Diels-Alder protocol35 
with diene 48 and aldehyde 49 catalyzed by (S,S)-50. The intermediate ketone was 
subjected to Luche reduction conditions to provide dihydropyran 47 in excellent yield and 
diastereoselectivity.   
 
TMSO
OMe
O
H
OPBB
O
OH
OPBB
1a) (S,S)-50, MTBE, 
mol sieves, -30 °C, 
b) TFA, RT, 72%
2) CeCl3•7H2O, NaBH4,
 MeOH, EtOH,
 -78 to 0 °C, 76%48 49 47
N N
t-Bu
t-Bu
O O
t-Bu
t-Bu
M
50:  M = Cr(BF4)
HH
13
 
Scheme 1.7: Synthesis of dihydropyran 47. 
 
With dihydropyran 47 in hand, attention turned to the construction of the C18-C21 THF 
ring system (Scheme 1.8). The synthesis of ester 51 was accomplished in three steps by 
esterification of acid 52 and dihydropyran 47, formation of an intermediate silyl ketene 
acetal and concomitant Ireland-Claisen rearrangement,36 followed by methylation with 
diazomethane gave methyl ester 51. With methyl ester 51 in hand, DIBAL reduction of 51 
and subsequent Wittig olefination gave diene 53, which was readily converted to diene 54 
by a two step transformation. At this point attention turned to the preparation of aldehyde 
55, accomplished by a ring closing metathesis reaction, followed by a two step 
hydrogenation/oxidation protocol. 
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OPBBC12H25
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54
2 steps
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13
1313
18
1818
OO
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OTBS
56
Mo(CHCMe2Ph)(NAr)
(OCMe(CF3)2)2, 
PhH, RT, 99%
OO
HC12H25
OTBS
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O
13 1322 22
 
Scheme 1.8: Synthesis of aldehyde 55. 
 
The completion of muconin (46) began with the vinyl zinc addition of 57 to aldehyde 55 to 
provide alcohol 58 with the undesired R-configuration at C12 (Scheme 1.9). This was 
corrected via an oxidation and reduction protocol. Hydrogenation of the C10 alkene 
provided alcohol 59, which was readily converted to muconin (46) in three further steps 
and was in all regards identical to the natural material.  
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Scheme 1.9: Synthesis of muconin (46). 
 
1.6.3 Marshall’s synthesis of asimicin 
 
In 1986, McLaughlin and co-workers isolated asimicin (60, Figure 1.12), a cytotoxic 
adjacent bis-THF acetogenin, from the bark and seed extracts of the pawpaw tree (Asimina 
triloba Dunal).37 Asimicin displayed high levels of cytotoxic activity against the human 
nasophyraneal carcinoma (9KB) and murine lymphocyte leukemia (9BS) cell lines with 
ED50 values of < 10-5 and < 10-7 µg/mL, respectively.20,38 
 
O O
OHOH
OH O
O
1524
asimicin 
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1
 
Figure 1.12: Acetogenin asimicin (60). 
 
In 2006, Marshall and co-workers reported the total synthesis of 60 (Scheme 1.10), 
utilizing a C2 symmetric precursor for the outside-in two-directional cyclization protocol 
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to install the core ether array and employed Grubbs cross metathesis methodology to 
append the butenolide side chain.39 The synthesis of the adjacent bis-THF core began with 
the synthesis of triene 61 from commercially available 4-penten-1-ol (62). Grubbs 
metathesis40 of alcohol 62 gave diol 63 in 82% yield with good E : Z selectivity. Oxidation 
of diol 63 under Swern oxidation conditions and subsequent Wittig olefination with 
carbethoxymethylene triphenylphosphorane gave triene 61 in excellent yield over the two 
steps. From triene 61, the next step was to install the C19-C20 stereochemistry in 
preparation for the stereoselective ring cyclization reaction. This was achieved by 
application of a selective Sharpless asymmetric dihydroxylation of 61, followed by 
mesylation to give 64. With C2-symmetric 64 in hand, the synthesis of bis-THF diol 65 
was accomplished in two further steps by double Sharpless dihydroxylation to give 66, 
followed by treatment of base mediated conditions to initiate the two-directional outside-in 
Williamson etherification reaction to furnish the anti-polyether core 65 of asimicin.  
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OH OEt
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EtO2C CO2Et
OHOH
1524
Grubbs II, 
CH2Cl2, 
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1) (COCl)2, DMSO, 
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2) Ph3P=CHCO2Et, RT,
 74% over 2 steps
1) AD-mix α, MeSO2NH2,
t-BuOH/H2O (1 : 1), 
0 °C, 73%
2) MsCl, Et3N, CH2Cl2,
0 °C, 99%
62 63 61
64
AD-mix β, MeSO2NH2,
t-BuOH/H2O (1 : 1), 0 °C
pyridine, reflux,
65% over 2 steps
66
O O
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OHOH
1524
65
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Scheme 1.10: Synthesis of the C15-C24 polyether core 65. 
 
Having successfully installed the adjacent bis-THF core of asimicin (60), attention turned 
to the introduction of the butenolide appendage through a desymmetrization reaction 
(Scheme 1.11). Firstly, diol 65 was transformed in four steps to furnish diene 67 and 
subsequent cross metathesis with 1-decene 68 gave the bis-THF diene 69 in excellent yield 
and stereoselectivity (E : Z = 10 : 1). An additional cross methathesis reaction was 
performed on 69 with butenolide alkene 70 to furnish asimicin precursor 71 in an 
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optimized 38% yield. The low yield of the cross reaction was attributed to both the 
recovery of starting material 69 (28%) as well as further cross-coupled products (30% 
combined yield). The majority of cross-coupled products recovered were recycled and 
subjected to the metathesis reaction conditions providing access to further quantities of 71. 
The final stages towards the synthesis of asimicin (60) relied on the diimide reduction of 
the C13/C25 olefins in 71 and resultant global deprotection furnished asimicin (60) in 80% 
yield over the final two steps. 
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Scheme 1.11: Synthesis of asimicin (60). 
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1.7 Isolation of chamuvarinin 
 
The crude plant extracts of Uvaria chamae have been used to treat Trypanosoma brucei 
(causative agent in West African sleeping sickness).41 Chamuvarinin (72) was isolated in 
2004 by Laurens and co-workers from the root extracts of the Senegalese Annonaceae 
bush banana plant Uvaria chamae, shown in Figure 1.13.42 Chamuvarinin (72) joins the 
subclass of acetogenins bearing a THP motif and is unique amongst the family as it is the 
first to contain an adjacent THF-THF-THP ether ring system. Initial biological evaluation 
of 72 against the KB 3-1 cervix cancer cell line displayed nanomolar cytotoxic activity 
with an IC50 value of 0.8 nM.  
 
O O O
O
O
OH
D C B
A
1528
36
34
chamuvarinin
72
* * *
           
Figure 1.13: Acetogenin chamuvarinin (72) and the annonaceae bush banana plant.   
 
The relative stereochemical assignment of the C15-C28 polyether array of chamuvarinin 
proved to be a difficult task. By analysis of the 1H and 13C NMR data and comparison with 
known acetogenin natural products, the C15 and C16 stereocentres were tentatively 
assigned with a threo relationship. The 1H and 13C NMR data of the C16-C19 THF ring 
system supported an anti configuration. The absolute stereochemical assignment of the 
C36 position of the butenolide moiety was determined as C36S by application of Latypov’s 
NMR method employing Pirkle’s reagent.43 Unfortunately, the relative stereochemistry of 
the C20-C28 polyether region was unable to be assigned upon initial isolation, which led to 
a possible 32 diastereomeric structures of 72. Therefore, synthetic studies towards 
chamuvarinin would require a highly flexible strategy to enable access to all possible 
diastereomeric variations if required.   
 
1.8 Biosynthesis and semi-synthetic study 
 
Chamuvarinin (72) was co-isolated from the root extracts along with three other known 
acetogenin compounds with squamocin (73) as the major component (Scheme 1.12).42 A 
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plausible biosynthetic link between squamocin (73) and chamuvarinin (72) was proposed 
and was envisioned to arise from an unsaturated triene chatenaytrienin-4 (74), which 
would undergo several stereoselective epoxidation reactions to give triepoxyrollin (75). 
Subsequent cyclization reactions would install the adjacent bis-THF-THF ring system in a 
stereoselective manner to provide desacetyluvaricin (76). Hydroxylation of 76 to install the 
C28 hydroxyl of squamocin (73) and further cyclization would construct the THP ring of 
chamuvarinin (72). 
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Scheme 1.12: Plausible biosynthetic pathway for chamuvarinin (72) from chatenaytrienin-4 (74). 
 
The stereochemical quandary was partially resolved in 2007 through the work of Poupon 
and co-workers (Scheme 1.13) based on the plausible biogenetic relationship between 
squamocin (73) and chamuvarinin (72).44 The THP ring system was hypothesized to arise 
via cyclization of the C24 alcohol to the C28 position of 73 or vice versa. Squamocin (73) 
was subjected to Amberlyst 15 and sodium iodide, which promoted the selective iodination 
of the alcohols and concomitant cyclization furnishing the syn-anti-anti diastereomer 77 in 
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17% yield. Application of Mitsunobu-type conditions to 73 resulted in the formation of a 
mixture of diastereomers 77 and the anti-anti-anti 78.  
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Scheme 1.13: Synthesis of diastereomeric structures of chamuvarinin (72). 
 
The two diastereomers 77 and 78 synthesized in the semi-synthetic study were biologically 
evaluated against Jurkat T cells to assess their ability to induce apoptosis. Both 
diastereomers were found to lose their potent apoptotic activities highlighting that the 
stereochemistry surrounding the polyether array system can have a profound affect on the 
biological profile. 
 
With both diastereomers 77 and 78 in hand, detailed analysis of the 1H and 13C NMR data 
showed that both the diastereomers synthesized from the ring cyclization conditions did 
not match the NMR data of natural chamuvarinin (72). This was evident from the 13C shift 
difference tables (Figure 1.14), which display major shift differences of >1 ppm for the 
C19 carbon and >6 ppm for the C24 and 28 carbons of the anti-THF-THF-THP ring 
system 78, indicating that the C24-C28 THP does not contain an anti-configuration.  
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3.45
3.64
3.40
3.82
3.87
3.88
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3.22
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81.4
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81.9
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80.0
81.8
81.9
73.2
72.2
74.1
83.2
82.0
82.5
83.0
80.3
77.8  
Figure 1.14: 13C NMR shift difference tables and 1H/13C NMR data for diastereomers 77 and 78. 
 
The shift differences for the anti-THF syn-THP diastereomer 77 displayed significantly 
less discrepancies for the C24, C28 ring system, eluding to the fact that the THP ring 
system of natural chamuvarinin (72) has syn-geometry. Upon detailed re-evaluation of the 
NMR data as well as comparison of literature for other acetogenin natural products, the 
relationship of the C19/C20 and C23/C24 was proposed to have threo-geometry. Hence, 
Poupon and co-workers proposed the following structures 79 and 80 for chamuvarinin with 
a syn-THP, syn-THF, anti-THF relationship, shown in Figure 1.15. 
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O O O
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79  
Figure 1.15: Proposed structures of chamuvarinin (72). 
 
1.9 Retrosynthetic strategy 
 
The semi-synthetic study conducted by Poupon and co-workers enabled the reduction of 
the possible 32 diastereomers down to 2. The majority of isolated acetogenins bear the 
15R-configuration at the carbinol stereocentre and due to a common biosynthetic pathway, 
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chamuvarinin (72) was likely to share this 15R-configuration, based on this likelihood we 
opted to pursue the 15R-diastereomeric series (80).8 An efficient and modular synthetic 
strategy was necessary to enable the assembly of diastereomeric variations of the THP ring 
system if required. The assembly of chamuvarinin (80) was envisioned to arise from key 
bond disconnections at C8-C9 and C20-C21 to give three key subunits, shown in Scheme 
1.14. The carbon backbone of chamuvarinin (80) was envisaged to arise from a late stage 
olefination at C8-C9 from advanced C1-C8 alcohol 81 and C9-C34 alcohol 82. Both the 
subunits act as a point of diversity enabling transformation to the appropriate precursors 
for the olefination of choice. The disconnection of the C20-C23 THF ring system of 82 
reveals the C9-C20 THF aldehyde 83 and C21-C34 alkyne 84, which would undergo an 
alkynylation and cyclization to construct the central THF core.  
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Scheme 1.14: Retrosynthetic strategy for the assembly of chamuvarinin (80).
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Chapter 2 
Results and Discussion 
 
2.1 Synthesis of the C1-C8 subunit 
 
2.1.1 Preparation of chiral epoxide  
 
The C1-C8 subunit 81 was accessed through adaptation of Marshall’s butenolide 
synthesis.45 The synthesis of the subunit 81 began with the preparation of (S)-propylene 
oxide (85), the source of the C36 stereocentre via Jacobsen hydrolytic kinetic resolution 
(HKR). 
 
Enantio-enriched epoxides are useful building blocks in organic chemistry, as they provide 
a platform for the introduction of various functional groups in a stereocontrolled manner. 
Over several decades there have been advances towards the synthesis of enantio-enriched 
epoxides, such as the Sharpless asymmetric epoxidation of allylic alcohols to access epoxy 
alcohols.46 Jacobsen and co-workers established a practical catalytic HKR methodology to 
access enantio-enriched terminal epoxides and 1,2-diols (Scheme 2.1).47  
 
O O O
RR R R
OH
OH
R
OH
OH
N N
t-Bu
t-Bu
O O
t-Bu
t-Bu
M
HH
N N
t-Bu
t-Bu
O O
t-Bu
t-Bu
M
HH
XX
Where M = Co, X = OAc(S,S)-86
(S,S)-86,
H2O
(R,R)-87, 
H2O
(R,R)-87
(±)
 
Scheme 2.1: General scheme for HKR reaction. 
 
The HKR methodology involves the reaction of a racemic epoxide with a salen cobalt (II) 
complex activated in the presence of an acid by aerobic oxidation. Prior to resolution, the 
salen Co (II) complex must undergo aerobic oxidation to the catalytically active Co (III) 
state 86 and 87. This can be achieved through two different methods, either isolation of the 
active Co (III) species or in situ generation.47a Thus, method A involves treatment of Co 
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(II) complex in toluene and AcOH with exposure to air for 30 minutes followed by 
removal of solvents in vacuo to afford active catalyst 86 and 87 as a black tar like residue, 
which then undergoes a reaction with racemic epoxide and H2O. Method B generates the 
active Co (III) complex in situ by aerobic oxidation in the presence of AcOH, H2O and 
racemic epoxide. After 16 hours, the enantio-enriched epoxide and 1,2-diol can be readily 
separated as required. 
 
2.1.2 Synthesis of the C1-C8 benzyl ether 
 
The synthesis of (S)-butenolide 81 began with the application of the Jacobsen HKR 
reaction with (±)-propylene oxide (88) to afford enantio-enriched (S)-propylene oxide (85) 
in 32% yield (Scheme 2.2).47a With (S)-epoxide 85 in hand, the next stage was to construct 
the lactone moiety to incorporate the desired C36S stereochemistry. Treatment of epoxide 
85 with the lithium enolate of (phenylthio)acetic acid 89 facilitated the ring opening of 
epoxide 85 and subsequent acid mediated ring closure furnished a diastereomeric mixture 
of thiolactone 90 in excellent yield.45,48 The mixture of diastereomers was inconsequential 
at this stage, as the stereochemistry at the C2-position would ultimately be removed.  
 
O
85
O
(S,S)-86, AcOH,
 H2O, PhMe, 
 32%
(±)-88
O
O
PhS
90
36
S OH
O
Ph
89
LDA, THF,  -78 °C
 to RT, then TsOH,
 PhMe, RT, 78%  
Scheme 2.2: Synthesis of thiolactone 90.  
 
Following the synthesis of lactone 90, synthesis of the alkyl side chain was required. 
Iodide 91 was accessed in two steps from commercially available 1,6-hexanediol 92 
(Scheme 2.3). Selective mono-benzylation of diol 92 with benzyl bromide and NaH gave 
alcohol 93 in 44% yield, which was subjected to an Appel reaction by treatment of 93 with 
PPh3 and iodine to provide iodide 91 in multigram quantities.  
 
HO BnO
93
BnO
91
OHOH I
BnBr, NaH,
DMF, 0 °C to RT, 
44%
PPh3, ImH, I2,
MeCN : Et2O (1 : 2),
 0 °C, 88%
92  
Scheme 2.3: Synthesis of iodide 91.  
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Coupling of iodide 91 and thiolactone 90 installed the side chain at the C2-position of 90 
(Scheme 2.4). Treatment of lactone 90 with LDA and subsequent exposure to iodide 91 as 
a solution in DMPU gave alkylated lactone 94 in excellent yield as a mixture of 
diastereomers (d.r. = 80 : 20). Installation of the α,β-unsaturated lactone was then 
accomplished by m-CPBA oxidation of the sulfide moiety to the intermediate sulfoxide, 
which then underwent thermal sulfoxide elimination by heating at 100 °C in toluene to 
yield butenolide 95 in excellent yield.  
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PhS BnO
O
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BnO PhS
O
O
361
LDA, DMPU, THF,
 -78 °C to RT, 75%
m-CPBA, CH2Cl2, 30 min
then PhMe, 100 °C, 3 h
75%
BnO
90 91 94
95
I
8
368 1
 
Scheme 2.4: Synthesis of benzyl ether 95.  
 
2.1.3 Synthesis of the C1-C8 alcohol 
 
With butenolide 95 in hand, conditions for the removal of the benzyl group were 
investigated, due to concerns over the reduction of the butenolide alkene (Scheme 2.5). 
Hydrogenation of benzyl ether 95 with 10% Pd/C and H2 proved to be unsuccessful even 
upon prolonged exposure to the catalyst (entry 1). Upon the use of Pearlman’s catalyst 
(20% Pd(OH)2/C) and H2, cleavage of the benzyl group was observed, but as expected 
reduction of the butenolide was also evident (entry 2). 
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Scheme 2.5: Synthesis of alcohol 81.  
 
In 1993, Holmes et. al. reported the use of boron halide reagents for the removal of benzyl 
ethers in the presence of alkenes.49 Based on these findings, debenzylation reaction 
conditions using the BCl3•SMe2 complex were investigated. Treatment of benzyl ether 95 
with the BCl3DMS complex in CH2Cl2 at room temperature gave desired alcohol 81 in 
35% yield, as well as decomposition products of 95 (entry 3). In an effort to optimize the 
yield of the reaction and reduce unwanted decomposition products, addition of the 
BCl3•SMe2 complex to 95 at -78 °C with gradual warming to room temperature over 8.5 
hours furnished alcohol 81 in 91% yield, with no sign of decomposition (entry 4). Addition 
of the BCl3•SMe2 complex to 95 at -15 °C with warming to 0 °C was also tested and 
resulted in efficient cleavage of the benzyl ether to give alcohol 81 in a slightly reduced 
75% yield (entry 5).  
 
2.1.4 Synthesis of the C1-C8 phosphonium salt 
 
At this stage alcohol 81 served as a divergent precursor for the final C8-C9 bond 
construction, which was initially envisaged to arise via Wittig olefination. Elaboration of 
alcohol 81 to the corresponding Wittig salt 96 was accomplished over a two step sequence 
(Scheme 2.6). Alcohol 81 was subjected to an Appel reaction to afford intermediate iodide 
97 in 73% yield. With iodide 97 in hand, attention turned to the preparation of the Wittig 
salt. This was accomplished by treatment of iodide 97 with a 40-fold excess of PPh3 in the 
presence of NaI and Hunig’s base to give Wittig salt 96 in 29% yield.50 To ensure no water 
was present, the phosphonium salt 96 was lyophilized using a freeze drier in preparation 
for the Wittig olefination.  
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Scheme 2.6: Synthesis of Wittig salt 96.  
 
2.1.5 Summary  
 
The synthesis of the divergent C1-C8 subunit 81 was completed in five steps in 12.8% 
overall yield from (±)-propylene oxide (88). A key step in the synthesis of 81 was the 
oxidation of sulfide 94 followed by the thermal sulfoxide elimination to give benzyl ether 
95. Alcohol 81 serves as a divergent precursor for the final C8-C9 bond construction of 
chamuvarinin (80). 
 
2.2 Synthesis of the C9-C20 subunit 
 
2.2.1 Synthesis of the C16-C20 aldehyde  
 
The synthesis of the C9-C20 subunit 83 followed the route previously established by 
Reddy and Osler within the Florence group (Scheme 2.7).51 Silyl protection of (±)-glycidol 
(98) gave 99, followed by application of Jacobsen’s HKR protocol with (R,R)-87 gave 
enantio-enriched (S)-TBS glycidol 100 in 81% e.e.47a With enantio-enriched epoxide 100 
in hand, the copper (I) promoted ring opening of 100 with allylmagnesium bromide gave 
alkene 101, the resultant C19 alcohol was protected as its TBS ether to give alkene 102 in 
62% yield. Access to the C16-C20 aldehyde 103 was accomplished via ozonolysis of 
alkene 102 followed by a reductive workup with PPh3 to afford 103, which was used 
directly in the Julia-Kocienski olefination reaction.  
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Scheme 2.7: Synthesis of aldehyde 103.  
 
2.2.2 Synthesis of the C9-C15 sulfone 
 
The C9-C20 skeleton of 83 was installed through a modified Julia-Kocienksi olefination 
reaction. With aldehyde 103 prepared, synthesis of the C9-C15 sulfone 104 coupling 
partner was required (Scheme 2.8). Sulfone 104 was readily prepared in three steps from 
commercially available 1,7-heptanediol (105). Selective mono-benzyl protection with 
benzyl bromide and NaH gave alcohol 106 in 57% yield. Transformation of alcohol 106 to 
the intermediate sulfide was achieved by Mitsunobu reaction of 106 with 1-phenyl-1H-
tetrazole-5-thiol, which was partially purified through a plug of silica and then subjected to 
ammonium molybdate catalyzed hydrogen peroxide oxidation52 to give sulfone 104 in 49% 
yield over the two steps. With both the C9-C15 sulfone 104 and C16-C20 aldehyde 103 
subunits in hand, the stage was now set for the C15-C16 bond construction by means of a 
Julia-Kocienski olefination.    
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Scheme 2.8: Synthesis of sulfone 104.  
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2.2.3 Classical Julia olefination 
 
In 1973, Julia and co-workers reported an alkene bond construction protocol via a 
reductive elimination step of an intermediate β-acyloxysulfone 107 (Scheme 2.9).53 The 
classical Julia olefination relied on formation of a sulfonyl anion 108 by deprotonation of 
phenyl sulfone 109 with base, subsequent addition to an aldehyde to give intermediate β-
alkoxysulfone 110 followed by an acylation and reductive elimination step with Na(Hg) to 
yield 111. This method gave access to the alkene functionality in a stereoselective manner 
with E-selective products.   
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R
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Scheme 2.9: Classical Julia olefination mechanism.  
 
2.2.4 Modified Julia olefination 
 
In the 1990’s, Julia and co-workers reported a modified Julia olefination reaction 
substituting the phenylsulfone for a heteroaryl sulfone derivative (Figure 2.1).54 
Benzothiazol-2-ylsulfones (BT sulfone) and a further three major modifications of the 
sulfone heterocycle have been reported, which all display various degrees of reactivity and 
stereoselectivity.55,56,57 
 
N
N
N N
Ph
N
N
N N
tBu
S
N N
benzothiazol
-2-yl (BT)
1-phenyl-1H-
tetrazol-5-yl (PT)
1-tert-butyl-1H-
tetrazol-5-yl (TBT) pyridin-2-yl (PYR)  
Figure 2.1: Heterocyclic variants of the modified Julia olefination. 
 
In comparison with the phenyl sulfone, the BT-sulfone protocol gives rise to the alkene 
product via an alternative pathway (Scheme 2.10).58,59 Initial treatment of BT-sulfone 112 
with a non-nucleophilic metal amide base and subsequent addition to an aldehyde occurs in 
an analogous manner to a classical Julia olefination to afford a mixture of β-alkoxysulfone 
diastereomers 113. The presence of the imine-like moiety within the BT-sulfone results in 
an unstable β-alkoxysulfone 113, initiating a Smiles rearrangement to afford a spirocyclic 
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intermediate 114, which breaks down to the corresponding sulfinate salt 115. In order for 
the elimination of sulfur dioxide and benzothiazolone 116 to occur, an anti-periplanar 
arrangement of the SO2 and OBT groups is required and upon elimination yields the alkene 
products.   
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Scheme 2.10: Mechanistic rationale for modified Julia olefination. 
 
The stereoselectivity of the modified Julia olefination is dependent upon the R and R1 
substituents of both the sulfone and carbonyl components. When the R and R1 groups are 
non-conjugated alkyl substituents, the resultant alkene product displays little or no 
stereocontrol. This is attributable to the poor diastereoselective addition of the aldehyde to 
the sulfone component. An example of this is outlined in Scheme 2.11, where treatment of 
BT-sulfone 117 with an aliphatic aldehyde 118 gave alkene 119 in a moderate yield and as 
a 49 : 51 mixture of E : Z isomers.58  
 
BT
O2
S
n-C8H17
n-C8H17CHO (118), 
LDA, THF, -78 °C to RT
48%,  E :  Z = 49 : 51
117 119  
Scheme 2.11: Synthesis of alkene 119. 
 
Alternatively, when the R group is a vinyl or aryl substituent and the R1 substituent is an 
alkyl group, the Z-alkene product dominates. This outcome can be explained by the 
stabilization of the metallated sulfone by the conjugated R group, which allows the β-
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alkoxysulfone to undergo retroaddition/addition reactions, which leads to the equilibration 
of the diastereomeric alkoxides 113 (Scheme 2.10). At this point the syn-diastereomer can 
readily undergo a fast Smiles rearrangement, which could explain the observed 
stereochemical bias towards the Z-alkene in this case. A prime example of this is outlined 
in Scheme 2.12, where the stabilized sulfone 120 undergoes an olefination reaction with a 
saturated aldehyde 118 to give alkene 121 in excellent yield and with modest 
diastereoselectivity for the Z-alkene (E : Z = 23 : 77). 
 
O2
S
BT
n-C8H17CHO (118), 
LDA, THF, -78 °C to RT
80%, E : Z = 23 : 77
n-C8H17
120 121  
Scheme 2.12: Synthesis of alkene 121. 
 
The situation with the BT-sulfone class becomes even more complex, when addition of a 
saturated/unsaturated BT-sulfone with a conjugated aldehyde forms an E-alkene (Scheme 
2.13). Aliphatic BT-sulfone 122 underwent an olefination reaction with conjugated 
aldehyde 123 to provide E-alkene 124 in excellent yield and stereoselectivity. 
 
BT
O2
S
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MeO
MeO
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 E : Z = 99 : 1
122
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Scheme 2.13: Synthesis of alkene 124. 
 
This stereochemical bias can be explained by an alternative pathway through the initial 
loss of the lithium benzothiazolone from spirocyclic intermediates 125 and 126 to give 
betaine conformers 127 and 128 (Scheme 2.14). Following a conformational equilibration 
to minimize interaction between R/R1 groups, the favoured conformer 128 stabilized by the 
unsaturation present within the aldehyde component, proceeds to lose sulfur dioxide 
accessing the E-alkene.   
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Scheme 2.14: Rationale for E-alkene. 
 
The BT-sulfones have several limitations associated with them: these include the 
stereochemical issues previously mentioned and also their propensity to undergo self-
condensation due to their susceptibility towards nucleophilic attack. In an effort to reduce 
this self-condensation, a Barbier protocol can be implemented, by treatment of a mixture of 
sulfone and aldehyde with base to generate the anion of sulfone in situ. At this point the 
self-condensation reaction competes with the addition to the carbonyl component. A 
limitation to this protocol is the sensitivity of the aldehyde component to the treatment of 
base. The self-condensation reaction can also be minimized through the premetallation of 
the sulfone at low temperatures previous to the addition of aldehyde. The stereoselectivity 
for the synthesis of alkenes employing the BT-sulfone was found to be dependent on the 
substituents of the sulfone and carbonyl components and also the choice of solvent.55 It 
was observed that increasing the solvent polarity had an inherent effect on the increased E-
selectivity (DME > THF > Et2O > PhMe).  
 
2.2.5 Modified Julia-Kocienski olefination 
 
In 1998, Kocienski and co-workers reported a 1-phenyl-1H-tetrazol-5-yl (PT) sulfone as an 
alternative to the BT-sulfone for the modified Julia olefination.55 An advantage over the 
BT-sulfone was the diminished tendency to self-condense and beneficially provide greater 
selectivity for the E-alkene. Kocienski exhibited the effect of both solvent polarity and 
base counterion on the outcome of the olefination reaction. An analogous trend to the BT-
sulfone was observed: increased solvent polarity enhanced the tendency towards the 
formation of E-alkenes (DME > THF > Et2O > PhMe). It was also noted that the use of a 
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different base counterion also enhanced the stereochemical outcome towards the E-alkene 
upon increasing the size of the counterion (Li+ < Na+ < K+).  
 
The mechanism of the modified Julia-Kocienski follows that of the BT-sulfone (Scheme 
2.15), initial deprotonation with base forms the lithium anion 129 and subsequent addition 
of a carbonyl component results in the β-alkoxysulfones 130 and 131.58 However, unlike 
the BT-sulfone, the addition of the aldehyde to the PT-sulfone predominantly forms the 
anti-adduct 131, due to the bulky nature of the phenyl substituent. The Smiles 
rearrangement orients the R groups in a syn-arrangement 132 to reduce the steric clash 
with the phenyl group and subsequent elimination of the sulfur dioxide and the PT group 
gives an E-alkene. 
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Scheme 2.15: Mechanism of modified Julia-Kocienski olefination.  
 
2.2.6 Recent applications of the modified Julia-Kocienski olefination  
 
In 2006, Hoffmann and co-workers reported a modified Julia-Kocienski olefination with a 
PT-sulfone for the total synthesis of THP containing acetogenin, jimenezin 133 (Scheme 
2.16).60 The structural similarity to chamuvarinin (72) provided an opportunistic chance to 
showcase a potential olefination strategy for the final C8-C9 bond construction of 
chamuvarinin (72). The assembly of sulfone 134 and aldehyde 135 to install the C6-C7 
bond of 136 was not reliant upon high levels of stereochemical induction due to the 
reduction of the resultant alkene. The olefination of sulfone 134 and aldehyde 135 was 
conducted in THF as the desired solvent with LiHMDS as base to provide alkene 136 in 
93% yield and as an inseparable mixture of E : Z isomers. 
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Scheme 2.16: Synthesis of alkene 136.60 
 
Recently published work from our group towards the synthesis of palmerolide C (137), 
outlined in Scheme 2.17, demonstrated an intricate assembly of PT-sulfone 138 and 
aldehyde 139 to install an E,E-diene moiety 140.61 Based upon our direct experience in the 
synthesis of chamuvarinin (72), the olefination was carried out in THF with NaHMDS as 
base. The synthesis of the C1-C24 framework of 140 was achieved in excellent yield and 
with high levels of E-selectivity (E : Z = 88 : 12). This application of the modified Julia-
Kocienski protocol demonstrated the versatility of this reaction and illustrated 
compatibility with the use of complex subunits 138 and 139 containing highly sensitive 
functionalities such as the dienyl iodide and the carbamate groups. 
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Scheme 2.17: Synthesis of C1-C24 diene 140.61 
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2.2.7 Synthesis of the C9-C20 epoxide  
 
The stage was now set for the first key bond construction at C15-C16 (Scheme 2.18). 
Thus, treatment of sulfone 104 in DME at -78 °C with NaHMDS and addition of aldehyde 
103 provided alkene 141, which was partially purified by a silica plug. The reaction 
proceeded with high levels of stereocontrol to give the desired E-alkene (E : Z = 97 : 3). 
The initial conditions employed for the C19 and C20 silyl deprotection of 141 was affected 
by treatment with TBAF. Due to the large volumes of TBAF required, a more suitable acid 
mediated methanolysis was adopted, which removed both silyl protecting groups cleanly to 
give diol 142 in 68% yield over three steps from alkene 102.  
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Scheme 2.18: Synthesis of epoxide 143.  
 
The next stage was to install the epoxide, treatment of diol 142 with triisopropyl benzene 
sulfonyl imidazole (TrisImH) selectively formed the primary sulfonate in situ and initiated 
a SN2 displacement by the secondary alkoxide to provide epoxide 143.62 With multigram 
quantities of epoxide 143 in hand, the next stage in the synthesis of the C9-C20 subunit 
synthesis required the construction of the C16-C19 THF ring system via Sharpless 
asymmetric dihydroxylation to install the C15 and C16 hydroxyls in a stereoselective 
manner. 
 
2.2.8 Sharpless asymmetric dihydroxylation 
 
The Sharpless asymmetric dihyroxylation has proven to be an invaluable tool in natural 
product synthesis to access enantioselective 1,2-diols from an alkene precursor.63 The 
dihydroxylation protocol requires the use of osmium tetroxide, a stoichiometric oxidant 
and a chiral ligand such as the PHAL ligands (Figure 2.2).  
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Figure 2.2: Enantiomerically enriched chiral ligands for Sharpless asymmetric dihydroxylation. 
 
Fortunately, the reagents required for the dihydroxylation are commercially available as a 
pre-prepared mixture containing K2OsO2(OH)4 as an osmium source, K3Fe(CN)6 as an 
oxidant, K2CO3 as a base and a chiral PHAL-based ligand. The reagents are available 
either as AD-mix β which contains ligand 144 or AD-mix α which contains ligand 145. An 
accepted Sharpless mnemonic,63b outlined in Scheme 2.19, assists in the prediction of the 
stereochemical outcome for the asymmetric dihydroxylation. The mnemonic denotes the 
substituents of the olefin as S, M and L for small, medium and large groups, and the 
enantiofacial selectivity is dependent upon which AD-mix is employed.  
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Scheme 2.19: Sharpless asymmetric dihydroxylation mnemonic. 
 
2.2.9 Synthesis of the C9-C20 aldehyde  
 
Construction of the C16-C19 THF ring was accomplished in two steps from epoxide 143 
(Scheme 2.20), employing the Sharpless asymmetric dihydroxylation protocol to yield an 
intermediate epoxydiol followed by base mediated ring closure to provide the 5-exo-tet 
THF diol 146 with excellent diastereoselectivity (d.r. = >97 : 3).64 Aldehyde 83 was 
prepared in a further three steps, TBS protection of diol 146 provided 147 in 96% yield and 
subsequent C20 silyl deprotection afforded C20 alcohol 148 in good yield with recovery of 
starting material 147 and diol 146. To complete the synthesis of the C9-C20 subunit 83, 
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alcohol 148 was subjected to Dess-Martin periodinane oxidation to provide 83 in 70% 
yield. 
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Scheme 2.20: Synthesis of aldehyde 83.  
 
2.2.10 Summary  
 
The synthesis of the C9-C20 subunit 83 was accomplished in twelve steps in 4.4% overall 
yield from (±)-glycidol (98). The initial synthesis of 83 employed TBAF for the C19/C20 
silyl deprotection, a more suitable acid mediated methanolysis method was adopted to 
cleanly access diol 142. Keys aspects of this synthetic approach relied on a Julia-Kocienski 
olefination strategy followed by a Sharpless asymmetric dihydroxylation protocol to install 
the C15-C16 hydroxyls in a stereoselective manner, which constructed the desired C16-
C19 anti-THF motif.  
 
2.3 Synthesis of the C21-C34 subunit 
 
2.3.1 Synthesis of the C23-C34 aldehyde 
 
The synthesis of the C21-C34 subunit 84 initially followed the route previously established 
by Reddy and Osler in the Florence group (Scheme 2.21).51 The synthesis began with a 
Jacobsen HKR of (±)-epoxyoctane 149 to provide enantio-enriched (S)-epoxyoctane 150 in 
43% yield. From (S)-150, construction of the THP ring was accomplished in two further 
steps by copper (I) promoted ring opening of 150 with freshly prepared 
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homoallylmagnesium bromide (151) to give alkene 152. Epoxidation with m-CPBA of 152 
followed by acid mediated ring closure triggered the 6-exo cyclization to provide a mixture 
of syn-153 and anti-154 THP diastereomers in a combined 69% yield (d.r. = 56 : 44).  
 
OH
O
OH
O
OH
O
homoallylMgBr (151), 
CuI, THF, Et2O, 
-40 °C to RT, 87%
m-CPBA,CH2Cl2, 0 °C then 
CSA, MeOH, 0 °C to RT, 69%,
d.r. 153 :  154  = 56 : 44
+
150 152
153154
O
149
(S,S)-86, 
AcOH, H2O, THF, 
0 °C to RT, 43%
2424
34 34
24
34
28
 
Scheme 2.21: Synthesis of alcohols 153 and 154. 
 
The stereochemistry of the THP alcohols was established by Dr. Reddy utilizing the 24R, 
28R-alcohol 155 (Scheme 2.22).65 Derivatization of alcohol 155 to the nitro benzoate ester 
156 enabled 1D nOe NMR experiments to be conducted. A siginificant nOe correlation of 
proton H24 with H28 confirmed the relative 2,6-syn stereochemistry.  
 
O
OH
155
O
O
156
O NO22-nitro benzoic acid, 
DIAD, PPh3, THF,
RT, 88%2428
2428
 
Scheme 2.22: Confirmation of relative stereochemistry of alcohol 155.  
 
Based on the relative assignment of the C24-C28 THP ring system of chamuvarinin 
suggested by Poupon and co-workers,44 the syn-153 diastereomer was progressed to alkyne 
84. Syn alcohol 153 was oxidized under Swern conditions to give the corresponding 
aldehyde 157 in excellent yield (Scheme 2.23).  
 
O
H
O
157
O
OH
153
(COCl)2, DMSO, 
Et3N, CH2Cl2,
 -78 °C, 88% 24
3434
24
 
Scheme 2.23: Synthesis of aldehyde 157. 
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2.3.2 Synthesis of the C21-C34 propargylic alcohols 
 
To install the desired alkyne functionality, addition of the lithium acetylide of TMS 
acetylene to aldehyde 157 provided a separable mixture of propargylic alcohols 158 and 
159 in 69% yield (Scheme 2.24). The addition proceeded with high levels of Felkin-Anh 
stereochemical induction (d.r. 158 : 159 = 11 : 89). Dr R. Vanga confirmed the 
configuration of the major product 159 to be the undesired 23R-stereochemistry by 
application of the advanced Mosher ester analysis method.65  
 
23
O
H
O
TMSn-BuLi, THF,
 -78 °C, 69%,
 d.r. 158 : 159  = 11 : 89
OH
TMS
O
157 158
23
O
TMS
OH
159
24
34 34 34  
Scheme 2.24: Synthesis of alkynes 158 and 159. 
 
The Felkin-Anh models, outlined in Figure 2.3, explain the observed 1,2-stereochemical 
induction.66 To ensure no eclipsing interactions are present, the largest substituent 
(oxygen) is situated perpendicular to the carbonyl group. The carbonyl group is more 
susceptible to nucleophilic attack when the largest group is an electronegative atom, due to 
the orbital overlap of the π* (C=O) and the σ* (C-X), which results in a lower energy 
conformation. The carbonyl is attacked by the nucleophile from the least hindered 
approach at an angle of 109°, known as the Bürgi-Dunitz angle.67 From the models, it was 
apparent that attack of aldehyde 157 with the TMS acetylene nucleophile provided the 
undesired 1,2-syn stereochemistry as the major Felkin-Anh product.  
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Figure 2.3: Felkin-Anh models for TMS acetylene addition to 157.  
 
With propargylic alcohol 159 in hand, a two step Mitsunobu protocol68 was required to 
invert the 23R-alcohol (Scheme 2.25). Treatment of 159 with 4-bromobenzoic acid, PPh3 
and DIAD resulted in an intermediate benzoyl ester and subsequent exposure of the crude 
ester reaction mixture to base mediated methanolysis cleaved both the ester and the silyl 
protecting group to provide the desired 23S-alkyne 160 in 58% yield over the two steps. 
The minor propargylic alcohol 158 was exposed to the same base mediated desilylation 
conditions to give 160 in excellent yield. Although alkyne 160 was accessed in gram 
quantities, the Mitsunobu inversion was not always reliable, with yields occasionally 
varying and a difficult chromatographic purification associated with the reaction. 
Therefore, it was concluded that direct access to alkyne 158 was desirable.  
 
23
O
TMS
OH
158
23
O
TMS
OH
159
23
O
H
OH
160
1) 4-bromobenzoic acid,
PPh3, DIAD, THF, 0 °C
2) K2CO3, MeOH, RT, 58%
K2CO3, MeOH, RT, 
93%
 
Scheme 2.25: Synthesis of alkyne 160. 
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2.3.3 Carreira alkynylation protocol 
 
In recent years a lot of attention has focused on the enantioselective additions of alkynes to 
aldehydes, such as the Shibasaki asymmetric alkynylation employing a catalytic In(III)/ 
BINOL complex.69 An example of this alkynylation methodology is outlined in Scheme 
2.26, aldehyde 161 was exposed to a catalytic In (III)/BINOL complex and subsequent 
addition of alkyne 162 furnished alkyne 163 in excellent yield and excellent 
enantioselectivity. 
 
H
O Ph OH
PhInBr3, (R)-BINOL,
Cy2NMe, CH2Cl2, 
40 °C, 95%, 97% e.e161 163
162
 
Scheme 2.26: Synthesis of alkyne 163.  
 
An alternative asymmetric alkynylation methodology was reported by Carreira and co-
workers utilizing an in situ generated zinc acetylide.70 The protocol relies on the use of 
zinc (II) triflate, a chiral N-methylephedrine and an amine base such as Et3N. The scope of 
this method tolerates the addition of alkynes to both aliphatic and aromatic aldehydes, but 
the yields are significantly lower for aromatic aldehydes due to an alternative reaction. The 
accepted mechanism for the Carreira alkynylation, shown in Scheme 2.27, generates a zinc 
acetylide in situ (164) from reaction of an alkyne with zinc (II) triflate and Et3N.  
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R
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Scheme 2.27: Proposed transition states for Carreira alkynylation.  
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The acetylide 164 subsequently co-ordinates to a chiral N-methylephedrine ligand to form 
complex 165. Upon addition of an aldehyde, the zinc co-ordinates to the oxygen, forming 
intermediate 166. The reactive zinc acetylide undergoes a nucleophilic addition to the 
carbonyl component (complex 167) to yield an enantioenriched propargylic alcohol 168. 
Either enantiomer of the propargylic alcohol can be accessed by variation of the chiral N-
methylephedrine ligand. This milder protocol provides an alternative method to the 
addition of base sensitive aldehydes in comparison with other metal acetylides such as 
magnesium and lithium.   
 
Carreira and co-workers have demonstrated that solvent choice is a contributing factor for 
the enantioselective zinc alkynylation of aldehydes (Scheme 2.28).70 The addition of 
alkyne 169 to aldehyde 161 was tested in three different solvents (toluene, THF and 
CH2Cl2) at room temperature to observe the effect on enantiopurity of the desired 
propargylic alcohol 170.70b The enantiomeric purity of propargylic adduct 170 when the 
reaction was conducted in toluene was determined to be 99% (entry 1), upon changing the 
solvent to THF, the enantio-selectivity diminished to 81% (entry 3). However, when the 
reaction was conducted in CH2Cl2 only a slight decrease in optical purity was observed 
(entry 2), 97% e.e. compared from 99% in toluene. From these results it appears that both 
CH2Cl2 and toluene access adduct 170 in high enantiopurity. Carreira and co-workers have 
also shown that a catalytic variant of this alkynylation protocol is achievable. 
 
H
O
H (CH2)2Ph
OH
(CH2)2Ph
Zn(OTf)2,Et3N,
(+)-N-methyl-
ephedrine, 23 °C
Solvent ee (%)
Toluene
CH2Cl2
THF
99
97
81
161 169 170
Entry
1
2
3
 
Scheme 2.28: Solvent effects on the synthesis of propargylic alcohol 170. 
 
2.3.4 Synthesis of the C21-C34 subunit 
 
In an effort to overturn the inherent selectivity of aldehyde 157, Carreira’s alkynylation 
protocol was employed (Scheme 2.29). Initial treatment of a solution of zinc triflate, (+)-N-
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methylephedrine, TMS acetylene and Et3N in CH2Cl2 at RT with aldehyde 157 provided 
propargylic alcohol 158 in moderate diastereoselectivity (entry 1, d.r. 158 : 159 = 71 : 29). 
  
23
O
H
O
TMS
 
    
Zn(OTf)2,Et3N,
(+)-N-methyl-
ephedrine
OH
TMS
Yield (%) 23S : 23RConditions
n-BuLi, -78 °C
Zn(OTf)2, Et3N,                     
N-methylephedrine
80 >95 : 5
11 : 8969
O
157 158
23S : 23RSolvent
>95 : 5
71 : 29
Temperature
RT
60 °C
60 °C
-Toluene
Toluene
Equivalents
Zn(OTf)2 : Ephedrine
1.1 : 1.2
0.2 : 0.22
1.3 : 1.5
CH2Cl2
Entry
1
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Scheme 2.29: Synthesis of alkyne 158.  
 
In an effort to improve the diastereoselectivity, the solvent was exchanged for toluene. The 
reaction conditions were altered and conducted with catalytic amounts of Zn(OTf)2 and 
(+)-N-methylephedrine at 60 °C in toluene, unfortunately, no trace of product was evident 
(entry 2). Gratifyingly using stoichiometric amounts of Zn(OTf)2 and (+)-N-
methylephedrine at 60 °C in toluene provided the desired 23S-propargylic alcohol 158 in 
80% yield and excellent diastereoselectivity (entry 3, d.r. 158 : 159 = >95 : 5). The chiral 
zinc acetylide addition provided efficient access to propargylic alcohol 158 in one step and 
in multigram quantities in comparison to the lithium acetylide addition, which required a 
Mitsunobu inversion protocol. 
 
With propargylic alcohol 158 in hand, the final steps to access the C21-C34 subunit 84 
required base mediated silyl deprotection of the alkynyl TMS group followed by the TBS 
protection of the C23 alcohol to give 84 in 85% yield over the two steps (Scheme 2.30). 
  
23
O
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OH
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O
H
OTBS
1) K2CO3, MeOH,
 RT, 93%
2) TBSCl, ImH,
 CH2Cl2, RT, 91%
158 84
28
 
Scheme 2.30: Synthesis of C21-C34 subunit 84. 
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2.3.5 Summary  
 
The synthesis of the C21-C34 subunit 84 was accomplished in seven steps from 
commercially available (±)-epoxyoctane 149 in 9% overall yield. Key improvements of the 
initial strategy involved the implementation of the Carreira alkynylation protocol to 
overturn the stereoselectivity of the C23 hydroxyl position. Assembly of aldehyde 157 
with the lithium acetylide of TMS acetylene followed by a Mitsunobu inversion protocol 
gave alkyne 160 in 40% yield over the three steps, by comparison the zinc acetylide 
addition followed by silyl deprotection gave alkyne 160 in 74% yield over two steps. 
Hence, the chiral zinc addition provided an efficient one pot protocol to gain exclusive 
access to alkyne 158. 
With all three advanced subunits in hand, attention turned to the assembly and construction 
of the central C20-C23 THF core of chamuvarinin (80) and the final C8-C9 bond 
construction, detailed in Chapter 3.  
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Chapter 3 
 
3.1 Synthesis of the C9-C34 alcohols 
 
Having established access to the three key subunits on multigram scale, the assembly of 
C21-C34 alkyne 84 and C9-C20 aldehyde 83 followed the route established by Murray, as 
outlined in Scheme 3.1.51 Deprotonation of alkyne 84 with n-BuLi in THF at -78 °C, 
followed by addition of the resulting lithium acetylide to aldehyde 83 proceeded under 
Felkin-Anh control to provide an inseparable mixture of propargylic alcohols 171 and 172 
in 68% yield with moderate diastereoselectivity (d.r. 171 : 172 = 75 : 25). 
 
n-BuLi, -78 °C, THF, 68%,
d.r. 171 : 172  = 75 : 25
+
O
OTBS
OBn
9
20H
O
20
O
34
OTBS
O
OTBS
OBn
9
23
O
H
OTBS
84 83
20O
34
OTBS
O
OTBS
R R1
171: R = OH, R1 = H
172: R = H, R1 = OH
9
TsNHNH2, NaOAc,
DME, H2O, 
reflux, 51%
20O
34
OTBS
O
OTBS 9OHOH
173 174OBn OBn  
 Scheme 3.1: Synthesis of alcohols 173 and 174. 
 
Following the successful C20-C21 bond construction, reduction of the C21-C22 alkyne 
was required. From the work carried out by Dr R. Murray, diimide reduction was found to 
be the most effective reduction protocol.71 Thus treatment of 171 and 172 relied on the in 
situ generation of diimide (N2H2) by refluxing tosyl hydrazine (TsNHNH2) in DME with 
slow addition of a solution of sodium acetate in water. The inseparable 75 : 25 mixture of 
propargylic alcohols 171 and 172 were subjected to these reaction conditions to afford a 
readily separable mixture of alcohols 173 and 174 in 40% and 11% yield. At this point, the 
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configuration of the major C20-diastereomer 173 was confirmed by Dr R. Murray through 
application of the advanced Mosher ester analysis method to be the 20S-173.51,72,73 The 
stereochemical outcome is consistent with the expected addition to aldehyde 83 proceeding 
under Felkin-Anh control, as detailed in Figure 3.1.  
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Figure 3.1: Felkin-Anh model for C20-C21 bond construction. 
 
3.2 Solvent effects on alkynylation 
 
In 2011, Pagenkopf and co-workers reported the synthesis of the C18-C34 fragment of 
amphidinolide C (175, Scheme 3.2).74 The final stages towards the synthesis of the C18-
C34 fragment relied upon a stereoselective alkynylation between aldehyde 176 and enyne 
177. It was observed that addition of 176 and 177 in THF at -78 °C provided 178 as a 75 : 
25 mixture of C24 diastereomers (entry 1). Screening of the alkynylation reaction in 
several solvents at -78 °C found that changing the solvent from THF to methyl t-butyl 
ether (MTBE) led to improved diastereoselectivity (entry 2, d.r. = 89 : 11). Further 
enhancement in diastereoselectivity was observed upon reducing the reaction temperature 
to -90 °C in MTBE furnishing alcohol 178 in excellent yield and diastereoselectivity (entry 
3, d.r. = 95 : 5). 
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Scheme 3.2: Synthesis of propargylic alcohol 178. 
 
3.3 Improvements of the C9-C34 assembly 
 
In line with Pagenkopf’s precedent, the alkynylation reaction of 84 with 83 was performed 
in MTBE at -90 °C (Scheme 3.3) in an effort to further enhance the diastereoselectivity of 
the reaction towards the 20S-alcohol 171. Gratifyingly the alkynylation proceeded 
smoothly to furnish 20S-171 in excellent yield, with essentially complete diastereocontrol 
at C20 as judged by 1H NMR (d.r. 171 : 172 = >95 : 5). Having achieved exclusive access 
to alcohol 171, diimide reduction of 171 furnished alcohol 173 in 62% yield providing 
efficient access to 173 in preparation for the C20-C23 THF ring formation.  
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Scheme 3.3: Synthesis of alcohol 173.  
 
3.4 C20-C23 THF ring formation 
 
With the desired stereochemistry at C20 installed in alcohol 173, construction of the C20-
C23 syn-THF ring system was required. Synthetic efforts to install the THF motifs found 
in acetogenins has predominantly focused on intramolecular Williamson etherification 
reactions utilizing 1,4-epoxy alcohols or activated 1,4-hydroxy sulfonate species, as 
outlined in section 1.6. By analogy, our strategy to prepare the central syn-THF motif was 
envisioned to arise from base mediated SN2 cyclization of the C24 alcohol through the use 
of an activated 1,4-hydroxy sulfonate species (Scheme 3.4). Activation of 20S-173 as its 
mesylate and subsequent exposure of the crude material to TBAF, resulted in cleavage of 
both the C15 and C23 silyl protecting groups and concomitant 5-exo cyclization furnished 
the desired adjacent THP-THF-THF polyether ring system 179 in an excellent 94% yield. 
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Scheme 3.4: Synthesis of alcohol 179. 
 
Having assembled the C9-C34 polyether backbone of chamuvarinin (80), rigorous 
assignment by 2D HSQC/HMBC NMR experiments enabled the definitive assignment of 
the 1H and 13C shifts of the C15-C28 ether array of 179. The 1H and 13C NMR data of the 
synthetic C9-C34 fragment were compared to natural chamuvarinin (72) to provide an 
early indication of the integrity of Poupon’s44 proposed assignment of the relative 
stereochemistry. Outlined in Figure 3.2 is the 1H NMR comparison of alcohol 179 with 
natural chamuvarinin (72). In particular, the 1H NMR comparison of the 3-4 ppm region 
(Figure 3.3) corresponding to the C15-C28 array proved particularly constructive. 
  
 
Figure 3.2: Overlay of 1H NMR of C9-C34 synthetic 179 and natural chamuvarinin (72).  
Natural chamuvarinin (400MHz, CDCl3) 
Synthetic C9-C34 (500MHz, CDCl3) 
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Figure 3.3: Expansion of 3.0-4.0 ppm 1H NMR overlay of synthetic C9-C34 subunit 179 and natural 
chamuvarinin (72). 
 
The shift difference tables (Figure 3.4) illustrate the 1H and 13C NMR ppm differences 
surrounding the C15-C28 ether array for natural chamuvarinin (72), synthetic alcohol 179 
and both the anti-THF-anti-THP 78 and anti-THF-syn-THP 77 diastereomers prepared by 
Poupon and co-workers. Initial comparison of the 1H NMR data reported for natural 
chamuvarinin (72) and synthetic 179 correlated well, except for the C20 proton of the syn-
THF motif, which showed a discrepancy of 0.1 ppm. However, analysis of the carbon 
shifts associated with the ether array correlated well with the natural material. By 
comparison of natural 72 to the data for diastereomers 77 and 78, major discrepancies of 
0.3 ppm for 1H NMR and >6 ppm for 13C NMR data were evident.  
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Figure 3.4: Shift difference tables comparing 1H NMR and 13C NMR; a) synthetic C9-C34 subunit 179, b) 
anti-THF-anti-THP 78, c) anti-THF-syn-THP 77 and d) corrected 179 with natural chamuvarinin (72).  
 
Based upon these findings, the original NMR data of natural chamuvarinin (72) were 
requested from Hocquemiller and co-workers.42 Evaluation of the isolation 1H NMR data 
for the natural material showed that the C20-proton of the syn-THF ring was located at 
3.83 ppm and not 3.93 ppm originally reported by Hocquemiller and co-workers. Input of 
this new information to the corrected 1H shift difference table indicated that both the 1H 
and 13C NMR data of 179 were essentially in agreement with that of the natural material. 
This provided the first real indication that the relative stereochemistry surrounding the 
C15-C28 array was correct. At this stage we were confident in the relative stereochemistry 
of the BCD ring system being assigned as 15R’, 16R’, 19R’, 20R’, 23S’, 24S’, 28S’.    
 
3.5 Synthesis of the C9-C34 alcohol 
 
With the adjacent THP-THF-THF ether core established, the next stage was to prepare the 
C9 terminus for coupling, in which alcohol 82 served as a divergent precursor (Scheme 
3.5). The C15-alcohol 179 was protected as its silyl ether using standard protection 
protocols (TBSOTf, 2,6-lut) to furnish TBS ether 180 in excellent yield. The TBS ether 
(a) (b)
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180 was subjected to Pearlman’s catalyst and H2 reaction conditions to affect the 
debenzylation at the C9-position to give alcohol 82 in 85% yield. With the divergent 
precursor in hand, alcohol 82 could readily be transformed into the desired functionality 
for C8-C9 bond construction.    
 
20% Pd(OH)2/C, H2, 
EtOH, RT, 85%
O O O
OTBS
O O O
OTBS
34
180
82
OH
OBn15
15
34
O O O
OH
34
179
OBn15
TBSOTf, 2,6-lut, CH2Cl2,
 -78 °C, 88%
 
Scheme 3.5: Synthesis of alcohol 82. 
 
3.6 C8-C9 bond construction  
 
With the C9-C34 alcohol 82 and C1-C8 butenolide 81 subunits in hand, attention was 
turned to the C8-C9 bond construction (Scheme 3.6). Our initial approach to construct the 
C8-C9 bond was based on a Wittig olefination reaction. In an effort to minimize the 
number of synthetic transformations on advanced material, alcohol 82 was oxidized with 
Dess-Martin periodinane to give aldehyde 181 in quantitative yield. The coupling of 
phosphonium salt 96 and aldehyde 181 utilized the reaction conditions employed by 
Paterson et.al. in their route to complete the total synthesis of spongistatin 1 and 
althohyrtin A.75 The initial olefination was attempted by Dr R. Murray by treatment of 
phosphonium salt 96 with NaHMDS and DMPU at -78 °C in THF to generate the ylide in 
situ and subsequent exposure to aldehyde 181, unfortunately did not provide the desired 
Wittig product 182. 
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Scheme 3.6: Synthesis of alkene 182. 
 
3.6.1 Wittig olefination model studies 
 
Due to the precious nature of aldehyde 181, olefination studies were conducted with 
phosphonium salt 96 and a model aldehyde 183 (Scheme 3.7). Previously prepared mono-
benzylated alcohol 93 was oxidized under Swern conditions to access model aldehyde 183. 
Phosphonium salt 96 was subjected to the previous reaction conditions to generate the 
ylide followed by addition of aldehyde 183. After work-up and purification, 1H NMR 
analysis did not show any evidence of coupled product 184. Further attempts at the 
olefination were made with the same reaction conditions but did not show any trace of the 
desired product. Therefore, an alternative coupling strategy was required. 
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Scheme 3.7: Synthesis of alkene 184. 
 
3.6.2 Julia-Kocienski olefination model studies 
 
Based upon experience within this project, the Julia-Kocienski olefination method was 
considered as an alternative for C8-C9 bond construction (Scheme 3.8). Elaboration of 
alcohol 81 to the corresponding sulfone 185 was achieved in two steps by treatment of 81 
under Mitsunobu conditions to form the intermediate sulfide 186, followed by ammonium 
molybdate catalyzed hydrogen peroxide oxidation to access sulfone 185 in 60% yield over 
the two steps.  
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Scheme 3.8: Synthesis of sulfone 185. 
 
With both coupling partners in hand, the bond construction was attempted using the 
optimized conditions previously established in the synthesis of the C9-C20 subunit 83 
(Scheme 3.9). Treatment of sulfone 185 with NaHMDS in DME at -78 °C followed by 
addition of model aldehyde 183 did not provide the desired product 184 (entry 1). It has 
been well documented that the Julia-Kocienski olefination has proven to be solvent and 
base dependent. Therefore, exchange of the solvent from DME to THF was hypothesized 
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to affect this olefination (entry 2). However, by 1H NMR no trace of product 184 was 
detected, but from the 1H and 13C NMR data analysis it appeared that direct treatment of 
sulfone 185 with base was affecting the lactone moiety. A plausible hypothesis for this 
observation was based on either the deprotonation of the γ-lactone, which could ultimately 
lead to a ring opened product or alternatively due to the presence of two functional 
moieties with similar pKa values, intra- and intermolecular attack of the sulfonyl anion on 
the lactone moiety may occur. Based on this hypothesis it was necessary for the sulfone 
and aldehyde coupling partners to be reversed. 
 
O
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S
185
N
N
N N
Ph
BnO
H
O183
O
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BnO
OutcomeConditions
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-
Entry
1
2
3614
for conditions 
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Scheme 3.9: Synthesis of alkene 184. 
 
3.6.3 Julia-Kocienski olefination reversed coupling partners 
 
As outlined in Scheme 3.10, model sulfone 187 was accessed in good yield over two steps 
through installation of an intermediate sulfide by treatment of alcohol 93 with the 
Mitsunobu conditions followed by ammonium-catalyzed hydrogen peroxide oxidation. The 
butenolide aldehyde 188 was accessed in 93% yield by Dess-Martin periodinane oxidation 
of alcohol 81. With the reversed coupling partners synthesized, sulfone 187 was 
deprotonated with NaHMDS in THF at -78 °C and subsequent addition of aldehyde 188 
and an elevation of reaction temperature to -50 °C afforded the desired coupled product 
184 in an acceptable 29% yield. 
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Scheme 3.10: Synthesis of alkene 184. 
 
3.6.4 Synthesis of the C9-C34 sulfone 
 
Having established reaction conditions for the Julia-Kocienski protocol from the model 
studies, advanced alcohol 82 was elaborated to sulfone 189 (Scheme 3.11). Transformation 
of the C9-C34 alcohol 82 to the corresponding sulfide 190 was achieved in 90% yield, but 
required forcing Mitsunobu reaction conditions (four equivalents of reagents) and extended 
reaction times (four hours). Having synthesized sulfide 190, the next step was to synthesize 
sulfone 189 in preparation for the Julia-Kocienski olefination reaction. Treatment of 
sulfide 190 with a 50-fold excess of the ammonium molybdate/hydrogen peroxide 
complex, showed slow conversion by TLC analysis to the desired sulfone 189 after 24 
hours. Therefore, the reaction mixture was further doped with additional oxidizing agents 
and after a further 24 hour period sulfone 189 was isolated in 80% yield.  
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Scheme 3.11: Synthesis of sulfone 189. 
 
3.6.5 Final steps to chamuvarinin 
 
With the key subunits in hand, the optimized model conditions for the olefination were 
transferred to the real system (Scheme 3.12). Gratifyingly, treatment of sulfone 189 with 
NaHMDS in THF at -78 °C followed by addition of aldehyde 188 with warming to -50 °C 
afforded the desired alkene 182 in 41% yield. With the C1-C34 carbon backbone of 
chamuvarinin in place, the final stages towards the synthesis of 80 required reduction of 
the alkene and cleavage of the C15 silyl protecting group. Reduction of alkene 182 was 
accomplished by diimide reduction (in situ generation of N2H2 by refluxing TsNHNH2 in 
DME with slow addition of NaOAc in H2O) to afford an intermediate alkane. However, 
due to the <5 mg scale, the excess tosyl hydrazine could not be readily removed by column 
chromatography. Hence, the crude alkane was directly subjected to acid mediated 
methanolysis to cleave the C15 silyl protecting group to yield the 15R, 16R, 19R, 20R, 23S, 
24S, 28S, 36S diastereomer 80 in 73% yield over two steps.  
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Scheme 3.12: Synthesis of chamuvarinin 80. 
 
3.7 Comparison of the synthetic and natural material 
 
With the target molecule synthesized, confirmation of the absolute stereochemistry was 
now the focus. The original copies of the 1H and 13C NMR data for natural chamuvarinin 
(72) obtained from Hocquemiller enabled a detailed comparison of the synthetic and 
natural material.42 Both the 1H and 13C shifts of the synthetic material 80 were in complete 
agreement with the natural product 72 (shown in Tables 3.1 and 3.2) as were the other 
spectroscopic data obtained (IR and mass spec). 
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Table 3.1: 1H NMR data for natural 72 and synthetic chamuvarinin 80 (CDCl3). 
 
Proton  
No. 
natural chamuvarinina 
(δH) c 
synthetic chamuvarininb 
(δH) 
   
3 2.29-2.22 md 2.28-2.23 m 
4 1.55 m 1.69-1.43 m 
5 1.29-1.25 m 1.33-1.20 m 
6 “ " 
7 “ " 
8 “ " 
9 “ " 
10 “ " 
11 “ " 
12 “ " 
13 “ " 
14 1.38 m 1.42-1.34 m 
15 3.37 m 3.40-3.33 m 
16 3.82 m 3.85-3.79 m 
17a 1.97 m 2.02-1.89 m 
17b 1.65 m 1.69-1.43 m 
18a 1.97 m  2.02-1.89 m 
18b 1.65 m 1.78-1.69 m 
19 3.93 m 3.93 dt (7.9, 6.1) 
20 3.86-3.80 me 3.85-3.79 m 
21a 1.92 m 1.87-1.78 m 
21b 1.71 m 1.69-1.43 m 
22a 1.92 m 1.87-1.78 m 
22b 1.71 m 1.78-1.69 m 
23 3.88 m 3.88 dt (6.5, 5.6) 
24 3.28 m 3.28 ddd (11.2, 5.6, 1.9) 
25a 1.48 m 1.69-1.43 m 
25b 1.26 m  1.33-1.20 m 
26a 1.82 m 1.87-1.78 m 
26b - 1.69-1.43 m 
27a 1.33 m 1.69-1.43 m 
27b 1.12 m  1.13 qd (10.9, 4.1) 
28 3.23 m 3.26-3.19 m 
29 1.52 m 1.42-1.34 m 
30 1.29-1.25 m 1.33-1.20 m 
31 “ " 
32 1.25 m " 
33 1.25 m " 
34 0.87 t (7.3) 0.87 t (7.1) 
35 6.98 d (1.5) 6.98 q (1.6) 
36 4.98 dq (6.7, 1.5) 4.99 qq (6.8, 1.7) 
 37 1.40  d (6.8)f 1.40 d (6.8) 
15-OH - 2.53 br s 
   
 
           aData from ref. 42. Data recorded at 400 MHz. 
bData recorded at 400 MHz 
cThe coupling constants are given in Hz and shown in parentheses. 
d-fDenotes proton shift altered relative to value quoted in isolation paper (based upon inspection of 
copies of original NMR spectra supplied by Dr E. Poupon); d = H3 2.29-2.22 m [2.24 t (7.4) in 
paper]; e = H20 3.86-3.80 m [3.93 m in paper]; f = H37 1.40 d (6.8) [1.42 d (6.7) in paper] 
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Table 3.2: 13C NMR data for natural 72 and synthetic chamuvarinin 80 (CDCl3). 
 
 
 
 
aData from ref. 42. Data recorded at 100 MHz. 
bData from 13C spectra provided by Dr E. Poupon. Data recorded at 100 MHz (CDCl3 calibrated to 76.996). 
cData recorded at 125 MHz (CDCl3 calibrated to 76.996 ppm).  
 
A small sample of the natural product was requested for HPLC analysis for comparison 
with synthetic 80, but unfortunately there was no material available. With the absence of 
an authentic sample, the optical rotation was measured and was found to be consistent with 
the literature, +9.9 (c 0.1, CHCl3) compared to lit +25 (c 0.026, CHCl3). Based on all the 
Carbon 
No. 
natural 
chamuvarinina 
(δC) 
natural 
chamuvarininb 
(δC) 
synthetic 
chamuvarininc 
(δC) 
    
1 173.8 173.9 173.9 
2 134.3 134.3 134.3 
15 74.1 74.1 74.1 
16 83.0 83.1 83.1 
19 81.4 81.4 81.5 
20 81.9 81.99 82.02 
23 82.0 82.04 82.06 
24 79.9 79.9 79.9 
28 77.8 77.8 77.9 
34 14.1 14.1 14.1 
35 148.8 148.8 148.8 
36 77.4 77.4 77.4 
37 19.2 19.2 19.2 
    
24 x CH2 31.8 (C32) 36.5 36.5 
 26.9 (C4) 33.5 33.5 
 25.7 (C14) 31.9 31.9 
 25.1 (C3) 31.4 31.4 
 23.4 (C26) 29.7 29.8 
 22.6 (C33) - 29.7 
 25.5-32.4 (18C 
undefined) 
29.6 (3C, br) 29.6 (2C) 
  29.5 29.5 
  29.4 (2C) 29.4(2C) 
  29.3 29.3 
  29.2 29.2 
  28.8 28.8 
  28.3 28.3 
  27.9 28.0 
  27.4 27.4 
  26.9 26.9 
  25.7 25.7 
  25.5 25.5 
  25.2 25.2 
  23.5 23.5 
  22.6 22.6 
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spectroscopic data obtained, the stereochemistry of chamuvarinin 72 was confirmed as 
15R, 16R, 19R, 20R, 23S, 24S, 28S, 36S. An overlay of the 1H NMR’s of synthetic and 
natural chamuvarinin is shown in Figure 3.5.51  
 
 
Figure 3.5: Overlay of 1H NMR of synthetic chamuvarinin (80) and natural chamuvarinin (72).  
 
3.8 Cytotoxic and anti-parasitic biological profiles 
 
Further evidence to support the absolute stereochemical assignment of chamuvarinin (72) 
was achieved by biological evaluation against HeLa cervix cancer cell line and both the 
bloodstream and procyclic forms of Trypanosoma brucei (causative agent in West-African 
sleeping sickness), as outlined in Table 3.3.76 Our synthetic material 80 displayed a low 
micromolar activity, with an ED50 value of 2.88 ± 0.66 µM, when screened against the 
HeLa cervix cancer cell line.  
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T. brucei (BSF)
ED50 (µM)
T. brucei (Pro)
ED50 (µM)
HeLa
ED50 (µM)
Selectivity 
Index
1.37 ± 0.08 1.9 ± 0.11 2.88 ± 0.66 2.1
O O O
O
O
OH
1528
34
36
chamuvarinin
80 = 72
 
Table 3.3: Biological profile of chamuvarinin (80). 
 
The synthetic material was biologically evaluated against a different cancer cell line to that 
of natural chamuvarinin, but displayed a similar trend to squamocin (73), which has been 
biologically evaluated against both the KB 3-1 (IC50 0.003 nM) and HeLa (ED50 0.04 µM) 
cell lines.42,77 The hypothesis for the observed reduction in levels of activity for 80 against 
the HeLa cell line in comparison to the KB 3-1 cell line may be due to the KB 3-1 cell line 
relying more heavily on the mitochondrion for cell proliferation.  
 
The annonaceous acetogenins have been extensively examined due to their promising 
cytotoxic potentials. However, their potential as anti-parasitic agents for the treatment of 
Neglected diseases has to date been largely overlooked. The large portion of the research 
towards the anti-parasitic activity has been based on the evaluation of crude extracts from 
the Annonaceae plants for their leishmanicidal and trypanocidal activities. In 1994, 
Hocquemiller and co-workers reported on the anti-parasitic activity for a small selection of 
acetogenins and found squamocin (73) to inhibit the bloodstream form of T. brucei with an 
IC100 of 16 µM.78 Interestingly synthetic chamuvarinin (80) was found to be an effective 
inhibitor of both the bloodstream and procyclic forms of T. brucei with ED50 values of 1.37 
± 0.08 µM and 1.90 ± 0.11 µM respectively, which is in line with the trypanocidal 
activities reported for squamocin (73) and provided further convincing evidence for the 
correct absolute stereochemical assignment of 72.51  
 
3.9 Summary 
 
With both the spectroscopic and biological data in hand, the unambiguous proof of the 
absolute stereochemical assignment of chamuvarinin (72) was secured as 15R, 16R, 19R, 
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20R, 23S, 24S, 28S, 36S through the first total synthesis. The synthesis was completed in 
1.5% overall yield over 20 steps in the longest linear sequence. A key step in the synthetic 
efforts towards chamuvarinin (72) relied on the alkynylation reaction of C21-C34 alkyne 
84 with C9-C20 aldehyde 83 to construct the C9-C34 carbon backbone of 72. This 
stereoselective lithium acetylide addition demonstrated the influence of reaction 
temperature and solvent choice on diastereoselectivity. With exclusive access to the 
desired C20-alcohol 171, the central C20-C23 syn-THF motif of 179 was constructed by 
application of a Williamson etherification reaction.     
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Chapter 4 
 
4.1 Revised approach to chamuvarinin 
 
Our initial synthesis of chamuvarinin (72) was completed in 20 steps in the longest linear 
sequence, in a 1.5% overall yield. This synthesis provided unambiguous proof of the 
relative and absolute stereochemical assignment surrounding the C15-C28 polyether core 
of the natural product.51 The promising biological results displayed by chamuvarinin (72) 
against both forms of T. brucei presented an opportunity to further explore the potential of 
this unique acetogenin as an anti-parasitic agent. Our initial synthetic strategy was 
designed solely to address the structural elucidation of chamuvarinin (72), providing 
limited opportunity to introduce any form of structural diversity. Therefore, in an effort to 
assemble chamuvarinin (72) and analogues in an efficient manner, a revised coupling 
strategy utilizing key subunits employed in our initial route was investigated. The key 
bond disconnections at C8-C9 and C20-C21 of 72 were maintained, however, the coupling 
of the key subunits were simply reversed. From the retrosynthetic strategy, outlined in 
Scheme 4.1, disconnection of the C20-C23 THF ring revealed the advanced C1-C20 THF 
aldehyde 191 and alkyne 84. The C1-C20 THF aldehyde 191 was envisaged to arise from a 
Julia-Kocienski olefination strategy to unite the C1-C8 and C9-C20 subunits 188 and 192 
respectively.  
 
O O O
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34
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Scheme 4.1: Revised retrosynthetic coupling strategy.  
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4.2 Synthesis of the C9-C20 sulfone  
 
The revised approach began with the three step synthesis of sulfone 192 from the C9-C20 
benzyl ether 147, previously prepared in the first generation synthesis (Scheme 4.2). 
Hydrogenolysis of benzyl ether 147 with Pearlman’s catalyst and H2 afforded the C9-
alcohol 193, which was then treated under the Mitsunobu conditions to provide sulfide 194 
in 89% yield over two steps. 
 
O
OTBS
OBn
9
TBSO
20 O
OTBS
OH
9
TBSO
20
O
OTBS
S
9
TBSO
20
20% Pd(OH)2/C,
 EtOH, H2, RT, 95%
PTSH, PPh3,DIAD, 
THF, 0 °C, 94%
147 193
194
N
N
NN
Ph
 
Scheme 4.2: Synthesis of sulfide 194.  
 
With sulfide 194 in hand, the next step required oxidation to the corresponding sulfone 
192. This proved to be problematic (Scheme 4.3). Treatment of sulfide 194 with H2O2 and 
catalytic ammonium molybdate in MeOH (entry 1) resulted in a separable mixture of 
starting material sulfide 194, intermediate sulfoxide and the desired sulfone 192 in a 
disappointing 25% yield. In an attempt to affect this transformation, alternative oxidation 
methods such as ruthenium trichloride and oxone were tested, but did not furnish the 
desired product 192. Therefore, optimization of the Mo(VI)/H2O2 oxidation protocol was 
required. A decrease from 40 to 20 mol% of ammonium molybdate (entry 2), addition of 
10 equivalents of H2O2 and a slight increase in temperature from room temperature to 40 
°C led to the oxidation of sulfide 194, but also resulted in C20 silyl cleavage. The crude 
reaction mixture was then subjected to TBS protection conditions (TBSCl, ImH) to provide 
the desired sulfone 192, albeit in a low yield. 
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YieldConditions
65%
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40 °C
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Scheme 4.3: Synthesis of sulfone 192. 
 
To ensure complete conversion of sulfide 194 to the sulfone, an increase in oxidizing 
reagents were used (entry 3). The reaction proceeded to cleave the C20 silyl group as 
before, but protection of the C20 alcohol with the more effective TBSOTf conditions 
provided sulfone 192 in a more acceptable 65% yield. It has been documented that the 
Mo(VI)/H2O2 complex can be stabilized by the addition of hexamethylphosphoramide 
(HMPA).61,79  Therefore, a Mo(VI)/H2O2/HMPA complex was prepared at 0 °C (entry 4) 
and added to a solution of sulfide 194 in MeOH with gradual warming to room 
temperature. Oxidation of 194 to the desired sulfone 192 over 48 hours proceeded in an 
excellent 81% yield. With optimized conditions to access multigram quantities of sulfone 
192, C8-C9 bond construction to install the butenolide sidechain was required.  
 
4.3 Synthesis of the C1-C20 aldehyde 
 
With both the C1-C8 aldehyde 188 and the C9-C20 sulfone 192 subunits in hand, Julia-
Kocienski olefination to install the C8-C9 bond was required, outlined in Scheme 4.4. 
Having established optimized reaction conditions for the olefination protocol from the first 
generation synthesis, sulfone 192 was treated with NaHMDS in THF at -78 °C and 
subsequent addition of aldehyde 188 with warming to -20 °C afforded the C1-C20 alkene 
195 in an excellent 87% yield. Our initial route to install the C8-C9 olefin in 72 proceeded 
in a modest 41% yield. By comparsion with the revised route C8-C9 bond construction 
was affected in 87% yield, demonstrating the effectiveness of our revised strategy. Acid 
mediated silyl deprotection of the primary C20 TBS ether cleanly afforded primary alcohol 
196. 
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Scheme 4.4: Synthesis of alcohol 196. 
 
The final step to achieve the synthesis of the C1-C20 aldehyde 191 relied upon the 
oxidation of alcohol 196, shown in Scheme 4.5. Dess-Martin periodinane oxidation of 
alcohol 196 gave aldehyde 191 in good yield (entry 1). However, an alternative oxidation 
method was investigated, due to the unreliability of the Dess-Martin periodinane oxidation 
on 196. Exposure of alcohol 196 to tetrapropylammonium perruthenate (TPAP) and N-
methylmorpholine oxide (NMO) in the presence of molecular sieves at 0 °C provided 
aldehyde 191 in 55% yield (entry 2). Several attempts at the TPAP oxidation method on 
alcohol 196 did not exceed 55%. Therefore, the Dess-Martin periodinane oxidation method 
was deemed the most preferable as the yield was never less than 50%. Recovery of starting 
material 196 was observed when oxidation did not go to completion and was recycled 
accordingly. The C1-C20 aldehyde 191 was prepared in 14 steps from known (S)-TBS 
glycidol 100 in 9% overall yield.  
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Scheme 4.5: Synthesis of aldehyde 191. 
 
4.4 C20-C21 bond construction 
 
Following the synthesis of the C1-C20 aldehyde 191, the C20-C21 bond construction was 
required. The initial strategy from the first generation synthesis relied on a lithium 
alkynylation protocol to construct the C20-C21 bond. However, due to concerns regarding 
the base sensitive nature of aldehyde 191, a milder alkynylation strategy was employed. 
The C1-C20 and C21-C34 subunit assembly was envisaged to arise from a Nozaki-
Hiyama-Kishi coupling reaction, which entailed the coupling of an alkynyl iodide and an 
aldehyde in the presence of chromium and catalytic nickel.   
 
4.4.1 Nozaki-Hiyama reaction 
 
In 1977, Nozaki and co-workers reported on the synthesis of homo-allylic alcohols via the 
addition of allylic halides to carbonyl compounds, such as ketones and aldehydes in the 
presence of a chromium (II) salt.80,81 The chromium (II) salts employed in the C-C bond 
forming reaction were the commercially available CrCl2 and the CrCl2 salt accessed from 
in situ reduction of CrCl3 by LiAlH4. The use of the Nozaki-Hiyama coupling reaction is 
displayed in Scheme 4.6. Treatment of aldehyde 197 with allylic bromide 198 and the 
CrCl3-LiAlH4 species in DMF afforded homoallylic alcohol 199 in 83% yield. 
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CrCl3-LiAlH4, 
DMF, RT, 83%H
O
Br
OH197 198 199  
Scheme 4.6: Synthesis of alcohol 199.  
 
Nozaki and co-workers further demonstrated the utility of this carbon-carbon bond forming 
reaction through the use of vinyl and aryl halides in the synthesis of allylic alcohols.82 
Vinyl iodide 200 was treated with aldehyde 201 in the presence of CrCl2 to afford allylic 
alcohol 202 in quantitative yield, shown in Scheme 4.7. The CrCl2 reagent was employed 
in favour of the previously reported CrCl3-LiAlH4 salt due to unsatisfactory reactivity. 
 
I
Me
Me
Ph
OH
PhCHO
CrCl2, DMF,
 RT, 100%
200 201 202  
Scheme 4.7: Synthesis of alcohol 202. 
 
4.4.2 Nozaki-Hiyama-Kishi reaction  
 
In 1986, Kishi and co-workers demonstrated the versatility of the Nozaki-Hiyama coupling 
protocol on a complex vinyl iodide 203 and base sensitive aldehyde 204 system to access 
the C8-C22 fragment 205 of the marine natural product palytoxin (206), shown in Scheme 
4.8.83 However, initial synthetic studies towards the coupling of both subunits produced 
unreliable results, which was attributed to the purity of the CrCl2 reagent. Based on this 
assumption, Kishi et.al. screened various transition metals as additives for the coupling 
reaction. 
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Scheme 4.8: Natural product palytoxin (206) and the synthesis of the C8-C22 fragment 205. 
  
They found that introduction of catalytic amounts of NiCl2 to the reaction mixture 
provided consistent access to a diastereomeric mixture of allylic alcohols 205 in excellent 
yield. En route to the synthesis of palytoxin (206), Kishi employed the 
chromium(II)/nickel(II) mediated coupling in two key bond forming steps to install the C7-
C8 and C84-C85 bonds of 206.84 The Nozaki-Hiyama-Kishi (NHK) reaction has proven to 
be a major tool in the synthesis of natural products such as halichondrin B85 (207, Figure 
4.1) as it can accommodate the coupling of vinyl, allyl, alkynyl halides and triflates with 
base sensitive carbonyl compounds and has demonstrated high levels of chemoselectivity 
towards aldehydes in the presence of other functional groups.86,87  
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Figure 4.1: Natural product halichondrin B (207). 
 
A proposed mechanism for the Nozaki-Hiyama-Kishi coupling reaction, is outlined in 
Scheme 4.9. The process involves the Cr(II) reduction of Ni(II) to Ni(0) which then 
undergoes an oxidative addition to the vinyl iodide 208, providing the vinyl nickel(II) 
species 209.83,88 Species 209 undergoes transmetallation with the Cr(III) to provide the 
vinyl chromium (III) species 210. At this point the nucleophilic species can add to an 
aldehyde to provide an allylic alcohol 211.  
   
X NiX Cr(III)
OH
R
Ni(0) Ni(II)
Cr(II)Cr(III)
RCHOX = I, Br, OTf
Cr(III)
208 209 210
211  
Scheme 4.9: Proposed mechanism for the NHK reaction. 
 
4.4.3 Model Nozaki-Hiyama-Kishi studies 
 
Application of the NHK coupling reaction to the revised coupling strategy of chamuvarinin 
(72) was preferred over the conventional lithium based alkynylation due to concerns over 
the base sensitive nature of aldehyde 191. With the aldehyde precursor in hand, the C21-
C34 alkynyl iodide subunit 212 (Scheme 4.10) was accessed in excellent yield by 
treatment of alkyne 84 with n-BuLi and iodine at -78 °C.  
 
O
34
OTBS
O
34
OTBS
I
n-BuLi, I2, THF, 
-78 °C, 98%
84 212  
Scheme 4.10: Synthesis of alkynyl iodide 212.  
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Due to the precious nature of aldehyde 191, a model NHK study was carried out utilizing 
the C21-C34 alkynyl iodide subunit 212 and a model aldehyde substrate 183 to investigate 
the optimal conditions for subunit assembly (Scheme 4.11). It was essential that the solvent 
of choice was degassed to ensure that no oxygen was present within the reaction mixture. 
To a suspension of CrCl2/20% NiCl2 in THF was added alkynyl iodide 212 followed by 
addition of aldehyde 183 at room temperature afforded an inseparable 1 : 1 diastereomeric 
mixture of alcohols 213 in 65% yield.  
 
O
34
OTBS
I
212
H
O
OBn
20% NiCl2, CrCl2, 
THF, RT, 65%
O
34
OTBS
213 OH
OBn
183 23 20 1523
 
Scheme 4.11: Synthesis of propargylic alcohol 213.  
 
4.4.4 Application of Nozaki-Hiyama-Kishi strategy for C20-C21 bond construction 
 
Following the success of the model study, the C20-C21 bond construction to install the C1-
C34 carbon backbone of chamuvarinin (72) was pursued (Scheme 4.12). The C21-C34 
alkynyl iodide 212 and C1-C20 aldehyde 191 subunits were subjected to the optimized 
NHK conditions. Unfortunately, 1H NMR analysis showed no trace of the propargylic 
alcohols 214 and 215 and only starting materials were recovered.     
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Scheme 4.12: Synthesis of propargylic alcohols 214 and 215. 
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4.4.5 Application of Carreira alkynylation protocol for C20-C21 bond construction 
 
After the disappointment of the NHK coupling reaction, an alternative coupling method 
was investigated. Previous success employing the Carreira alkynylation protocol in the 
synthesis of C21-C34 alkyne subunit 84 deemed this alkynylation as an attractive coupling 
strategy for the C20-C21 bond construction (Scheme 4.13). The alkyne 84 was subjected to 
the previously optimized coupling conditions, treatment of alkyne 84 with Zn(OTf)2/N-(+)-
methylephedrine and Et3N in toluene followed by the addition of aldehyde 191 at room 
temperature did not provide any trace of the desired product and only starting materials 
were recovered. 
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Scheme 4.13: Synthesis of propargylic alcohols 214 and 215. 
 
4.4.6 Lithium acetylide addition for C20-C21 bond construction  
 
Given alternate methods for the C20-C21 bond construction had proved to be unsuccessful, 
we decided to attempt the coupling of alkyne 84 with aldehyde 191 using the previously 
employed lithium acetylide conditions (Scheme 4.14). The alkynylation reaction involved 
the treatment of 5 equivalents of alkyne 84 with 3.5 equivalents of n-BuLi in THF at -78 
°C to prepare the lithium acetylide in situ (entry 1). Subsequent addition of aldehyde 191 
provided the coupled product as an inseparable mixture of propargylic alcohols 214 and 
215 in an optimized 56% yield with modest diastereoselectivity (d.r. 214 : 215 = 75 : 25).  
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for conditions 
see table
Conditions
3.5 eq n-BuLi, 5 eq 84, THF, -78 °C
Entry
1
2
Yield
56%
4.2 eq n-BuLi, 5 eq 84, MTBE, -90 °C 29%
R R1
20
1
d.r.
214 :  215
75 : 25
>95 : 5
214 :  R = OH, R1 = H
215 : R = H, R1 = OH
84
1
 
Scheme 4.14: Synthesis of propargylic alcohols 214 and 215.  
 
Having established a viable coupling strategy to access the desired propargylic alcohols 
214 and 215, the next step focussed on the refinement of the alkynylation to give exclusive 
formation of adduct 214 to improve the overall efficiency of accessing chamuvarinin (72). 
Hence, Pagenkopf’s74 solvent effect was exploited (entry 2), a slight increase in the 
equivalents of base, employing MTBE as the reaction solvent and lowering the reaction 
temperature to -90 °C furnished alcohol 214 in a modest 29% yield with excellent 
diastereoselectivity (d.r. 214 : 215 = >95 : 5).  
 
4.5 C20-C23 THF ring formation  
 
With the C1-C34 backbone in place, the final stages towards the synthesis of chamuvarinin 
relied upon diimide reduction of the C8-alkene and C20-alkyne, C20-hydroxyl activation 
and basic silyl deprotection to affect the 5-exo cyclization to access 72. The inseparable 
mixture of propargylic alcohols 214 and 215 (Scheme 4.15, entry 1) were subjected to 
diimide reduction to provide the readily separable major alcohol 216 and minor alcohol 
217 in an overall combined 46% yield. Having achieved exclusive access to propargylic 
alcohol 214 through addition performed in MTBE, diimide reduction of 214 furnished 
alcohol 216 in 90% yield (entry 2). Based upon these results, the alkynylation reaction 
performed in the solvent MTBE and subsequent diimide reduction provided alcohol 216 in 
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26% yield over the two steps in comparison to the reaction performed in THF, which gave 
alcohol 216 in 15% yield over the two steps. 
 
TsNHNH2,
 NaOAc,DME, 
H2O, 100 °C
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34
OTBS
O
OTBS
O
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R R1
214 : R= OH, R1 = H
215 : R = H, R1 = OH
20O
34
OTBS
O
OTBS
O
O
R R1
216 : R= OH, R1 = H
217 : R = H, R1 = OH1
1
Alkyne
214 and 215
Entry
1
2
 Yield
216 34% : 217 12%
214 216 90%  
Scheme 4.15: Synthesis of alcohols 216 and 217. 
 
Installation of the central C20-C23 ring was all that remained to complete chamuvarinin 
(72), shown in Scheme 4.16. Activation of the C20-hydroxyl of alcohol 216 as it’s 
mesylate and subsequent base promoted 5-exo tet cyclization of the crude material, 
unfortunately did not provide the desired outcome (entry 1). An alternative base mediated 
ring closing step using K2CO3 in methanol was also shown to affect this transformation89 
(Dr Murray in the Florence group enabled the ring closure of the C20-C23 THF ring in the 
first generation synthesis of 72 with these conditions). 
 
O O O
O
O
OH
1528
34
36
20O
34
OTBS
OH
O
OTBS
O
O chamuvarinin
72
ConditionsEntry Yield
-
-
57% from 216
216
for conditions
see table
1) MsCl, Et3N, CH2Cl2, 0 °C 2) TBAF, THF, 0 °C to RT
1) MsCl, Et3N, CH2Cl2, 0 °C 2) 3 N HCl, MeOH, 0 °C 3) K2CO3, MeOH, RT
1) MsCl, Et3N, CH2Cl2, 0 °C 2) 3 N HCl, MeOH, 0 °C 3) pyridine, 65 °C
1
2
3
1
 
Scheme 4.16: Synthesis of chamuvarinin (72). 
 
Treatment of the crude mesylate with 3 N hydrochloric acid in methanol promoted C15 
and C23-silyl cleavage and subsequent exposure to basic conditions to promote cyclization 
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again did not provide 72 (entry 2). The final attempt to close the central C20-C23 ring 
exploited conditions used by Koert and co-workers in the synthesis of jimenezin 133 (entry 
3).60 The crude mesylate was subjected to acid mediated silyl deprotection of the C15 and 
C23 TBS ethers. Upon workup, the crude diol was heated in pyridine at 65 °C for 18 hours 
to promote the intramolecular Williamson reaction to afford chamuvarinin (72) in 57% 
yield over three steps with only the need for one chromatographic purification step.90  
 
4.6 Butenolide base epimerization studies 
 
Several groups have reported on the base catalyzed γ-epimerization of the butenolide 
moiety.91 Marshall and co-workers showed that treatment of butenolide 218 in the presence 
of neat diethylamine (Et2NH) at room temperature resulted in the epimerization of the γ-
stereocentre (Scheme 4.17, entry 1), which was evident by a 20% decrease in 
enantiopurity.91b Refluxing butenolide 218 in Et2NH diminished the enantiopurity of 218 
and resulted in complete epimerization (entry 2). Upon changing to Et3N as the solvent at 
room temperature, no evidence of epimerization was observed (entry 3). In 2000, Wu and 
co-workers91c reported similar observations to that reported by Marshall et.al.91b 
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for conditions
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218 
>98% ee
218
218 ee (%)Conditions
80
0
~98
Entry
1
2
3
Et2NH, 23 °C, 16 h
Et2NH, reflux, 24 h
Et3N, 23 °C, 16 h
3636
 
Scheme 4.17: Base epimerization of the 36S-218 stereocentre. 
 
Based on these epimerization studies, concerns were raised regarding the final cyclization 
of alcohol 216 to form chamuvarinin (72) upon exposure to neat pyridine at 65 °C. Hence, 
a control experiment (Scheme 4.18) was conducted on butenolide alcohol 81 to evaluate 
the effect of these cyclization conditions on the epimerization of the γ-stereocentre. After 
subjecting alcohol 81 to the conditions for 18 hours, the optical rotation of the alcohol was 
measured and no apparent epimerization was observed. From this study it was clear that 
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exposure of the butenolide moiety to prolonged heating in pyridine did not result in γ-
epimerization. 
 
O
O
HO
O
O
HO
pyridine, 
65 °C, 18 h
36368 8
81
[α]D = +35.5 (c 1.03, CHCl3)
81
[α]D = +37.0 (c 1.55, CHCl3)  
Scheme 4.18: Base epimerization experiment of the 36S-81 stereocentre. 
 
4.7 Summary 
 
The revised synthesis of chamuvarinin (72) was completed in 17 steps in the longest linear 
sequence and 2.2% overall yield. This revised coupling strategy accessed chamuvarinin 
(72) in an efficient manner reducing the overall number of linear steps from the first 
generation synthesis of 20 to 17 with a slight improvement in overall yield (2.2% 
compared from 1.5%). An attractive feature of this revised coupling strategy enables the 
assembly of non-natural acetogenin analogues from advanced intermediates, which are 
detailed in Chapter 5.  
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Chapter 5 
 
5.1 Trypanocidal and Leishmanicidal activities of annonaceous acetogenins 
 
Since the initial discovery of the first annonaceous acetogenin, much attention has 
focussed on their cytotoxic activities. In recent years their anti-parasitic activities have 
slowly gained more attention, with a few studies focussing on their leishmanicidal and 
trypanocidal activities.77,92,93 The crude extracts of Annona glauca were evaluated by 
Hocquemiller and co-workers against three different strains of leishmania, one of which 
was Leishmania donovani (causative agent of visceral leishmaniasis), as well as 
Trypanosoma cruzi (causative agent of Chagas disease).93 The dichloromethane extract 
displayed good activity against all three strains of Leishmania with an IC100 value of 25 
µg/mL. The acetogenins isolated from the dichloromethane extract were independently 
screened for their Leishmania activity and the results showed that of the nine acetogenins 
isolated only two were inactive. The most active acetogenins against the three strains of 
Leishmania were annonacin A (219) and goniothalamicin (220), which displayed IC100 
values of 16.8 and 8.4 µM, respectively (Figure 5.1). 
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Figure 5.1: Acetogenins annonacin A (219), goniothalamicin (220), squamocin (73), glaucanisin (221) and 
annonacin (222) isolated from Annona glauca. 
 
The acetogenins isolated from Annona glauca were also screened for their activity against 
the bloodstream form of T. cruzi.93 There were four acetogenins that displayed potent 
activities (Figure 5.1), the bis-THF acetogenins, squamocin (73) and glaucanisin (221) and 
the mono-THF acetogenins annonacin A (219) and annonacin (222). All four exhibited 
significant reductions in the number of parasites, 67%, 78%, 71% and 85 %, respectively 
at a concentration of 250 µg/mL.  
 
In 2003, Hocquemiller and co-workers reported the screening of crude extracts of Uvaria 
chamae against T. brucei and found that the root and stem bark extracts showed some 
encouraging trypanocidal activity.41 In contrast to the reported Leishmania and T. cruzi 
activities of acetogenins, the activity of isolated acetogenins against T. brucei has been 
largely unexplored. The only reported case was in 1994 by Sahpaz and co-workers, who 
described the trypanocidal activity of acetogenins isolated from the seeds of Annona 
senegalensis (Figure 5.2).78,94 Squamocin (73) and senegalene (223) exhibited low 
micromolar activities against the bloodstream form of T. brucei with IC100 values of 16 
µM.   
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Figure 5.2: Acetogenins squamocin (73) and senegalene (223). 
 
5.2 Elucidation of pharmacophore of annonaceous acetogenins 
  
Over the last three decades, several studies have focussed on the effect of both the 
stereochemistry of the polyether core and the γ-lactone on Complex I inhibition. The ether 
core of the acetogenins is hypothesized to act as an anchor by binding to the membrane 
surface in a hydrophilic manner, which in turn allows the reactive γ-lactone moiety to elicit 
a potent biological response.95 The natural occurrence in acetogenins of long flanking 
hydrophobic sidechains appears not to impact activity, but is thought to act as an anchor 
providing a hydrophobic interaction, which aligns the acetogenin in the membrane. An 
area that has proven to be controversial is the effect of stereochemical variation of the THF 
ring systems on Complex I inhibition. Several groups have stated that the stereochemistry 
of the THF ring systems is not essential for potent inhibition,96 whereas others have shown 
that a change in stereochemistry within the THF cores does have an impact on Complex I 
inhibition.97 In 2000, Miyoshi and co-workers demonstrated that a combination of the ether 
core and lactone moiety linked by an alkyl spacer unit were essential for potent 
inhibition.96 The synthesis of simplified structural analogues 224 and 225 enabled a direct 
comparison to natural acetogenin bullatacin 19 (Figure 5.3). Bullatacin 19 displayed low 
nanomolar inhibition of NADH oxidase, whereas the simplified structural analogues 224 
and 225 were devoid of any activity. From this study, Miyoshi et al. proposed that both the 
ether core and lactone moiety bind co-operatively to Complex I, which provided proof that 
for the acetogenins to elicit a biological response the union of both these pharmacophoric 
components are essential. 
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Figure 5.3: Acetogenin bullatacin 19, analogues 224 and 225 and their NADH oxidase activity. 
 
5.3 Synthesis of non-natural chamuvarinin-like analogues 
 
Having completed the synthesis of chamuvarinin (72), our attention turned to the synthesis 
of non-natural chamuvarinin-like analogues. This was primarily in response to the low 
micromolar activity displayed by our synthetic material towards both the bloodstream and 
procyclic forms of T. brucei. The analogue synthesis utilized advanced intermediates from 
both the first generation and revised coupling routes and were accomplished in no more 
than two steps via standard deprotection protocols. Their trypanocidal and cytotoxic 
activities were then assessed.  
 
5.3.1 Generation I analogues 
 
With all the advanced intermediates from the first generation synthesis in hand, the 
synthesis of the truncated analogues began with the preparation of triol 226 (Scheme 5.1). 
The rationale towards the synthesis of 226 was dictated by the presence of the hydrophobic 
sidechains in natural acetogenins. Hence, it was hypothesized that removal of this alkyl 
side chain and replacement with a hydroxyl group would impact on the activity. Synthesis 
of 226 was accomplished in 78% yield by treatment of the C9-C20 diol 146 with 
Pearlman’s catalyst and H2.  
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Scheme 5.1: Synthesis of triol 226. 
 
The truncated open chain C9-C34 tetrol 227 (Scheme 5.2) was prepared in two steps from 
alcohol 173 by subjecting 173 to Pearlman’s catalyst and H2, which resulted in 
debenzylation of the C9-benzyl ether. The resultant intermediate diol was then subjected to 
acid mediated desilylation conditions to cleave both the C15 and C23 silyl protecting 
groups to afford tetrol 227 in 45% yield over the two steps.  
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45% over 2 steps
 
Scheme 5.2: Synthesis of tetrol 227. 
 
With the advanced C9-C34 BCD alcohol 82 in hand (Scheme 5.3), the synthesis of BCD 
diol 228 was accomplished in 82% yield by exposure of alcohol 82 to acid mediated 
desilylation conditions. 
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Scheme 5.3: Synthesis of diol 228. 
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5.3.2 Synthesis of 36-epi chamuvarinin 
 
The stereochemistry of the C15-C28 ether array of chamuvarinin (72) was confirmed by 
spectroscopic and biological data obtained in the first total synthesis, however, additional 
confirmation came from the synthesis of 36-epi chamuvarinin (229, Scheme 5.5). The (R)-
aldehyde 230 was prepared from (R)-propylene oxide 231 in an analogous manner as (S)-
85 (Scheme 5.4). The synthesis began with the lithium enolate addition of lactone 232 to 
iodide 91 to provide thiolactone 233. Oxidation and thermal sulfoxide elimination of 233 
gave benzyl ether 234, which underwent C8-benzyl cleavage to give alcohol 235. Dess-
Martin periodinane oxidation of 235 gave (R)-aldehyde 230 in excellent yield.  
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230: R = CHO
1
BCl3•  DMS, 
CH2Cl2, -15 °C, 85%
DMP, NaHCO3, CH2Cl2,
 0 °C to RT, 85%
 
Scheme 5.4: Synthesis of (R)-aldehyde 230. 
 
With the sulfone 189 and aldehyde 230 subunits in hand, Julia-Kocienski olefination 
installed the C8-C9 bond to give alkene 236 in 71% yield (Scheme 5.5). In the final stages 
towards the synthesis of 229, alkene 236 was subjected to the diimide reduction conditions 
to provide crude intermediate alkane, which was treated under acid mediated desilylation 
conditions to cleave the C15 silyl protecting group and furnish 36-epi chamuvarinin (229) 
in 74% yield over the two steps. In all respects 229 could not be readily distinguished from 
72 by NMR spectroscopy but the specific rotation was of the same magnitude but opposite 
polarity [229: 
€ 
[α]D20  = -11.9 (c 0.52, CHCl3) and 72: 
€ 
[α]D20  = +9.9 (c 0.1, CHCl3)].90 
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Scheme 5.5: Synthesis of 36-epi chamuvarinin 229.  
 
5.3.3 Synthesis of 8,9-alkenyl analogues  
 
En route to the synthesis of chamuvarinin (72) and 36-epi chamuvarinin (229), 
intermediate 8E-alkenes 182 and 236 were isolated (Scheme 5.6). The 36S-alkene 182 was 
subjected to acid mediated desilylation conditions to provide 36S-alcohol 237 in 26% 
yield. By analogy to 36S-182, 36R-236 was treated with the acidic conditions to give (R)-
238 in excellent yield. The rationale behind the synthesis of alcohols 237 and 238 was to 
observe the effect on biological activity by imparting some rigidity within the spacer.  
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Scheme 5.6: Synthesis of 8,9-alkenyl alcohols 237 and 238. 
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5.3.4 Generation II analogues  
 
The revised coupling strategy enabled efficient access to chamuvarinin (72) and advanced 
analogues. The Julia-Kocienski olefination provided access to the C1-C20 alkene 195 
(Scheme 5.7), which underwent diimide reduction to yield the corresponding intermediate 
alkane and was subsequently subjected to acid mediated desilylation cleaving both the C15 
and C20 silyl protecting groups to give diol 239 in 87% yield over the two steps. 
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Scheme 5.7: Synthesis of diol 239. 
 
The advanced C1-C34 alcohols 216 and 217 enabled the synthesis of 
chamuvarinin/mucocin hybrids (Scheme 5.8), which provided an opportunity to observe 
the effect on biological activity by altering the central polyether array through a relatively 
minor structural modification. Both the 20S-alcohol 216 and 20R-alcohol 217 were 
subjected to the acid mediated silyl deprotection conditions to cleave the C15 and C23 silyl 
groups to afford triols 240 and 241 in 75% yield. 
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Scheme 5.8: Synthesis of triols 240 and 241. 
 
 
 
 
  Results and Discussion
  
 86 
5.4 Cytotoxic and trypanocidal profiles of structural analogues 
 
With a range of non-natural chamuvarinin-like analogues in hand, our attention turned to 
their trypanocidal and cytotoxic properties by screening against the HeLa cancer cell line 
and both forms of T. brucei (Table 5.1).76  In comparison to chamuvarinin (72), all 
analogues were essentially inactive towards HeLa but displayed slightly reduced levels of 
activity towards the bloodstream and procyclic forms of T. brucei. The C1-C8 butenolide 
alcohol 81 was devoid of any activity (entry 2), as was the simple C9-C20 triol 226 (entry 
3). 
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Analogue
T. brucei (BSF)
ED50 (µM)
chamuvarinin
81
226
227
228
229
237
238
239
240
241
1.37 ± 0.08
>1000
528 ± 19.6
69.7 ± 2.5
51.0 ± 3.8
>100
36.7 ± 2.9
9.6 ± 1.1
575 ± 35 
13.5 ± 0.8
27.3 ± 2.0
T. brucei (Pro)
ED50 (µM)
1.9 ± 0.11
>1000
>1000
27.6 ± 0.9
78.9 ± 2.7
>100
36.5 ± 4.1
18.9 ± 2.8
354 ± 23
18.6 ± 0.5
15.2 ± 2.0
HeLa
ED50 (µM)
2.88 ± 0.66
>1000
>1000
>100
>100
>100
>100
>100
132 ± 14
>100
151 ± 7.4
Selectivity Index
2.1
-
>1.9
>1.4
>1.9
>2.7
>2.7
>10
0.23
>7
5.5
Entry
1
2
3
4
5
6
7
8
9
10
11
 
Table 5.1: Trypanocidal and cytotoxic activities for chamuvarinin (72) and analogues 226-229 and 237-241, 
selectivity index refers to the parasitic inhibition versus mammalian HeLa inhibition. 
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Upon introduction of the butenolide sidechain to the C9-C20 triol 226, a minor increase in 
activity of 239 was observed for the procyclic form of T. brucei and the HeLa cell line 
(entry 9), but was still essentially inactive. Therefore, replacement of the hydrophobic 
sidechain with a hydroxyl group resulted in loss of activity. Truncated analogues 227 and 
228 displayed moderate micromolar activities towards T. brucei (entry 4 and 5). 
Incorporation of the butenolide sidechain gave analogue 240, which resulted in a five-fold 
increase in activity towards bloodstream form of T. brucei, while remaining essentially 
inactive against HeLa (entry 10), also 20R diastereomer 241 displayed good micromolar 
activity (entry 11). In an analogous manner, incorporation of the sidechain to analogue 228 
provided natural product chamuvarinin (72), which gave a 36-fold increase in activity 
towards bloodstream T. brucei (entry 1). Both the 36S-8-alkenyl 237 (entry 7) and 36R-8-
alkenyl 238 (entry 8) analogues displayed good trypanocidal micromolar activities, but 
unexpectedly the un-natural 36R-238 was more potent than the 36S-237 diastereomer, 
which was an interesting observation as 36-epi chamuvarinin (229) was devoid of activity 
(entry 6). It was hypothesized that the installation of some rigidity to the C3-C15 alkyl 
spacer of 238 resulted in a conformational change of the molecule, which enabled 
analogue 238 to potentially act at a different protein target. The most interesting outcome 
of these non-natural chamuvarinin-like analogues were that the open chain analogues 240 
and 241 displayed low micromolar activities towards the bloodstream form of T. brucei but 
remained essentially inactive against HeLa.  
 
5.5 Summary  
 
The synthesis and biological evaluation of non-natural chamuvarinin-like analogues 226-
229 and 237-241 has demonstrated that selective parasite activity could be attained through 
relatively minor structural modifications to the central polyether array. These observations 
have formed the basis of a more focussed study through the design and synthesis of 
simplified structural analogues as potential T. brucei inhibitors, detailed in Chapter 6.  
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Chapter 6 
 
6.1 African sleeping sickness 
 
Infectious parasitic diseases are an ever-growing health concern in Developing countries 
due to the lack of prevention methods and effective therapeutic agents. In recent years the 
battle against Neglected tropical diseases has slowly attracted the attention of global 
funding agencies providing an opportunity to develop safe and effective treatments in an 
effort to control or even eradicate some of these diseases.98 One of these prevalent 
Neglected tropical diseases is African sleeping sickness or Human African 
Trypanosomiasis (HAT), caused by the parasite Trypanosoma brucei. HAT is a major 
health concern in sub-Saharan Africa threatening more than 60 million people. The World 
Health Organization (WHO) has estimated that the annual mortality rate stands at 
approximately 8000 with less than 30,000 new cases per year.99 
 
African sleeping sickness, caused by the parasite Trypanosoma brucei, is transmitted by 
tsetse flies to humans through bites. The life cycle of T. brucei is shown in Figure 6.1. The 
tsetse fly, harbouring the pathogenic parasite transmits metacyclic trypomastigotes into the 
mammalian bloodstream.94 The metacyclic trypomastigotes transform into rapidly dividing 
bloodstream trypomastigotes, some of which relocate to the central nervous system and 
replicate by binary fission. The bloodstream trypomastigotes are then transmitted to 
another tsetse fly upon taking a blood meal from the mammalian host. The parasites 
transform into dividing procyclic trypomastigotes in the midgut of the fly, upon leaving the 
midgut they differentiate into epimastigotes where they migrate to the salivary glands of 
the tsetse fly and the life cycle can begin again. 
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Figure 6.1: Life cycle of T. brucei.100 
 
There are two subtypes of HAT, East African trypanosomiasis (caused by T. brucei 
rhodesiense) and West African trypanosomiasis (caused by T. brucei gambiense) both of 
which left untreated are invariably fatal.101 Treatment for HAT is limited, and is dependent 
upon the stage of the disease. There are currently four drugs (Figure 6.2) on the market for 
the treatment of sleeping sickness, which have varying degrees of human toxicity.102 
Pentamidine 242 and suramin 243 are used in the first stages of the disease, and 
melarsoprol 244 and eflornithine 245 are used in the second stages once the parasite has 
crossed the blood-brain barrier and invaded the central nervous system. Unfortunately, 
these drugs are difficult to administer and have undesirable side effects. Melarsoprol 244 is 
an arsenic based drug dating back to 1947, which is extremely toxic and can lead to 
encephalopathic syndrome (disease of the brain). The areas most affected by HAT are 
poverty stricken and eflornithine 245 is an expensive drug, hence a combinatorial therapy 
(NECT) consisting of Eflornithine 245 and Nifurtimox 246 (used to treat Chagas disease) 
has been introduced.103 The use of NECT against HAT has proven to be just as effective as 
the treatment with eflornithine 245 alone. However, an increasing problem associated with 
most parasitic diseases is drug resistance, highlighting the urgent demand for the 
development of new drug molecules and their clinical implementation in effective drug 
therapies.  
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Figure 6.2: Current drugs for treatment of African trypanosomiasis.  
 
6.2 Synthesis of simplified structural analogues 
 
The trypanocidal activities of chamuvarinin (72) and the non-natural analogues detailed in 
Chapter 5, prompted our interest into the design of further simplified analogues, which 
maintain an effective biological profile. The open chain C1-C34 analogue 240 displayed 
good micromolar activity towards T. brucei with only a 10-fold decrease in activity in 
comparison to chamuvarinin (72). This relatively minor structural modification prompted 
us to consider incorporating an alternative central heterocyclic spacer (Figure 6.3). The 
rationale for the analogue design was based on the structural simplification of 
chamuvarinin (72) whilst retaining the important biological features present within the 
acetogenin natural products, hence a 1,4-triazole motif was introduced, which was 
hypothesized to be an effective spatial mimic of the central C20-C23 THF moiety of 72. 
The heterocyclic spacer was envisioned to arise from the coupling of two ether containing 
subunits and the butenolide head would be appended to the ether core by a long alkyl 
spacer.  
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Figure 6.3: Rationale for analogue design.  
 
The substitution of the central THF moiety with a 1,4-triazole scaffold was beneficial, due 
to the synthetic effort required for the preparation of THF moieties, and the difficulty in 
preparing an adjacent bis THP-THF-THF ring system. Further structural simplification 
came from the substitution of the C16-C19 THF ring (ether 1, Figure 6.3) for the more 
readily accessible and manageable THP motifs.  
 
6.2.1 1,3- Dipolar cycloaddition reactions 
 
The 1,3-dipolar cycloaddition reaction (1,3-DC) was first discovered in 1888 by Buchner, 
who described the reaction of α,β-unsaturated esters with diazoacetic ester.104 However, it 
was not until the pioneering work of Huisgen in the 1960’s that 1,3-dipoles became an 
established concept in organic chemistry.105 Over the last sixty years, the 1,3-DC reaction 
has gained considerable synthetic interest as it provides a fast and efficient way of 
installing heterocyclic ring systems containing a variety of functional groups and has been 
instrumental in the efforts towards the synthesis of natural products.106 
A highly attractive 1,3-dipole is the azide moiety, which is synthetically useful in the 
preparation of primary amine groups, yet their potential in medicinal chemistry has not yet 
been fully explored due to safety concerns. An example, shown in Scheme 6.1, of the 
utility of a 1,3-DC reaction between an azide and olefinic moiety was highlighted in the 
enantioselective synthesis of alkaloid natural product (-)-swainsonine (247).107  
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Scheme 6.1: Synthesis of (-)-swainsonine (247).  
 
Treatment of tosylate 248 with sodium azide in DMF at 80 °C, displaced the tosylate group 
with an azide moiety and resulted in an intramolecular 1,3-DC reaction with the alkene 
moiety forming the intermediate triazoline 249, followed by the elimination of nitrogen to 
furnish cyclic imine 250. With 250 in hand, a series of four transformations provided 
access to (-)-swainsonine (247) in an enantioselective manner in 7 overall steps, 
highlighting the synthetic use of azides as 1,3-dipoles.   
 
6.2.2 1,2,3-triazole motifs 
 
A nitrogen heterocycle that has gained considerable attention over the last few decades is 
the 1,2,3-triazole scaffold, accessed from 1,3-DC reactions. These nitrogen heterocycles 
are of great synthetic interest to medicinal chemists as they have shown to be biologically 
important scaffolds in the synthesis of potential anti-cancer vaccines108 and HIV protease 
inhibitors.109 The 1,2,3-triazole motif can be accessed through a Huisgen 1,3-DC reaction 
(Scheme 6.2) between an azide and an alkynyl component, however, this thermal reaction 
generates a mixture of 1,4 and 1,5-regioisomers. In 2002, Sharpless110 and Meldal111 
independently demonstrated the utility of a copper catalyzed 1,3-DC reaction of azides and 
terminal alkynes (CuAAC) to access exclusively the 1,4-triazole regioisomer. This so-
called “click reaction”112 is a high yielding process, tolerating a range of functional groups, 
can be conducted in an aqueous media at room temperature with reaction times typically 
between 6 and 36 hours. 
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Scheme 6.2: Synthesis of 1,4 and 1,5-triazoles.  
 
The proposed mechanistic cycle (Scheme 6.3) of the CuAAC reaction initially begins with 
the generation of an active Cu(I) catalyst from reduction of a Cu(II) salt with sodium 
ascorbate.113 The terminal acetylene forms a copper acetylide species 251, which reacts 
with the azide functionality to give species 252, resulting from the loss of a ligand from the 
copper. Attack of the terminal nitrogen atom on the acetylide (C2-position) results in a 
copper (III) metallacycle 253. This unusual six-membered metallacycle 253 undergoes a 
ring contraction step to access a triazolyl intermediate 254, which upon hydrolysis 
provides the desired 1,4-triazole product 255.  
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R
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Scheme 6.3: Proposed catalytic cycle for CuAAC. 
 
6.2.3 Synthesis of azide and alkyne subunits 
 
The synthesis of simplified structural analogues with a 1,4-triazole motif incorporated as 
the central ring system were accessed by the CuAAC reaction. The 1,4-triazole analogues 
were envisioned to arise from coupling azide and terminal alkyne building blocks utilizing 
intermediates established in the first generation synthesis of 72. The azide subunit 256 
(Scheme 6.4) was accessed in 71% yield by application of Mitsunobu conditions to alcohol 
153 by treatment of with PPh3, Hunig’s base, DIAD and DPPA.114 The anti-azide 257 was 
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prepared in an analogous manner to 256 by undergraduate Mr Petty in the Florence 
group.115 
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THF, 0 °C to RT, 71%
O
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257
 
Scheme 6.4: Synthesis of azide 256 and structure of anti-azide 257.  
 
With azides 256 and 257 in hand, attention was then focussed on the synthesis of the 
alkyne subunit (Scheme 6.5). Initial studies were directed towards the synthesis of the anti-
alkyne diastereomer 258 via a two step homologation sequence. Swern oxidation of anti-
alcohol 154 to the corresponding aldehyde 259 was achieved in excellent yield. The next 
stage was incorporation of the terminal alkyne by homologation of aldehyde 259 via the 
Ohira-Bestmann modification.116 Aldehyde 259 was subjected to the base promoted 
addition to dimethyl 1-diazo-2-oxophosphonate 260 to provide an inseparable mixture of 
syn-261 and anti-258 diastereomers (d.r. 261 : 258 = 60 : 40). The reasoning for the 
observed diastereomeric mixture and enhanced selectivity towards the syn-alkyne 261 was 
due to base mediated epimerization of the anti-aldehyde 259 to the more 
thermodynamically stable syn-aldehyde 157 prior to alkynylation.  
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 -78 °C, 88% 260
O
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Scheme 6.5: Synthesis of alkynes 258 and 261. 
 
6.2.4 Synthesis of bis-THP triazole analogue 
  
The inseparable mixture of alkynyl diastereomers 258 and 261 was taken forward to 
establish optimal click conditions to access the bis-THP-triazole analogues and to ascertain 
their levels of biological activity. With the key subunits in hand, the stage was now set to 
install the central 1,4-triazole motif (Scheme 6.6), treatment of azide 256 and alkynes 258 
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and 261 with copper sulfate and sodium ascorbate in aqueous t-BuOH at room temperature 
provided an inseparable diastereomeric mixture of triazoles 262 and 263. Initial biological 
evaluation of the diastereomeric mixture against the bloodstream and procyclic forms of T. 
brucei maintained reasonable micromolar activities (ED50 = 21.4 ± 1.0 and 34.9 ± 0.8 µM, 
respectively) validating the applicability of the initial concept.76 Based on these biological 
results, synthetic routes towards the preparation of pure diastereomeric variants of the 
alkyne motif were explored. 
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256 258 + 261
262
O
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T. brucei BSF ED50 = 21.4 ± 1.0 µM  
Scheme 6.6: Synthesis of triazoles 262 and 263.  
 
6.2.5 Synthesis of anti-alkyne  
 
Having established that anti-aldehyde 259 would undergo epimerization to syn-aldehyde 
157 on submission to mildly basic Ohira-Bestmann homologation conditions, an 
alternative homologation strategy to access the anti-alkyne was required (Scheme 6.7). The 
homologation of anti-aldehyde 259 was envisioned to arise from application of the Corey-
Fuchs reaction.117 Preliminary treatment of aldehyde 259 with carbon tetrabromide (CBr4) 
and PPh3 at 0 °C with slow warming to room temperature did not provide the desired 1,1-
dibromo olefin 264 (entry 1).  
 
  Results and Discussion
  
 96 
O
258
O
H
259
O
for conditions 
see table
O
264
Br
Br
n-BuLi, THF, 
-78 °C, 70%
Entry
1
2
3
Conditions
CBr4, PPh3, CH2Cl2, 0 °C to RT
CBr4, PPh3, CH2Cl2, -78 to 0 °C
CBr4, PPh3, CH2Cl2, -78 °C
Yield
-
11%
81%  
Scheme 6.7: Synthesis of anti-alkyne 258. 
 
Addition of aldehyde 259 at -78 °C to the ylide reaction mixture with warming to 0 °C 
over 3 hours provided the first signs of product 264, albeit in a disappointing 11% yield 
(entry 2). From the previous conditions it appeared that 264 was achievable as long as the 
reaction temperature remained below 0 °C, hence addition of aldehyde 259 at -78 °C and 
subsequent work-up after 45 minutes provided 1,1-dibromo alkene 264 in excellent 81% 
yield with no observed epimerization (entry 3). Following the homologation of 259, the 
next stage relied on the manipulation of 1,1-dibromo alkene 264 to the desired alkyne. This 
was accomplished by treatment of dibromo alkene 264 with two equivalents of n-BuLi at -
78 °C to furnish exclusively anti-alkyne 258 in 70% yield. Having established a viable 
homologation approach to access gram quantities of anti-alkyne 258, the synthesis of the 
syn-alkyne scaffold was required.  
 
6.2.6 Synthesis of syn-alkyne  
 
Based on the previous results from the Ohira-Bestmann alkynylation of anti-aldehyde 259, 
it was apparent that the most thermodynamically stable aldehyde under these basic 
conditions was the syn-diastereomer. With syn-alcohol 153 in hand (Scheme 6.8), 153 was 
oxidized under Swern conditions to afford aldehyde 157 in excellent yield. The aldehyde 
157 was then subjected to the Ohira-Bestmann homologation reaction conditions to access 
exclusively syn-alkyne 261 in 72% yield.  
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Scheme 6.8: Synthesis of syn-alkyne 261.  
 
6.2.7 Synthesis and biological profiles of triazole analogues 
 
With efficient access to diastereomeric variations of key subunits established, the stage 
was now set to construct the 1,4-triazole scaffold under click conditions (Scheme 6.9). 
Both the azide and alkyne counter parts were envisioned to mimic the B and D rings of 
chamuvarinin (72) and following a 1,3-DC reaction would access the central triazole C-
ring, hypothesized to mimic the central C20-C23 THF ring of 72. The assembly of the 
building blocks gave three diastereomeric triazole analogues 262, 263 and 265, achieved in 
moderate to excellent yields (entries 1, 2 and 3). The triazole analogue 266 was prepared in 
an analogous manner by undergraduate researcher Mr Petty in the Florence group.115  
 
With the bis-THP triazole analogues in hand, their biological activity towards T. brucei 
inhibition was assessed, shown in Table 6.1.76 In an effort to determine the triazole 
stereochemistry responsible for the micromolar activity observed for the mixture of 262 
and 263, analogues 262 and 263 were independently screened. It was found that the syn-
syn analogue 262 (entry 3) displayed modest micromolar activity against the bloodstream 
form of T. brucei, whereas the syn-anti analogue 263 (entry 4) exhibited only a 5-fold 
decrease in activity towards the bloodstream form of T. brucei (ED50 = 7.6 ± 0.3 µM) in 
comparison to natural product chamuvarinin (72) and displayed excellent selectivity for 
parasitic inhibition over the mammalian HeLa cell line (selectivity index of 21.9). The 
remaining analogues 265 and 266 displayed moderate micromolar activities towards T. 
brucei, with 266 displaying signs of selective parasite inhibition (entries 5 and 6). The 
synthesis and assembly of the building blocks to construct the 1,4-triazole scaffold was 
achieved in an overall six longest linear sequence in comparison to chamuvarinin (72), 
which required 17 steps in the longest linear sequence. From the initial set of 
diastereomeric triazoles, it was clear that the stereochemistry of the THP moieties 
influenced the biological profile. As potential leads for T. brucei inhibitors, the simplified 
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triazoles warranted further investigation into their specific mode of action and 
identification of the protein target.  
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Scheme 6.9: Synthesis of triazole analogues 262-263 and 265-266. 
 
Analogue
T. brucei (BSF)
ED50 (µM)
chamuvarinin
262 + 263
262
263
265
266
1.37 ± 0.08
21.4 ± 1.0
48.7 ± 3.5
7.6 ± 0.3
24.6 ± 1.4
37.2 ± 6.6
T. brucei (Pro)
ED50 (µM)
1.9 ± 0.11
34.9 ± 0.8
103.3 ± 3.5
1.1 ± 0.1
65.0 ± 3.1
81.5 ± 4.5
HeLa
ED50 (µM)
2.88 ± 0.66
>100
>100
166.6 ± 18.0
33.0 ± 2.4
>500
Selectivity 
Index
2.1
>5
>2
21.9
1.3
>6
Entry
1
2
3
4
5
6  
Table 6.1: Biological profiles of triazole analogues 262-263 and 265-266, selectivity index refers to parasitic 
inhibition versus mammalian HeLa inhibition.  
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6.2.8 Synthesis of simplified azide subunits 
 
To ascertain further structure activity relationships (SAR) of the triazole analogues, a 
selection of substituted analogues were prepared, determining the role of both the 1,4-
triazole and THP motifs. The preparation of the simple azide precursors, shown in Scheme 
6.10, began with the synthesis of 1-azido octanol 267, which was accomplished in 27% 
yield in one step by application of the Mitsunobu protocol to commercially available 1-
octanol 268.114  
 
OH N3
PPh3, Hunig's base, 
DIAD, DPPA, THF,
0 °C to RT, 27%
268 267  
Scheme 6.10: Synthesis of azide 267. 
 
Based on the previous biological results obtained for chamuvarinin (72) and the non-
natural chamuvarinin-like analogues, it was clear that introduction of the butenolide side 
chain (A-ring) resulted in increased T. brucei inhibition. Hence, butenolide alcohol (81, 
Scheme 6.11) was transformed to azide 269 by application of the Mitsunobu reaction 
conditions used previously. 
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81 269  
Scheme 6.11: Synthesis of azide 269. 
 
6.2.9 Synthesis and biological evaluation of triazole analogues  
 
With all the azide and alkyne subunits in hand, synthesis of the structural analogues was 
required (Scheme 6.12). Firstly, removal of the B-ring from the bis THP triazole analogues 
and replacement with a hydrophobic alkyl side chain (entry 1) was achieved by treatment 
of azide 256 and 1-octyne with the optimized click conditions to afford 270 in 68% yield. 
Removal of the D-ring and replacement with a hydrophobic alkyl side chain was 
accomplished by assembly of azide 267 and alkyne 261 to furnish triazole 271 in 77% 
yield (entry 2). At this point incorporation of the butenolide A-ring would enable a direct 
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comparison with analogue 271. Triazole 272 was achieved in excellent yield by application 
of the click conditions to azide 269 and alkyne 261 (entry 3). Further structural 
simplification was possible by complete removal of both the B and D ring systems and 
replacement with an alkyl side-chain and an alkyl spacer unit with the A ring appended on 
the end terminus. Triazole 273 was synthesized in excellent yield by coupling azide 269 
and 1-octyne (entry 4).     
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Scheme 6.12: Synthesis of triazole analogues 270-273. 
 
With the simplified triazole analogues 270-273 in hand, their biological activity towards T. 
brucei inhibition was then assessed, shown in Table 6.2.76 From analysis of the results, it 
was found that analogues 270 and 271 displayed significantly reduced activities towards 
the bloodstream form of T. brucei (entries 2 and 3), which initially suggested that both 
THP motifs were required for the desired biological effect. It was hypothesized that 
incorporation of the butenolide side chain would result in an increase in biological activity, 
previously observed for the non-natural acetogenin analogues. Hence, analogue 272 
enabled a direct comparison to the alkyl analogue 271. A small increase in trypanocidal 
activity from 271 to 272 towards the bloodstream form of T. brucei was evident (ED50 = 
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108.9 ± 7.7 and 50.0 ± 5.2 µM respectively) with 272 displaying selective parasite activity 
(SI = >20, entry 4). The biological data of analogues 271 and 272 supported our previous 
hypothesis that a combination of both the ether and butenolide moieties would elicit a 
more potent biological response. 
 
Analogue
T. brucei (BSF)
ED50 (µM)
chamuvarinin
270
271
272
273
1.37 ± 0.08
70.1 ± 6.7
108.9 ± 7.7
50.0 ± 5.2
15.6 ± 0.3
T. brucei (Pro)
ED50 (µM)
1.9 ± 0.11
70.8 ± 5.8
255.0 ± 10.1
115.5 ± 8.5
30.8 ± 1.7
HeLa
ED50 (µM)
2.88 ± 0.66
150.0 ± 25.0
>500
>1000
102.8 ± 9.5
Selectivity 
Index
2.1
2.1
>5
>20
6.6
Entry
1
2
3
4
5
 
 Table 6.2: Biological profiles of triazole analogues 270-273, selectivity index refers to the parasitic 
inhibition versus mammalian HeLa inhibition.  
 
The simplified alkyl analogue 273 gave a surprising yet interesting biological result (entry 
5). It was originally hypothesized that complete removal of the B and D ring systems and 
replacement with hydrophobic side chains would result in the loss of micromolar activity. 
On the contrary, analogue 273 displayed low micromolar parasitic activity with an ED50 
value of 15.6 ± 0.3 µM, as well as some selectivity towards the parasite (SI = 6.6). In order 
to gain a greater understanding of the biological profile, the mode of action of these 
triazole analogues have to be established as the simplified analogue 273 may be targeting a 
protein site distinct from the bis-THP analogues.  
 
6.2.10 Replacement of the butenolide moiety 
 
In 2006 Poupon and co-workers focussed on the replacement of the pharmacophoric 
butenolide moiety present in acetogenin natural product squamocin (73), incorporating a 
variety of γ-ketoamides, γ-ketoesters and furan moieties.118 The analogues synthesized 
were screened against KB 3-1 cell lines to evaluate their cytotoxicity and their 
mitochondrial Complex I inhibition. One of the analogues of particular interest was furan 
analogue 274. Furan 274 was synthesized in one step by treatment of squamocin (73) with 
DIBAL (Scheme 6.13), which resulted in the reduction of the lactone to the corresponding 
lactol and subsequent elimination upon addition of acetic acid furnished furan 274. 
Biological testing of furan 274 resulted in diminished cytotoxic activity against KB 3-1 
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cells. However, when tested against Complex I inhibition, furan 274 displayed potent 
activity with an IC50 value of 2.4 nM, which was only 3 times weaker in potency than that 
of natural product 73, IC50 value of 0.9 nM. 
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 -78°C, then AcOH, 
warm to RT, 87%
 
Scheme 6.13: Synthesis of furan 274. 
 
6.2.11 Synthesis of furan analogue 
 
Having observed only a 3-fold decrease in mitochondrial inhibition of squamocin analogue 
274, simplified triazole 273 (Scheme 6.14) was subjected to the reduction conditions 
reported by Poupon et.al. to furnish furan 275 in a moderate 54% yield.118 The rationale 
for the synthesis of 275 was the complete removal of stereochemistry providing an 
extremely simplified structural analogue. 
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DIBAL, CH2Cl2,
 -78°C, then AcOH, 
warm to RT, 54%
273 275  
Scheme 6.14: Synthesis of furan 275. 
 
The simplified furan analogue displayed moderate micromolar activity against both forms 
of T. brucei but was essentially inactive against HeLa cell line, with an ED50 value of 34.0 
± 1.5 and 56.1 ± 2.9 µM, respectively (Table 6.3).76 
 
T. brucei (BSF)
ED50 (µM)
34.0 ± 1.5
T. brucei (Pro)
ED50 (µM)
56.1 ± 2.9
HeLa
ED50 (µM)
~230
Selectivity 
Index
>6.6  
Table 6.3: Biological profile of furan 275, selectivity index refers to parasitic inhibition versus mammalian 
HeLa inhibition.  
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6.3 Synthesis of azide and alkyne subunits with terminal oxygenation 
 
The initial hypothesis of exchanging the B and C THF rings present in chamuvarinin (72) 
for the 1,4-triazole and THP motifs had proven to be an effective modification, providing 
access to simplified structural analogues, which have exhibited promising anti-parasitic 
activities. Having observed the biological effect of introducing the butenolide appendage 
to the non-natural chamuvarinin-like and triazole analogues, the next stage in the SAR 
cycle of the triazole analogues was the incorporation of terminal oxygenation in both the 
azide and alkyne coupling partners, in the hope of further enhancing the anti-parasitic 
activities of the bis-THP analogues, while also providing functional handles for further 
elaboration.  
 
6.3.1 Synthesis of THP alcohols 
 
The synthesis of these subunits began with the benzyl protection of commercially available 
5-hexen-1-ol (276) to give alkene 277 in excellent yield (Scheme 6.15). The resultant 
alkene was subjected to m-CPBA epoxidation conditions to provide racemic epoxide 278 
in 75% yield. To install the desired stereochemistry at the C6-position present within the 
final THP alcohols 279 and 280, required application of the Jacobsen HKR protocol to 
racemic epoxide 278 to provide enantio-enriched epoxide 281 in 42% yield and 99% e.e. 
The next step in the synthesis utilized chemistry previously established by Dr Reddy51,65 
within the Florence group. Copper catalyzed homoallyl magnesium bromide (151) addition 
to epoxide 281 gave alcohol 282 in 99% yield. This was followed by m-CPBA epoxidation 
of the terminal alkene and subsequent in situ acid mediated ring closure to install the 
desired 6-exo-tet THP motif as a separable mixture of syn-279 and anti-280 alcohol 
diastereomers in a combined 77% yield. 
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OBn
O
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(S,S)-86, AcOH,
 H2O, PhMe,
 0 °C to RT, 42%homoallylMgBr (151),
CuI, THF, Et2O,
-40 °C to RT, 99%
 
Scheme 6.15: Synthesis of alcohols 279 and 280. 
 
6.3.2 Synthesis of the azide and alkyne subunits 
 
With the diastereomeric alcohols 279 and 280 in hand, the alcohols could now 
independently be manipulated to both the azide and alkyne subunits utilizing the 
aforementioned reactions conditions (Scheme 6.16). The synthesis of syn-alkyne 283 was 
accessed in two steps from syn-alcohol 279 through Swern oxidation to the intermediate 
aldehyde 284, which was then subjected to the Ohira-Bestmann homologation reaction to 
furnish alkyne 283 in 77% yield over the two steps.  
 
O
OBn
283
O
H
OBn
284
O
O
P
O
N2
OMe
OMe
K2CO3, MeOH, 
RT, 88%
O
OH
OBn
279
(COCl)2, DMSO,
 Et3N, CH2Cl2,
 -78 °C to RT, 87% 260
 
Scheme 6.16: Synthesis of alkyne 283.  
 
Having synthesized the syn-alkyne 283, access to the anti-alkyne 285 was then required 
(Scheme 6.17). Anti-alkyne 285 was accessed in three steps from alcohol 280 by Swern 
oxidation to give the corresponding aldehyde 286 in excellent yield. Aldehyde 286 then 
underwent a Corey-Fuchs homologation to give 1,1-dibromo alkene 287 in 92% yield, 
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followed by subsequent treatment of 287 with two equivalents of n-BuLi to furnish anti-
alkyne 285 in 82% yield. 
 
O
OBn 285
O
H
OBn 286
O
CBr4, PPh3, 
CH2Cl2, -78 °C, 92%
O
OBn 287
Br
Br
n-BuLi, THF, 
-78 °C, 82%
O
OH
OBn 280
(COCl)2, DMSO,
 Et3N, CH2Cl2,
 -78 °C to RT, 83%
 
Scheme 6.17: Synthesis of alkyne 285. 
 
Following the assembly of the alkyne subunits, the benzyl ether THP alcohol 279 (Scheme 
6.18) was manipulated to the corresponding azide 288 by application of the Mitsunobu 
reaction conditions to provide syn-azide 288 in 98% yield.  
 
O
OH
OBn 279
O
N3
OBn 288
PPh3, Hunig's base, 
DIAD, DPPA, THF,
 0 °C to RT, 98% O N3
294
 
Scheme 6.18: Synthesis of azide 288 and structure of (R)-syn azide 294. 
 
6.3.3 Assembly and biological profiles of triazole analogues 
 
With the terminal oxygenation installed and the key subunits synthesized, the 
diastereomeric triazole analogues were assembled (Scheme 6.19, entries 1-4) using the 
optimized click conditions providing access to four diastereomeric triazole analogues 289-
292 in good yields. Having ascertained from previous triazole analogues 262-263 that the 
stereochemistry of the THP moieties appears to have an inherent affect on biological 
activity, the D-THP ring for analogue 289 was exchanged for the enantiomeric (R)-syn 
series. Triazole 293 (entry 5) was prepared from a click reaction between syn-alkyne 283 
and (R)-syn azide 294 (prepared by undergraduate researcher Mr Petty in the Florence 
group).115  
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Scheme 6.19: Synthesis of triazole analogues 289-293. 
 
The cytotoxic and trypanocidal activities of triazole analogues 289-293 were assessed 
(Table 6.4), from the data both the analogues 289 and 290 displayed good micromolar 
activities towards T. brucei inhibition (entries 2 and 3), whereas analogue 291 resulted in 
diminished activity (entry 4).76 Analogue 292 exhibited selective anti-parasitic activity 
with a selectivity index of 23 (entry 5) and displayed a low micromolar activity towards 
the bloodstream form of T. brucei with only 2-fold decrease in activity compared to natural 
product chamuvarinin (72). The analogue 293 containing the (R,R)-syn stereochemistry 
displayed analogous cytotoxic and trypanocidal micromolar activities to 289 (entry 6).  
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Analogue
T. brucei (BSF)
ED50 (µM)
chamuvarinin
289
290
291
292
293
1.37 ± 0.08
8.7 ± 0.5
10.1 ± 0.4
467.2 ± 40.3
3.1 ± 0.1
8.2 ± 0.4
T. brucei (Pro)
ED50 (µM)
1.9 ± 0.11
15.6 ± 0.3
72.3 ± 5.3
236.6 ± 23.8
48.7 ± 3.6
15.5 ± 1.0
HeLa
ED50 (µM)
2.88 ± 0.66
45.5 ± 2.5
76.0 ± 3.0
>1000
71.4 ± 4.1
37.5 ± 1.5
Selectivity 
Index
2.1
5.3
7.5
>2
23
4.6
Entry
1
2
3
4
5
6  
Table 6.4: Biological profiles of triazole analogues 289-293, selectivity index refers to the parasitic inhibition 
versus mammalian HeLa inhibition.  
 
6.3.4 Synthesis of triazole alcohol analogues 
 
Having installed the terminal oxygenation, the stage was now set to remove the benzyl 
ethers from triazole analogues 289-293 in preparation for the incorporation of the 
butenolide side chain, shown in Scheme 6.20. Analogues 289-293 were subjected to 
standard hydrogenation conditions (20% Pd(OH)2/C and H2) and resulted in efficient 
cleavage of the benzyl ethers to afford alcohols 295-299 in excellent yields (entries 1-5).  
 
The alcohol analogues were screened for their cytotoxic and trypanocidal activities, as 
shown in Table 6.5.76 It was observed that both 295 and 296 (entries 2 and 3) displayed 
low micromolar activities towards both T. brucei and HeLa, with analogue 295 exhibiting 
activities comparable to natural product chamuvarinin (72) with ED50 values of 1.8 ± 0.1 
and 1.37 ± 0.08 µM, respectively. Analogues 297 and 298 (entries 4 and 5) showed 
diminished cytotoxic and trypanocidal activities, whereas analogue 299 (entry 6) displayed 
a good micromolar activity against the bloodstream form of T. brucei with a slight increase 
in parasitic activity. Alcohol analogue 295 has shown comparable levels of activity against 
the bloodstream form of T. brucei to that of chamvarinin (72). These analogues have 
provided a platform for the synthesis of a new class of potential T. brucei inhibitors.  
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Scheme 6.20: Synthesis of alcohols 295-299. 
 
Analogue
T. brucei (BSF)
ED50 (µM)
chamuvarinin
295
296
297
298
299
1.37 ± 0.08
1.8 ± 0.1
17.5 ± 1.0
223.2 ± 21.8
72.4 ± 3.9
19.2 ± 1.1
T. brucei (Pro)
ED50 (µM)
1.9 ± 0.11
0.8 ± 0.1
25.4 ± 1.3
87.9 ± 4.5
68.3 ± 7.2
42.9 ± 2.4
HeLa
ED50 (µM)
2.88 ± 0.66
7.0 ± 1.0
26.9 ± 1.1
415.8 ± 35.3
59.7 ± 2.5
101.0 ± 10.4
Selectivity 
Index
2.1
3.9
1.5
1.9
0.8
5.3
Entry
1
2
3
4
5
6  
Table 6.5: Biological profiles of alcohols 295-299, selectivity index refers to the parasitic inhibition versus 
mammalian HeLa inhibition.  
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 6.3.5 Julia-Kocienski olefination  
 
With the triazole alcohol analogues 295-299 in hand, the opportunity to install the 
butenolide was apparent. Incorporation of the butenolide side chain was envisioned to arise 
from a Julia-Kocienski olefination strategy employed in the first and revised syntheses of 
chamuvarinin (72). The comparable levels of biological activity of alcohol 295 to that of 
72 against the bloodstream form of T. brucei prompted the incorporation of the butenolide 
to 295 in the hope of potentially achieving nanomolar activity (Scheme 6.21). 
Transformation of alcohol 295 to sulfone 300 was accomplished in two steps by treatment 
of 295 under Mitsunobu conditions with 1H-mercaptophenyltetrazole to install sulfide 301 
in 67% yield. Oxidation of sulfide 301 with the ammonium molybate-hydrogen peroxide 
complex furnished sulfone 300 in excellent yield.  
 
O
N
N
NO
S
N N
N
N
Ph
O
N
N
NO
S
N N
N
N
Ph
O
O
O
N
N
NO
OH
 PTSH, PPh3, 
DIAD, THF,
 0 °C to RT, 67%
(NH4)6Mo7O24•4H2O, 
H2O2, MeOH, 0 °C to
RT, 91%
295 301
300
 
Scheme 6.21: Synthesis of sulfone 300. 
 
With the two coupling partners 300 and 188 in hand, optimized reaction conditions from 
the first and revised syntheses were employed in the Julia-Kocienski olefination reaction 
(Scheme 6.22). Treatment of sulfone 300 with NaHMDS at -78 °C followed by dropwise 
addition of aldehyde 188 afforded alkene 302 in 61% yield. The final stage in the synthesis 
of triazole 303 was reduction of alkene 302 to the corresponding alkane 303. Application 
of the diimide reduction conditions (60-fold excess of TsNHNH2 and NaOAc in DME/H2O 
at reflux) to alkene 302 delivered triazole 303 in excellent yield.  
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Scheme 6.22: Synthesis of triazole 303. 
 
6.3.6 Synthesis of furan analogue 
 
Having synthesized the target molecule, efforts to further reduce the complexity of 
analogue 303 were undertaken. In an analogous manner to the work carried out by Poupon 
and co-workers on the reduction of the butenolide moiety of cytotoxic acetogenin 
squamocin (73) to the furan analogue 274, furan triazole 304 was synthesized.118 Triazole 
303 was subjected to the DIBAL reduction conditions to furnish furan 304 in excellent 
yield. Evaluation of the trypanocidal and cytotoxic activities of analogue 303, surprisingly 
showed that 303 was devoid of any activity by comparison to the truncated alcohol 
analogue 295 (ED50 values of >500 and 1.8 ± 0.1 µM, respectively).76 Unfortunately furan 
analogue 304 has yet to be biologically evaluated, but is presumed to be inactive.  
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Scheme 6.23: Synthesis of furan 304. 
 
6.3.7 Reversal of butenolide side chain  
 
Having synthesized triazole butenolide 303 and found that it was devoid of any biological 
activity, the incorporation of the butenolide side chain on the D-ring was required to ensure 
that reversed analogue 305 was also devoid of any activity (Scheme 6.24). Hence, 
synthesis of 305 was carried out in an analogous manner to 303. Azide 288 and alkyne 261 
were subjected to the click conditions to afford triazole 306 and subsequent removal of the 
benzyl protecting group utilizing standard hydrogenation protocols gave alcohol 307 in 
41% yield over two steps. Treatment of alcohol 307 with the Mitsunobu conditions gave 
sulfide 308 in 76% yield, which was subjected to molybdenum-hydrogen peroxide 
oxidation conditions to furnish sulfone 309 in 94% yield. 
 
O
N
N
NO
S
PTSH, PPh3, DIAD,
THF, 0 °C to 
RT, 76%
(NH4)6Mo7O24•4H2O, 
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H2O, t-BuOH,
 RT, 41%
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N
N
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Scheme 6.24: Synthesis of sulfone 309. 
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With the key subunits in hand, application of the Julia-Kocienski olefination to sulfone 309 
and aldehyde 188 gave alkene 310 in 65% yield (Scheme 6.25). The final step towards the 
synthesis of triazole analogue 305 relied upon diimide reduction (60-fold excess of 
TsNHNH2 and NaOAc in DME/H2O at reflux) of alkene 310 gave alkane 305 in 75% 
yield.  
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Scheme 6.25: Synthesis of triazole 305. 
 
The biological profile for the reversed triazole analogue 305 has shown some interesting 
results (Table 6.6, entry 2).76 Analogue 305 displayed low micromolar activities towards 
both forms of T. brucei with ED50 values of 3.22 ± 0.13 and 5.74 ± 0.61 µM, respectively 
and showed increased parasitic activity with a selectivity index of 15.8. These results 
indicate that we have initially functionalized the wrong subunit. 
O
N
N
NO
O
O
303  
Analogue
T. brucei (BSF)
ED50 (µM)
303
305
>500
3.22 ± 0.13
T. brucei (Pro)
ED50 (µM)
>1000
5.74 ± 0.61
HeLa
ED50 (µM)
>1000
50.8 ± 3.7
Selectivity 
Index
N/A
15.8
Entry
1
2  
Table 6.6: Biological profile for triazoles 303 and 305, selectivity index refers to parasitic inhibition versus 
mammalian HeLa inhibition.  
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6.3.8 C9-C10 bond construction via Williamson etherification 
 
Having successfully assembled butenolide triazoles 303 and 305 and prior to the biological 
data, efforts to reduce the number of synthetic linear steps were investigated (Scheme 
6.26). Incorporation of the side chain was envisioned to arise from a Williamson 
etherification reaction, initially tested on a model system with previously prepared iodide 
97 and alcohol 311. Preliminary treatment of alcohol 311 with sodium hydride followed by 
addition of iodide 97 at 0 °C with warming to room temperature did not provide any trace 
of the desired ether product 312 and following several unsuccessful attempts, studies 
towards ether formation were terminated. 
 
O
O
I
TBSO OH
O
O
O
TBSO
NaH, THF, 
0 °C to RT
97
311
312
X
 
Scheme 6.26: Attempted synthesis of ether 312. 
 
6.3.9 C9-C10 bond construction via amide coupling  
 
An alternative amide coupling strategy was investigated utilizing the butenolide aldehyde 
188 and triazole alcohol 295 precursors. Further manipulation of both subunits would 
access either the carboxylic acid or amine functionalities in preparation for an amide 
linkage. Therefore, aldehyde 188 was readily transformed to carboxylic acid 313 in 
quantitative yield via a Pinnick oxidation (Scheme 6.27). 
 
O
O
H
O
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O
O
HO
O
313
NaClO2, NaH2PO4 •2H2O,
2-methyl-2-butene, t-BuOH, 
H2O, 0 °C to RT, 100%
 
Scheme 6.27: Synthesis of acid 313.  
 
With the acid 313 in hand, manipulation of alcohol 295 to the corresponding amine 314 
was envisioned to arise from a one step Mitsunobu-Staudinger protocol (Scheme 6.28).114 
Initial attempts to introduce the azide moiety to 295 in situ with stoichiometric amounts of 
Mitsunobu reagents proved challenging. In an attempt to affect this transformation a 4-fold 
excess of reagents were used. However, by TLC analysis conversion to azide 315 was not 
  Results and Discussion
  
 114 
evident and only recovery of starting material was observed, which was confirmed by 1H 
NMR analysis. At this point reversal of the coupling partners was ensued.  
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Scheme 6.28: Synthesis of amine 314.  
 
6.3.10 Reversal of amide coupling partners 
 
With alcohol 295 in hand, acid 316 was accessed via a two step oxidation procedure 
(Scheme 6.29). Dess-Martin oxidation of alcohol 295 gave aldehyde 317 and subsequent 
Pinnick oxidation of aldehyde 317 furnished acid 316 in quantitative yield without the 
need for further purification.  
 
O
O
N
N
NO
H
O
O
N
N
NO
OH
O
OH
N
N
NO
DMP, NaHCO3, 
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to RT, 100%
NaClO2, NaH2PO4 •2H2O,
2-methyl-2-butene, t-BuOH,
 H2O, 0 °C to RT, 100%
295 317
316  
Scheme 6.29: Synthesis of acid 316.  
 
The synthesis of amine 318 was envisioned to arise from a one pot Mitsunobu-Staudinger 
reduction protocol from starting material alcohol 81 (Scheme 6.30), which would generate 
intermediate azide 269 in situ. Direct hydrogenation of azide 269 with palladium was not 
an option as previous studies showed the hydrogenation of the α,β-unsaturated lactone. 
Treatment of alcohol 81 with stoichiometric quantities of Mitsunobu reagents formed the 
intermediate azide 269 (evident by TLC analysis) and subsequent addition of a further 
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equivalent of PPh3 to initiate the Staudinger reduction did not provide any trace of the 
desired amine 318. Preliminary investigations into an alternative C9-C10 bond coupling 
strategy were unsuccessful and placed on hold due to time constraints.   
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DIAD, DPPA, 
THF, 0 °C to RT
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X
 
Scheme 6.30: Synthesis of amine 318.  
 
6.3.11 Synthesis of 1,5-triazole analogue 
 
The successful synthesis and biological evaluation of the 1,4-triazole analogues prompted 
the synthesis of the 1,5-regioisomer to explore the effect of spatial arrangement on the 
cytotoxic and trypanocidal activities (Scheme 6.31). The 1,5-regioisomer 319 was 
envisioned to arise from the thermal Huisgen 1,3-dipolar cycloaddition of alkyne 283 and 
azide 256. Preliminary attempts at heating a mixture of azide 256 and alkyne 283 in 
toluene at 100 °C for 24 hours provided trace amounts of a 1 : 1 mixture of both the 1,4 
and 1,5-regioisomers 289 and 319 (entry 1). Prolonged exposure of 283 and 256 in toluene 
at 100 °C for 86 hours again only provided trace amounts of product as a mixture of 
regioisomers and with recovery of starting materials (entry 2). 
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OBn
283
O
N3
256
N
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see table
O
OBn 319
Conditions ProductEntry
1
2
3
PhMe, 100 °C, 24 h
PhMe, 100 °C, 86 h
Cp*RuCl(COD), PhMe, 100 °C, 24 h
trace
trace
-
 
Scheme 6.31: Synthesis of 1,5-triazole 319. 
 
An alternative ruthenium catalyzed azide-alkyne cycloaddition (RuAAC) reaction was 
attempted, which has been documented to afford exclusively the 1,5-regioisomer (entry 
3).119 Hence, treatment of azide 283 and alkyne 256 in toluene with 
  Results and Discussion
  
 116 
chloro(pentamethylcyclopentadienyl)(cyclooctadiene)ruthenium(II) catalyst was heated at 
100 °C for 24 hours, consumption of starting materials had occurred but no trace of the 
desired product was evident. Based upon these synthetic efforts the synthesis of the 1,5-
regioisomer was placed on hold. 
 
6.4 Replacement of heterocyclic ring  
 
The assembly and biological assessment of triazole analogues 289-293 has validated the 
initial concept that trypanocidal activity can be maintained upon replacement of the B and 
C rings present in chamuvarinin with THP and triazole scaffolds. Having synthesized a 
series of triazole analogues, the stage was now set to incorporate alternative heterocycles 
and assess their biological activities.  
 
6.4.1 [3 + 2] isoxazole cycloaddition reactions 
 
The synthesis of 3,5-isoxazolines or isoxazole scaffolds can be achieved by [3+2]-
cycloaddition reactions between an alkene or alkyne and a nitrile oxide subunit. Much 
attention has been focused on the assembly of isoxazolines due to their synthetic utility in 
natural product synthesis and medicinal chemistry.106,120 The isoxazoline motif is a masked 
building block for the installation of β-hydroxycarbonyl compounds, amino alcohols and 
amino acids, which can be accessed through reductive ring cleavage.  The nitrile oxide 
precursor can be prepared in two ways, either from treatment of an oxime precursor with 
an oxidant such as sodium hypochlorite or by the reaction of phenyl isocyanate and a nitro 
component, otherwise known as a Mukaiyama reaction.121 Non-stabilized aliphatic nitrile 
oxides tend to be generated in situ due to their instability and tendency to dimerize to the 
furoxan.  
In 2001, Carreira and co-workers reported the synthetic applicability of the isoxazoline 
motif in the synthesis of polyketide natural product epothilone A (320), shown in Scheme 
6.32.122 Oxime 321 was treated with tert-butyl hypochlorite to generate the nitrile oxide in 
situ with concomitant cycloaddition to allylic alcohol 322 afforded isoxazoline 323 in a 
diastereoselective manner. Having implemented the masked 1,3-diol, Carreira and co-
workers manipulated the isoxazoline 323 through several steps to ultimately install the 
desired stereochemistry at the C13 and C15 positions of epothilone A (320). 
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Scheme 6.32: Synthesis of isoxazoline 323 in the synthesis of epothilone A (320). 
 
6.4.2 Synthesis of 3,5-isoxazole analogue 
 
The 1,4-triazole motif has proven to be an advantageous heterocyclic spacer unit, 
successfully mimicking the central 2,5-THF ring found in 72. A 3,5-isoxazole heterocycle, 
presumed to adopt a similar conformation to the triazole motif, was envisioned to arise 
from an analogous [3+2] cycloaddition approach. The oxime precursor 324 for the 
assembly of the 3,5-isoxazole 325, shown in Scheme 6.33, was synthesized in excellent 
yield by the condensation of aldehyde 284 with hydroxylamine hydrochloride.  
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Scheme 6.33: Synthesis of oxime 324. 
 
With the oxime 324 and alkyne 261 subunits in hand, attention was then focused on the 
construction of the 3,5-isoxazole through the screening of oxidizing agents (Scheme 6.34), 
however, the preparation of the hydroximoyl chloride in situ proved to be problematic. 
Initial oxidation of oxime 324 with commercial NaOCl at 0 °C, followed by subsequent 
exposure to a solution of alkyne 261 in CH2Cl2 and Et3N did not provide any trace of the 
desired product 325 (entry 1).  
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Scheme 6.34: Synthesis of isoxazole 325.  
 
Lowering the reaction temperature from 0 °C to -30 °C did not provide the desired product. 
At this stage a change in oxidant was required, N-chlorosuccimide was employed at both 0 
°C and -30 °C, but again did not provide any trace of product 325 (entry 2). The absence of 
any trace of product was presumably due to the instability of the intermediate hydroximoyl 
chloride. Fortunately, Carreira and co-workers reported the use of chiral aliphatic nitrile 
oxides to access 3,5-isoxazolines employing t-BuOCl as the oxidant at -78 °C.122 
Treatment of oxime 324 at -78 °C with t-BuOCl and exposure to alkyne 261 with slow 
warming to room temperature over 16 h provided the first indication of product 325, albeit 
in a disappointing 17% yield (entry 3). The isoxazole analogue 325 has displayed high 
levels of selective parasitic inhibition against the bloodstream form of T. brucei, shown in 
Table 6.7, with an ED50 value of 4.53 ± 0.24 µM and a selectivity index of 23.8, 
demonstrating that selective parasite inhibition can be achieved through modification of 
the heterocyclic ring.76 
 
T. brucei (BSF)
ED50 (µM)
4.53 ± 0.24
T. brucei (Pro)
ED50 (µM)
19.6 ± 3.1
HeLa
ED50 (µM)
107.8 ± 4.9
Selectivity 
Index
23.8  
Table 6.7: Biological profile for isoxazole 325, selectivity index refers to parasitic inhibition versus 
mammalian HeLa inhibition.  
 
6.4.3 Synthesis of dihydropyran triazole 
 
Having established a viable synthetic route to the assembly of triazole analogues, the next 
stage envisioned the incorporation of a dihydropyran (DHP) ring system in place of the D-
ring, in an effort to further reduce the simplicity of the triazole analogues (Scheme 6.35). 
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The synthesis of the dihydropyran alkyne 326 was accomplished in five steps from (S)-
epoxyoctane 150. The synthesis of 326 began with the silyl protection of propargyl alcohol 
327 as its TMS ether 328, which was used directly in the following reaction. Exposure of 
328 to n-BuLi generated the lithium acetylide species and subsequent addition to (S)-150 
gave alkyne 329 in 60% yield. 
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327 328
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Scheme 6.35: Synthesis of dihydropyran-alkyne 326. 
 
 Alkyne 329 was then subjected to flow hydrogenation conditions to access diol 330, 
which was oxidized under TEMPO/BAIB conditions to the corresponding lactone 331, 
achieved in 61% yield over the two steps.123 The final stages towards the synthesis of 326, 
relied upon the addition of TMS acetylene to lactone 331 to provide an inseparable mixture 
of open chain alcohol 332 as well as the intermediate lactols in a combined 79% yield. 
Dehydrative cyclization of alcohol 332 with catalytic (±)-CSA in benzene under Dean and 
Stark conditions for 30 minutes gave the desired DHP-alkyne 326 in a moderate 54% 
yield.  
 
With alkyne 326 in hand, synthesis of triazole 333 was pursued (Scheme 6.36). 
Application of the previously optimized click conditions to the assembly of azide 288 and 
alkyne 326 gave the desired triazole 333. Unfortunately, upon 1H NMR analysis and mass 
spectrometry data it was evident that the product was an inseparable 1 : 1 mixture of 333 
and an additional triazole product. Analysis of the mass spectrometry data indicated that 
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the addition of H2O had occurred, which appeared to be ring-opened product 334 (entry 1). 
In an effort to reduce this side-reaction, an alternative solvent system for the cycloaddition 
was investigated. Varying the solvent from an aqueous t-BuOH/H2O media to DMF 
initially looked promising by TLC anaylsis, however, 1H NMR analysis indicated the 
presence of a mixture of 333 and 334 (entry 2). 
 
O
OBn
N3
O
CuSO4•5H2O, 
Na ascorbate, RT
326
O
N
N
NO
OBn
333288
Solvent Product
t-BuOH, H2O
 (1 : 1 mixture)
333 : 334
1 : 1
DMF 333 : 3341 : 1
N
N
NO
OBn
334
OH
O
Entry
1
2
 
Scheme 6.36: Synthesis of DHP-triazole 333. 
 
In an effort to exclusively obtain 333, the mixture of open and closed triazole analogues 
333 and 334 were subjected to the dehydrative cyclization conditions utilized for the 
synthesis of DHP-alkyne 326 (Scheme 6.37). However, by 1H NMR analysis no change in 
the ratio of starting material triazoles was apparent. Based on the results, it was evident 
that the cycloaddition reaction of alkyne 326 and azide 288 had to be performed in an 
anhydrous environment to prevent the addition of water to the reactive DHP triazole 
product 333. Hence, an alternative cycloaddition protocol to install this DHP motif was 
required. 
 
O
N
N
NO
OBn
333
N
N
NO
OBn
334
OH
O
O
N
N
NO
OBn
333
(±)-CSA, benzene,
 reflux
X
 
Scheme 6.37: Ring closure of triazoles 333 and 334. 
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6.4.4 Synthesis of dihydropyran isoxazole 
 
The triazole cycloaddition of 333 proved to be problematic in an aqueous environment, 
hence, an alternative [3+2]-cycloaddition protocol under anhydrous conditions was 
required to install the desired DHP motif (Scheme 6.38). Application of the 
aforementioned isoxazole reaction conditions to oxime 324 generated the hydroximoyl 
chloride in situ and subsequent exposure to a solution of alkyne 326 and Et3N with slow 
warming to room temperature over a 24 hour period furnished the desired DHP-isoxazole 
335 in a reasonable 38% yield. The DHP isoxazole analogue 335 is currently in the process 
of being biologically evaluated.  
 
O
OBn
H
N
OH
O
O
OBn
O
N
O
t-BuOCl, Et3N, CH2Cl2,
 -78 °C to RT, 38%
326
324 335  
Scheme 6.38: Synthesis of isoxazole 335. 
 
6.4.5 Synthesis of spiroketal analogue 
 
To further enhance the analogue library and explore the impact on trypanocidal activity, 
the [3+2]-cycloaddition products were replaced with a spiroketal motif, which would adopt 
a different conformation to the triazole analogues (Scheme 6.39). The previously prepared 
lactone 331 and alkyne 84 provided an ideal platform for the construction of this spiroketal 
336. With key intermediates at hand, formation of the lithium acetylide of 84 by treatment 
with n-BuLi and subsequent addition of lactone 331 provided the open chain alcohol 337 
in a moderate 44% yield.  
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52%
O
OTBS
O
84 331 337
336  
Scheme 6.39: Synthesis of spiroketal 336. 
 
Reduction of the alkyne to the corresponding alkane was achieved using flow 
hydrogenation conditions (5% Pt/C), followed by in situ acid mediated methanolysis to 
cleave the silyl protecting group and promote concomitant cyclization to furnish the 
anomerically stabilized spiroketal 336 in 52% yield. With the spiroketal 336 in hand, its 
biological activity was screened against both the bloodstream and procyclic forms of T. 
brucei (Table 6.8).76 Spiroketal 336 was essentially inactive against the HeLa cell line and 
the procyclic form of T. brucei and showed low level activity towards the bloodstream 
form of T. brucei with an ED50 value of 283.5 ± 16.5 µM.    
 
T. brucei (BSF)
ED50 (µM)
283.5 ± 16.5
T. brucei (Pro)
ED50 (µM)
>500
HeLa
ED50 (µM)
>1000
Selectivity 
Index
>3.5  
Table 6.8: Biological profile for spiroketal 336, selectivity index refers to parasitic inhibition versus 
mammalian HeLa inhibition.  
 
6.5 Biological profile summary 
 
The SAR data has provided some insight into the structural features required for potent 
inhibition of T. brucei, shown in Table 6.9. From the initial set of diastereomeric triazole 
data it was evident that the stereochemistry of the THP motifs has a profound effect on the 
inhibition profile. Direct comparison of alkyl analogues 263 and 265 (entries 4 and 7) 
showed that changing the stereochemistry of the D-ring from the syn to the anti-
configuration resulted in a 3-fold loss in activity. It is also clear that the stereochemistry of 
the B-ring has an effect on T. brucei inhibition, as shown by comparison of 262 and 263 
(entries 1 and 4) and 265 and 266 (entries 7 and 10), which resulted in a 6.4 and 1.5-fold 
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loss in activity. Introduction of terminal oxygenation as a handle for further manipulation 
resulted in a clearer SAR profile.  
 
O
R
N
N
NO
O
R
N
N
NO
O
R
N
N
NO
O
R
N
N
NO
O
R
N
N
NO
262: R = Et
289: R = OBn
295: R = OH
T. brucei (BSF)
ED50 (µM)
48.7 ± 3.5
8.7 ± 0.5
1.8 ± 0.1
T. brucei (Pro)
ED50 (µM)
103.3 ± 3.5
15.6 ± 0.3
0.8 ± 0.1
HeLa
ED50 (µM)
>100
45.5 ± 2.5
7.0 ± 1.0
Selectivity 
Index
>2
5.3
3.9
263: R = Et
290: R = OBn
296: R = OH
265: R = Et
291: R = OBn
297: R = OH
266: R = Et
292: R = OBn
298: R = OH
293: R = OBn
299: R = OH
7.6 ± 0.3
10.1 ± 0.4
17.5 ± 1.0
1.1 ± 0.1
72.3 ± 5.3
25.4 ± 1.3
166.6 ± 18.0
76.0 ± 3.0
26.9 ± 1.1
21.9
7.5
1.5
24.6 ± 1.4
467.2 ± 40.3
223.2 ± 21.8
65.0 ± 3.1
236.6 ± 23.8
87.9 ± 4.5
33.0 ± 2.4
>1000
415.8 ± 35.3
1.3
>2
1.9
37.2 ± 6.6
3.1 ± 0.1
72.4 ± 3.9
81.5 ± 4.5
48.7 ± 3.6
68.3 ± 7.2
>500
71.4 ± 4.1
59.7 ± 2.5
>6
23
0.8
8.2 ± 0.4
19.2 ± 1.1
15.5 ± 1.0
42.9 ± 2.4
37.5 ± 1.5
101.0 ± 10.4
4.6
5.3
Analogue R groupEntry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
 
Table 6.9: SAR data for ethyl analogues 262-263 and 265-266, benzyl analogues 289-293 and alcohol 
analogues 295-299, selectivity index refers to parasitic inhibition versus mammalian HeLa inhibition. 
 
Comparison of analogues 290 and 291 (entries 5 and 8) showed that upon changing the 
stereochemistry of the D-ring from the syn to the anti-configuration resulted in a 46-fold 
reduction in T. brucei inhibition. The benzyl analogues have indicated that a syn-
configuration of the D-ring is necessary for potent inhibition and that possibly the 
stereochemistry of the B-ring is not as important as first believed. The alcohol analogues 
displayed a similar trend to the benzyl ether analogues that a syn-configured D-ring is 
necessary for good micromolar activities, analogues 295, 296 and 299 (entries 3, 6 and 14). 
However, it was also evident from the data that in the case of the alcohol analogues, 
stereochemistry of the B-ring can affect activity, shown by analogues 297 and 298 (entries 
9 and 12), upon changing the stereochemistry from anti to syn resulted in a 3-fold increase 
in activity. Comparison of the alkyl, benzyl and alcohol analogues of 262, 289 and 295 
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(entries 1, 2 and 3) as a whole have indicated the increased activity in transforming the side 
chain of the B-ring from an ethyl linkage, to a benzyl ether followed by an alcohol. 
Alcohol 295 has shown comparable levels of activity against T. brucei inhibition to that of 
natural product chamuvarinin (72), 1.8 ± 0.1 and 1.37 ± 0.08 µM, respectively. 
Interestingly, analogue 293 (entry 13) displayed comparable levels of activity to that of 
289 (entry 2), but upon removal of the benzyl group analogue 299 (entry 14) resulted in a 
11-fold decrease in activity compared to 295 (entry 3). The introduction of an alcohol 
group for analogues 296, 298 and 299  (entries 6, 12 and 14) appears to have reduced the 
levels of activity, indicating that the benzyl group may be potentially interacting with 
residues at the protein target site, which an alcohol group cannot accommodate. The benzyl 
group may also be able to more readily insert itself into the lipophilic membrane, whereas 
the hydrophilic alcohol incurs a greater penalty for membrane insertion or they are 
alternatively interacting at a different protein site. It is also evident that removal of the 
benzyl group has an inherent affect on the selectivity index. From these results it appears 
that the syn-stereochemistry of the D-THP motif is required for a potent biological 
response. Work is currently underway to determine the specific mode of action and protein 
target for these analogues, which will enable further SAR studies to be conducted.         
 
6.5.1 Alternative heterocyclic spacer 
 
The 1,4-triazole motif has proven to be an advantageous heterocyclic spacer unit and has 
successfully mimicked the central C20-C23 THF ring found in 72. Further SAR studies 
have focused on the replacement of the triazole motif with an isoxazole heterocycle, 
presumed to adopt a similar conformation (Table 6.10). Triazole analogue 289 (entry 1) 
exhibited low micromolar activity against T. brucei with an ED50 value of 8.7 ± 0.5 µM. A 
key difference in replacing the triazole with an isoxazole motif is the removal of the 
methylene group at the 1-position of the triazole. The isoxazole analogue 325 displayed 
low micromolar activity against the bloodstream form of T. brucei, ED50 value of 4.53 ± 
0.24 µM and displayed an increased selectivity index of 23.8, almost 5-fold greater than 
the triazole analogue 289. Based on these biological profiles, the alternative heterocyclic 
spacer has proven to be advantageous and may presumably be a better mimic for 
chamuvarinin (72), due to the direct connectivity of the heterocycle ring systems. This 
initial isoxazole analogue warrants further SAR investigations. 
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O
OBn
O
N
O
325
O
OBn
N
N
NO
289
Analogue
T. brucei (BSF)
ED50 (µM)
289
325
8.7 ± 0.5
4.53 ± 0.24
T. brucei (Pro)
ED50 (µM)
15.6 ± 0.3
19.6 ± 3.1
HeLa
ED50 (µM)
45.5 ± 2.5
107.8 ± 4.9
Selectivity 
Index
5.2
23.8
Entry
1
2  
Table 6.10: Biological profiles for analogues 289 and 325, selectivity index refers to parasitic inhibition 
versus mammalian HeLa inhibition.  
 
6.5.2 Simplified side chain replacement  
 
Our initial hypothesis relied on the presence of both the bis-THP and central 1,4-triazole 
motifs for potent T. brucei inhibition. The initial biological data supported this assumption, 
with decreased activities observed when the THP motifs were replaced with hydrophobic 
alkyl side chains. On the contrary, simplified analogue 273 displayed a surprising 
micromolar parasitic activity with an ED50 value of 15.6 ± 0.3 µM (Table 6.11, entry 1). 
To further reduce the complexity and stereochemistry present within these analogues, 
simplified furan analogue 275 (entry 2) was synthesized.  
 
O
N
NN O
273
O
N
NN
275
Analogue
T. brucei (BSF)
ED50 (µM)
273
275
15.6 ± 0.3
34.0 ± 1.5
T. brucei (Pro)
ED50 (µM)
30.8 ± 1.7
56.1 ± 2.9
HeLa
ED50 (µM)
102.8 ± 9.5
~230
Selectivity 
Index
6.6
>6.6
Entry
1
2  
 
Table 6.11: Biological profiles for analogues 273 and 275, selectivity index refers to parasitic inhibition 
versus mammalian HeLa inhibition.  
 
The furan 275 exhibited a two-fold decrease in activity against the bloodstream form of T. 
brucei and was essentially devoid of any activity against the HeLa cell line. These results 
indicate that the butenolide moiety is not an essential function for potent inhibition as the 
furan analogue can be tolerated. The butenolide moiety may be eliciting a slightly 
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increased biological response due to biochemical changes such as ring opening of the 
lactone. Based on all the SAR data, this low micromolar activity for 273 may be attributed 
to an interaction at the protein target distinct from the bis-THP triazole analogues. In order 
to gain a better understanding and further modify our analogues the mode of action has to 
be established.   
 
6.5.3 Side chain replacement 
 
The synthesis of triazole analogues with terminal oxygenation has provided a functional 
handle for further elaboration (Table 6.12). The biological data for the non-natural 
chamuvarinin-like analogues have shown that introduction of the butenolide side chain 
resulted in a >5-fold increase in T. brucei activity. With alcohol 295 (entry 1) displaying 
comparable levels of activity to chamuvarinin (72), the next stage was to incorporate the 
butenolide moiety in an effort to further reduce the activity and potentially provide an 
analogue with nanomolar activity. Surprisingly, analogue 303 (entry 2) was devoid of any 
activity against T. brucei with an ED50 value of >500 µM.  
 
O
OH
N
N
NO
295
O
N
N
NO
O
O
303
O
N
N
NO
O
O
305
Analogue
T. brucei (BSF)
ED50 (µM)
295
303
305
1.8 ± 0.1
>500
3.22 ± 0.13
T. brucei (Pro)
ED50 (µM)
0.8 ± 0.1
>1000
5.74 ± 0.61
HeLa
ED50 (µM)
7.0 ± 1.0
>1000
50.8 ± 3.7
Selectivity 
Index
3.9
N/A
15.8
Entry
1
2
3  
Table 6.12: Biological profiles for analogues 295, 303 and 305, selectivity index refers to parasitic inhibition 
versus mammalian HeLa inhibition.  
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The biological data for the reversed butenolide analogue 305 displayed low micromolar 
selective activities against both forms of T. brucei with ED50 values of 3.22 ± 0.13 and 
5.74 ± 0.61 µM respectively and a selectivity index of 15.8 (entry 3). Based on these 
biological profiles it appears that incorporation of the butenolide in a directional manner 
has significant affects on T. brucei inhibition, shown in Figure 6.4 are molecular modelling 
diagrams of both the butenolide triazole analogues 303 and 305.124 From all the SAR data, 
it appears that the next step will be to test the free alcohol analogue 307, which will 
presumably be less active than 305 but should maintain micromolar activity. The 
incorporation of an alcohol group for analogue 295 had a positive affect on activity, 
substituting the alkyl side chain for a 4-carbon chain terminating in a hydroxyl in an 
analogous manner to 295 may potentially increase the activity of 305 to nanomolar 
activity. These results definitively prove that both the mode of action and protein target 
have to be a priority in order to move forward with SAR studies.  
     
Figure 6.4: Molecular modelling of butenolide triazole analogues 305 and 303.  
 
6.6 Determination of protein target and specific mode of action  
 
The library of non-natural acetogenin and triazole analogues have exhibited low 
micromolar trypanocidal activities and have demonstrated selective anti-parasitic activity 
can be achieved through minor structural modifications. However, the specific protein 
target for the potent T. brucei inhibition is currently undetermined for these analogues. The 
acetogenin natural products mode of action has been established and they are well known 
to target and inhibit the mitochondrial Complex I protein within mammalian cells, 
therefore, it is hypothesized that the analogues are targeting a protein in the mitochondrion 
of the parasite.  
 
305 303
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The parasite T. brucei relies upon two mitochondrial electron transport chains for survival, 
the first is a cytochrome dependent oxidase (COX) and the other a cytochrome 
independent alternative oxidase (AOX).125 The alternative oxidase is a diiron protein, 
which is found in African trypanosomes, fungi and several plant species. It catalyzes the 
four-electron reduction of dioxygen to water by ubiquinol.126 The bloodstream and 
procyclic forms of T. brucei rely on differing respiratory pathways, as outlined in Scheme 
6.40; the procyclic form relies on the mitochondrial COX, glycerol-3-phosphate 
dehydrogenase (GPDH), an alternative NADH oxidoreductase (NDH-2)127,128 and the 
AOX, whereas the bloodstream form does not possess this cytochrome dependent protein 
and relies solely on the GPDH, NDH-2 and AOX, also known as the Trypanosome 
alternative oxidase (TAO)129 for aerobic respiration. The rotenone insensitive alternative 
oxidoreductase NDH-2 functions in an analogous manner to Complex I recycling cytosolic 
NADH to NAD+, whereas Complex I replenishes mitochondrial NAD+. The glycerol-3-
phosphate oxidase (GPO) system is a necessary function for continuous glycolysis in the 
bloodstream form of T. brucei as it enables the regeneration of glycosomal NAD+ from 
NADH through the reduction of dihydroxyacetone phosphate (DHAP) by GPDH.130 The 
glycerol-3-phosphate generated in this process is shuttled by the GPO system to the 
mitochondrion where it initiates the reduction of ubiquinone (17) to ubiquinol (18) 
ultimately leading to the reduction of oxygen. The bloodstream form utilizes blood glucose 
as their energy source and is reliant upon this reoxidation of NADH for parasite survival, 
hence inhibition of TAO would result in parasitic death. The procyclic form of T. brucei 
uses primarily proline as an energy source and utilizes COX for ATP generation. The 
procyclic form also utilizes TAO but to a much lesser extent. The TAO protein, which is 
not found in mammalian hosts including humans would be an attractive target for the 
development of specific anti-trypanosomal drugs.  
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Scheme 6.40: Energy metabolism in bloodstream and procyclic forms of T. brucei. *Procyclic T. brucei use 
proline for energy source. 
 
Biological studies towards the elucidation of the protein target and the precise mode of 
action for the triazole analogues are currently underway. In an effort to establish whether 
the analogues are disrupting the mitochondrial functions, treatment of the mitochondria 
with mitochondrial selective fluorescent dyes such as MitoTracker Green and Red 
(MTG/MTR) in combination with cell imaging will be instrumental in assessing the 
membrane potential of the mitochondria.131 Accumulation of MTR in the mitochondria 
enables the dye to covalently bind to the cysteine residues of the mitochondrial proteins. 
However, if the specific protein target for the lead triazole compounds is the mitochondria, 
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the triazole compounds should accumulate in the mitochondria and prevent the MTR from 
crossing the membrane barrier, hence no fluorescence in the mitochondria should be 
evident. Mitotracker Green (MTG) binds to the membrane regardless of potential. The next 
stage will be to incorporate fluorescent and affinity tags to the lead triazole compounds for 
cell imaging and the identification of specific protein targets. Preliminary investigations 
incorporating a biotin tag are currently underway and are detailed in section 6.6.2.   
 
6.6.1 TAO inhibitors 
 
One of the most well known inhibitors of TAO is salicylhydroxamic acid (SHAM-338, 
Figure 6.5), which selectively inhibits TAO at micromolar activity with an IC50 value of 
4.0 µM.132 The introduction of SHAM (338) to the bloodstream and procyclic forms of T. 
brucei targets the oxidation of ubiquinol (18) to ubiquinone (17). This inhibition leads to 
the reduction in the amount of ubiquinone (17) present in the mitochondrion and results in 
the depletion of glycosomal NADH levels, ultimately leading to a decline in ATP 
production. The inhibition causes the parasite to assume an anaerobic respiration pathway, 
however, this is detrimental to the bloodstream form of the parasite as T. brucei cannot 
survive for prolonged periods of time under these conditions. The inhibition of TAO in the 
procyclic form of T. brucei by comparison is not fatal to the parasite, as the procyclic form 
can undertake the cytochrome dependent pathway (Complex III/IV) as an alternative 
means for respiration. However, inhibition of both the Complex III/IV and TAO pathways 
at the same time prevents the growth of T. brucei, hence TAO is essential for the survival 
of both forms of T. brucei.125 
 
OH
N
H
O
HO
SHAM 338
IC50 = 4 µM  
Figure 6.5: TAO inhibitor SHAM (338). 
 
Ascofuranone 339, shown in Figure 6.6, is a potent nanomolar (IC50 value of 0.13 ± 0.04 
nM) inhibitor of TAO and was isolated from the fungus Ascochyta viciae.132,133 Recent 
structure activity relationship studies have given some insight into the pharmacophore and 
protein interactions of ascofuranone 339.  
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Figure 6.6: Ascofuranone 339, potent inhibitor of TAO, asterisk represents an asymmetric carbon. 
 
The SAR showed that the furanone moiety is not essential but the formyl, hydroxyl and 
isoprene groups are recognized by the protein and are required for potent inhibition.132 
Therefore, ascofuranone 339 represents a potential lead compound for the design and 
development of a novel class of drugs for the treatment of Human African 
Trypanosomiasis. Recently the group of Kita and co-workers126 have reported the crystal 
structure of the diiron carboxylate TAO protein with inhibitor ascofuranone 339 bound in 
the ubiquinol binding site, Figure 6.7. By comparison with Complex I of the mitochondria, 
the TAO binding site is not buried within a cavity of several subunits but is relatively 
exposed. 
 
 
                            
Figure 6.7: Crystal structures of TAO with ascofuranone 339 bound in the ubiquinol cavity. Figures prepared 
by Dr Lindsay Tulloch, Florence group. 
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6.6.2 Synthesis of bi-directional triazole analogue 
 
The synthesis of a bis-functionalized triazole analogue 340 would be beneficial, as it 
would provide an opportunity to incorporate an affinity tag, which would assist in the 
identification of the specific protein target.   
The synthesis towards triazole 340 (Scheme 6.41) began with the debenzylation of alkyne 
283 by treatment with the BCl3DMS complex to give alkyne 341 in 78% yield. Assembly 
of the triazole motif was accomplished utilizing the click reaction conditions, hence alkyne 
341 was coupled with azide 288 to furnish triazole 340 in 33% yield.  
 
O
N
N
NO
OBn
OH340
N3O
OBn 288
CuSO4•5H2O, 
Na ascorbate, 
H2O, t-BuOH,
 RT, 33%
O
OH 341
O
OBn 283
BCl3•DMS, CH2Cl2,
 -15 °C, 78%
 
Scheme 6.41: Synthesis of triazole 340. 
 
With the bis-functionalized analogue 340 in hand, the stage was set to incorporate an 
affinity tag, such as the biotin linker 342 (Scheme 6.42). The synthesis of a biotinylated 
triazole analogue would enable the use of avidin beads, which can specifically recognize 
and bind to the biotin moiety. Pull down experiments can then be performed to identify 
specific target proteins.134 Unfortunately, the preliminary investigation into the assembly 
of commercially available biotin linker 342 and triazole 340 to furnish biotin-linked 
analogue 343 were unsuccessful. Further synthetic studies to couple these two subunits are 
currently underway in the Florence group. 
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Scheme 6.42: Attempted synthesis of biotin-linked triazole 343.  
 
6.7 Summary  
 
A focused library of simplified triazole analogues have been synthesized and found to be 
biologically active against the bloodstream and procyclic forms of T. brucei. Structure 
activity relationships have alluded to the essential structural features and stereochemistry 
required for potent inhibition. The triazole analogue 295 has displayed comparable levels 
of T. brucei inhibition to that of natural product chamuvarinin (72), ED50 values of 1.8 ± 
0.1 and 1.37 ± 0.08 µM, respectively. By comparison to chamuvarinin (72), the alcohol 
triazole analogues 295-299 can be assembled in an overall 10 linear steps in comparison to 
the 17 overall linear steps required for 72. The isoxazole analogue 325 displayed low 
micromolar activity against the bloodstream form of T. brucei, ED50 value of 4.53 ± 0.24 
µM and displayed an increased selectivity index of 23.8, almost 5-fold greater than the 
triazole analogue 289. The synthesis of butenolide triazole analogues 303 and 305 have 
shown that incorporation of the butenolide in a directional manner has significant affects 
on T. brucei inhibition, ED50 values of >500 and 3.22 ± 0.13 µM, respectively. The 
synthesis of these simplified triazole/isoxazole analogues has provided a platform for the 
basis of a new class of potential T. brucei inhibitors. Further structure activity relationships 
and protein identification studies are currently underway to determine both the protein 
target and mode of action of these analogues.   
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Chapter 7 
 
7.1 Summary and future work  
 
The first total synthesis of chamuvarinin (72) was completed in 1.5% overall yield with a 
longest linear sequence of 20 steps (Scheme 7.1). This provided unambiguous proof of the 
relative and absolute stereochemical assignment of the natural product. The biological 
activity displayed by chamuvarinin (72) against both forms of T. brucei presented an 
opportunity to further explore the potential of this unique acetogenin as an anti-parasitic 
agent for the treatment of Human African Trypanosomiasis. 
Following the initial synthesis, a revised synthetic strategy towards chamuvarinin (72) was 
completed in 17 steps in the longest linear sequence in 2.2% overall yield. An attractive 
feature of this revised strategy enabled the assembly of non-natural chamuvarinin-like 
analogues. This small handful of analogues displayed selective parasitic inhibition through 
relatively minor changes surrounding the central C20-C23 THF ring.  
 
+
O
OTBS
OBn
9
20H
O
23
O
H
OTBS
84 83
O
O
O
1
83 steps
H
O O O
OTBS
S
O2
189
188
N
N
NN
Ph
15
34
O O O
O
O
OH
1528
34
36
1
chamuvarinin
 80 = 72
7 steps
O
OTBS
S
O2
9
TBSO
O
O
O
H 36
1
8
20
192
188
N
N
NN
Ph
O
34
OTBS
O
OTBS
214
O O O
O
O
OH
1528
34
36
chamuvarinin
72
OH
2 steps
4 steps
O
O
15
36
 
Scheme 7.1: Summary of first and revised syntheses of chamuvarinin 72. 
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Based on the observations, a small library of simplified triazole analogues have been 
synthesized and found to be biologically active against the bloodstream and procyclic 
forms of T. brucei. The triazole analogue 295 has displayed comparable levels of T. brucei 
inhibition to that of natural product chamuvarinin (72) (ED50 values of 1.8 ± 0.1 and 1.37 ± 
0.08 µM, respectively) and was synthesized in an overall 9 linear steps in comparison to 
the 17 linear steps required for 72. Furthermore isoxazole analogue 325 has displayed 
selective low micromolar parasitic inhibition, providing an opportunity to design and 
develop further isoxazole analogues. The synthesis of butenolide triazole analogues 303 
and 305 have shown that incorporation of the butenolide in a directional manner has 
significant affects on T. brucei inhibition. The design and synthesis of these simplified 
triazole/isoxazole analogues has provided a platform for the basis of a new class of 
potential T. brucei inhibitors. Further SAR and protein identification studies are currently 
underway to determine both the protein target and mode of action of these analogues. 
 
Synthesis of heterocyclic analogues 
 
Having synthesized a small library of heterocyclic analogues, the biological profiles have 
provided scope for further SAR studies. A simple SAR comparison of analogues 273 and 
275 with an analogue possessing an alternative heterocyclic ring, such as an isoxazole, was 
considered. The synthesis of simplified isoxazole analogue 344 was envisioned to arise 
from the manipulation of butenolide alcohol 81 via a three step protocol (Scheme 7.2). 
Reduction of alcohol 81 with DIBAL, subsequent oxidation and condensation with 
hydroxylamine hydrochloride would provide the oxime 345 precursor. Following the 
synthesis of oxime 345, isoxazole analogue 344 was envisaged to arise from treatment of 
oxime 345 with N-chlorosuccimide followed by addition of 1-octyne. The simplified 
isoxazole 344 analogue would enable a direct biological comparison with analogues 273 
and 275.  
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344  
Scheme 7.2: Synthesis of simplified isoxazole analogue 344. 
 
The initial SAR studies involving the design and development of triazole analogues have 
provided a platform for the basis of a new class of potential T. brucei inhibitors. Current 
iterative SAR studies are underway to determine the optimal: 
1) Heterocyclic spacer- isoxazole analogue 325 has displayed increased selective parasitic 
inhibition in comparison to its triazole counter part 289. 
2) Variation of butenolide moiety- substitution with a furan motif has resulted in only a 2-
fold decrease in activity, which suggests that the butenolide moiety is not an essential 
component.  
3) Identify the optimal ring size and stereochemistry of ether ring systems 1 and 2, as well 
as potentially exchanging the ether moiety for an alternative ring system. 
4) Identify the optimal alkyl spacer between the butenolide and heterocyclic core. 
The 1,4-triazole motif has proven to be an advantageous replacement for the central C20-
C23 THF ring system of chamuvarinin (72). Alternative replacements for the heterocyclic 
spacer could readily be prepared and would adopt similar conformations to both the 
isoxazole and triazole motifs (Figure 7.1). Some heterocycle replacements of interest 
include furan 346, pyrrole 347, thiophene 348, oxazole 349, thiazole 350 and imidazole 
351 scaffolds. Further design may involve the replacement of the heterocycle with a 
flexible ether linkage such as bis-THP analogue 352, this would adopt a different 
conformation to the aromatic motifs. From computer modeling it appears that the triazole 
hydrogen is bonding to the oxygen on one of the THP motifs. By removing this interaction 
it will be beneficial to observe the impact on T. brucei inhibition. Alternatively introducing 
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a propargyl motif 353 in place of the heterocycle and possibly introducing an alternative 
heteroatom such as a fluorine. Other alternative motifs include the di-amide analogue 354 
as well as analogue 355 with a 3-carbon spacer unit between the bis-THP motifs. In terms 
of replacements for the ether moieties, an alternative maybe to introduce a piperidine ring 
system 356 or couple the ether and triazole motifs in a reversed order 357. As observed 
from analogues 273 and 275 the butenolide head does not appear to be an essential 
function for T. brucei inhibition as the furan 275 was tolerated. Replacements for the 
butenolide head may involve the incorporation of a lactam 358, pyrazole 359 or δ-lactone 
360 ring systems.  
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Figure 7.1: Ether, heterocycle and head replacements. 
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Protein identification studies are currently underway to determine the both the protein 
target and mode of action of these analogues.  Preliminary investigations into synthesizing 
a biotinylated tag for protein identification proved unsuccessful (Scheme 7.3). Following 
the assembly of the biotin tag and to enable photoaffinity labeling studies, the biotinylated 
triazole analogue 343 will be further incorporated with a photoreactive diazirine group 
such as 361 to give 362.  
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Scheme 7.3: Synthesis of photolabelled triazole TAG 362.  
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Chapter 8 
Experimental 
 
General Experimental Details 
 
All experiments were performed in flame dried glassware under a positive pressure of 
Argon with magnetic stirring unless otherwise stated. 
 
8.1 General procedures 
 
1H NMR (nuclear magnetic resonance) spectra were recorded on Bruker Avance 300 
(300.1 MHz), Bruker Avance II 400 (400.1 MHz), Bruker Avance 500 (500.1 MHz) and 
Bruker Avance III 500 (500.1 MHz) instruments and referenced using deuterated 
chloroform and benzene. The chemical shifts are given in parts per million (ppm) on the 
delta (δ) scale. The solvent peak was used as a reference value, for 1H NMR: CDCl3 = 7.26 
ppm, C6D6 = 7.16, for 13C NMR: CDCl3 = 77.00, C6D6 = 128.06. The multiplicity of each 
signal is indicated by: s (singlet); br s (broad singlet); d (doublet); dd (doublet of doublets); 
t (triplet); q (quartet); quin (quintet); or m (multiplet); coupling constant (J) and 
interpretation. Coupling constants were taken directly from the spectra and are 
uncorrected. The number of protons (n) for a given resonance is indicated by nH.  
 
13C NMR spectra were recorded on a Bruker Avance 300 (75 MHz), Bruker Avance II 400 
(100 MHz), Bruker Avance 500 (125 MHz) or Bruker Avance III 500 (125 MHz) at 
ambient probe temperature using an internal deuterium lock. The chemical shift data for 
each signal are reported in ppm on the δ scale (δ TMS = 0).  
 
Infrared (IR) spectra were recorded on a Perkin-Elmer Paragon series 1000 FTIR 
spectrophotometer as thin films. Wavelengths of maximum absorbance (νmax) are quoted in 
cm-1. Only selected, characteristic IR absorption data are provided for each compound.  
 
Optical rotations were measured with a Perkin-Elmer 341 polarimeter at 589 nm (sodium 
D line) in a cell with a pathlength of 1 dm and concentrations (c) were reported in g/100 
mL. Specific rotations are denoted as 
€ 
[α]D20 . 
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High and Low Resolution Mass Spectroscopy (HRMS and LRMS) were recorded using a 
Thermo Fisher LTQ Orbitrap XL mass spectrometer, Finnigan MAT 900 XLT mass 
spectrometer, Micromass Quattro II mass spectrometer, Waters ZQ4000 mass spectrometer 
or a Thermofisher DSQ-II mass spectrometer by the EPSRC National Mass Spectrometry 
service (Swansea) using Electron Impact (EI), Chemical Ionization (CI), Electrospray 
Ionization (ES), Fast Atom Bombardment (FAB), Atmospheric Pressure Chemical 
Ionization (APCI) or Atmospheric Solids Analysis Probe (ASAP) techniques. Other 
spectra were recorded on a Thermo Fisher Q Exactive mass spectrometer or a Waters 
micromass LCT using ES techniques at the University of St Andrews Mass Spectrometry 
service (School of Chemistry and Biomolecular Sciences). 
  
Analytical thin layer chromatography were carried out on Merck Kieselgel 60 F254 plates 
with visualization by ultraviolet light (254 nm) and/or heating the plate after staining with 
either a solution of 20% ceric ammonium molybdate w/v in H2O or 20% potassium 
permanganate w/v in H2O.  
 
Flash Column Chromatography were carried out on Merck silica gel 60 (40-63 µm) under 
a positive pressure of compressed air. 
 
Kugelrohr bulb-to-bulb distillations were carried out using a Büchi B-585 machine. 
Boiling points are the actual oven temperatures.   
 
Reagents and solvents were purified by standard means. Dimethylsulfoxide (DMSO) was 
dried over CaH2, distilled under high vacuum and stored over 4Å molecular sieves. 
Methanol was distilled from CaH2 in a recycling still under nitrogen. Dichloromethane 
(CH2Cl2), toluene, tetrahydrofuran (THF) and diethyl ether (Et2O) were dried by passage 
through two columns of alumina using a MBRAUN (SPS-800) solvent purification system. 
Oxalyl Chloride was distilled from CaH2 into K2CO3 under argon. Anhydrous DMF was 
purchased from Aldrich UK and dried by distillation from 4Å molecular sieves under 
argon atmosphere. Methyl tert-butyl ether (MTBE) was dried over CaSO4, passed over 
basic alumina, distilled at atmospheric pressure and stored over 4Å molecular sieves. 
Diisopropylamine, triethylamine (Et3N), diisopropylethylamine (iPr2EtN) and 2,6-lutidine 
were dried over CaH2, distilled at atmospheric pressure and stored over CaH2. All other 
reagents were used as purchased from Sigma Aldrich UK, Acros Organics UK, Alfar 
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Aesar UK or TCI Europe. All other chemicals were used as received, except where 
otherwise stated in the experimental procedures. All experiments were performed under 
anhydrous conditions and an inert atmosphere of argon, using a vacuum manifold with 
argon passed through calcium chloride and self-indicating silica gel unless otherwise 
stated. Petroleum ether refers to the fraction boiling between 40-60 oC. Room temperature 
refers to the temperature approximately 25 °C. 
 
Miscellaneous: The term “brine” describes a saturated aqueous solution of sodium chloride 
in deionized water. Reactions performed at -78 °C were achieved with a mixture of acetone 
and dry ice and -100 °C was achieved with MeOH and liquid nitrogen.  
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8.2 Preparation of reagents  
 
(S,S)-1,2-diammoniumcyclohexane-mono-(-)-tartrate salt135  
To a solution of D-(-)-tartaric acid (20.1 g, 134 mmol) in H2O (90 mL) was slowly added 
(±)-1,2-diaminocyclohexane (32.4 mL, 266 mmol) at RT. Glacial acetic acid (13.7 mL, 
240 mmol) was added and the reaction slurry was cooled to RT over 2 h with vigorous 
stirring. The precipitate was filtered and washed with cold H2O (15 mL) and MeOH (4 × 
25 mL). Purification by recrystallization from hot water (~1 : 10 w/v) provided tartrate salt 
(7.74 g, 23%) as a white solid. 
   
(S,S)-N,N’-bis(3,5-di-tert-butyl-salicylidene)-1,2-cyclohexanediamine136 
To a suspension of 2,4-di-tert-butylphenol (4.12 g, 20.0 mmol), MgCl2 (3.81 g, 40.0 
mmol) and paraformaldehyde (1.32 g, 44.0 mmol) in THF (80 mL) at RT was added Et3N 
(5.60 mL, 40.2 mmol) and the mixture heated at reflux. After 2 h, a solution of tartrate salt 
(2.65 g, 10.0 mmol) and K2CO3 (3.12 g, 22.5 mmol) in EtOH/H2O (30 mL, 1 : 1) was 
added dropwise to the reaction mixture at RT and the reaction mixture was heated at 80 °C. 
After 3 h, the reaction mixture was cooled and quenched by the addition of H2O (100 mL) 
and the organics were extracted with CH2Cl2 (3 × 100 mL). The combined organic extracts 
were washed with brine (100 mL), dried (MgSO4) and concentrated in vacuo. Purification 
by recrystallization from acetone provided the salicylidene ligand (2.40 g, 44%) as a 
yellow solid. 
 
[(S,S)-N,N’-bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediaminato] cobalt (II)47a  
A solution of cobalt (II) acetate tetrahydrate (1.10 g, 4.40 mmol) in MeOH (20 mL) at RT 
was added to a solution of salicylidene ligand (2.00 g, 3.67 mmol) in CH2Cl2 (20 mL) via 
cannula. After 15 min, the reaction mixture was cooled at 0 °C for 30 mins. The resultant 
solid was collected by filtration and washed with cold MeOH (2 × 50 mL). The solid was 
dried in a vacuum oven at 40 °C for 5 h to provide (S,S)-salen catalyst 86 (1.65 g, 75%) as 
a red solid.  
 
1-Hydroxy-1,2-benziodoxol-3(1H)-one-1-oxide (IBX)137  
To a solution of oxone (114 g, 185 mmol) in deionized H2O (455 mL) at RT was added 2-
iodobenzoic acid (35.0 g, 141 mmol) and the reaction mixture heated at 70 °C with 
mechanical stirring. After 3 h, the reaction slurry was cooled to 5 °C. After 1.5 h, the 
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mixture was filtered, washed with H2O (6 × 60 mL) and acetone (2 × 70 mL) to provide 
IBX (34.8 g, 87%) as a white crystalline solid and was dried at RT for 16 h.  
 
1,1,1-Triacetoxy-1,1-dihydro-1,2-benziodoxol-3(1H)-one (Dess-Martin Periodinane)138  
To a solution of TsOHH2O (173 mg, 909 µmol) and acetic anhydride (138 mL) at RT was 
added IBX (34.6 g, 123 mmol) and the reaction mixture was equipped with a CaH2 drying 
tube and heated at 80 °C. After 2 h, the reaction mixture was cooled in an ice-water bath 
and the resultant suspension was filtered and washed with Et2O (5 × 30 mL) to provide 
DMP (42.0 g, 80%) as a white crystalline solid and stored in a freezer. Before each use, the 
solid was washed with Et2O (5 × 30 mL) and dried under vacuum for 16 h. 
 
Homoallyl magnesium bromide (151)65 
 
BrMg  
 
To activated magensium turnings (4.68 g, 193 mmol) in Et2O (20 mL) at RT was added 
dropwise 4-bromo-1-butene (14.7 mL, 145 mmol) in THF (40 mL). The reaction mixture 
was refluxed for 2 h and the freshly prepared solution (~2.4 M solution) was used directly 
in the preparation of 152 and 282. 
 
Dimethyl diazo-2-oxopropylphosphonate (Ohira-Bestmann reagent 260)139  
 
Me
O
P
N2
OMe
O
OMe
 
To a solution of dimethyl-2-oxopropylphosphonate (7.00 g, 42.0 mmol) in toluene (40 mL) 
at 0 °C was added NaH (1.50 g, 60% dispersion in oil, 62.0 mmol), followed by the slow 
addition of 4-acetamidobenzene-sulfonyl azide (9.37 g, 39.0 mmol) in THF (10 mL) with 
warming to RT. After 16 h, the reaction mixture was diluted with Pet. Ether (30 mL), 
filtered over Celite and washed with Et2O (40 mL). The solvent was removed in vacuo and 
the oil purified by flash column chromatography (70% EtOAc/Hexane) to afford dimethyl 
diazo-2-oxopropylphosphonate 260 (5.60 g, 69%) as a yellow oil. 
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t-Butylhypochlorite122  
t-BuOCl 
 
To a vigorously stirred solution of NaOCl (28 mL, ~1.08 M solution, 29.9 mmol) at 0 °C 
was added in one portion a mixture of t-BuOH (2 mL, 20.9 mmol) and AcOH (1.3 mL, 
23.2 mmol). After 12 min, the organic layer was separated, washed with brine (5 mL) and 
dried (CaCl2). Filtration over glass wool afforded pure t-BuOCl as a cloudy yellow 
solution, which was used without characterization. The solution could be stored in a fridge 
over CaCl2 in an amber bottle for 3 months.  
 
Trimethyl(prop-2-yn-1-yloxy)silane (328)140 
 
OTMS  
To a solution of propargyl alcohol 327 (5.00 g, 89.2 mmol) in pentane (60 mL) at 0 °C was 
added Et3N (12.0 mL, 86.5 mmol) followed by the addition of TMSCl (9.40 g, 86.5 
mmol). After 2 h at 0 °C, the reaction mixture was warmed to RT for 20 mins and the 
precipitate filtered over celite. The precipitate was washed with pentane (30 mL) and 
concentrated in vacuo to provide 328 (4.79 g, 42%). The crude was used without further 
purification.  
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8.3 Experimental for Chapter 2 
(S)-methyloxirane (85)  
O
36
 
To a solution of (S,S)-salen catalyst 86 (313 mg, 0.52 mmol) in toluene (6 mL) was added 
acetic acid (311 µL, 5.43 mmol). The solution was left for 30 min, open to air at RT. The 
resultant brown suspension was concentrated in vacuo. To the residue was added (±)-
propylene oxide 88 (18.0 mL, 257 mmol), the solution was cooled to 0 °C and H2O (2.56 
mL, 140 mmol) was added dropwise over 5 min. The solution was allowed to warm to RT 
and left for 16 h. Purification by vacuum transfer (36 °C, atm pressure) afforded (S)-
epoxide 85 (4.81 g, 32%) as a colourless liquid. 
€ 
[α]D20-18.3 (c 5.83, CCl4), lit 
€ 
[α]D20  -18.6 (c 5.83, CCl4)141; 1H NMR (300 MHz, CDCl3) δ 
3.02-2.97 (1H, m, H36), 2.76 (1H, dd, J = 4.7, 4.1 Hz, H35a), 2.44 (1H, dd, J = 5.1, 2.7 Hz, 
H35b), 1.32 (3H, d, J = 5.2 Hz, H37). 
  
(5S)-5-Methyl-3-(phenylsulfanyl)-dihydrofuran-2-one (90)45  
 
O
O
PhS
36
 
 
To a solution of diisopropylamine (6.77 mL, 48.0 mmol) in THF (70 mL) at  0 °C was 
added n-BuLi (41.4 mL, 1.16 M solution in hexane, 48.0 mmol). After 15 min, the solution 
was cooled to -78 °C and (phenylthio)acetic acid 89 (3.63 g, 22.0 mmol) in THF (17 mL) 
was added. After 1 h at -78 °C, (S)-propylene oxide 85 (1.81 mL, 26.0 mmol) was added in 
one portion and the solution was warmed to RT and stirred for 16 h. The solution was 
diluted with Et2O (25 mL) and 6 M HCl (30 mL) was added. The organics were extracted 
with Et2O (3 × 100 mL) and the combined organic extracts were dried (MgSO4), filtered 
and concentrated in vacuo. The resultant oil was dissolved in toluene (45 mL) and p-TsOH 
(88.0 mg, 4.62 mmol) was added. After 16 h, MgSO4 was added and the suspension stirred 
for 15 min, then filtered and concentrated in vacuo. Purification by flash column 
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chromatography (10% EtOAc/Pet. Ether) afforded a 1.6 : 1 diastereomeric mixture of 
lactone 90 (3.54 g, 78%) as a yellow oil.  
Rf 0.36 and 0.45 (20% EtOAc/Pet. Ether); 1H NMR (300 MHz, CDCl3) δ 7.58-7.52 (4H, 
m, ArH), 7.40-7.29 (6H, m, ArH), 4.60-4.48 (2H, m, H36 major + H36 minor), 3.97 (1H, dd, J = 
10.7, 9.0 Hz, H2 major), 3.91 (1H, dd, J = 8.5, 3.7 Hz, H2 minor), 2.74 (1H, ddd, J = 13.2, 9.0, 
6.0 Hz, H35a major), 2.38 (1H, ddd, J = 13.7, 6.3, 3.7 Hz, H35a minor), 2.26 (1H, dt, J = 13.7, 
8.3 Hz, H35b minor), 1.85 (1H, ddd, J = 13.2, 10.7, 9.1 Hz, H35b major), 1.37 (3H, d, J = 6.3 Hz, 
H37 minor), 1.34 (3H, d, J = 6.2 Hz, H37 major). 
 
6-(benzyloxy)hexan-1-ol (93)142  
 
BnO
OH
1
6
 
 
To a suspension of NaH (1.62 g, 60% dispersion in mineral oil, 67.7 mmol) in DMF (45 
mL) at 0 °C was added 1,6-hexanediol 92 (5.00 g, 42.3 mmol). After 30 min, benzyl 
bromide (7.24 g, 42.3 mmol) was added dropwise and left to warm to RT over 16 h. The 
solution was quenched by slow addition of MeOH (3 mL), followed by CH2Cl2 (50 mL) 
and H2O (50 mL). The organics were extracted with CH2Cl2 (4 × 50 mL) and the combined 
organic extracts were washed with brine (120 mL), dried (MgSO4), filtered and 
concentrated in vacuo. Purification by flash column chromatography (10% EtOAc/Pet. 
Ether) provided mono protected alcohol 93 (3.92 g, 44%) as a colourless oil.  
Rf 0.17 (20% EtOAc/Pet. Ether); 1H NMR (300 MHz, CDCl3) δ 7.39-7.26 (5H, m, ArH), 
4.51 (2H, s, OCH2Ar), 3.66-3.60 (2H, m, H1), 3.47 (2H, t, J = 6.5 Hz, H6), 1.69-1.54 (4H, 
m, H2 + H5), 1.47-1.35 (4H, m, H3-4); 13C NMR (75 MHz, CDCl3) δ 138.7, 128.4, 127.6, 
127.5, 72.9, 70.3, 63.0, 32.7, 29.7, 26.0, 25.6. 
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6-(benzyloxy)-1-iodohexane (91)143  
BnO
I
6
1
 
To a solution of alcohol 93 (1.52 g, 7.30 mmol) in MeCN/Et2O (45 mL, 1 : 2) at 0 °C was 
added imidazole (550 mg, 8.03 mmol), PPh3 (2.11 g, 8.03 mmol) and iodine (2.04 g, 3.15 
mmol) successively. After 30 min, the reaction mixture was quenched by the addition of 
Na2S2O3 (15 mL, 10 wt% aqueous solution). The resultant mixture was left to stir for 20 
min and the organics were extracted with Et2O (4 × 50 mL). The combined organic 
extracts were dried (MgSO4), filtered and concentrated in vacuo. Purification by flash 
column chromatography (10% EtOAc/Pet. Ether) provided iodide 91 as a yellow oil (2.05 
g, 88%). 
Rf 0.97 (25% EtOAc/Pet. Ether); 1H NMR (300 MHz, CDCl3) δ 7.38-7.29 (5H, m, ArH), 
4.51 (2H, s, OCH2Ar), 3.47 (2H, t, J = 6.5 Hz, H1), 3.19 (2H, t, J = 7.0 Hz, H6), 1.89-1.79 
(2H, m, H5), 1.68-1.59 (2H, m, H2), 1.46-1.39 (4H, m, H3-4). 
 
(5S)-3-(6-(benzyloxy)hexyl)-5-methyl-3-(phenylsulfanyl)-dihydrofuran-2-one (94) 
 
O
O
BnO PhS
368 1
 
 
To a solution of diisopropylamine (727 µL, 5.19 mmol) in THF (12 mL) was added n-BuLi 
(5.95 mL, 1.0 M solution in hexane, 5.95 mmol) at 0 °C for 15 min. The solution was 
cooled to -78 °C and a solution of lactone 90 (1.00 g, 4.76 mmol) in THF (1.7 mL) was 
added dropwise. After 30 min, a solution of iodide 91 (1.67 g, 5.24 mmol) in DMPU (3.40 
mL, 1.55 mmol/mL of 91) was added in one portion and the reaction was allowed to warm 
to RT overnight. The solution was quenched by addition of 0.5 M HCl (75 mL) and the 
organics extracted with Et2O (4 × 50 mL). The combined organic extracts were dried 
(MgSO4), filtered and concentrated in vacuo. Purification by flash column chromatography 
(5→10% EtOAc/Pet. Ether) provided alkylated lactone 94 (1.42 g, 75%), as a 3 : 1 mixture 
of diastereomers as a yellow oil.    
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Rf 0.55 and 0.61 (15% EtOAc/Pet. Ether); IR (NaCl) 3062, 2931, 2856, 1765, 1188, 1105 
cm-1; 1H NMR (300 MHz, CDCl3) δ 7.58-7.51 (2H, m, ArH), 7.42-7.30 (8H, m, ArH), 
4.67-4.43 (3H, m, H36 + OCH2Ar), 3.46 (2H, t, J = 6.6 Hz, H8), 2.50 (1H, dd, J = 13.9, 7.6 
Hz, H35a), 1.96 (1H, dd, J = 14.0, 6.9 Hz, H35b), 1.81-1.73 (2H, m, H6), 1.64-1.57 (4H, m, 
H4 + H7), 1.41-1.33 (4H, m, H3 + H5), 1.19 (3H, d, J = 6.3 Hz, H37); 13C NMR (75 MHz, 
CDCl3) δ 177.1, 138.6, 136.8, 130.4, 129.7, 129.0, 128.3, 127.6, 127.5, 73.2, 72.9, 70.2, 
56.2, 40.1, 36.4, 29.6, 29.3, 25.9, 24.6, 21.5; HRMS (ES+) Calc for C24H34O3NS 
[M+NH4]+ 416.2254, found 416.2255. 
 
(5S)-3-(6-(benzyloxy)hexyl)-5-methyl-2,5-dihydrofuran-2-one (95) 
 
O
O
361
BnO
8
 
 
To a solution of lactone 94 (1.28 g, 3.21 mmol) in CH2Cl2 (10 mL) at 0 °C was added m-
CPBA (780 mg, 4.50 mmol). After 30 min, the reaction mixture was quenched by the 
addition of saturated aqueous NaHCO3 (10 mL) and the organics were extracted with 
CH2Cl2 (3 × 10 mL). The combined organic extracts were dried (MgSO4), filtered and 
concentrated. The residue was dissolved in toluene (10 mL) and the solution was heated at 
100 °C for 3 h, after which the reaction was cooled to room temperature and concentrated 
in vacuo. Purification by flash column chromatography (3→10% EtOAc/Pet. Ether) 
provided butenolide 95 (825 mg, 89%) as a colourless oil. 
Rf 0.22 (15% EtOAc/Pet. Ether); 
€ 
[α]D20  +24.1 (c 1.1, CHCl3); IR (NaCl) 2926, 2854, 1748 
cm-1; 1H NMR (300 MHz, CDCl3) δ 7.37-7.31 (5H, m, ArH), 6.98 (1H, app q, J = 1.6 Hz, 
H35), 5.04-4.95 (1H, m, H36), 4.51 (2H, s, OCH2Ar), 3.47 (2H, t, J = 6.5 Hz, H8), 2.30-2.24 
(2H, m, H3), 1.68-1.52 (4H, m, H4 + H7), 1.47-1.36 (7H, m, H5-6 + H37); 13C NMR (75 
MHz, CDCl3) δ 173.9, 148.9, 138.6, 134.2, 128.3, 127.6, 127.5, 72.9, 70.3, 60.4, 29.6, 
29.0, 27.3, 25.9, 25.1, 19.2; HRMS (ES+) Calc for C18H28O3N [M+NH4]+ 306.2064, found 
306.2066. 
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(5S)- 3-(6-hydroxyhexyl)-5-methyl-2,5-dihydrofuran-2-one (81) 
 
O
O 1
HO
368
 
 
To a solution of benzyl ether 95 (48.0 mg, 0.17 mmol) in CH2Cl2 (2 mL) at -15 °C was 
added BCl3·DMS (170 µL, 2.0 M solution in CH2Cl2, 0.34 mmol) dropwise. After 4 h, the 
reaction was quenched by the addition of saturated aqueous NaHCO3 (5 mL) and the 
organics were extracted with Et2O (3 × 5 mL). The combined organic extracts were dried 
(MgSO4), filtered and concentrated in vacuo. Purification by flash column chromatography 
(50% EtOAc/Pet. Ether) provided alcohol 81 (30.0 mg, 91%), as a colourless oil.  
Rf 0.10 (50% EtOAc/Pet. Ether); 
€ 
[α]D20  +35.5 (c 1.03, CHCl3); IR  (NaCl) 3392, 2931, 
2859, 1733 cm-1; 1H NMR (300 MHz, CDCl3) δ 6.99 (1H, m, H35), 5.03-4.96 (1H, m, 
H36), 3.64 (2H, t, J = 6.6 Hz, H8), 2.27 (2H, m, H3), 1.62-1.53 (4H, m, H4 + H7), 1.42-1.36 
(7H, m, H5-6 + H37); 13C NMR (125 MHz, CDCl3) δ 173.9, 149.0, 134.0, 77.4, 62.7, 32.5, 
28.8, 27.3, 25.3, 25.0, 19.1; HRMS (ES+) Calc for C11H19O3 [M+H]+ 199.1329, found 
199.1328. 
 
(5S)- 3-(6-iodohexyl)-5-methyl-2,5-dihydrofuran-2-one (97) 
 
O
O 1
I
368
 
 
To a solution of alcohol 81 (110 mg, 0.56 mmol) in MeCN/Et2O (3 mL, 1 : 2) at 0 °C was 
added imidazole (40.0 mg, 0.59 mmol), PPh3 (160 mg, 0.61 mmol) and iodine (150 mg, 
0.59 mmol). After 30 min, the reaction mixture was quenched by addition of saturated 
aqueous Na2S2O3 (5 mL, 10 wt% aqueous solution) and the resultant biphasic mixture was 
left for 20 min. The organics were extracted with Et2O (3 × 5 mL) and the combined 
organic layers were dried (MgSO4), filtered and concentrated in vacuo. Purification by 
flash column chromatography (50% EtOAc/Pet. Ether) provided iodide 97 (120 mg, 73%) 
as a yellow oil. 
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Rf 0.86 (50% EtOAc/Pet. Ether); 1H NMR (400 MHz, CDCl3) δ 7.01 (1H, m, H35), 5.04-
4.98 (1H, m, H36), 3.20 (2H, t, J = 7.0 Hz, H8), 2.31-2.27 (2H, m, H3), 1.87-1.80 (2H, m, 
H7), 1.62-1.56 (2H, m, H4), 1.48-1.34 (7H, m, H5-6 + H37). 
 
(S)-5-methylfuran-2(5H)-one phosphonium salt (96)  
 
O
O 1
IPh3P
8 36
 
 
To a solution of iodide 97 (120 mg, 0.39 mmol) in MeCN/MeOH (22 mL, 9 : 1) was added 
iPr2NEt (95.6 µL, 0.55 mmol), NaI (880 mg, 5.89 mmol) and PPh3 (4.12 g, 15.7 mmol) and 
the mixture was refluxed for 16 h. The solvent was removed under reduced pressure and 
CH2Cl2 (20 mL) was added. The resultant suspension was filtered over Celite and the 
filtrate was concentrated in vacuo. Purification by flash column chromatography (3% 
MeOH/CH2Cl2) and removal of excess water was carried out using a speed vacuum to 
provide phosphonium salt 96 (64.0 mg, 25%) as a colourless solid.  
Rf 0.41 (5% MeOH/CH2Cl2); 
€ 
[α]D20+2.45 (c 0.29, CHCl3); IR (NaCl) 2930, 2860, 1747, 
1438 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.87-7.79 (5H, m, ArH), 7.74-7.65 (5H, m, 
ArH), 7.36-7.29 (5H, m, ArH), 7.22-7.21 (1H, m, H35), 5.05-5.00 (1H, m, H36), 3.80-3.73 
(2H, m, H8), 2.27-2.23 (2H, m, H3), 1.78-1.61 (4H, m, H6-7), 1.56-1.49 (2H, m, H4), 1.44-
1.34 (5H, m, H5 + H37); HRMS (ES+) Calc for C29H32O2P [M-I]+ 443.2134, found 
443.2131. 
 
tert-butyldimethyl(oxiran-2-ylmethoxy)silane (99)144 
 
TBSO
O19  
 
To a solution of glycidol 98 (19.8 g, 267 mmol) in CH2Cl2 (250 mL) at RT was added 
imidazole (13.7 g, 201 mmol) and TBSCl (20.2 g, 134 mmol). After 16 h, the reaction 
mixture was quenched with saturated aqueous NH4Cl (100 mL) and the organics were 
extracted with CH2Cl2 (3 x 100 mL). The combined organic extracts were washed with 
brine (100 mL), dried (MgSO4) and concentrated in vacuo. Purification by flash column 
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chromatography (6% EtOAc/Hexane) provided TBS glycidol 99 (21.2 g, 84 %), as a 
colourless oil. 
Rf 0.59 (10% EtOAc/Pet. Ether); 1H NMR (300 MHz, CDCl3) δ 3.84 (1H, dd, J = 11.9, 
3.2 Hz, H20a), 3.65 (1H, dd, J = 11.9, 4.8 Hz, H20b), 3.07 (1H, dddd, J = 4.8, 4.1, 3.2, 2.7 
Hz, H19), 2.78 (1H, dd, J = 5.2, 4.1 Hz, H18a), 2.62 (1H, dd, J = 5.2, 2.7 Hz, H18b), 0.89 
(9H, s, SiC(CH3)3), 0.07 (3H, s, SiCH3), 0.06 (3H, s, SiCH3). 
 
tert-butyldimethyl[(2S)-oxiran-2-ylmethoxy]silane (100)47a  
 
TBSO
O19  
 
To a solution of (±)-TBS glycidol 99 (21.2 g, 113 mmol) and (R,R)-Co(II) salen catalyst 87 
(348 mg, 0.56 mmol) in THF (1.8 mL) was added a catalytic amount of AcOH (129 µL, 
2.25 mmol). The reaction mixture was stirred at RT for 30 min, cooled to 0 °C and H2O 
(1.12 mL, 62.2 mmol) was added. The reaction mixture was stirred for 16 h at RT. The 
solvent was removed under reduced pressure. Purification by Kugelrohr distillation (140 
°C, 1 mbar) provided (S)-TBS glycidol 100 (8.36 g, 39%) as a colourless oil. 
Rf 0.59 (10% EtOAc/Pet. Ether); 
€ 
[α]D20  +9.0 (c 3.1, C6H6), lit 
€ 
[α]D20  +11.0 (c 3.9, C6H6); 1H 
NMR (300 MHz, CDCl3) δ 3.84 (1H, dd, J = 11.9, 3.2 Hz, H20a), 3.65 (1H, dd, J = 11.9, 
4.8 Hz, H20b), 3.07 (1H, dddd, J = 4.8, 4.1, 3.2, 2.7 Hz, H19), 2.78 (1H, dd, J = 5.2, 4.1 Hz, 
H18a), 2.62 (1H, dd, J = 5.2, 2.7 Hz, H18b), 0.89 (9H, s, SiC(CH3)3), 0.07 (3H, s, SiCH3), 
0.06 (3H, s, SiCH3). 
 
1-(tert-butyldimethylsilyloxy)-hex-5-en-2-ol (101)51,65 
 
 
TBSO
OH
19
16
 
 
To a solution of (S)-TBS-glycidol ether 100 (8.36 g, 44.4 mmol) and copper iodide (845 
mg, 4.44 mmol) in THF (270 mL) at -40 °C was added allylmagnesium bromide (66.5 mL, 
1.0 M solution in Et2O, 66.5 mmol). The resultant black reaction mixture was stirred at this 
temperature for 30 min before being allowed to warm to RT over a period of 2 h. The 
reaction mixture was quenched with saturated aqueous NH4Cl (100 mL) and the organics 
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were extracted with Et2O (3 x 50 mL). The combined organic extracts were dried 
(Na2SO4), filtered and concentrated in vacuo. Purification by flash column 
chromatography (10% EtOAc/Hexane) provided alcohol 101 (9.92 g, 97%), as a colourless 
oil. 
Rf 0.77 (20% EtOAc/Hexane); 1H NMR (300 MHz, CDCl3) δ 5.83 (1H, dddd, J = 16.9, 
13.2, 10.3, 6.6 Hz, H16), 5.04 (1H, app ddt, J = 17.1, 5.2, 1.7 Hz, CHtrans), 4.96 (1H, app 
ddt, J = 10.2, 5.1, 1.7 Hz, CHcis), 3.65 (2H, m, H19 + H20a), 3.40 (1H, m, H20b), 2.31-2.06 
(2H, m, H17), 1.57-1.42 (2H, m, H18), 0.90 (9H, s, SiC(CH3)3), 0.07 (6H, s, 2 x SiCH3). 
 
5,6-(bis-tert-butyldimethylsilyloxy)-hex-1-ene (102) 51,65 
 
 
TBSO
OTBS
19 16
 
 
To a stirred solution of alcohol 101 (6.16 g, 26.7 mmol) in CH2Cl2 (100 mL) were added 
imidazole (3.64 g, 53.5 mmol) and DMAP (620 mg, 5.08 mmol), followed by TBSCl (6.05 
g, 40.1 mmol). The resultant mixture was stirred for 16 h at RT. The reaction mixture was 
then quenched with saturated aqueous NH4Cl (100 mL) and the organics were extracted 
with CH2Cl2 (3 x 50 mL). The combined organic extracts were washed with brine (100 
mL), dried (Na2SO4) and concentrated in vacuo. Purification by flash column 
chromatography (1% EtOAc/Hexane) provided bis-TBS ether 102 (7.00 g, 62%), as a 
colourless oil. 
Rf  0.45 (10% EtOAc/Pet.Ether); 1H NMR (300 MHz, CDCl3) δ 5.83 (1H, dddd, J = 17.0, 
13.2, 10.2, 6.5 Hz, H16), 5.01 (1H, app ddt, J = 17.0, 5.3, 1.6 Hz, CHtrans), 4.94 (1H, ddt, J 
= 10.1, 4.6, 1.2 Hz, CHcis), 3.71-3.62 (1H, m, H19), 3.52 (1H, dd, J = 9.8, 5.4 Hz, H20a), 
3.40 (1H, dd, J = 9.8, 6.5 Hz, H20b), 2.23-1.98 (2H, m, H17), 1.72-1.58 (1H, m, H18a), 1.53-
1.39 (1H, m, H18b), 0.88 (9H, s, SiC(CH3)3), 0.88 (9H, s, SiC(CH3)3), -0.04 (3H, s, SiCH3), 
-0.04 (3H, s, SiCH3), -0.05 (6H, s, 2 x SiCH3).  
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7-(benzyloxy)-heptan-1-ol (106)145 
 
OHBnO
9 15  
 
To a suspension of NaH (2.90 g, 60% dispersion in mineral oil, 121 mmol) in DMF/THF 
(150 mL, 5 : 1) at 0 °C was added 1,7-heptanediol 105 (15.0 g, 114 mmol) and TBAI (1.39 
g, 3.76 mmol). After 30 min, benzyl bromide (12.9 g, 76.0 mmol) was added dropwise and 
left to warm to RT over 16 h. The solution was quenched by slow addition of MeOH (3 
mL), followed H2O (100 mL). The organics were extracted with CH2Cl2 (5 × 50 mL) and 
the combined organic extracts were washed with brine (120 mL), dried (Na2SO4), filtered 
and concentrated in vacuo. Purification by flash column chromatography (10% 
EtOAc/Hexane) provided alcohol 106 (14.4 g, 57%) as a colourless oil.  
Rf 0.50 (20% EtOAc/Hexane); 1H NMR (400 MHz, CDCl3) δ 7.39-7.32 (4H, m, ArH), 
7.31-7.27 (1H, m, ArH), 4.51 (2H, s, OCH2Ar), 3.68-3.61 (2H, m, H15), 3.47 (2H, t, J = 6.6 
Hz, H9), 1.68-1.52 (4H, m, H10 + H14), 1.45-1.30 (6H, m, H11-13), 1.25 (1H, br s, OH). 
 
[7-(benzyloxy)heptyl]sulfonyl-1-phenyl-1H-1,2,3,4-tetrazole (104) 51,65 
 
O2
S
N N
N
N
Ph
BnO
9 15
 
 
To a solution of alcohol 106 (9.01 g, 40.5 mmol) in THF (120 mL) at 0 ºC was added 1-
phenyl-1H-tetrazole-5-thiol (9.39 g, 52.7 mmol), PPh3 (13.8 g, 52.7 mmol) followed by 
drop-wise addition of DIAD (10.4 mL, 52.7 mmol) and the reaction mixture warmed to 
RT. After 4 h, the reaction mixture was quenched by addition of saturated aqueous NH4Cl 
(75 mL). The organics were extracted with EtOAc (3 × 30 mL), dried (Na2SO4) and 
concentrated in vacuo. The crude reaction mixture was partially purified by filtration over 
a pad of silica (10% EtOAc/Hexane) to provide crude sulfide, which was used directly in 
the next step without the need for further purification. 
A mixture of ammonium molybdate (5.83 g, 4.71 mmol) and hydrogen peroxide (53.0 mL, 
30% v/v solution in H2O, 468 mmol) was stirred at 0 ºC for 15 min. The resulting bright 
yellow solution was added drop-wise at 0 ºC to a solution of crude sulfide in MeOH (120 
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mL). After 20 h, the reaction mixture was diluted with MeOH (40 mL) and filtered. The 
filtrate was partitioned between H2O (30 mL) and CH2Cl2 (70 mL). The organics were 
extracted with CH2Cl2 (3 × 50 mL), dried (Na2SO4), filtered and concentrated in vacuo. 
Purification by flash column chromatography (5% EtOAc/Hexane) provided sulfone 104 
(8.16 g, 49%) as a colourless oil. 
Rf  0.25 (25% EtOAc/Pet.Ether); 1H NMR (300 MHz, CDCl3) δ  7.65-7.58 (2H, m, ArH), 
7.57-7.52 (4H, m, ArH), 7.29-7.23 (3H, m, ArH), 7.23-7.19 (1H, m, ArH), 4.50 (2H, s, 
OCH2Ar), 3.77-3.69 (2H, m, H15), 3.46 (2H, t, J = 6.3 Hz, H9), 2.02-1.88 (2H, m, H10), 
1.67-1.60 (2H, m, H14), 1.54-1.45 (2H, m, H11), 1.43-1.32 (4H, m, H12-13). 
 
(2S,5E)-12-(benzyloxy)-dodec-5-ene-1,2-diol (142) 51,65 
 
HO
OBn
OH
19
9
 
 
A solution of alkene 102 (4.74 g, 11.1 mmol) and Na2CO3 (3.30 g, 31.2 mmol) in CH2Cl2 
(400 mL) was cooled to -78 ºC and O3 was bubbled through the mixture until a blue colour 
persisted. To the reaction mixture was added PPh3 (5.83 g, 22.3 mmol) and the mixture 
was allowed to warm to RT. After 3 h, the reaction mixture was filtered, concentrated in 
vacuo and hexane (30 mL) was added. The solution was cooled (0 ºC) and a white 
precipitate formed. The mixture was filtered, washed with cold hexane (30 mL) and the 
filtrate concentrated in vacuo. This procedure was repeated until no more precipitate 
formed. The crude aldehyde 103 was used directly in the next step, without the need for 
further purification. 
To a solution of sulfone 104 (5.04 g, 12.2 mmol) in DME (40 mL) at -78 ºC was added 
NaHMDS (9.40 mL, 2.0 M solution in THF, 18.7 mmol). After 5 min, a solution of crude 
aldehyde 103 in DME (5 mL) was added drop-wise via cannula and the reaction mixture 
was allowed to warm to -50 ºC. After 1 h, saturated aqueous NH4Cl (30 mL) was added 
and the reaction mixture was warmed to RT. The organics were extracted with EtOAc (3 × 
20 mL) and the combined organic extracts were washed with brine (50 mL), dried 
(Na2SO4), filtered and concentrated in vacuo. The crude mixture was partially purified by 
filtration over a pad of silica and the alkene 141 was used directly in the next step, without 
the need for further purification.  
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To a solution of crude alkene 141 in MeOH/CH2Cl2 (70 mL, 1 : 1) at 0 ºC was added (±)-
CSA (520 mg, 2.24 mmol). After 2 h, the reaction mixture was quenched by addition of 
saturated aqueous NaHCO3 (40 mL). The organics were extracted with CH2Cl2 (3 × 30 
mL) and the combined organic extracts were washed with brine (50 mL), dried (Na2SO4), 
filtered and concentrated in vacuo. Purification by flash column chromatography (40→60% 
EtOAc/Hexane) provided diol 142 (2.30 g, 68%) as a colourless oil. 
Rf 0.2 (25% EtOAc/Hexane); 1H NMR (300 MHz, CDCl3) δ 7.35-7.32 (4H, m, ArH), 
7.30-7.26 (1H, m, ArH), 5.50-5.33 (2H, m, H15-16), 4.49 (2H, s, OCH2Ar), 3.76-3.66 (1H, 
m, H19), 3.62 (1H, dd, J = 11.0, 3.0 Hz, H20a), 3.49-3.38 (3H, m, H20b + H9), 2.36 (2H, app 
broad s, 2 x OH), 2.22-2.00 (2H, m, H17), 1.99 (2H, dd, J = 11.9, 6.4 Hz, H14), 1.66-1.54 
(2H, m, H18), 1.53-1.43 (2H, m, H13), 1.40-1.28 (6H, m, H10-12). 
 
(2S)-2-[(3E)-10-(benzyloxy)dec-3-en-1-yl]oxirane (143) 51,65 
 
 
OBn
O 919  
 
To a suspension of NaH (578 mg, 60 wt% dispersion in mineral oil, 15.0 mmol) in THF 
(60 mL) at 0 ºC was added a solution of diol 142 (2.30 g, 7.51 mmol) in THF (5 mL). The 
reaction mixture was allowed to warm to RT over 1 h before being re-cooled to 0 ºC. A 
solution of N-(2,4,6-triisopropyl benzenesulfonyl)imidazole (2.51 g, 7.51 mmol) in THF (5 
mL) was carefully added via cannula and the reaction mixture was allowed to warm to RT. 
After 2 h, the reaction mixture was quenched with MeOH (5 mL), followed by saturated 
aqueous NH4Cl (40 mL). The organics were separated with Et2O (3 × 20 mL) and the 
combined organic extracts were washed with brine (50 mL), dried (Na2SO4), filtered and 
concentrated in vacuo. Purification by flash column chromatography (5→10% 
EtOAc/Hexane) provided epoxide 143 (1.94 g, 90%) as a colourless oil. 
Rf  0.5 (25% EtOAc/Pet. Ether); 1H NMR (300 MHz, CDCl3) δ 7.35-7.32 (4H, m, ArH), 
7.30-7.26 (1H, m, ArH), 5.52-5.34 (2H, m, H15-16), 4.50 (2H, s, OCH2Ar), 3.46 (2H, t,  J = 
6.6 Hz, H9), 2.96-2.88 (1H, m, H19), 2.74 (1H, dd, J = 5.0, 4.0 Hz, H20a),  2.47 (1H, dd, J = 
5.0, 2.7 Hz, H20b),  2.24-2.09 (2H, m, H18), 2.02-1.92 (2H, m, H17), 1.66-1.54  (4H, m, H13-
14),  1.41-1.24 (6H, m, H10-12). 
 
  Experimental
   
 156 
(2R,5R)-5-[7-(benzyloxy)-(1R)-hydroxyheptyl]-2-(hydroxymethyl)tetrahydrofuran 
(146) 51,65 
 
O
OH
OBn
9
20HO
 
 
To a solution of epoxide 143 (2.99 g, 10.4 mmol) in t-BuOH/H2O (100 mL, 1 : 1) at 0 ºC 
was added AD-mix-β (15.6 g, 1.50 g/mmol of 143) and methane sulfonamide (1.97 g, 20.8 
mmol) and the reaction mixture was allowed to warm to RT. After 16 h, the reaction 
mixture was quenched by the addition of sodium thiosulfate (31.0 g, 125 mmol) and stirred 
for 1 h. After dilution with EtOAc (70 mL) and water (40 mL), the organics were extracted 
with EtOAc (3 × 30 mL) and the combined organic extracts were washed with brine (40 
mL), dried (Na2SO4), filtered and concentrated in vacuo. The resulting crude diol epoxide 
was dissolved in MeOH (60 mL) at 0 ºC and K2CO3 (10.0 g, 72.4 mmol) was added. After 
4 h, EtOAc (50 mL) and NH4Cl (25 mL) were added. The organics were extracted with 
EtOAc (3 × 30 mL) and the combined organic extracts were dried (Na2SO4), filtered and 
concentrated in vacuo. Purification by flash column chromatography (40→50% 
EtOAc/Hexane) gave tetrahydrofuran diol 146 (2.76 g, 82%), as a colourless viscous oil. 
Rf 0.2 (30% EtOAc/Pet. Ether); 1H NMR (300 MHz, CDCl3) δ  7.36-7.32  (4H, m, ArH), 
7.31-7.27 (1H, m, ArH), 4.50 (2H, s, OCH2Ar), 4.17-4.02 (1H, m, H16), 3.87-3.72 (2H, m, 
H19 + H20a), 3.58-3.39 (4H, m, H9 + H15 + H20b), 2.36 (1H, app broad s, C15-OH), 2.13 (1H, 
app broad s, C20-OH), 2.00-1.91 (2H, m, H17), 1.87-1.70 (2H, m, H18), 1.69-1.59 (2H, m, 
H14), 1.54-1.43 (2H, m, H13), 1.42-1.31 (6H, m, H10-12). 
  
(2R,5R)-5-[7-(benzyloxy)-(1R)-(tert-butyldimethylsilyloxy)heptyl]-2-(tert 
butyldimethylsilyloxy) methyl)tetrahydrofuran (147) 51,65 
 
 
O
OTBS
OBn
9
20TBSO
 
 
To a solution of diol 146 (2.76 g, 8.56 mmol) in CH2Cl2 (50 mL) at -78 ºC was added 2,6-
lutidine (5.00 mL, 42.9 mmol) and TBSOTf (4.30 mL, 18.7 mmol). After 1.5 h, the 
reaction was quenched by addition of saturated aqueous NH4Cl (40 mL). The organics 
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were extracted with CH2Cl2 (3 × 20 mL) and the combined organic extracts were dried 
(Na2SO4), filtered and concentrated in vacuo. Purification by flash column 
chromatography (5% EtOAc/Hexane) provided bis-TBS ether 147 (4.52 g, 96%) as a 
colourless oil. 
Rf 0.4 (10% EtOAc/Hexane); 
€ 
[α]D20  +9.4 (c 0.18, CHCl3), lit 
€ 
[α]D20  +12.1 (c 1.9, CHCl3); 
1H NMR (300 MHz, CDCl3) δ 7.35-7.31 (4H, ArH), 7.31-7.26 (1H, m, ArH), 4.50 (2H, s, 
OCH2Ar), 4.10-4.03 (1H, m, H15), 3.99-3.92 (1H, m, H20a), 3.61 (2H, m, H16 + H20b), 3.52 
(1H, dd, J = 10.3, 4.6 Hz, H19), 3.45 (2H, t, J = 6.6 Hz, H9), 1.97-1.74 (2H, m,  H17a+ H18a), 
1.74-1.57 (4H, m, H14 + H17b + H18b), 1.45-1.20 (8H, m, H10-13), 0.88 (18H, s, 2 x 
Si(CH3)3), 0.05 (3H, s, SiCH3), 0.04 (3H, s, SiCH3), 0.04 (6H, s, 2 x SiCH3). 
 
(2R,5R)-5-[7-(benzyloxy)-(1R)-(tert-butyldimethylsilyloxy)heptyl]-2-(hydroxymethyl) 
tetrahydrofuran (148) 51,65 
 
 
O
OTBS
OBn
9
20HO
 
 
To a solution of bis-tert-butyldimethylsilyl ether 147 (395 mg, 0.72 mmol) in 
MeOH/CH2Cl2 (5 mL, 1 : 4) at 0 ºC was added (±)-CSA (16.7 mg, 71.8 µmol). After 1.5 h, 
the reaction was quenched by addition of saturated aqueous NaHCO3 (5 mL). The organics 
were extracted with CH2Cl2 (3 × 5 mL) and the combined organic extracts were dried 
(Na2SO4), filtered and concentrated in vacuo. Purification by flash column 
chromatography (5% EtOAc/Pet. Ether) provided alcohol 148 (199 mg, 63%) as a 
colourless oil. 
Rf 0.4 (25% EtOAc/Pet. Ether); 1H NMR (300 MHz, CDCl3) δ 7.35-7.31 (4H, m, ArH), 
7.31-7.26 (1H, m, ArH), 4.50 (2H, s, OCH2Ar), 4.13-4.10 (1H, m, H15), 3.99-3.92 (1H, m, 
H16), 3.75 (1H, dd, J = 11.2, 3.0 Hz, H19), 3.61-3.55 (1H, m, H20a), 3.49-3.42 (3H, m, H9 + 
H20b), 2.43 (1H, app broad s, OH), 1.96-1.78 (4H, m, H17-18), 1.69-1.53 (4H, m, H10 + H14), 
1.41-1.27 (6H, m, H11-13), 0.90 (9H, s, SiC(CH3)3), 0.07 (3H, s, SiCH3), 0.07 (3H, s, 
SiCH3). 
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(2R,5R)-5-[7-(benzyloxy)-(1R)-(tert-butyldimethylsilyloxy)heptyl]-2-oxo-
tetrahydrofuran (83) 51,65 
 
 
O
OTBS
OBn
9
20H
O
 
 
To a solution of alcohol 148 (101 mg, 0.23 mmol) in CH2Cl2 (3 mL) at 0 ºC was added 
NaHCO3 (97.0 mg, 1.16 mmol) followed by Dess-Martin periodinane (294 mg, 0.69 
mmol). The reaction mixture was stirred at 0 ºC for 30 min, followed by warming to RT 
over an additional 1 h. The reaction mixture was re-cooled to 0 ºC, prior to the addition of 
cold hexane (2 mL) and cold toluene (2 mL). The resultant white suspension was filtered 
through Celite and washed with excess hexanes (5 mL). The filtrate was concentrated in 
vacuo and purification by flash column chromatography (10% EtOAc/Hexane) provided 
aldehyde 83 (70.6 mg, 70%) as a colourless oil. 
Rf 0.32 (10% EtOAc/Pet. Ether); 1H NMR (400 MHz, CDCl3) δ 9.66 (1H, d, J = 1.9 Hz, 
H20), 7.37-7.25 (5H, m, ArH), 4.51 (2H, s, OCH2Ar), 4.35-4.27 (1H, m, H19), 4.10-4.02 
(1H, m, H16), 3.68-3.60 (1H, m, H15), 3.48 (2H, t, J = 6.6 Hz, H9), 2.23-2.09 (1H, m, H18a), 
2.02-1.85 (2H, m, H17a + H18b), 1.84-1.70 (1H, m, H17b), 1.69-1.49 (3H, m, H10 + H14a), 
1.48-1.21 (7H, m, H11-13 + H14b),  0.89 (9H, s, SiC(CH3)3), 0.08 (3H, s, SiCH3), 0.07 (3H, 
s, SiCH3). 
 
(2S)-2-hexyloxirane (150)47a  
 
O2834
 
 
To a solution of (±)-1,2-epoxyoctane 149 (15.0 g, 117 mmol) and (S,S)-Co(II) salen 
catalyst 86 (362 mg, 0.59 mmol) in THF (3 mL) at RT was added a catalytic amount of 
AcOH (134 µL, 2.34 mmol). After 30 min, the reaction mixture was cooled to 0 °C and 
H2O (1.16 mL, 64.3 mmol) was added. After 16 h, the solvent was removed under reduced 
pressure. Purification by Kugelrohr distillation (70 °C, 2 mbar) provided (S)-1,2-
epoxyoctane 150 (6.46 g, 43%) as a colourless oil. 
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Rf 0.86 (5% EtOAc/Pet. Ether); 
€ 
[α]D20 -8.8 (c 2.4, CHCl3), lit 
€ 
[α]D20  -8.9 (c 1.8, CHCl3)146; 
1H NMR (300 MHz, CDCl3) δ 2.88-2.83 (1H, m, H28), 2.70 (1H, dd, J = 5.0, 4.3 Hz, H27a), 
2.41 (1H, dd, J = 5.1, 2.7 Hz, H27b), 1.53-1.37 (4H, m, H29-30), 1.32-1.27 (6H, m, H31-33), 
0.85 (3H, t, J = 6.9 Hz, H34). 
 
(6S)-dodec-1-en-6-ol (152) 51,65 
 
OH
34
28
 
 
To a solution of (S)-1,2-epoxyoctane 150 (6.18 g, 48.2 mmol) and copper(I)iodide (1.19 g, 
6.26 mmol) in THF (50 mL) at -40 °C was added freshly prepared homoallylmagnesium 
bromide (60 mL, ~2.4 M solution, 144 mmol) via cannula. The resulting black solution 
was allowed to warm to RT over 2 h, before being quenched by the addition of saturated 
aqueous NH4Cl (60 mL). The organics were extracted with Et2O (3 x 40 mL), dried 
(Na2SO4), filtered and concentrated in vacuo. Purification by flash column 
chromatography (5% EtOAc/Hexane) provided alcohol 152 (7.88 g, 89%) as a colourless 
oil. 
Rf  0.4 (25% EtOAc/Pet. Ether); 1H NMR (300 MHz, CDCl3) δ 5.81 (1H, dddd, J = 16.9, 
13.3, 10.1, 6.7 Hz, H24), 5.05-4.92 (1H, m, H23a), 4.97-4.92 (1H, m, H23b), 3.65-3.53 (1H, 
m, H28), 2.12-2.02 (2H, m, H25), 1.97 (1H, app broad s, OH), 1.46-1.37 (6H, m, H26-27 + 
H29), 1.32-1.25 (8H, m, H30-33), 0.88 (3H, t, J = 7.0 Hz, H34). 
 
(2S,6S)-6-hexyl-2-(hydroxymethyl)tetrahydropyran (153) and (2R,6S)-6-hexyl-2-
(hydroxymethyl) tetrahydropyran (154) 51,65 
 
O
OH24
34   
O
OH24
34  
 
To a solution of hydroxy olefin 152 (3.53 g, 19.2 mmol) in CH2Cl2 (90 mL) at 0 °C was 
added m-CPBA (5.77 g, 33.4 mmol) and the reaction mixture was allowed to warm to RT. 
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After 3 h, the reaction mixture was cooled to 0 oC and (±)-CSA (950 mg, 4.09 mmol) was 
added and the solution left to warm to RT over 16 h. The reaction mixture was quenched 
by the addition of saturated aqueous NaHCO3 (100 mL). The organics were extracted with 
CH2Cl2 (3 x 30 mL), dried (Na2SO4), filtered and concentrated in vacuo. Purification by 
flash column chromatography (0→2% Et2O/Hexane) gave a separable 55 : 44 mixture of 
diastereomeric alcohols 153 and 154 (combined 2.76 g, 72% yield) as colourless oils.  
153: Rf 0.3 (25% EtOAc/Pet. Ether); 1H NMR (300 MHz, CDCl3) δ 3.61-3.39 (3H, m, 
H23-24), 3.34-3.24 (1H, m, H28), 2.13 (1H, br d, J = 6.3 Hz, OH), 1.90-1.78 (1H, m, H26a), 
1.64-1.46 (3H, m, H25a + H26b + H27a), 1.46-1.24 (10H, m, H29-33),1.24-1.09 (2H, m, H25b + 
H27b), 0.88 (3H, t, J = 6.6 Hz, H34). 
154: Rf 0.4 (25% EtOAc/Pet. Ether); 1H NMR (300 MHz, CDCl3) δ  3.81-3.70 (2H, m, 
H24 + H28), 3.65 (1H, ddd, J = 11.0, 8.4, 2.9 Hz, H23a), 3.45 (1H, ddd, J = 11.2, 8.4, 3.6 Hz, 
H23b), 2.09 (1H, app dd, J = 8.4, 3.1 Hz, OH), 1.75-1.51 (5H, m, H25-26 + H27a), 1.44-1.27 
(11H, m, H27b + H29-33), 0.86 (3H, t, J = 7.0 Hz, H34). 
 
(2S,6S)-6-hexyl-2-oxo-tetrahydropyran (157) 51,65 
 
 
O
H
O
2328
 
 
To a solution of oxalyl chloride (1.71 mL, 19.8 mmol) in CH2Cl2 (60 mL) at -78 °C was 
added dimethyl sulfoxide (1.68 mL, 23.7 mmol). The reaction mixture was stirred at this 
temperature for 30 min before the addition of alcohol 153 (1.98 g, 9.90 mmol) as a solution 
in CH2Cl2 (10 mL) via cannula. The reaction was stirred for a further 1 h, before the 
dropwise addition of Et3N (9.60 mL, 69.0 mmol). The reaction mixture was then stirred at 
-78 oC for 20 min, -55 oC for 15 min and finally -20 oC for 45 min. After the addition of 
saturated aqueous NH4Cl (50 mL), the organics were extracted with CH2Cl2 (3 x 30 mL) 
and the combined organic extracts were dried (Na2SO4), filtered and concentrated in 
vacuo. Purification by flash column chromatography (10% EtOAc/Pet. Ether) provided 
aldehyde 157 (1.72 g, 88%) as a colourless oil, which was used without further 
characterization. 
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Rf 0.55 (20% EtOAc/Pet. Ether); 1H NMR (300 MHz, CDCl3) δ 9.62 (1H, s, H23), 3.79 
(1H, dd, J = 11.7, 2.6 Hz, H24), 3.39-3.31 (1H, m, H28), 1.96-1.89 (1H, m, H25a), 1.84-1.77 
(1H, m, H26a), 1.66-1.39 (5H, m, H25b + H26b + H27a+ H29), 1.34-1.15 (9H, m, H27b + H30-
33), 0.88 (3H, t, J = 6.8 Hz, H34). 
 
(2S,6S)-6-(hexyl)-2-[(1S)-3-(trimethylsilyl)-prop-2-yn-1-ol]tetrahydropyran (158) and 
(2S,6S)-6-(hexyl)-2-[(1R)-3-(trimethylsilyl)-prop-2-yn-1-ol]tetrahydropyran (159) 51,65 
 
23
O
TMS
OH
23
O
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OH
2828
 
 
Method A 
To a solution of TMS acetylene (1.38 mL, 9.67 mmol) in THF (17 mL) at -78 °C was 
added  n-BuLi (6.05 mL, 1.6 M solution in hexane, 9.67 mmol). After 1 h, a solution of  
aldehyde 157 (960 mg, 4.84 mmol) in THF (3 mL) was added via cannula. After 2 h, the 
reaction mixture was quenched by the addition of saturated aqueous NH4Cl (20 mL). The 
organics were extracted with Et2O (3 x 20 mL), washed with brine (10 mL), dried 
(Na2SO4), filtered and concentrated in vacuo. Purification by flash column 
chromatography (5% EtOAc/Hexane) provided a separable mixture of major diastereomer 
159 (0.53 g), minor diastereomer 158 (0.23 g) and a mixture of 158 and 159 (0.23 g) as 
colourless oils, in a combined yield of 69% with a d.r. = 89 : 11. 
 
Method B 
To a mixture of Zn(OTf)2 (4.68 g, 12.9 mmol) and (+)-N-methylephedrine (2.66 g, 14.8 
mmol) at RT was added toulene (55 mL) and Et3N (2.10 mL, 15.1 mmol). After 2h, TMS 
acetylene (5.60 mL, 39.3 mmol) was added and stirred at RT for 20 min. Following 
addition of alkyne, aldehyde 157 (1.72 g, 8.70 mmol) was added as a solution in toluene (5 
mL) via cannula and the solution heated at 70 °C. After 16 h, the reaction was quenched by 
addition of saturated aqueous NH4Cl (30 mL), the organics were extracted with CH2Cl2 (3 
× 30 mL), washed with brine (40 mL), dried (Na2SO4), filtered and concentrated in vacuo. 
Purification by flash column chromatography (2% EtOAc/Hexane) provided alcohol 158 
(2.07 g, 80%), as a colourless oil, with a diastereomeric ratio >97:3 by 1H NMR.  
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158: Rf 0.55 (5% EtOAc/Hexane); 1H NMR (300 MHz, CDCl3) δ 4.18 (1H, dd, J = 8.0, 
2.5 Hz, H23), 3.34 (1H, ddd, J = 11.4, 8.0, 1.9 Hz, H24), 3.35-3.26 (1H, m, H28), 2.87 (1H, 
d, J = 2.5 Hz, OH), 1.93-1.75 (2H, m, H25a + H26a), 1.63-1.49 (2H, m, H26b + H27a), 1.49-
1.12 (12H, m, H25b + H27b + H29-33), 0.88 (3H, t, J = 7.0 Hz, H34), 0.17 (9H, s, Si(CH3)3). 
159: Rf 0.51 (5% EtOAc/Hexane); 1H NMR (400 MHz, CDCl3)  δ 4.41 (1H, dd, J = 5.5, 
3.7 Hz, H23), 3.44 (1H, ddd, J = 11.0, 3.8, 2.3 Hz, H24), 3.35-3.28 (1H, m, H28), 2.47 (1H, 
d, J = 5.6 Hz, OH), 1.92-1.85 (1H, m, H26a), 1.70-1.64 (1H, m, H25a),1.56-1.45 (2H, m, 
H26b + H27a), 1.44-1.35 (2H, m, H29), 1.34-1.24 (8H, m, H30-33), 1.24-1.11 (2H, m, H25b + 
H27b), 0.88 (3H, t, J = 7.7 Hz, H34), 0.17 (9H, s, Si(CH3)3). 
 
(2S,6S)-6-(hexyl)-2-[(1S)-prop-2-yn-1-ol]tetrahydropyran (160) 51,65 
 
 
23
O
H
OH
28
 
 
Method A 
To a solution of alcohol 159 (400 mg, 1.35 mmol) in Et2O (30 mL) at RT was added PPh3 
(708 mg, 2.70 mmol), 4-bromobenzoic acid (542 mg, 2.70 mmol) and DIAD (401 µL, 2.02 
mmol). After 16 h, the reaction mixture was quenched by the addition of H2O (30 mL). 
The organics were extracted with EtOAc (3 × 20 mL), dried (Na2SO4), filtered and 
concentrated in vacuo. To a solution of crude ester in EtOH (40 mL) at RT was added 
K2CO3 (746 mg, 5.40 mmol) and the reaction mixture was left for 4 h. The solution was 
quenched by addition of saturated aqueous NH4Cl (30 mL). The organics were extracted 
with EtOAc (4 × 20 mL), dried (Na2SO4), filtered and concentrated in vacuo. Purification 
by flash column chromatography (3% EtOAc/Hexane) provided alcohol 160 (175 mg, 
58%) as a colourless oil. 
 
Method B 
To a solution of alkyne 158 (227 mg, 0.77 mmol) in MeOH (25 mL) at 0 °C was added 
K2CO3 (318 mg, 2.30 mmol). The reaction mixture was allowed to warm to RT and stirred 
for 4 h, before saturated aqueous NH4Cl (50 mL) was added and the resulting mixture was 
diluted with EtOAc (10 mL). The organics were extracted with EtOAc (3 x 20 mL), dried 
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(Na2SO4), filtered and concentrated in vacuo. Purification by flash column 
chromatography (5% EtOAc/Pet. Ether) gave alcohol 160 (160 mg, 93%), as a colourless 
oil (which was identical in all regards to material prepared by method A). 
Rf 0.41 (5% EtOAc/Pet. Ether); 1H NMR (400 MHz, CDCl3) δ 4.19 (1H, ddd, J = 7.8, 2.7, 
2.3 Hz, H23), 3.38 (1H, ddd, J = 11.4, 7.8, 2.2 Hz, H24), 3.35-3.29 (1H, m, H28), 2.87 (1H, 
d, J = 2.8 Hz, OH), 2.44 (1H, d, J = 2.2 Hz, H21), 1.91-1.79 (2H, m, H25a + H26a), 1.63-1.45 
(2H, m, H26b + H27a), 1.44-1.36 (2H, m, H29), 1.34-1.24 (8H, m, H30-33 ), 1.24-1.11 (2H, m, 
H25b + H27b), 0.88 (3H, t, J = 6.8 Hz, H34). 
 
(2S,6S)-2-[(1S)-1-(tert-butyldimethylsilyloxy)-prop-2-ynyl]-6-hexyl-tetrahydropyran 
(84) 51 
 
 
23
O
H
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28
 
 
To a solution of alcohol 160 (197 mg, 0.88 mmol) in CH2Cl2 (10 mL) at RT was added 
TBSCl (260 mg, 1.73 mmol) and imidazole (120 mg, 1.76 mmol). After 16 h, the solution 
was quenched by the addition of saturated aqueous NH4Cl (10 mL). The organics were 
extracted with CH2Cl2 (3 × 25 mL) and the combined organic extracts were dried 
(MgSO4), filtered and concentrated in vacuo. Purification by flash column chromatography 
(1% EtOAc/Pet. Ether) provided alkyne 84 (270 mg, 91%), as a colourless oil. 
Rf 0.86 (5% EtOAc/Pet. Ether); 
€ 
[α]D20  -0.99 (c 1.03, CHCl3), lit 
€ 
[α]D20  -0.5 (c 1.0, 
CHCl3)147; 1H NMR (300 MHz, CDCl3) δ 4.27 (1H, dd, J = 5.9, 2.2 Hz, H23), 3.34 (1H, 
ddd, J = 11.2, 5.9, 2.2 Hz, H24), 3.31-3.21 (1H, m, H28), 2.35 (1H, d, J = 2.2 Hz, H21), 1.92-
1.80 (2H, m, H25a + H26a), 1.55-1.37 (4H, m, H26b + H27a + H29), 1.33-1.21 (9H, m, H25b + 
H30-33), 1.19-1.09 (1H, m, H27b), 0.92 (9H, s, SiC(CH3)3), 0.88 (3H, t, J = 7.1 Hz, H34), 0.14 
(3H, s, SiCH3), 0.12 (3H, s, SiCH3). 
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8.4 Experimental details for Chapter 3 
 
(1S,4S)-1-[(2R’,5R’)-5’-(7-benzyloxy)-(1R)-(tert-butyldimethylsilyloxy)heptyl-
tetrahydrofuran-2-yl]-4-[(2S’’,6S’’)-6-hexyltetrahydropyran-2-yl]-but-2-yn-ol (171) 
 
20
O
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Method A  
To a solution of alkyne 84 (280 mg, 0.83 mmol) in THF (3 mL) at -78 ºC was added n-
BuLi (510 µL, 1.6 M solution in hexane, 0.82 mmol). Over 10 min, the temperature was 
raised to -50 ºC, then lowered to -78 ºC and a solution of aldehyde 83 (70.6 mg, 0.16 
mmol) in THF (1 mL) was added via cannula. After 1.5 h, the reaction mixture was 
quenched by the addition of saturated aqueous NH4Cl (5 mL), the organics were extracted 
with CH2Cl2 (3 × 5 mL), washed with brine (5 mL), dried (Na2SO4), filtered and 
concentrated in vacuo. Purification by flash column chromatography (1→4% 
EtOAc/Hexane) provided alkynes 171 and 172 as a 3 : 1 mixture of C20 diastereomers 
(86.1 mg, 68%), as a colourless oil. (A small quantity of major diastereomer 171 was 
separated by column chromatography for characterization, separation of the C20 
diastereomers proved readily amenable following alkyne reduction). 
 
Method B  
To a solution of alkyne 84 (230 mg, 0.68 mmol) in MTBE (3 mL) at 0 ºC was added n-
BuLi (419 µL, 1.6 M solution in hexane, 0.67 mmol). The temperature was then lowered to 
-90 ºC and after 10 min a solution of aldehyde 83 (57.9 mg, 0.13 mmol) in MTBE (1 mL) 
was added via cannula. After 4 h, saturated aqueous NH4Cl (5 mL) and CH2Cl2 (5 mL) 
were added. The organics were extracted with CH2Cl2 (3 × 10 mL), washed with brine (5 
mL), dried (Na2SO4), filtered and concentrated in vacuo. Purification by flash column 
chromatography (1→4% EtOAc/Hexane) provided alkyne 171 (79.3 mg, 77%), as a 
colourless oil (> 95:5 C20 diastereomer). 
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171-major diastereomer: Rf 0.10 (5% EtOAc/Pet. Ether); 
€ 
[α]D20  +6.10 (c 0.59, CHCl3); 
IR (NaCl) 3442, 2929, 2856, 1456, 1363, 1251, 1102, 836, 776 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.38-7.32 (4H, m, ArH), 7.31-7.28 (1H, m, ArH), 4.51 (2H, s, OCH2Ar) 4.49-
4.45 (1H, m, H20), 4.33 (1H, dd, J = 6.7, 1.6 Hz, H23), 4.16-4.09 (1H, m, H19), 4.08-3.89 
(1H, m, H16), 3.68-3.52 (1H, m, H15), 3.47 (2H, t, J = 6.6 Hz, H9), 3.31 (1H, ddd, J = 11.2, 
6.7, 1.9 Hz, H24), 3.28-3.18 (1H, m, H28), 2.32 (1H, d, J = 6.0 Hz, OH), 2.03-1.74 (5H, m, 
H17a + H18 + H25a+ H26a), 1.73-1.58 (3H, m, H10 + H17b), 1.57-1.08 (22H, m, H11-14 + H25b + 
H26b + H27 + H29-33), 0.97-0.82 (21H, m, 2 × SiC(CH3)3 + H34), 0.13 (3H, s, SiCH3), 0.12 
(3H, s, SiCH3), 0.08 (3H, s, SiCH3), 0.06 (3H, s, SiCH3); 13C NMR (100 MHz, CDCl3) δ 
138.7, 128.4, 127.6, 127.5, 85.2, 83.3, 83.1, 81.4, 80.6, 77.8, 75.1, 72.8, 70.4, 66.9, 64.5, 
36.5, 33.1, 32.9,  31.9, 31.4, 29.8, 29.5, 28.4, 27.9, 27.6, 26.8, 26.7, 26.2, 26.0, 25.8, 25.6, 
25.4, 23.3, 22.7, 18.3, 18.3, 14.1, -4.1, -4.5, -4.6, -4.9; HRMS (ES+) calc. for 
C45H84O6NSi2 [M+NH4]+ 790.5832, found 790.5832. 
 
(1S,4S)-1-[(2R’,5R’)-5’-(7-benzyloxy)-(1R)-(tert-butyldimethylsilyloxy)heptyl-
tetrahydrofuran-2-yl]-4-[(2S’’,6S’’)-6-hexyltetrahydropyran-2-yl]-butan-1-ol (173) 
 
20O
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OTBS
O
OTBS 9OH
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Method A: 
A solution of alkynes 171 and 172 (53.1 mg, 68.7 µmol) and TsNHNH2 (770 mg, 4.14 
mmol) in DME (6 mL) was heated under reflux. To the reaction solution was added a 
solution of NaOAc (561 mg, 4.14 mmol) in H2O (6 mL) over a period of 4 h. After this 
time, the reaction solution was cooled and diluted with H2O (10 mL) and EtOAc (10 mL). 
The organics were extracted with EtOAc (3 × 10 mL) and the combined organic extracts 
were washed with 3 M HCl (3 × 10 mL), saturated aqueous NaHCO3 (30 mL) and brine 
(30 mL). The organic extracts were dried (Na2SO4), filtered and concentrated in vacuo. 
Purification by flash column chromatography (1→4% EtOAc/Hexane) provided alcohol 
173 (21.3 mg, 40 %) and minor diastereomer 174 (6.10 mg, 11%), as colourless oils. 
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Method B: 
A solution of alkyne 171 (5.90 mg, 7.64 µmol) and TsNHNH2 (85.3 mg, 0.46 mmol) in 
DME (1 mL) was heated under reflux. To the reaction solution was added a solution of 
NaOAc (62.3 mg, 0.46 mmol) in H2O (1 mL) over a period of 4 h. After this time, the 
reaction solution was cooled and diluted with H2O (5 mL) and EtOAc (5 mL). The 
organics were extracted with EtOAc (3 × 5 mL) and the combined organic extracts were 
washed with 3M HCl (3 × 5 mL), saturated aqueous NaHCO3 (15 mL) and brine (15 mL). 
The organic extracts were dried (Na2SO4), filtered and concentrated in vacuo. Purification 
by flash column chromatography (10% EtOAc/Hexane) provided alcohol 173 (3.70 mg, 62 
%), as a colourless oil. 
173: Rf 0.40 (15% EtOAc/Pet. Ether); 
€ 
[α]D20  +2.6 (c 1.1, CHCl3); IR (NaCl) 3442, 2928, 
1460, 1363, 1097, 835, 775 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.37-7.32 (4H, m, ArH), 
7.31-7.28 (1H, m, ArH), 4.51 (2H, s, OCH2Ar), 3.90 (1H, dt, J = 8.4, 5.9 Hz, H16), 3.83 
(1H, app. td, J = 7.1, 3.7 Hz, H19), 3.77-3.72 (1H, m, H20), 3.64 (1H, dt, J = 5.6, 5.6 Hz, 
H23), 3.57-3.51 (1H, m, H15), 3.47 (2H, t, J = 6.6 Hz, H9), 3.30-3.19 (2H, m, H24 + H28), 
2.42 (1H, d, J = 5.1, OH), 1.97-1.76 (4H, m, H17a + H18 + H26a), 1.70-1.49 (8H, m, H10 + 
H17b + H22 + H25a + H26b + H27a), 1.49-1.23 (20H, m, H11-14 + H21 + H29-33), 1.23-1.05 (2H, 
m, H25b + H27b), 0.90-0.83 (21H, m, 2 × SiC(CH3)3 + H34), 0.06 (3H, s, SiCH3), 0.056 (3H, 
s, SiCH3), 0.054 (3H, s, SiCH3), 0.04 (3H, s, SiCH3); 13C NMR (100 MHz, CDCl3) δ 
138.7, 128.4, 127.6, 127.5, 82.6, 82.2, 80.8, 78.1, 75.4, 74.5, 72.9, 72.0, 70.5, 36.4, 33.0, 
31.9, 31.4, 31.0, 29.8, 29.5, 28.8, 28.5, 28.0, 26.2, 26.0, 26.0, 25.7, 25.6, 25.4, 25.3, 23.6, 
22.7, 18.3, 18.3, 14.1, -4.1, -4.2, -4.6 (2C); HRMS (ES+) Calc. for C45H88O6NSi2 
[M+NH4]+ 794.6147, found 794.6145. 
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(1R,4S)-1-[(2R’,5R’)-5’-(7-benzyloxy)-(1R)-(tert-butyldimethylsilyloxy)heptyl-
tetrahydrofuran-2-yl]-4-[(2S’’,6S’’)-6-hexyltetrahydropyran-2-yl]-butan-1-ol (174) 
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OTBS
O
OTBS 9OH
OBn
 
 
174: Rf 0.45 (15% EtOAc/Pet. Ether); IR (NaCl) 3442, 2929, 2856, 1462, 1363, 1093, 
835, 775 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.36-7.33 (4H, m, ArH), 7.31-7.28 (1H, m, 
ArH), 4.51 (2H, s, OCH2Ar), 3.90-3.83 (1H, m, H16), 3.82-3.73 (1H, m, H19), 3.63-3.52 
(2H, m, H15 + H23), 3.47 (2H, t, J = 6.6 Hz, H9), 3.40-3.33 (1H, m, H20), 3.28-3.18 (2H, m, 
H24 + H28), 2.52 (1H, d, J = 3.4, OH), 1.96-1.77 (3H, m, H17a + H18a + H26a), 1.67-1.49 (7H, 
m, H10 + H17b + H18b + H25a + H27a + H26b), 1.46-1.22 (22H, m, H11-14 + H21-22 + H29-33), 
1.21-1.06 (2H, m, H25b + H27b), 0.93-0.82 (21H, m, 2 × SiC(CH3)3 + H34), 0.07 (3H, s, 
SiCH3), 0.059 (3H, s, SiCH3), 0.057 (3H, s, SiCH3), 0.049 (3H, s, SiCH3); 13C NMR (100 
MHz, CDCl3) δ 138.7, 128.4, 127.6, 127.5, 82.6, 82.2, 78.0, 75.0, 74.7, 72.9, 70.5, 36.5, 
33.1, 31.9, 31.4, 31.0, 29.8, 29.5, 26.2, 26.0, 26.0, 25.8, 25.5, 25.4, 23.7, 22.7, 18.3, 14.1, -
4.05, -4.08, -4.6 (2C); HRMS (ES+) Calc. for C45H88O6NSi2 [M+NH4]+ 794.6145, found 
794.6145. 
 
(2R,5S)-2-[(2R’,5R’)-5’-(7-benzyloxy)-(1R)-(hydroxyheptyl)-tetrahydrofuran-2-yl]-5-
[(2S’’,6S’’)-6-hexyltetrahydropyran-2-yl]tetrahydrofuran (179) 
 
O O O
OH
34
OBn15
9
28
 
 
To a solution of alcohol 173 (21.3 mg, 27.4 µmol) in CH2Cl2 (2 mL) at 0 ºC was added 
Et3N (26.7 µL, 192 µmol) and MsCl (10.6 µL, 137 µmol). After 1 h, saturated aqueous 
NH4Cl (5 mL) and CH2Cl2 (5 mL) were added. The organics were extracted with CH2Cl2 
(3 × 5 mL) and the combined organic extracts were washed with H2O (10 mL), brine (10 
mL), dried (Na2SO4), filtered and concentrated in vacuo. The crude mesylate was dissolved 
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in THF (2 mL) and cooled to 0 °C and TBAF (690 µL, 1.0 M solution in THF, 0.69 mmol) 
was added. The reaction was warmed to RT and after 22 h the reaction mixture was 
quenched by addition with H2O (5 mL) and EtOAc (5 mL). The organics were extracted 
with EtOAc (3 × 5 mL) and the combined organic extracts were washed brine (20 mL), 
dried (Na2SO4), filtered and concentrated in vacuo. Purification by flash column 
chromatography (35% EtOAc/Hexane) provided alcohol 179 (13.4 mg, 94%), as a 
colourless oil. 
Rf 0.42 (50% EtOAc/Pet. Ether); 
€ 
[α]D20  -1.8 (c 0.5, CHCl3); IR (NaCl) 3453, 2928, 2856, 
1454, 1357, 1172, 1092, 1070, 910, 733, 695 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.36-
7.32 (4H, m, ArH), 7.31-7.28 (1H, m, ArH), 4.51 (2H, s, OCH2Ar), 3.93 (1H, dt, J = 7.6, 
6.2 Hz, H19), 3.89 (1H, dt, J = 6.8, 5.7 Hz, H23), 3.87-3.81 (2H, m, H16 + H20), 3.47 (2H, t, 
J = 6.6 Hz, H9), 3.41-3.34 (1H, m, H15), 3.30 (1H, ddd, J = 10.1, 5.5, 1.8 Hz, H24), 3.31-
3.27 (1H, m, H28), 2.53 (1H, br s, OH), 2.01-1.91 (2H, m, H17a+ H18a), 1.87-1.79 (3H, m, 
H21a + H22a + H26a), 1.79-1.70 (2H, m, H18b+ H22b), 1.70-1.45 (7H, m, H10 + H14a + H17b+ 
H21b + H25a + H26b + H27a), 1.43-1.20 (18H, m, H11-13, + H14b + H25b + H29-33), 1.20-1.10 
(1H, app dq, J = 12.4, 3.8 Hz, H27b), 0.88 (3H, t, J = 6.9, H34); 13C NMR (75 MHz, CDCl3) 
δ 138.7, 128.3, 127.6, 127.5, 83.1, 82.1, 82.0, 81.5, 79.9, 77.9, 74.1, 72.9, 70.5, 36.5, 33.4, 
31.9, 31.5, 29.7, 29.6, 29.4, 28.9, 28.4, 28.0, 27.4, 26.9, 26.2, 25.7, 25.6, 23.5, 22.7, 14.1; 
HRMS (ES+) Calc. for C33H58O5N [M+NH4]+ 548.4304, found 548.4310.  
 
(2R,5S)-2-[(2R’,5R’)-5’-(7-benzyloxy)-(1R)-(tert-butyldimethylsilyloxy)heptyl-
tetrahydrofuran-2-yl]-5-[(2S’’,6S’’)-6-hexyltetrahydropyran-2-yl]tetrahydrofuran 
(180)  
 
O O O
OTBS
34
OBn1528
9
 
 
To a solution of alcohol 179 (28.8 mg, 54.3 µmol) in CH2Cl2 (2 mL) at -78 ºC was added 
2,6-lutidine (11.7 µL, 163 µmol) and TBSOTf (18.7 µL, 81.4 µmol). After 1 h, a saturated 
aqueous solution of NH4Cl (5 mL) and CH2Cl2 (5 mL) were added. The organics were 
extracted with CH2Cl2 (3 × 5 mL) and the combined organic extracts were dried (Na2SO4), 
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filtered and concentrated in vacuo. Purification by flash column chromatography (1→5% 
EtOAc/Hexane) provided TBS ether 180 (30.7 mg, 88%), as a colourless oil. 
Rf 0.61 (20% EtOAc/Pet. Ether); 
€ 
[α]D20  +6.2 (c 1.0, CHCl3); IR (NaCl) 2928, 2850, 1459, 
1363, 1250, 1087, 833, 775 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.37-7.32 (4H, m, ArH), 
7.31-7.28 (1H, m, ArH), 4.51 (2H, s, OCH2Ar), 4.02-3.91 (2H, m, H16 + H19), 3.90-3.82 
(2H, m, H20 + H23), 3.67-3.59 (1H, m, H15), 3.47 (2H, t, J = 6.6 Hz, H9), 3.30 (1H, ddd, J = 
11.5, 5.6, 1.9 Hz, H24), 3.27-3.18 (1H, m, H28), 1.99-1.78 (5H, m, H17a + H18a +  H21a + H22a 
+ H26a) 1.77-1.58 (6H, m, H10 + H17b + H18b + H21b + H22b), 1.58-1.21 (22H, m, H11-14 + H25 
+ H26b + H27a + H29-33),  1.14 (1H, app qd, J = 11.2, 4.2 Hz, H27b), 0.95-0.81 (12H, m, 
SiC(CH3)3 + H34), 0.08 (3H, s, SiCH3), 0.05 (3H, s, SiCH3); 13C NMR (100 MHz, CDCl3) 
δ 138.7, 128.3, 127.6, 127.5, 82.3, 81.9, 81.8, 81.5, 80.2, 77.8, 74.8, 72.9, 70.5, 36.6, 32.3, 
31.9, 31.5, 29.8, 29.7, 29.4, 28.3, 27.9, 27.5, 27.1, 26.8, 26.2, 26.0, 25.9, 25.6, 23.5, 22.7, 
18.2, 14.1, -4.2, -4.6; HRMS (ES+) Calc. for C39H72O5NSi [M+NH4]+ 662.5172, found 
662.5174.  
 
(2R,5S)-2-[(2R’,5R’)-5’-(1R)-(tert-butyldimethylsilyloxy)-7-(hydroxyheptyl)-
tetrahydrofuran-2-yl]-5-[(2S’’,6S’’)-6-hexyltetrahydropyran-2-yl]tetrahydrofuran 
(82) 
 
O O O
OTBS
OH15
34
28
9
 
 
To a solution of benzyl ether 180 (30.7 mg, 47.6 µmol) in EtOH (2 mL) at RT was added 
Pd(OH)2 on carbon (6.70 mg, 20% wt on carbon, 9.52 µmol). The reaction system was 
purged with H2 and left under a positive pressure of H2. After 1.5 h, the reaction mixture 
was filtered through Celite with EtOH (15 mL). The filtrate was concentrated in vacuo and 
purification by flash column chromatography (20% EtOAc/Hexane) provided alcohol 82 
(22.5 mg, 85%), as a colourless oil. 
Rf 0.34 (20% EtOAc/Pet. Ether); 
€ 
[α]D20  +7.3 (c 1.1, CHCl3); IR (NaCl) 3403, 2928, 2856, 
1613, 1462, 1374, 1250, 1067, 833, 775 cm-1; 1H NMR (500 MHz, CDCl3) δ 4.02-3.90 
(2H, m, H16 + H19), 3.90-3.81 (2H, m, H23 + H20), 3.68-3.60 (3H, m, H9 + H15), 3.30 (1H, 
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dd, J = 10.9, 5.6 Hz, H24), 3.27-3.19 (1H, m, H28), 1.93-1.78 (5H, m, H17a + H18a + H21a + 
H22a + H26a), 1.77-1.64 (4H, m, H17b + H18b + H21b + H22b), 1.62-1.42 (7H, m, H10 + H14 + 
H25a+ H27a + H29a), 1.41-1.20 (17H, m, H11-13 + H25b + H26b + H29b + H30-33), 1.14 (1H, app 
qd, J = 12.4, 4.1 Hz,  H27b), 0.96-0.81 (12H, m, SiC(CH3)3 + H34), 0.07 (3H, s, SiCH3), 
0.05 (3H, s, SiCH3); 13C NMR (75 MHz, CDCl3) δ 82.3, 81.9, 81.5, 80.2, 77.8, 74.7, 63.0, 
36.6, 32.8, 32.2, 31.9, 31.5, 29.7, 29.4, 28.3, 27.9, 27.5, 27.0, 26.8, 26.0, 25.9, 25.7, 25.6, 
23.5, 22.7, 18.2, 14.1, -4.2, -4.6; HRMS (ES+) Calc. for C32H66O5NSi [M+NH4]+ 
572.4699, found 572.4705.  
 
6-(benzyloxy)hexanal (183)142 
 
H
O
OBn
1
6
 
 
To a stirred solution of oxalyl chloride (705 µL, 8.16 mmol) in CH2Cl2 (10 mL) at -78 °C 
was added dimethyl sulfoxide (695 µL, 9.79 mmol). The reaction mixture was stirred at 
this temperature for 30 min before the addition of alcohol 93 (850 mg, 4.08 mmol) as a 
solution in CH2Cl2 (3 mL) via cannula. The reaction was stirred for a further 1 h, before 
the dropwise addition of Et3N (3.97 mL, 28.6 mmol). The reaction mixture was then stirred 
at -78 oC for 20 min, -55 oC for 15 min and finally -20 oC for 45 min. After the addition of 
saturated aqueous NH4Cl (10 mL), the organics were extracted with CH2Cl2 (3 x 10 mL) 
and the combined organic extracts were dried (Na2SO4), filtered and concentrated in 
vacuo. Purification by flash column chromatography (2% EtOAc/Pet. Ether) provided 
aldehyde 183 (250 mg, 30%) as a colourless oil. 
Rf 0.56 (20% EtOAc/Pet. Ether); 1H NMR (300 MHz, CDCl3) δ 9.76 (1H, t, J = 1.8 Hz, 
H1), 7.36-7.27 (5H, m, ArH), 4.50 (2H, s, OCH2Ar), 3.47 (2H, t, J = 6.4 Hz, H6), 2.44 (2H, 
td, J = 7.3, 1.8 Hz, H2), 1.70-1.60 (4H, m, H3 + H5), 1.48-1.37 (2H, m, H4).  
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(5S)-5-methyl-3-(6-(sulfanyl-1-phenyl-1H-1,2,3,4-tetrazol-5-yl)hexyl)-2,5-
dihydrofuran-2-one (186) 
 
O
O 1
SN
N
N N
Ph
368
 
 
To a solution of alcohol 81 (100 mg, 0.50 mmol) in THF (4 mL) at 0 °C was added 1-
Phenyl-1H-tetrazole-5-thiol (120 mg, 0.66 mmol), PPh3 (170 mg, 0.66 mmol) and DIAD 
(130 µL, 0.66 mmol) dropwise and the reaction mixture was allowed to warm to RT over 
1.5 h. The reaction mixture was quenched by addition of saturated aqueous NH4Cl (5 mL) 
and EtOAc (5 mL). The aqueous layer was extracted with EtOAc (3 × 5 mL) and the 
combined organic extracts were dried (Na2SO4), filtered and concentrated in vacuo. 
Purification by flash column chromatography (5→20% EtOAc/Pet. Ether) provided sulfide 
186 (155 mg, 86%) as a colourless oil. 
Rf 0.15 (25% EtOAc/Pet. Ether); 
€ 
[α]D20  +12.1 (c 0.61, CHCl3); IR (NaCl) 2928, 2856, 
1751, 1318, 1196, 1119, 762, 722, 695 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.59-7.53 (5H, 
m, ArH), 7.01-6.99 (1H, m, H35), 4.97-4.91(1H, m, H36), 3.40 (2H, t, J = 7.4 Hz, H8), 2.30-
2.25 (2H, m, H3), 1.88-1.81 (2H, m, H7), 1.62-1.55 (2H, m, H4), 1.54-1.46 (2H, m, H6), 
1.44-1.36 (5H, m, H5 + H37); 13C NMR (100 MHz, CDCl3) δ 173.8, 154.4, 149.1, 134.0, 
133.7, 130.1, 129.8, 123.9, 77.2, 33.2, 29.0, 28.5, 28.2, 27.2, 25.1, 19.2; HRMS (ES+) Calc 
for C18H23O2N4S [M+H]+ 359.1536, found 359.1534. 
 
(5S)-5-methyl-3-(6-(sulfonyl-1-phenyl-1H-1,2,3,4-tetrazol-5-yl)hexyl)-2,5-
dihydrofuran-2-one (185) 
 
O
O 1
O2
SN
N
N N
Ph
368
 
 
To a mixture of ammonium molybdate (240 mg, 194 µmol) and H2O2 (320 µL, 30% v/v 
solution in H2O, 2.82 mmol) at 0 °C for 15 min was added a solution of sulfide 186 (155 
mg, 432 µmol) in MeOH (3 mL). The solution was allowed to warm to RT and stirred for 1 
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h, followed by addition of the remaining oxidant and left overnight. The solution was 
diluted with MeOH and filtered. The filtrate was partitioned between H2O and CH2Cl2 and 
the organic layer was collected. The aqueous layer was extracted with CH2Cl2 (3 × 5 mL), 
dried (Na2SO4), filtered and concentrated in vacuo. Purification by flash column 
chromatography (5→15% EtOAc/Pet. Ether) provided sulfone 185 (120 mg, 70%) as a 
colourless oil. 
Rf 0.31 (30% EtOAc/Pet. Ether); 
€ 
[α]D20+12.8 (c 1.03, CHCl3);  IR (NaCl) 1747, 1151 cm-1; 
1H NMR (400 MHz, CDCl3) δ 7.72-7.59 (5H, m, ArH), 7.02-7.00 (1H, m, H35), 5.04-4.98 
(1H, m, H36), 3.76-3.72 (2H, m, H8), 2.31-2.27 (2H, m, H3), 2.02-1.94 (2H, m, H7), 1.61-
1.54 (4H, m, H4 + H6), 1.47-1.41 (5H, m, H5 + H37); 13C NMR (75 MHz, CDCl3) δ 173.7, 
153.4, 149.2, 133.8, 133.0, 131.5, 129.7, 125.0, 77.4, 55.8, 28.4, 27.7, 27.0, 25.0, 21.9, 
19.2; HRMS (ES+) Calc for C18H26O4N5S [M+NH4]+ 408.1700, found 408.1700. 
 
[6-(benzyloxy)hexyl]sulfonyl-1-phenyl-1H-1,2,3,4-tetrazole (187) 
 
BnO
O2
S
N N
N
N
Ph
1
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To a solution of alcohol 93 (519 mg, 2.49 mmol) in THF (10 mL) at 0 °C was added 1-
Phenyl-1H-tetrazole-5-thiol (577 mg, 3.24 mmol), PPh3 (850 mg, 3.24 mmol) and DIAD 
(640 µL, 3.24 mmol) dropwise and the reaction mixture was allowed to warm to RT over 
1.5 h. The reaction mixture was quenched by addition of saturated aqueous NH4Cl and 
EtOAc. The organics were extracted with EtOAc (3 × 10 mL) and the combined organic 
extracts were dried (Na2SO4), filtered and concentrated in vacuo. Purification by flash 
column chromatography (5→10% EtOAc/Pet. Ether) provided intermediate sulfide (600 
mg, 65%) as a colourless oil. To a mixture of ammonium molybdate (830 mg, 0.67 mmol) 
and H2O2 (1.14 mL, 10.1 mmol) at 0 °C for 15 min was added a solution of intermediate 
sulfide (559 mg, 1.52 mmol) in MeOH (7 mL). The solution was allowed to warm to RT, 
left for 1 h, then the remaining oxidant was added and the solution left overnight. The 
solution was diluted with MeOH and filtered. The filtrate was partitioned between H2O 
and CH2Cl2 and the organic layer was collected. The aqueous layer was extracted with 
CH2Cl2 (3 × 10 mL), dried (Na2SO4), filtered and concentrated in vacuo. Purification by 
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flash column chromatography (5→10% EtOAc/Pet. Ether) provided sulfone 187 (437 mg, 
72%) as a colourless oil. 
Rf 0.56 (20% EtOAc/Pet. Ether); IR (NaCl) 2927, 2856, 1497, 1341, 1152, 763, 688 cm-1; 
1H NMR (400 MHz, CDCl3) δ 7.72-7.68 (2H, m, ArH), 7.65-7.59 (3H, m, ArH), 7.37-7.33 
(4H, m, ArH), 7.32-7.28 (1H, m, ArH), 4.51 (2H, s, OCH2Ar), 3.75-3.71 (2H, m, H1), 3.48 
(2H, t, J = 6.3 Hz, H6), 2.01-1.94 (2H, m, H5), 1.67-1.61 (2H, m, H2), 1.57-1.45 (4H, m, 
H3-4); 13C NMR (75 MHz, CDCl3) δ 153.4, 138.5, 133.0, 131.4, 129.6, 128.3, 127.6, 
127.5, 125.0, 72.9, 69.9, 55.9, 29.3, 27.9, 25.6, 21.9; HRMS (CI+) Calc for C20H28O3N5S 
[M+NH4]+ 418.1907, found 418.1905. 
 
6-[(5S)-5-methyl-2-oxo-2,5-dihydrofuran-3-yl]hexanal (188) 
 
O
O
1
O
H
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To a solution of alcohol 81 (40.4 mg, 0.20 mmol) in CH2Cl2 (2 mL) at 0 °C was added 
NaHCO3 (86.0 mg, 1.02 mmol) and Dess-Martin periodinane (259 mg, 0.61 mmol). The 
reaction mixture was kept at 0 °C for 30 min and then warmed to RT for 1 h. The reaction 
mixture was cooled to 0 °C and addition of cold hexane (5 mL) and cold toluene (5 mL) 
afforded a white suspension. The suspension was filtered through celite and washed with 
hexane. The filtrate was concentrated in vacuo and purification by flash column 
chromatography (50% EtOAc/Pet. Ether) provided aldehyde 188 as a colourless oil (37.0 
mg, 94%), which was used without further characterization. 
Rf 0.18 (20% EtOAc/Pet. Ether); 1H NMR (300 MHz, CDCl3) δ 9.77 (1H, t, J = 1.7 Hz, 
H8), 7.01-6.99 (1H, m, H35), 5.04-4.96 (1H, m, H36), 2.48-2.42 (2H, td, J = 7.4, 1.6 Hz, 
H7), 2.31-2.25 (2H, m, H3), 1.69-1.53 (4H, m, H4 + H6), 1.44-1.35 (5H, m, H5 + H37).  
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(5S)-3-[12-(benzyloxy)dodec-6-ene]-5-methyl-2,5-dihydrofuran-2-one (184) 
 
O
O 1
BnO
3614
 
 
To a solution of sulfone 187 (132 mg, 0.33 mmol) in THF (2 mL) at -78 °C was added 
NaHMDS (330 µL, 1 M solution in THF, 0.33 mmol). After 10 min, a solution of aldehyde 
188 (53.9 mg, 0.27 mmol) in THF (1 mL) was added dropwise via cannula. The reaction 
mixture was warmed to -20 °C. After 2.5 h, saturated aqueous NH4Cl (5 mL) was added 
and the reaction mixture was warmed to RT. The organics were extracted with EtOAc (3 x 
5 mL) and the combined organic extracts were washed with brine (10 mL), dried 
(Na2SO4), filtered and concentrated in vacuo. Purification by flash column 
chromatography (5% EtOAc/Pet. Ether) provided alkene 184 (29.4 mg, 29%) as a 
colourless oil.   
Rf 0.84 (20% EtOAc/Pet. Ether); IR (thin film) 2930, 2855, 1753, 1559, 1454, 1317 cm-1; 
1H NMR (500 MHz, CDCl3) δ 7.36-7.27 (5H, m, ArH), 6.98-6.97 (1H, m, H35), 5.42-5.32 
(2H, m, H8-9), 5.01-4.96 (1H, m, H36), 4.50 (2H, s, OCH2Ar), 3.46 (2H, t, J = 6.7 Hz, H14), 
2.28-2.24 (2H, m, H3), 2.04-1.91 (4H, m, H7 + H10), 1.63-1.60 (2H, m, H13), 1.57-1.52 
(2H, m, H4), 1.41-1.32 (8H, m, H5-6 + H11-12), 1.40 (3H, d, J = 6.8 Hz, H37); 13C NMR (125 
MHz, CDCl3) δ 173.9, 148.9, 138.7, 134.2, 130.4, 130.1, 128.3, 127.6, 127.4, 77.4, 72.8, 
70.4, 32.5, 32.4, 29.6, 29.4, 29.2, 28.6, 27.2, 25.7, 25.1, 19.2; HRMS (ES+) Calc for 
C24H38O3N [M+NH4]+ 388.2846, found 388.2845. 
 
(2R,5S)-2-[(2R’,5R’)-5’-(1R)-(tert-butyldimethylsilyloxy)-7-(sulfanyl-1-phenyl-1H-
1,2,3,4-tetrazol-5-yl)heptyl)-tetrahydrofuran-2-yl]-5-[(2S’’,6S’’)-6-
hexyltetrahydropyran-2-yl]tetrahydrofuran (190) 
 
 
O O O
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S N
N
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34  
To a solution of alcohol 82 (31.6 mg, 57.0 µmol) in THF (3 mL) at 0 °C was added 1-
phenyl-1H-tetrazole-5-thiol (41.0 mg, 230 µmol) and PPh3 (60.0 mg, 230 µmol) followed 
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by DIAD (45.0 µL, 230 µmol) dropwise. The reaction mixture was warmed to RT over 4 h, 
then quenched by the addition of saturated aqueous NH4Cl (2 mL) and EtOAc (5 mL). The 
organics were extracted with EtOAc (3 × 5 mL), dried (Na2SO4), filtered and concentrated 
in vacuo. Purification by flash column chromatography (10% EtOAc/Pet. Ether) provided 
sulfide 190 (40.6 mg, 99%), as a colourless oil. 
Rf 0.89 (20% EtOAc/Pet. Ether); 
€ 
[α]D20  +5.0 (c 0.96, CHCl3); IR (NaCl) 2929, 2856, 2360, 
2342, 1500, 1463, 1247, 1074 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.62-7.54 (5H, m, 
ArH), 3.99-3.91 (2H, m, H16 + H19), 3.90-3.83 (2H, m, H20 + H23), 3.65-3.59 (1H, m, H15), 
3.40 (2H, t, J = 7.3 Hz, H9), 3.30 (1H, ddd, J = 11.5, 5.6, 1.9 Hz, H24), 3.26-3.20 (1H, m, 
H28), 1.94-1.75 (7H, m, H10 + H17a + H18a + H21a + H22a + H26a) 1.75-1.59 (4H, m, H17b + 
H18b + H21b + H22b), 1.57-1.21 (22H, m, H11-14 + H25 + H26b + H27a + H29-33), 1.14 (1H, app 
qd, J = 11.1, 4.1 Hz,  H27b), 0.91-0.86 (12H, m, H34 + SiC(CH3)3), 0.07 (3H, s, SiCH3), 
0.04 (3H, s, SiCH3); 13C NMR (75 MHz, CDCl3) δ 154.3, 136.0, 130.0, 129.7, 123.8, 82.2, 
81.8, 81.5, 80.1, 77.8, 77.2, 74.6, 36.5, 33.3, 32.1, 31.9, 31.5, 29.4, 29.3, 29.0, 28.6, 28.3, 
27.9, 27.4, 27.0, 26.7, 26.0, 25.7, 25.5, 23.5, 22.6, 18.0, 14.1, -4.2, -4.6; HRMS (ES+) 
Calc. for C39H70O4N5SSi [M+NH4]+ 732.4912, found 732.4911. 
 
(2R,5S)-2-[(2R’,5R’)-5’-(1R)-(tert-butyldimethylsilyloxy)-7-(sulfonyl-1-phenyl-1H-
1,2,3,4-tetrazol-5-yl)heptyl)-tetrahydrofuran-2-yl]-5-[(2S’’,6S’’)-6-
hexyltetrahydropyran-2-yl]tetrahydrofuran (189) 
 
 
O O O
OTBS
S
O2
N
N
NN
Ph
15
34  
 
To a solution of sulfide 190 (10.5 mg, 14.7 µmol) in MeOH (1.5 mL) at 0 °C was added 
ammonium molybdate (472 mg, 0.38 mmol) and H2O2 (140 µL, 30% v/v solution in H2O, 
0.85 mmol). After 16 h at RT further ammonium molybdate (112 mg, 90.0 µmol) and 
H2O2 (70 µL, 30% v/v solution in H2O, 0.43 mmol) were added. After 20 h, the reaction 
mixture was diluted with MeOH (3 mL) and filtered. The filtrate was partitioned between 
H2O (3 mL) and CH2Cl2 (3 mL). The organics were extracted with CH2Cl2 (3 × 5 mL), 
dried (Na2SO4), filtered and concentrated in vacuo. Purification by flash column 
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chromatography (10% EtOAc/Pet. Ether) provided sulfone 189 (8.50 mg, 77%), as a 
colourless oil. 
Rf 0.83 (20% EtOAc/Pet. Ether); 
€ 
[α]D20  +5.3 (c 0.85, CHCl3); IR (NaCl) 2929, 2857, 2365, 
2346, 1342, 1252, 1154, 1076 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.73-7.69 (2H, m, 
ArH), 7.65-7.59 (3H, m, ArH), 3.99-3.91 (2H, m, H16 + H19), 3.90-3.81 (2H, m, H20 + H23), 
3.76-3.72 (2H, m, H9), 3.64-3.60 (1H, m, H15), 3.30 (1H, ddd, J = 10.9, 5.6, 1.3 Hz, H24), 
3.26-3.19 (1H, m, H28), 2.01-1.78 (7H, m, H10 + H17a + H18a + H21a + H22a + H26a) 1.77-1.59 
(4H, m, H17b + H18b + H21b + H22b), 1.58-1.21 (22H, m, H11-14 + H25 + H26b + H27a + H29-33), 
1.14 (1H, app qd, J = 11.1, 4.0 Hz,  H27b), 0.93-0.83 (12H, m, H34 + Si(C(CH)3), 0.07 (3H, 
s, SiCH3), 0.05 (3H, s, SiCH3); 13C NMR (100 MHz, CDCl3) δ 153.5, 133.0, 131.4, 129.7, 
125.1, 82.2, 81.9, 81.8, 81.6, 80.1, 77.8, 74.5, 56.0, 36.5, 32.0, 31.9, 31.5, 29.7, 29.4, 29.2, 
28.3, 28.2, 27.8, 27.4, 26.9, 26.7, 26.0, 25.6, 25.5, 23.5, 22.6, 22.0, 18.2, 14.1, -4.2, -4.6; 
HRMS (ES+) Calc. for C39H70O6N5SSi [M+NH4]+ 764.4811, found 764.4809. 
 
(2R,5S)-2-[(2R’,5R’)-5’-(1R)-(tert-butyldimethylsilyloxy)-13-[(5S)-3-(5-methyl-2,5-
dihydrofuran-2-one)tridec-7-ene)-tetrahydrofuran-2-yl]-5-[(2S’’,6S’’)-6-
hexyltetrahydropyran-2-yl]tetrahydrofuran (182) 
 
O O O
O
O
OTBS
1528
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36
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To a solution of sulfone 189 (18.4 mg, 25.0 µmol) in THF (4 mL) at -78 °C was added 
NaHMDS (160 µL, 0.2 M solution in THF, 32.0 µmol). After 10 min, a solution of 
aldehyde 188 (29.0 mg, 148 µmol) in THF (2 mL) was added dropwise via cannula. The 
reaction mixture was warmed to -20 °C. After 4 h, saturated aqueous NH4Cl (2 mL) was 
added, and the reaction mixture was warmed to RT. The organics were extracted with 
EtOAc (3 x 5 mL) and the combined organic extracts were washed with brine (10 mL), 
dried (Na2SO4), filtered and concentrated in vacuo. Purification by flash column 
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chromatography (15% EtOAc/Hexane) provided alkene 182 (7.20 mg, 41%) as a 
colourless oil.   
Rf 0.83 (20% EtOAc/Pet. Ether); 
€ 
[α]D20  +10.6 (c 0.36, CHCl3); IR (NaCl) 2929, 2856, 
2361, 2342, 1760 cm-1; 1H NMR (400 MHz, CDCl3) δ 6.98 (1H, app q, J = 1.6 Hz, H35), 
5.40-5.35 (2H, m, H8-9), 4.99 (1H, ddq, J = 7.8, 6.8, 1.6 Hz, H36), 4.00-3.89 (2H, m, H16 + 
H19), 3.89-3.82 (2H, m, H20 + H23), 3.65-3.59 (1H, m, H15), 3.29 (1H, ddd, J = 9.6, 5.6, 1.9 
Hz, H24), 3.26-3.18 (1H, m, H28), 2.26 (2H, ddt, J = 8.0, 7.5, 1.7 Hz, H3), 2.02-1.93 (4H, m, 
H7 + H10), 1.93-1.77 (5H, m, H17a + H18a + H21a + H22a + H26a), 1.77-1.63 (4H, m, H17b + 
H18b + H21b + H22b), 1.59-1.06 (29H, m, H4-6 + H11-14 + H25 + H26b + H27a + H29-33), 1.40 
(3H, d, J = 6.8 Hz, H37), 1.14 (1H, app qd, J = 11.3, 4.0 Hz, H27b), 0.91-0.84 (12H, m, 
SiC(CH3)3 + H34), 0.06 (3H, s, SiCH3), 0.04 (3H, s, SiCH3); 13C NMR (125 MHz, CDCl3) 
δ 173.9, 148.9, 134.3, 130.6, 130.0, 82.3, 81.9, 81.8, 81.5, 80.1, 77.8, 77.4, 74.7, 36.5, 
32.6, 32.4, 32.2, 31.9, 31.5, 29.7, 29.6, 29.5, 29.4, 29.3, 28.7, 28.3, 27.9, 27.5, 27.3, 27.2, 
27.0, 26.7, 26.0, 25.8, 25.6, 25.1, 23.5, 22.6, 19.2, 18.2, 14.1, -4.2, -4.6; HRMS (ES+) Calc 
for C43H76O6SiNa [M+Na]+ 739.5307, found 739.5309. 
 
Chamuvarinin (80 = 72)  
 
 
O O O
O
O
OH
1528
34
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A solution of alkene 182 (3.40 mg, 4.74 µmol) and TsNHNH2 (53.0 mg, 284 µmol) in 
DME (0.5 mL) was heated to reflux. To the reaction solution was added NaOAc (39.0 mg, 
284 µmol) in H2O (0.5 mL) over 3 h. The reaction mixture was cooled and diluted with 
H2O (3 mL) and EtOAc (3 mL). The organics were extracted with EtOAc (3 x 5 mL) and 
the combined organic extracts were washed with 3 N HCl (3 x 5 mL), NaHCO3 (10 mL) 
and brine (10 mL), dried (Na2SO4), filtered and concentrated in vacuo. The crude residue 
was filtered through silica (20% EtOAc/Hexane) and the filtrate concentrated in vacuo. 
The crude alkane was redissolved in in MeOH (1.0 mL) with stirring at 0 °C and 3 N HCl 
  Experimental
   
 178 
(0.3 mL) was added. After 45 min with warming to RT, the reaction mixture was quenched 
by the addition of saturated aqueous NaHCO3 (3 mL). The organics were extracted with 
CH2Cl2 (3 x 5 mL). The combined organic extracts were dried (Na2SO4), filtered and 
concentrated in vacuo. Purification by flash column chromatography (35% 
EtOAc/Hexane) provided chamuvarinin 80 (2.1 mg, 73%), as a colourless oil.   
Rf 0.17 (20% EtOAc/Pet. Ether); IR (NaCl) 2926, 2855, 1721, 1438, 1171, 1120, 721 cm-
1; 
€ 
[α]D20  +9.9 (c 0.1, CHCl3), lit 
€ 
[α]D20  +27 (c 0.026, CHCl3)42; 1H NMR (400 MHz, CDCl3) 
see Table 8.1; 13C NMR (125 MHz, CDCl3) see Table 8.2; HRMS (ES+) Calc. for 
C37H64O6Na [M+Na]+ 627.4601, found 627.4606. 
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Table 8.1: 1H NMR data for natural and synthetic chamuvarinin (CDCl3). 
 
Proton  
No. 
natural chamuvarinina 
(δH) c 
synthetic chamuvarininb 
(δH) 
   
3 2.29-2.22 md 2.28-2.23 m 
4 1.55 m 1.69-1.43 m 
5 1.29-1.25 m 1.33-1.20 m 
6 “ " 
7 “ " 
8 “ " 
9 “ " 
10 “ " 
11 “ " 
12 “ " 
13 “ " 
14 1.38 m 1.42-1.34 m 
15 3.37 m 3.40-3.33 m 
16 3.82 m 3.85-3.79 m 
17a 1.97 m 2.02-1.89 m 
17b 1.65 m 1.69-1.43 m 
18a 1.97 m  2.02-1.89 m 
18b 1.65 m 1.78-1.69 m 
19 3.93 m 3.93 dt (7.9, 6.1) 
20 3.86-3.80 me 3.85-3.79 m 
21a 1.92 m 1.87-1.78 m 
21b 1.71 m 1.69-1.43 m 
22a 1.92 m 1.87-1.78 m 
22b 1.71 m 1.78-1.69 m 
23 3.88 m 3.88 dt (6.5, 5.6) 
24 3.28 m 3.28 ddd (11.2, 5.6, 1.9) 
25a 1.48 m 1.69-1.43 m 
25b 1.26 m  1.33-1.20 m 
26a 1.82 m 1.87-1.78 m 
26b - 1.69-1.43 m 
27a 1.33 m 1.69-1.43 m 
27b 1.12 m  1.13 qd (10.9, 4.1) 
28 3.23 m 3.26-3.19 m 
29 1.52 m 1.42-1.34 m 
30 1.29-1.25 m 1.33-1.20 m 
31 “ " 
32 1.25 m " 
33 1.25 m " 
34 0.87 t (7.3) 0.87 t (7.1) 
35 6.98 d (1.5) 6.98 q (1.6) 
36 4.98 dq (6.7, 1.5) 4.99 qq (6.8, 1.7) 
 37 1.40  d (6.8)f 1.40 d (6.8) 
15-OH - 2.53 br s 
   
 
           aData from ref. 42. Data recorded at 400 MHz. 
bData recorded at 400 MHz 
cThe coupling constants are given in Hz and shown in parentheses. 
d-fDenotes proton shift altered relative to value quoted in isolation paper (based upon inspection of 
copies of original NMR spectra supplied by Dr E. Poupon); d = H3 2.29-2.22 m [2.24 t (7.4) in 
paper]; e = H20 3.86-3.80 m [3.93 m in paper]; f = H37 1.40 d (6.8) [1.42 d (6.7) in paper] 
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Table 8.2: 13C NMR data for natural and synthetic chamuvarinin (CDCl3). 
 
 
 
 
aData from ref. 42. Data recorded at 100 MHz. 
bData from 13C spectra provided by Dr E. Poupon. Data recorded at 100 MHz (CDCl3 calibrated to 76.996). 
cData recorded at 125 MHz (CDCl3 calibrated to 76.996 ppm). 
 
 
 
 
 
Carbon 
No. 
natural 
chamuvarinina 
(δC) 
natural 
chamuvarininb 
(δC) 
synthetic 
chamuvarininc 
(δC) 
    
1 173.8 173.9 173.9 
2 134.3 134.3 134.3 
15 74.1 74.1 74.1 
16 83.0 83.1 83.1 
19 81.4 81.4 81.5 
20 81.9 81.99 82.02 
23 82.0 82.04 82.06 
24 79.9 79.9 79.9 
28 77.8 77.8 77.9 
34 14.1 14.1 14.1 
35 148.8 148.8 148.8 
36 77.4 77.4 77.4 
37 19.2 19.2 19.2 
    
24 x CH2 31.8 (C32) 36.5 36.5 
 26.9 (C4) 33.5 33.5 
 25.7 (C14) 31.9 31.9 
 25.1 (C3) 31.4 31.4 
 23.4 (C26) 29.7 29.8 
 22.6 (C33) - 29.7 
 25.5-32.4 (18C 
undefined) 
29.6 (3C, br) 29.6 (2C) 
  29.5 29.5 
  29.4 (2C) 29.4(2C) 
  29.3 29.3 
  29.2 29.2 
  28.8 28.8 
  28.3 28.3 
  27.9 28.0 
  27.4 27.4 
  26.9 26.9 
  25.7 25.7 
  25.5 25.5 
  25.2 25.2 
  23.5 23.5 
  22.6 22.6 
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8.5 Experimental details for Chapter 4 
 
(2R,5R)-2-(tert-butyldimethylsilyloxy)methyl)-5-[(1R)-(tert-butyldimethylsilyloxy)-7-
hydroxyheptyl] tetrahydrofuran (193) 
 
O
OTBS
OH
9
16TBSO
 
 
 
To a solution of benzyl ether 147 (556 mg, 1.01 mmol) in EtOH (20 mL) at RT was added 
Pd(OH)2 on carbon (141 mg, 20% wt on carbon, 0.20 mmol). The reaction system was 
purged with H2 and left under a positive pressure of H2. After 1.5 h, the reaction mixture 
was filtered through Celite with EtOH (50 mL). The filtrate was concentrated in vacuo to 
provide alcohol 193 (441 mg, 95%), as a colourless oil. 
Rf 0.43 (15% EtOAc/Pet. Ether); 
€ 
[α]D20  +8.97 (c 1.50, CHCl3); IR (thin film) 3374, 2929, 
2858, 1472, 1253, 1092 cm-1; 1H NMR (300 MHz, CDCl3) δ 4.01-3.89 (2H, m, H16 + H19), 
3.65-3.51 (5H, m, H9 + H15 + H20), 1.98-1.80 (2H, m, H17a + H18a), 1.78-1.63 (2H, m, H17b 
+ H18b), 1.60-1.51 (3H, m, H10 + H14a), 1.43-1.21 (7H, m, H11-13 + H14b), 0.88 (18H, m, 2 × 
SiC(CH3)3), 0.06-0.04 (12H, m, 2 × SiCH3); 13C NMR (125 MHz, CDCl3) δ 82.0, 79.6, 
74.7, 65.9, 63.0, 32.7, 32.5, 29.6, 28.5, 27.1, 26.0, 25.9, 25.8, 25.7, 18.3, 18.2, -4.2, -4.7, -
5.3 (2C); HRMS (ES+) Calc for C24H56O4NSi2 [M+NH4]+ 478.3742, found 478.3731. 
 
(2R,5R)-2-(tert-butyldimethylsilyloxy)methyl)-5-[(1R)-(tert-butyldimethylsilyloxy)-7-
(sulfanyl-1-phenyl-1H-1,2,3,4-tetrazol-5-yl)heptyl]tetrahydrofuran (194) 
 
O
OTBS
S
9
16TBSO N
N
NN
Ph  
 
 
To a solution of alcohol 193 (3.59 g, 7.80 mmol) in THF (60 mL) at 0 °C was added 1-
phenyl-1H-tetrazole-5-thiol (5.56 g, 31.2 mmol) and PPh3 (8.18 g, 31.2 mmol) followed by 
DIAD (6.20 mL, 31.2 mmol) dropwise.  The reaction mixture was warmed to RT over 4 h, 
then quenched by the addition of saturated aqueous NH4Cl (60 mL). The organics were 
extracted with EtOAc (3 × 20 mL), dried (Na2SO4), filtered and concentrated in vacuo. 
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Purification by flash column chromatography (5% EtOAc/Hexane) provided sulfide 194 
(4.57 g, 94%), as a yellow oil. 
Rf 0.68 (15% EtOAc/Pet. Ether); 
€ 
[α]D20  +7.25 (c 0.9, CHCl3); IR (thin film) 2928, 2855, 
1597, 1086 cm-1; 1H NMR (300 MHZ, CDCl3) δ 7.61-7.51 (5H, m, ArH), 4.02-3.87 (2H, 
m, H16 + H19), 3.63-3.51 (3H, m, H15 + H20), 3.38 (2H, t, J = 7.3 Hz, H9), 1.95-1.74 (4H, 
m, H10 + H17a + H18a), 1.71-1.59 (2H, m, H17b + H18b), 1.48-1.29 (8H, m, H11-14), 0.88 (9H, 
s, SiC(CH3)3), 0.86 (9H, s, SiC(CH3)3), 0.05- 0.02 (12H, m, 2 × SiCH3); 13C NMR (75 
MHz, CDCl3) δ 154.5, 133.7, 130.0, 129.7, 123.8, 81.9, 79.6, 74.6, 65.9, 33.3, 32.5, 29.2, 
29.0, 28.6, 28.5, 27.1, 26.0, 25.9, 25.6, 18.3, 18.2, -4.2, -4.7, -5.3 (2C); HRMS (ES+) Calc 
for C31H60O3N5SSi2 [M+NH4]+ 638.3950, found 638.3938. 
 
(2R,5R)-2-(tert-butyldimethylsilyloxy)methyl)-5-[(1R)-(tert-butyldimethylsilyloxy)-7-
(sulfonyl-1-phenyl-1H-1,2,3,4-tetrazol-5-yl)heptyl]tetrahydrofuran (192) 
  
O
OTBS
S
9
16TBSO N
N
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PhO O  
 
 
To a solution of sulfide 194 (1.25 g, 2.01 mmol) in MeOH (20 mL) at 0 °C was added a 
solution of ammonium molybdate (249 mg, 0.20 mmol) and H2O2 (2.28 mL, 30% v/v 
solution in H2O, 20.1 mmol) in HMPA (2 mL). After 20 h, the reaction mixture was 
quenched by the addition of H2O (20 mL). The organics were extracted with CH2Cl2 (3 × 
15 mL), dried (Na2SO4), filtered and concentrated in vacuo. Purification by flash column 
chromatography (10% EtOAc/Pet. Ether) provided sulfone 192 (1.06 g, 81%), as a 
colourless oil. 
Rf 0.43 (10% EtOAc/Pet. Ether); 
€ 
[α]D20  +5.0 (c 0.76, CHCl3); IR (thin film) 2928, 2857, 
1342, 1088 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.72-7.68 (2H, m, ArH), 7.64-7.58 (3H, 
m, ArH), 4.03-3.97 (1H, m, H19), 3.95-3.90 (1H, m, H16), 3.75-3.71 (2H, m, H9), 3.64-3.48 
(3H, m, H15 + H20), 1.99-1.84 (2H, m, H10 + H17a + H18a), 1.72-1.64 (2H, m, H17b + H18b), 
1.54-1.43 (3H, m, H11 + H14a), 1.42-1.29 (5H, m, H12-13 + H14b), 0.89 (9H, s, SiC(CH3)3), 
0.88 (9H, s, SiC(CH3)3), 0.06-0.04 (12H, m, 2 × SiCH3); 13C NMR (75 MHz, CDCl3) δ 
153.4, 133.0, 131.4, 129.7, 125.0, 81.9, 79.6, 74.6, 65.9, 55.9, 32.4, 29.1, 28.5, 28.1, 27.1, 
25.9, 25.9, 25.4, 21.9, 18.3, 18.2, -4.2, -4.7, -5.3 (2C); HRMS (ES+) Calc for 
C31H60O5N5SSi2 [M+NH4]+ 670.3848, found 670.3837. 
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(2R,5R)-2-[(tert-butyldimethylsilyloxy)methyl]-5-[(1R,7E)-1-(tert-
butyldimethylsilyloxy)-13-(5S)-3-(5-methyl-2,5-dihydrofuran-2-one)tridec-7-
ene]tetrahydrofuran (195) 
 
 
O
OTBS
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O
1
 
 
 
To a solution of sulfone 192 (41.4 mg, 63.0 µmol) in THF (3 mL) at -78 °C was added 
NaHMDS (470 µL, 0.2 M solution in THF, 94.0 µmol). After 10 min, a solution of 
aldehyde 188 (48.9 mg, 250 µmol) in THF (2 mL) was added dropwise via cannula. The 
reaction mixture was warmed to -20 °C. After 2.5 h, saturated aqueous NH4Cl (2 mL) was 
added, and the reaction mixture was warmed to RT. The organics were extracted with 
EtOAc (3 x 5 mL) and the combined organic extracts were washed with brine (10 mL), 
dried (Na2SO4), filtered and concentrated in vacuo. Purification by flash column 
chromatography (15% EtOAc/Hexane) provided alkene 195 (33.5 mg, 85%) as a 
colourless oil.   
Rf 0.53 (15% Acetone/Hexane); 
€ 
[α]D20  +19.5 (c 0.81, CHCl3); IR (thin film) 2928, 2857, 
1761, 1653, 1084 cm-1; 1H NMR (300 MHz, CDCl3) δ 6.98 (1H, app q, J = 1.6 Hz, H35), 
5.45-5.32 (2H, m, H8 + H9), 4.99 (1H, qq, J = 6.7, 1.7 Hz, H36), 4.03-3.89 (2H, m, H16 + 
H19), 3.66-3.49 (3H, m, H15 +H20), 2.26 (2H, ddt, J = 8.6, 7.4, 1.6 Hz, H3), 2.04-1.80 (6H, 
m, H7 + H10 + H17a + H18a), 1.75-1.63 (2H, m, H17b + H18b), 1.55-1.50 (2H, m, H4), 1.46-
1.25 (12H, m, H5-6 + H11-14), 1.40 (3H, d, J = 6.8 Hz, H37), 0.89 (18H, m, 2 × SiC(CH3)3), 
0.06 (3H, s, SiCH3), 0.05 (3H, s, SiCH3), 0.05 (3H, s, SiCH3), 0.04 (3H, s, SiCH3); 13C 
NMR (75 MHz, CDCl3) δ 173.8, 148.8, 134.3, 130.6, 130.0, 82.0, 79.6, 77.2, 74.8, 66.0, 
32.5, 32.4, 29.7, 29.6, 29.4, 29.2, 28.6, 28.5, 27.2, 26.0, 26.0, 25.9, 25.8, 25.1, 19.2, 18.3, 
18.2, -4.2, -4.6, -5.3 (2C); HRMS (ES+) Calc. for C35H70O5NSi2 [M+NH4]+ 640.4787, 
found 640.4784. 
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(2R,5R)-5-[(1R,7E)-1-(tert-butyldimethylsilyloxy)-13-(5S)-3-(5-methyl-2,5-
dihydrofuran-2-one)tridec-7-ene]-2-(hydroxymethyl)-tetrahydrofuran (196) 
 
O
OTBS
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HO O
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To a solution of bis-tert-butyldimethylsilyl ether 195 (184 mg, 295 µmol) in 
MeOH/CH2Cl2 (3 mL, 1 : 4) at 0 ºC was added (±)-CSA (6.80 mg, 29.3 µmol). After 1.5 h, 
saturated aqueous NaHCO3 (5 mL) and CH2Cl2 (5 mL) were added. The organics were 
extracted with CH2Cl2 (3 × 10 mL) and the combined organic extracts were dried 
(Na2SO4), filtered and concentrated in vacuo. Purification by flash column 
chromatography (20%  EtOAc/Hexane) provided alcohol 196 (94.5 mg, 63%) as a 
colourless oil. 
Rf 0.45 (35% EtOAc/Hexane); 
€ 
[α]D20  +16.2 (c 0.87, CHCl3); IR (thin film) 3480, 2928, 
2855, 1755, 1082 cm-1; 1H NMR (400 MHz, CDCl3) 6.97 (1H, q, J =1.5 Hz, H35), 5.42-
5.29 (2H, m, H8 + H9), 4.98 (1H, qq, J = 6.8, 1.8 Hz, H36), 4.09-4.02 (1H, m, H19), 3.90 
(1H, dt, J = 7.9, 6.3 Hz, H16), 3.64-3.61 (1H, m, H20a), 3.58-3.54 (1H, m, H15), 3.46 (1H, 
dd, J = 11.5, 6.0 Hz, H20b), 2.25 (2H, ddt, J = 8.9, 7.3, 1.7 Hz, H3), 2.02-1.86 (6H, m, H7 + 
H10 + H17a + H18a), 1.73-1.61 (2H, m, H17b + H18b), 1.59-1.50 (2H, m, H4), 1.45-1.27 (12H, 
m, H5-6 + H11-14), 1.39 (3H, d, J = 6.8 Hz, H37), 0.88 (9H, s, SiC(CH3)3), 0.06 (3H, s, 
SiCH3), 0.04 (3H, s, SiCH3); 13C NMR (100 MHz ,CDCl3) δ 173.8, 148.8, 134.2, 130.5, 
130.0, 82.0, 79.4, 77.4, 75.0, 64.9, 32.9, 32.5, 32.4, 29.5, 29.3, 29.2, 28.6, 27.8, 27.7, 27.2, 
25.9, 25.5, 25.1, 19.2, 18.2, -4.2, -4.6; HRMS (ES+) Calc. for C29H56O5NSi [M+NH4]+ 
526.3922, found 526.3920. 
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(2R,5R)-5-[(1R,7E)-(tert-butyldimethylsilyloxy)-13-(5S)-3-(5-methyl-2,5-
dihydrofuran-2-one)tridec-7-ene]-2-oxo-tetrahydrofuran (191) 
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To a solution of alcohol 196 (143 mg, 0.28 mmol) in CH2Cl2 (4 mL) at 0 ºC was added 
NaHCO3 (118 mg, 1.40 mmol) followed by Dess-Martin periodinane (357 mg, 0.84 
mmol). The reaction mixture was stirred at 0 ºC for 30 min, followed by warming to RT 
over an additional 1 h. The reaction mixture was re-cooled to 0 ºC, prior to the addition of 
cold hexane (5 mL) and cold toluene (5 mL). The resultant white suspension was 
concentrated in vacuo to remove CH2Cl2 and purification by flash column chromatography 
(15% EtOAc/Hexane) provided aldehyde 191 (98.6 mg, 69%) as a colourless oil. 
Rf 0.55 (30% EtOAc/Hexane); 
€ 
[α]D20  +30.7 (c 1.08, CHCl3); IR (thin film) 2928, 2855, 
1755, 1736, 1080 cm-1; 1H NMR (300 MHz, CDCl3) δ 9.64 (1H, d, J = 2.0 Hz, H20), 6.98 
(1H, app q, J = 1.5 Hz, H35), 5.43-5.30 (2H, m, H8 + H9), 4.98 (1H, qq, J = 6.8, 1.8 Hz, 
H36), 4.28 (1H, ddd, J = 7.7, 6.9, 2.0 Hz, H19), 4.07-4.00 (1H, m, H16), 3.61 (1H, app q, J = 
5.0 Hz, H15), 2.25 (2H, ddt, J = 8.9, 7.5, 1.6 Hz, H3), 2.20-2.11 (1H, m, H18a), 2.01-1.84 
(6H, m, H7 + H10 + H17a + H18b), 1.81-1.69 ( 1H, m, H17b), 1.59-1.46 (3H, m, H4 + H14a), 
1.44-1.22 (11H, m, H5-6 + H11-13 + H14b), 1.39 (3H, d, J = 6.8 Hz, H37), 0.87 (9H, s, 
SiC(CH3)3), 0.06 (3H, s, SiCH3), 0.05 (3H, s, SiCH3); 13C NMR (100 MHz ,CDCl3) δ 
203.0, 173.8, 148.8, 134.2, 130.4, 130.0, 83.3, 83.0, 77.4, 74.5, 33.1, 32.5, 32.4, 29.5, 29.3, 
29.2, 28.6, 27.5, 27.2, 26.9, 25.9, 25.4, 25.1, 19.2, 18.2, -4.3, -4.5; HRMS (ES+) Calc. for 
C29H54O5NSi [M+NH4]+ 524.3766, found 524.3755. 
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(2S,6S)-2-[(1S)-(tert-butyldimethylsilyloxy)-3-iodo-prop-2-ynyl]-6-
(hexyl)tetrahydropyran (212) 
 
O
34
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I
23
 
 
To a solution of alkyne 84 (203 mg, 0.60 mmol) and n-BuLi (750 µL, 1.6 M solution in 
hexane, 1.20 mmol) in THF (5 mL) at -78 °C was added a solution of iodine (191 mg, 0.75 
mmol) in THF (5 mL). After 2 h, saturated aqueous NH4Cl (10 mL) was added and the 
organics extracted with EtOAc (5 × 10 mL). The combined organic extracts were washed 
with brine (20 mL), dried (Na2SO4), filtered and concentrated in vacuo. Purification by 
flash column chromatography (2% EtOAc/Hexane) provided iodide 212 (274 mg, 98%) as 
a colourless oil. 
Rf 0.31 (5% EtOAc/Hexane); 
€ 
[α]D20  +1.4 (c 1.0, CHCl3); IR (thin film) 2930, 2857, 1472, 
1462, 1379, 1339, 1252 cm-1; 
1H NMR (400 MHz, C6D6) δ 4.62 (1H, d, J = 6.3 Hz, H23), 
3.41 (1H, ddd, J = 11.1, 6.3, 2.1 Hz, H24), 3.15-3.09 (1H, m, H28), 1.85-1.81 (1H, m, H25a), 
1.65-1.46 (2H, m, H26a + H29a), 1.39-1.16 (12H, m, H25b + H26b + H27a + H29b + H30-33), 
1.11-1.05 (1H, m, H27b), 1.01 (9H, s, SiC(CH3)3), 0.91 (3H, t, J = 6.9 Hz, H34), 0.21 (3H, s, 
SiCH3), 0.16 (3H, s, SiCH3); 13C NMR (400 MHz, C6D6) δ 94.6, 81.0, 78.1, 68.9, 36.9, 
32.3, 31.7, 29.9, 27.2, 26.1, 25.9, 23.5, 23.1, 18.6, 14.4, 2.5, -4.4, -4.7; HRMS (ES+) Calc. 
for C20H41O2NISi [M+NH4]+ 482.1946, found 482.1941. 
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(2S,6S)-2-[9-(benzyloxy)-(1S)-(tert-butyldimethylsilyloxy)-non-2-yn-4-ol]-6-
(hexyl)tetrahydropyran (213) 
 
O
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A suspension of NiCl2 (32.0 mg, 248 µmol) and CrCl2 (121 mg, 992 µmol) in dry degassed 
THF (2 mL) was stirred for 1 h at RT. To the green suspension was added, via canula, a 
solution of aldehyde 183 (50.9 mg, 0.25 mmol) and iodide 212 (163 mg, 351 µmol) in 
THF (3 mL). The resultant brown solution was stirred for 16 h at RT. To the soultion was 
added saturated aqueous NaHCO3 (5 mL) and EtOAc (5 mL) and the mixture filtered over 
celite. The organics were extracted with EtOAc (3 × 10 mL), washed with brine (15 mL), 
dried (Na2SO4), filtered and concentrated in vacuo. Purification by flash column 
chromatography (10% EtOAc/Hexane) provided alcohol 213 as a 1 : 1 mixture of C20 
diastereomers (87.4 mg, 65%), as an orange oil. 
Rf 0.61 (20% EtOAc/Hexane); IR (thin film) 3429, 2930, 2857, 1722, 1456, 1362, 1250 
cm-1; 1H NMR (300 MHz, CDCl3) δ 7.35-7.27 (5H, m, ArH), 4.50 (2H, s, OCH2Ar), 4.38 
(1H, br t, J = 6.5 Hz, H20), 4.32 (0.5H, dd, J = 6.6, 1.4 Hz, H23), 4.32 (0.5H, dd, J = 6.6, 1.5 
Hz, H23), 3.47 (2H, t, J = 6.6 Hz, H15), 3.30 (1H, ddd, J = 11.2, 6.7, 1.9 Hz, H24), 3.26-3.20 
(1H, m, H28), 1.87-1.59 (7H, m, H16 + H19 + H25a + H26), 1.55-1.36 (5H, m, H17 + H27a + 
H29), 1.32-1.11 (12H, m, H18 + H25b + H27b + H30-33), 0.91 (9H, s, SiC(CH3)3), 0.91-0.85 
(3H, m, H34), 0.13 (3H, s, SiCH3), 0.11 (3H, s, SiCH3); 13C NMR (300 MHz, CDCl3) δ 
138.6, 128.3, 127.6, 127.5, 86.3, 84.3, 80.6, 77.9, 72.9, 70.3, 66.9, 62.5, 37.6, 36.4, 31.8, 
31.3, 29.7, 29.4, 26.8, 25.9, 25.8, 25.4, 25.0, 23.3, 22.6, 18.3, 14.1, -4.7, -4.8; HRMS (CI+) 
Calc. for C33H60O4NSi [M+NH4]+ 562.4286, found 562.4275. 
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(1S,4S)-4-[(tert-butyldimethylsilyloxy)-(2S’,6S’)-6-hexyltetrahydropyran-2-yl]-1-
[(2R’’,5R’’)-5’’-(1R,7E)-1-(tert-butyldimethylsilyloxy)-13-[(5S)-3-(5-methyl-2,5-
dihydrofuran-2-one)tridec-7-ene)-tetrahydrofuran-2-yl]-but-2-yn-1-ol (214)   
and (1R,4S)-4-[(tert-butyldimethylsilyloxy)-(2S’,6S’)-6-hexyltetrahydropyran-2-yl]-1-
[(2R’’,5R’’)-5’’-(1R,7E)-1-(tert-butyldimethylsilyloxy)-13-[(5S)-3-(5-methyl-2,5-
dihydrofuran-2-one)tridec-7-ene)-tetrahydrofuran-2-yl]-but-2-yn-1-ol (215) 
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Method A 
To a solution of alkyne 84 (329 mg, 973 µmol) in THF (2 mL) at -78 ºC was added n-BuLi 
(425 µL, 1.6 M solution in hexane, 680 µmol). After 10 min, a solution of aldehyde 191 
(98.6 mg, 195 µmol) in THF (1 mL) was added via cannula. After 1.5 h, saturated aqueous 
NH4Cl (5 mL) and EtOAc (5 mL) were added. The organics were extracted with EtOAc (3 
× 5 mL), washed with brine (5 mL), dried (Na2SO4), filtered and concentrated in vacuo. 
Purification by flash column chromatography (5% EtOAc/Hexane) provided alkynes 214 
and 215 as a 3:1 mixture of C20 diastereomers (92.7 mg, 56%), as a colourless oil.  
 
Method B 
To a solution of alkyne 84 (100 mg, 296 µmol) in MTBE (1 mL) at 0 ºC was added n-BuLi 
(156 µL, 1.6 M solution in hexane, 248 µmol). The temperature was then lowered to -90 ºC 
and after 10 min a solution of aldehyde 191 (30.2 mg, 59.0 µmol) in MTBE (1 mL) was 
added via cannula. After 4 h, saturated aqueous NH4Cl (5 mL) and CH2Cl2 (5 mL) were 
added. The organics were extracted with CH2Cl2 (3 × 5 mL), washed with brine (5 mL), 
dried (Na2SO4), filtered and concentrated in vacuo. Purification by flash column 
chromatography (5→10% EtOAc/Hexane) provided alkyne 214 (14.6 mg, 29%), as a 
colourless oil (> 95:5 C20 diastereomer).  
Rf 0.53 (20% EtOAc/Hexane); 
€ 
[α]D20  +19.4 (c 0.84, CHCl3); IR (thin film) 3486, 2928, 
2855, 1759, 1099 cm-1; 
1H NMR (300 MHz, CDCl3) δ 6.98 (1H, app q, J = 1.5 Hz, H35), 
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5.45-5.30 (2H, m, H8-9), 4.99 (1H, qq, J = 6.7, 1.6 Hz, H36), 4.48-4.43 (1H, m, H20), 4.33-
4.28 (1H, m, H23), 4.15-4.08 (1H, m, H19), 4.06-3.99 (1H, m, H16), 3.58-3.51 (1H, m, H15), 
3.30 (1H, ddd, J = 11.1, 6.1, 1.8 Hz, H24), 3.25-3.21 (1H, m, H28), 2.27 (2H, ddt, J = 8.9, 
7.6, 1.6 Hz, H3), 2.02-1.67 (8H, m, H7 + H10 + H17 + H18a + H25a), 1.58-1.49 (3H, m, H4 + 
H27a), 1.46-1.24 (25H, m, H5-6 + H11-14 + H18b + H26 + H29-33), 1.40 (3H, d, J = 6.8 Hz, H37), 
1.21-1.11 (2H, m, H25b + H27b), 0.91-0.85 (21H, m, H34 + 2 × SiC(CH3)3), 0.12 (3H, s, 
SiCH3), 0.10 (3H, s, SiCH3), 0.06 (3H, s, SiCH3), 0.05 (3H, s, SiCH3); 13C NMR (75 MHz, 
CDCl3) δ 173.7, 148.8, 134.2, 130.4, 130.0, 85.1, 83.2, 83.0, 81.4, 80.6 77.7, 77.3, 75.1, 
66.8, 64.5, 36.4, 33.0, 32.5, 32.3, 31.8, 31.3, 29.5, 29.4, 29.2, 28.6, 27.8, 27.2, 26.8, 26.6, 
25.9, 25.7, 25.4, 25.3, 25.1, 23.2, 22.6, 19.1, 18.2, 18.2, 14.0, -4.2, -4.6, -4.7, -4.9; HRMS 
(ES+) Calc. for C49H92O7NSi2 [M+NH4]+ 862.6407, found 862.6405. 
 
(1S,4S)-4-[(tert-butyldimethylsilyloxy)-(2S’,6S’)-6-hexyltetrahydropyran-2-yl]-1-
[(2R’’,5R’’)-5’’-(1R)-(tert-butyldimethylsilyloxy)-13-[(5S)-3-(5-methyl-2,5-
dihydrofuran-2-one)tridecyl)-tetrahydrofuran-2-yl]-butan-1,4-diol (216) 
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Method A 
A solution of alkynes 214 and 215 (65.1 mg, 77.0 µmol) and TsNHNH2 (860 mg, 4.62 
mmol) in DME (7 mL) was heated to reflux. To the reaction solution was added NaOAc 
(628 mg, 4.62 mmol) in H2O (7 mL) over 3 h. The reaction mixture was cooled and diluted 
with H2O (5 mL) and EtOAc (5 mL). The organics were extracted with EtOAc (3 x 5 mL) 
and the combined organic extracts were washed with 3 N HCl (3 x 5 mL), NaHCO3 (10 
mL) and brine (10 mL), dried (Na2SO4), filtered and concentrated in vacuo. Purification by 
flash column chromatography (5% EtOAc/Hexane) provided a readily separable mixture 
of diasteromers alkane 216 (22.0 mg, 34%) and alkane 217 (8.00 mg, 12%), as colourless 
oils. 
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Method B 
A solution of alkyne 214 (14.6 mg, 17.0 µmol) and TsNHNH2 (193 mg, 1.04 mmol) in 
DME (1 mL) was heated to reflux. To the reaction solution was added NaOAc (141 mg, 
1.04 mmol) in H2O (1 mL) over 3 h. The reaction mixture was cooled and diluted with 
H2O (3 mL) and EtOAc (5 mL). The organics were extracted with EtOAc (3 x 5 mL) and 
the combined organic extracts were washed with 3 N HCl (3 x 5 mL), NaHCO3 (10 mL) 
and brine (10 mL), dried (Na2SO4), filtered and concentrated in vacuo. Purification by 
flash column chromatography (5→10% EtOAc/Hexane) provided alkane 216 (13.3 mg, 
90%), as a colourless oil. 
Rf 0.57 (20%EtOAc/Hexane); 
€ 
[α]D20  +7.76 (c 0.98, CHCl3); IR (thin film) 3495, 2928, 
2855, 1759, 1086 cm-1; 1H NMR (400 MHz, CDCl3) δ 6.99 (1H, app q, J = 1.5 Hz, H35), 
4.99 (1H, qq, J = 6.8, 1.6 Hz, H36), 3.90 (1H, dt, J = 8.2, 6.3 Hz, H16), 3.83 (1H, td, J = 7.1, 
3.5 Hz, H19), 3.75-3.71 (1H, m, H20), 3.64 (1H, app q, J = 5.5 Hz, H23), 3.55-3.51 (1H, m, 
H15), 3.28-3.20 (2H, m, H24 + H28), 2.26 (2H, ddt, J = 8.9, 7.2, 1.7 Hz, H3), 1.95-1.78 (4H, 
H17a + H18 + H26a), 1.69-1.51 (7H, m, H4 + H17b + H22 + H25a + H27a), 1.49-1.21 (33H, m, 
H5-14 + H21 + H26b + H29-33), 1.40 (3H, d, J = 6.8 Hz, H37), 1.19-1.07 (2H, m, H25b + H27b), 
0.89-0.88 (21H, m, H34 + 2 × SiC(CH3)3), 0.07-0.05 (12H, m, 2 × SiCH3); 13C NMR (75 
MHz, CDCl3) δ 173.9, 148.8, 134.3, 82.5, 82.2, 80.8, 78.0, 77.4, 75.4, 74.5, 72.0, 36.4, 
33.0, 31.8, 31.4, 29.8, 29.6 (2C), 29.5, 29.5, 29.3, 29.2, 28.8, 28.5, 28.0, 27.4, 26.0 (2C), 
26.0 (2C), 25.7, 25.6, 25.4, 25.3, 25.2, 23.6, 22.6, 19.2, 18.3, 18.2, 14.1, -4.1, -4.2, -4.57, -
4.59; HRMS (ES+) Calc. for C49H94O7Si2Na [M+Na]+ 873.6436, found 873.6443. 
 
(1R,4S)-4-[(tert-butyldimethylsilyloxy)-(2S’,6S’)-6-hexyltetrahydropyran-2-yl]-1-
[(2R’’,5R’’)-5’’-(1R)-(tert-butyldimethylsilyloxy)-13-[(5S)-3-(5-methyl-2,5-
dihydrofuran-2-one)tridecyl)-tetrahydrofuran-2-yl]-butan-1,4-diol (217) 
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Rf 0.63 (20% EtOAc/Hexane); 
€ 
[α]D20  +3.33 (c 0.63, CHCl3); IR (thin film) 3482, 2926, 
2855, 1761, 1086 cm-1; 1H NMR (400 MHz, CDCl3) δ 6.99 (1H, app q, J = 1.5 Hz, H35), 
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4.99 (1H, qq, J = 7.0, 2.2 Hz, H36), 3.88-3.83 (1H, m, H19), 3.80-3.75 (1H, m, H16), 3.61-
3.53 (2H, m, H20 + H23), 3.38-3.34 (1H, m, H15), 3.26-3.19 (2H, m, H24 + H28), 2.29-2.24 
(2H, m, H3), 1.93-1.88 (2H, m, H17a + H18a), 1.86-1.80 (2H, m, H22a + H26a), 1.63-1.60 (3H, 
m, H14a + H17b + H18b), 1.58-1.48 (5H, m, H4 + H25a + H26b + H27a), 1.45-1.22 (32H, m, H5-
13 + H14b + H21 + H22b + H29-33), 1.40 (3H, d, J = 6.8 Hz, H37), 1.20-1.03 (2H, m, H25b + 
H27b), 0.90-0.87 (21H, m, H34 + 2 × SiC(CH3)3), 0.07-0.05 (12H, m, 2 × SiCH3); 13C NMR 
(75 MHz, CDCl3) δ 173.9, 148.8, 134.3, 82.6, 82.2, 81.1, 78.0, 77.2, 75.3, 75.0, 74.7, 36.4, 
33.2, 31.9, 31.9, 31.4, 29.9, 29.7, 29.6, 29.5, 29.5, 29.4, 29.3, 29.2, 28.6, 28.4, 27.4, 26.0, 
26.0, 25.8, 25.8, 25.6, 25.5, 25.3, 25.2, 23.7, 22.7, 22.6, 19.2, 18.3, 14.1, -4.1, -4.1, -4.6 
(2C); HRMS (ES+) Calc. for C49H94O7Si2Na [M+Na]+ 873.6436, found 873.6446.  
 
Chamuvarinin (72) 
O O O
O
O
OH
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To a solution of alcohol 216 (9.50 mg, 11.0 µmol) in CH2Cl2 (1 mL) at 0 ºC was added 
Et3N (11.0 µL, 78.0 µmol) and MsCl (4.3 µL, 56.0 µmol). After 1.5 h, saturated aqueous 
NH4Cl (2 mL) and CH2Cl2 (5 mL) were added. The organics were extracted with CH2Cl2 
(3 × 5 mL) and the combined organic extracts were washed with H2O (5 mL), brine (5 
mL), dried (Na2SO4), filtered and concentrated in vacuo. The crude mesylate was dissolved 
in CH2Cl2/MeOH (2.5 mL, 1 : 4), cooled to 0 °C and 3 N HCl (0.3 mL) was added. After 2 
h with warming to RT, the reaction mixture was quenched by the addition of saturated 
aqueous NaHCO3 (5 mL). The organics were extracted with CH2Cl2 (3 x 5 mL). The 
combined organic extracts were washed with brine (10 mL), dried (Na2SO4), filtered and 
concentrated in vacuo. The crude diol was dissolved in pyridine (1 mL) and heated to 65 
°C. After 16 h, H2O (2 mL) was added and the organics extracted with CH2Cl2 (3 × 5 mL). 
The combined organic layers were dried (Na2SO4) and concentrated in vacuo. Purification 
by flash column chromatography (10→25% EtOAc/Hexane) afforded chamuvarinin 72 
(3.8 mg, 57% over 3 steps) as a colourless oil. Data identical in all respects to 80. 
€ 
[α]D20  +7.9 (c 0.28, CHCl3). 
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8.6 Experimental details for Chapter 5 
 
(2R,5R)-2-(hydroxymethyl)-5-[(1R)-(hydroxy)-7-(hydroxyheptyl]tetrahydrofuran 
(226) 
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To a solution of benzyl ether 146 (32.7 mg, 102 µmol) in EtOH (3 mL) at RT was added 
Pd(OH)2 on carbon (14.2 mg, 20% wt on carbon, 20.3 µmol). The reaction system was 
purged with H2 and left under a positive pressure of H2. After 1 h, the reaction mixture was 
filtered through Celite with EtOH (15 mL). The filtrate was concentrated under reduced 
pressure and purification by flash column chromatography (5% MeOH/CH2Cl2) provided 
triol 226 (18.3 mg, 78%), as a colourless oil. 
Rf 0.05 (80% EtOAc/Hexane); 
€ 
[α]D20  +5.39 (c 1.55, CHCl3); IR (thin film) 3385, 2928, 
2857, 1653 cm-1: 1H NMR (300 MHz, CDCl3) δ 4.12-4.06 (1H, m, H19), 3.84-3.78 (1H, m, 
H16), 3.74-3.58 (3H, m, H9 + H20a), 3.49 (1H, dd, J = 11.7, 6.2 Hz, H20b), 3.43-3.37 (1H, m, 
H15), 2.03-1.90 (2H, m, H17a + H18a), 1.77-1.62 (2H, m, H17b + H18b), 1.56-1.51 (3H, m, H10 
+ H14a), 1.37-1.34 (7H, m, H11-13 + H14b); 13C NMR (75 MHz, CDCl3) δ 82.9, 79.8, 74.1, 
64.7, 62.8, 33.1, 32.6, 29.3, 28.5, 27.8, 25.6, 25.4; HRMS (CI+) Calc. for C12H25O4 
[M+H]+ 233.1747, found 233.1747. 
 
(1S,4S)-4-[(2S’,6S’)-6-hexyltetrahydropyran-2-yl]-1-[(2R’’,5R’’)-5’’-(1R)-(1,7-
dihydroxyheptyl)-tetrahydrofuran-2-yl]-butan-1,4-diol (227) 
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To a solution of benzyl ether 173 (30.3 mg, 39.0 µmol) in EtOH (3 mL) at RT was added 
Pd(OH)2 on carbon (5.50 mg, 20% wt on carbon, 7.80 µmol). The reaction system was 
purged with H2 and left under a positive pressure of H2. After 1.5 h, the reaction mixture 
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was filtered through Celite with EtOH (15 mL). The filtrate was concentrated in vacuo and 
purification by flash column chromatography (30% EtOAc/Hexanes) provided 
intermediate diol (18.4 mg, 69%), as a colourless oil. To a solution of diol (18.4 mg, 27.0 
µmol) in MeOH (5 mL) at 0 °C was added 3 N HCl (800 µL) and the solution warmed to 
RT. After 1 h, saturated aqueous NaHCO3 (4 mL) was added and the organics extracted 
with CH2Cl2 (3 × 5 mL). The combined organic layers were dried (Na2SO4), filtered and 
concentrated in vacuo. Purification by flash column chromatography (60→70% 
EtOAc/Hexane) afforded alcohol 227 (8.00 mg, 65%) as a colourless oil. 
Rf 0.15 (80% EtOAc/Hexane); 
€ 
[α]D20  +0.88 (c 0.8, CHCl3); IR (thin film) 3406, 2929, 2859 
cm-1; 1H NMR (400 MHz, CDCl3) δ 3.87-3.78 (2H, m, H16 + H19), 3.72 (1H, ddd, J = 9.2, 
4.3, 2.9 Hz, H20), 3.63 (2H, t, J = 6.6 Hz, H9), 3.44 (1H, ddd, J = 8.9, 7.0, 2.8 Hz, H23), 
3.40-3.36 (1H, m, H15), 3.30-3.24 (1H, m, H28), 3.14 (1H, ddd, J = 11.2, 7.0, 1.7 Hz, H24), 
3.09 (1H, broad s, OH), 2.44 (1H, broad s, OH), 2.05-1.84 (4H, m, H17a + H18 + H26a), 
1.78-1.64 (3H, m, H17b + H21a + H22a), 1.62-1.46 (7H, m, H10 + H21b + H22b + H25a + H26b + 
H27a), 1.45-1.26 (18H, m, H11-14 + H29-33), 1.26-1.12 (2H, m, H25b + H27b), 0.90 (3H, t, J = 
7.1 Hz, H34); 13C NMR (100 MHz, CDCl3) δ 83.1, 82.3, 80.5, 78.0, 74.3, 74.2, 72.3, 63.0, 
36.4, 33.1, 32.7, 31.8, 31.4, 29.4, 29.3, 29.2, 29.1, 28.5, 27.3, 26.4, 25.6, 25.6, 25.5, 23.2, 
22.6, 14.1; HRMS (ES+) Calc. for C26H51O6 [M+H]+ 459.3680, found 459.3679. 
 
(2R,5S)-5-[(2S’,6S’)-6-hexyltetrahydropyran-2-yl]-2-[(2R’’,5R’’)-5’’-(1,7-
dihydroxyheptyl)-tetrahydrofuran-2-yl]-tetrahydrofuran (228) 
 
O O O
OH
9
34
OH
 
 
To a solution of alcohol 82 (11.3 mg, 20.4 µmol) in MeOH (4 mL) at 0 °C was added 3 N 
HCl (800 µL) and the solution warmed to RT. After 1 h, saturated aqueous NaHCO3 (5 
mL) was added and the organics extracted with CH2Cl2 (3 × 5 mL). The combined organic 
layers were dried (Na2SO4), filtered and concentrated in vacuo. Purification by flash 
column chromatography (50% EtOAc/Hexane) afforded diol 228 (7.40 mg, 82%) as a 
colourless oil. 
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Rf 0.2 (40% EtOAc/Hexane); 
€ 
[α]D20  -4.62 (c 0.52, CHCl3); IR (thin film) 3443, 2929, 2857 
cm-1; 1H NMR (300 MHz, CDCl3) δ 3.96-3.80 (4H, m, H16 + H19 + H20 + H23), 3.63 (2H, t, 
J = 6.6 Hz, H9), 3.40-3.34 (1H, m, H15), 3.29 (1H, ddd, J = 11.1, 5.4, 1.8 Hz, H24), 3.23-
3.20 (1H, m, H28), 2.01-1.90 (2H, m, H17a + H18a), 1.89-1.77 (3H, m, H18b + H21a + H22a), 
1.76-1.69 (1H, m, H22b), 1.64-1.44 (8H, m, H10 + H17b + H21b + H25a + H26 + H27a), 1.43-
1.23 (19H, m, H11-14 + H25b + H29-33), 1.20-1.08 (1H, m, H27b), 0.87 (3H, t, J = 7.0 Hz, H34); 
13C NMR (75 MHz, CDCl3) δ 83.0, 82.1, 82.0, 81.5, 79.9, 77.9, 74.1, 63.0, 36.1, 33.4, 
32.7, 31.9, 31.4, 29.4, 29.4, 28.8, 28.3, 28.0, 27.4, 26.9, 25.6 (2C), 25.5, 23.5, 22.6, 14.1; 
HRMS (ES+) Calc. for C26H52O5N [M+NH4]+ 458.3840, found 458.3839. 
 
(R)-methyloxirane (231)47a 
O
36
 
To a solution of (R,R)-salen catalyst 87 (313 mg, 0.52 mmol) in toluene (6 mL) was added 
acetic acid (311 µL, 5.43 mmol). The solution was left for 30 min, open to air at RT. The 
resultant brown suspension was concentrated in vacuo. To the residue was added (±)-
propylene oxide 88 (18.1 mL, 259 mmol), the solution was cooled to 0 °C and H2O (2.57 
mL, 143 mmol) was added dropwise over 5 min. The solution was allowed to warm to RT 
and left for 16 h. Purification by vacuum transfer (36 °C, atm pressure) afforded (R)-
epoxide 231 (5.05 g, 34%) as a colourless liquid. 
€ 
[α]D20+18.2 (c 5.73, CCl4), lit 
€ 
[α]D20  +18.0 (c 5.73, CCl4)148; 1H NMR (300 MHz, CDCl3) δ 
3.02-2.97 (1H, m, H36), 2.76 (1H, dd, J = 4.7, 4.1 Hz, H35a), 2.44 (1H, dd, J = 5.1, 2.7 Hz, 
H35b), 1.32 (3H, d, J = 5.2 Hz, H37). 
  
(5R)-5-Methyl-3-(phenylsulfanyl)-dihydrofuran-2-one (232)45  
 
O
O
PhS
361
 
 
To a solution of diisopropylamine (8.31 mL, 58.9 mmol) in THF (70 mL) was added n-
BuLi (36.8 mL, 1.6 M solution in Hexane, 58.9 mmol,) at 0 °C for 15 min. The solution 
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was cooled to -78 °C and a solution of (phenylthio)acetic acid 89 (4.50 g, 26.8 mmol) in 
THF (10 mL) was added. After 1 h at -78 °C, (R)-propylene oxide 231 (2.24 mL, 32.1 
mmol) was added in one portion and the solution was warmed to RT and stirred overnight. 
The solution was diluted with Et2O (40 mL) and 6 N HCl (60 mL) was added. The 
organics were extracted with Et2O (3 × 50 mL) and the combined organic extracts were 
dried (MgSO4), filtered and concentrated in vacuo. The resultant oil was dissolved in 
toluene (45 mL) and p-TsOH (107 mg, 563 µmol) was added and the reaction mixture was 
left at RT overnight. After addition of MgSO4 the solution was stirred for 15 min, filtered 
and concentrated in vacuo. Purification by flash column chromatography (10% EtOAc/Pet. 
Ether) afforded a 2 : 1 diastereomeric mixture of lactone 232 (3.83 g, 68%) as a yellow oil.  
Rf 0.36 and 0.45 (20% EtOAc/Pet. Ether); 1H NMR (400 MHz, CDCl3) δ 7.58-7.52 (4H, 
m, ArH), 7.40-7.29 (6H, m, ArH), 4.60-4.48 (2H, m, H36 major + H36 minor), 3.97 (1H, dd, J = 
10.7, 9.0 Hz, H2 minor), 3.91 (1H, dd, J = 8.5, 3.7 Hz, H2 major), 2.74 (1H, ddd, J = 13.2, 9.0, 
6.0 Hz, H35a minor), 2.38 (1H, ddd, J = 13.7, 6.3, 3.7 Hz, H35a major), 2.26 (1H, dt, J = 13.7, 
8.3 Hz, H35b major), 1.85 (1H, ddd, J = 13.2, 10.7, 9.1 Hz, H35b minor), 1.37 (3H, d, J = 6.3 Hz, 
H37 major), 1.34 (3H, d, J = 6.2 Hz, H37 minor). 
 
(5R)-3-(6-(benzyloxy)hexyl)-5-methyl-3-(phenylsulfanyl)-dihydrofuran-2-one (233) 
 
 
O
O
BnO
PhS
1
36
8
 
 
 
To a solution of diisopropylamine (1.10 mL, 7.78 mmol) in THF (12 mL) was added n-
BuLi (5.58 mL, 1.6 M solution in hexane, 8.92 mmol) at 0 °C for 15 min. The solution was 
cooled to -78 °C and a solution of lactone R-232 (1.50 g, 7.14 mmol) in THF (3 mL) was 
added dropwise. After 30 min, a solution of iodide 91 (2.50 g, 7.85 mmol) in DMPU (5.1 
mL, 1.55 mmol/mL of 91) was added in one portion and the reaction was allowed to warm 
to RT overnight. The solution was quenched by addition of 0.5 N HCl (20 mL) and the 
aqueous extracted with Et2O (4 × 25 mL). The combined organic extracts were dried 
(MgSO4), filtered and concentrated in vacuo. Purification by flash column chromatography 
(5% EtOAc/Pet. Ether) provided a 5 : 1 mixture of alkylated lactone diastereomers 233 
(2.14 g, 75%) as a yellow oil.    
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Rf 0.36 and 0.45 (15% EtOAc/Hexane); IR (thin film) 2934, 2859, 1763, 1186, 1105 cm-1; 
1H NMR (400 MHz, CDCl3) δ 7.57-7.51 (2H, m, ArH), 7.41-7.27 (8H, m, ArH), 4.93-4.44 
(3H, m, H36 + OCH2Ar), 3.45 (2H, t, J = 6.5 Hz, H8), 2.49 (1H, dd, J = 14.0, 7.6 Hz, H35a), 
1.95 (1H, dd, J = 13.9, 6.7 Hz, H35b), 1.81-1.73 (1H, m, H3a), 1.64-1.57 (3H, m, H3b + H7), 
1.42-1.23 (6H, m, H4-6), 1.18 (3H, d, J = 6.3 Hz, H37); 13C NMR (100 MHz, CDCl3) δ 
177.0, 138.5, 136.7, 130.3, 129.6, 128.9, 128.2, 127.5, 127.4, 73.1, 72.8, 70.1, 56.1, 40.0, 
36.3, 29.5, 29.3, 25.9, 24.5, 21.4; HRMS (ES+) Calc for C24H34O3NS [M+NH4]+ 416.2254, 
found 416.2252. 
 
(5R)-3-(6-(benzyloxy)hexyl)-5-methyl-2,5-dihydrofuran-2-one (234) 
 
O
O
BnO 1
36
8
 
 
 
To a solution of lactone 233 (2.14 g, 5.37 mmol) in CH2Cl2 (30 mL) at 0 °C was added m-
CPBA (1.30 g, 7.51 mmol). After 30 min, the reaction mixture was quenched by the 
addition of saturated aqueous NaHCO3 (20 mL) and the organics were extracted with 
CH2Cl2 (3 × 20 mL). The combined organic extracts were dried (MgSO4), filtered and 
concentrated. The residue was dissolved in toluene (25 mL) and the solution was heated at 
100 °C for 3 h, after which the reaction was cooled to RT and concentrated in vacuo. 
Purification by flash column chromatography (5% EtOAc/Pet. Ether) provided butenolide 
234 (1.16 g, 75%) as a colourless oil. 
Rf 0.23 (15% EtOAc/Hexane); 
€ 
[α]D20  -28.1 (c 1.11, CHCl3); IR (thin film) 2934, 2859, 
1751, 1117, 1074 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.37-7.27 (5H, m, ArH), 6.97 (1H, 
app q, J = 1.5 Hz, H35), 4.99 (1H, qq, J = 6.8, 1.8 Hz, H36), 4.49 (2H, s, OCH2Ar), 3.46 
(2H, t, J = 6.5 Hz, H8), 2.27 (2H, ddt, J = 8.6, 7.4, 1.7 Hz, H3), 1.66-1.51 (4H, m, H4 + H7), 
1.46-1.32 (4H, m, H5-6), 1.39 (3H, d, J = 6.8 Hz, H37); 13C NMR (75 MHz, CDCl3) δ 
173.8, 148.9, 138.6, 134.1, 128.3, 127.6, 127.4, 77.4, 72.8, 70.3, 29.6, 28.9, 27.3, 25.9, 
25.1, 19.2; HRMS (ES+) Calc for C18H25O3 [M+H]+ 289.1798, found 289.1800. 
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(5R)-3-(6-hydroxyhexyl)-5-methyl-2,5-dihydrofuran-2-one (235) 
 
O
O
HO 1
36
8
 
 
To a solution of benzyl ether 234 (1.16 g, 4.02 mmol) in CH2Cl2 (20 mL) at -15 °C was 
added BCl3·DMS (4.02 mL, 2.0 M solution in CH2Cl2, 8.04 mmol) dropwise. After 4 h, the 
reaction was quenched by the addition of saturaed aqueous NaHCO3 (20 mL) and the 
organics were extracted with Et2O (3 × 25 mL). The combined organic extracts were dried 
(MgSO4), filtered and concentrated in vacuo. Purification by flash column chromatography 
(50% EtOAc/Pet. Ether) provided alcohol 235 (680 mg, 85%), as a colourless oil.  
Rf 0.37 (60% EtOAc/Hexane); 
€ 
[α]D20  -41.0 (c 1.06, CHCl3); IR  (thin film) 3422, 2933, 
2860, 1740 cm-1; 1H NMR (300 MHz, CDCl3) δ 6.99 (1H, app q, J = 1.5 Hz, H35), 4.99 
(1H, qq, J = 6.8, 1.8 Hz, H36), 3.63 (2H, t, J = 6.5 Hz, H8), 2.27 (2H, ddt, J = 8.6, 7.5, 1.7 
Hz, H3), 1.61-1.51 (4H, m, H4 + H7), 1.44-1.35 (4H, m, H5-6), 1.40 (3H, d, J = 6.8 Hz, H37); 
13C NMR (75 MHz, CDCl3) δ 173.9, 149.1, 134.0, 77.4, 62.6, 32.4, 28.8, 27.3, 25.3, 25.0, 
19.1; HRMS (ES+) Calc for C11H19O3 [M+H]+ 199.1329, found 199.1328. 
 
6-[(5R)-5-methyl-2-oxo-2,5-dihydrofuran-3-yl]hexanal (230) 
 
 
O
O
O
H
1
36
8
 
 
 
To a solution of alcohol 235  (83.4 mg, 0.42 mmol) in CH2Cl2 (3 mL) at 0 °C was added 
NaHCO3 (178 mg, 2.10 mmol) and Dess-Martin periodinane (540 mg, 1.27 mmol). The 
reaction mixture was kept at 0 °C for 30 min and then warmed to RT for 1 h. The reaction 
mixture was cooled to 0 °C and addition of cold hexane (5 mL) and cold toluene (5 mL) 
afforded a white suspension. The suspension was filtered through celite and washed with 
hexane. The filtrate was concentrated in vacuo and purification by flash column 
chromatography (50% EtOAc/Pet. Ether) provided aldehyde 230 (70.0 mg, 85%) as a 
colourless oil, which was used without further characterization. 
  Experimental
   
 198 
Rf 0.63 (60% EtOAc/Hexane); IR (thin film) 2936, 2862, 1749, 1722 cm-1; 1H NMR (300 
MHz, CDCl3) δ 9.73 (1H, t, J = 1.7 Hz, H8), 6.99 (1H, app q, J = 1.5 Hz, H35), 4.99 (1H, 
qq, J = 6.8, 1.7 Hz, H36), 2.45 (2H, td, J = 7.2, 1.7 Hz, H7),  2.27-2.21 (2H, m, H3), 1.67-
1.49 (4H, m, H4 + H6), 1.41-1.31 (2H, m, H5), 1.37 (3H, d, J = 6.8 Hz, H37). 
 
 
(2R,5S)-2-[(2R’,5R’)-5’-(1R,7E)-1-(tert-butyldimethylsilyloxy)-13-[(5R)-3-(5-methyl-
2,5-dihydrofuran-2-one)tridec-7-ene)-tetrahydrofuran-2-yl]-5-[(2S’’,6S’’)-6-
hexyltetrahydropyran-2-yl] tetrahydrofuran (236) 
 
15
28
34
O O O
OTBS
O
O
1
 
 
 
To a solution of sulfone 189 (23.3 mg, 31.0 µmol) in THF (4 mL) at -78 °C was added 
NaHMDS (203 µL, 0.2 M solution in THF, 40.6 µmol). After 10 min, a solution of 
aldehyde 230 (29.9 mg, 152 µmol) in THF (2 mL) was added dropwise via cannula. The 
reaction mixture was warmed to -20 °C. After 4 h, saturated aqueous NH4Cl (2 mL) was 
added, and the reaction mixture was warmed to RT. The organics were extracted with 
EtOAc (3 x 5 mL) and the combined organic extracts were washed with brine (10 mL), 
dried (Na2SO4), filtered and concentrated in vacuo. Purification by flash column 
chromatography (20% EtOAc/Hexane) provided 236 (15.8 mg, 71%) as a colourless oil.   
Rf 0.53 (25% EtOAc/Hexane); 
€ 
[α]D20  -5.94 (c 1.58, CHCl3); IR (NaCl) 2930, 2857, 1759, 
1080 cm-1; 1H NMR (400 MHz, CDCl3) δ 6.98 (1H, app q, J = 1.5 Hz, H35), 5.43-5.32 
(2H, m, H8 + H9), 4.99 (1H, qq, J = 6.8, 1.8 Hz, H36), 3.98-3.90 (2H, m, H16 + H19), 3.88-
3.82 (2H, m, H20 + H23), 3.63-3.59 (1H, m, H15), 3.29 (1H, ddd, J = 11.4, 5.6, 1.4 Hz, H24), 
3.25-3.20 (1H, m, H28), 2.26 (2H, ddt, J = 8.7, 7.1, 1.6 Hz, H3), 2.02-1.93 (4H, m, H7 + 
H10), 1.91-1.77 (5H, m, H17a + H18a + H21a + H22a + H26a), 1.76-1.63 (4H, m, H17b + H18b + 
H21b + H22b), 1.58-1.45 (6H, m, H4 + H14a + H25a + H26b + H27a), 1.41-1.23 (22H, m, H5-6 + 
H11-13 + H14b + H25b + H29-33), 1.40 (3H, t, J = 6.8 Hz, H37), 1.20-1.08 (1H, m, H27b), 0.88-
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0.87 (12H, m, SiC(CH3)3 + H34), 0.06 (3H, s, SiCH3), 0.04 (3H, s, SiCH3); 13C NMR (100 
MHz, CDCl3) δ 173.8, 148.8, 134.3, 130.6, 129.9, 82.3, 81.9, 81.8, 81.5, 80.1, 77.8, 77.4, 
74.7, 36.5, 32.6, 32.4, 32.2, 31.9, 31.5, 29.6, 29.5, 29.4, 29.2, 28.6, 28.3, 27.9, 27.5, 27.2, 
27.0, 26.7, 26.0, 25.8, 25.5, 25.1, 23.5, 22.6, 19.2, 18.2, 14.1, -4.2, -4.6; HRMS (ES+) Calc 
for C43H76O6SiNa [M+Na]+ 739.5309, found 739.5302. 
 
36-epi chamuvarinin (229) 
 
O O O
O
O
OH
1528
34
36
 
 
 
A solution of alkene 236 (8.70 mg, 12.0 µmol) and TsNHNH2 (135.5 mg, 728 µmol) in 
DME (1.1 mL) was heated to reflux. To the reaction solution was added NaOAc (99.0 mg, 
728 µmol) in H2O (1.1 mL) over 3 h. The reaction mixture was cooled and diluted with 
H2O (3 mL) and EtOAc (3 mL). The organics were extracted with EtOAc (3 x 5 mL) and 
the combined organic extracts were washed with 3 N HCl (3 x 5 mL), NaHCO3 (10 mL) 
and brine (10 mL), dried (Na2SO4), filtered and concentrated in vacuo. The crude residue 
was filtered through silica (20% EtOAc/Hexane) and the filtrate concentrated in vacuo. 
The crude alkane was redissolved in MeOH (2 mL) with stirring at 0 °C and 3 N HCl (0.5 
mL) was added. After 45 min with warming to RT, the reaction mixture was quenched by 
the addition of saturated aqueous NaHCO3 (3 mL). The organics were extracted with 
CH2Cl2 (3 x 5 mL). The combined organic extracts were dried (Na2SO4), filtered and 
concentrated in vacuo. Purification by flash column chromatography (40% 
EtOAc/Hexane) provided 36-epi chamuvarinin 229 (5.40 mg, 74%), as a colourless oil.   
Rf 0.12 (25% EtOAc/Hexane); 
€ 
[α]D20  -11.9 (c 0.52, CHCl3); IR (NaCl) 3487, 2926, 2855, 
1755 cm-1; 1H NMR (500 MHz, CDCl3) δ 6.98 (1H, app q, J = 1.5 Hz, H35), 4.99 (1H, qq, 
J = 6.7, 1.7 Hz, H36), 3.93 (1H, dt, J = 7.8, 6.1 Hz, H19), 3.90-3.87 (1H, m, H23), 3.86-3.81 
(2H, m, H16 + H20), 3.39-3.35 (1H, m, H15), 3.29 (1H, ddd, J = 11.4, 5.4, 1.9 Hz, H24), 
3.26-3.21 (1H, m, H28), 2.26 (2H, ddt, J = 8.8, 7.5, 1.5 Hz, H3), 2.01-1.91 (2H, m, H17a + 
H18a), 1.88-1.80 (3H, m, H17b + H22a + H26a), 1.78-1.59 (4H, m, H18b + H21 + H22b), 1.57-
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1.44 (5H, m, H4 + H25a + H26b + H27a), 1.42-1.22 (33H, m, H5-14 + H25b + H29-33), 1.40 (3H, 
d, J = 6.8 Hz, H37), 1.18-1.10 (1H, m, H27b), 0.87 (3H, t, J = 6.7 Hz, H34); 13C NMR (125 
MHz, CDCl3) δ 173.9, 148.8, 134.3, 83.1, 82.1, 82.0, 81.4, 79.9, 77.8, 77.4, 74.1, 36.5, 
33.5, 31.9, 31.4, 29.8, 29.7, 29.6 (2C), 29.6, 29.5, 29.4, 29.3, 29.2, 28.8, 28.3, 28.0, 27.4 
(2C), 26.9, 25.7, 25.5, 25.2, 23.5, 22.6, 19.2, 14.1; HRMS (ES+) Calc for C37H68O6N 
[M+NH4]+ 622.5041, found 622.5038. 
 
(2R,5S)-2-[(2R’,5R’)-5’-(1R,7E)-1-(hydroxy)-13-[(5S)-3-(5-methyl-2,5-dihydrofuran-2-
one)tridec-7-ene)-tetrahydrofuran-2-yl]-5-[(2S’’,6S’’)-6-hexyltetrahydropyran-2-
yl]tetrahydrofuran (237) 
 
15
28
34
O O O
OH
O
O
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To a solution of alkene 182 (900 µg, 1.25 µmol) in MeOH (1 mL) with stirring at 0 °C was 
added 3 N HCl (100 µL). After 45 min with warming to RT, the reaction mixture was 
quenched by the addition of saturated aqueous NaHCO3 (3 mL). The organics were 
extracted with CH2Cl2 (3 x 5 mL). The combined organic extracts were dried (Na2SO4), 
filtered and concentrated in vacuo. Purification by flash column chromatography (25% 
EtOAc/Hexane) provided alkene 237 (200 µg, 26%), as a colourless oil.   
Rf 0.17 (25% EtOAc/Hexane); 
€ 
[α]D20  +44.1 (c 0.02, CHCl3); IR (thin film) 3509, 2920, 
2851, 1751, 1458, 1076 cm-1; 1H NMR (500 MHz, CDCl3) δ 6.98 (1H, m, H35), 5.42-5.34 
(2H, m, H8 + H9), 5.02-4.99 (1H, m, H36), 3.93 (1H, dt, J = 7.6, 6.1 Hz, H19), 3.89 (1H, dt, 
J = 6.6, 5.6 Hz, H23), 3.86-3.82 (2H, m, H16 + H20), 3.39-3.35 (1H, m, H15), 3.31-3.27 (1H, 
m, H24), 3.26-3.21 (1H, m, H28), 2.28-2.25 (2H, m, H3), 2.04-1.92 (6H, m, H7 + H10 + H17a 
+ H18a), 1.87-1.80 (3H, m, H17b + H22a + H26a), 1.77-1.68 (2H, m, H18b + H22b), 1.63-1.46 
(7H, m, H4 + H21 + H25a + H26b + H27a), 1.42-1.22 (23H, m, H5-6 + H11-14 + H25b + H29-33), 
1.40 (3H, d, J = 6.8 Hz, H37), 1.18-1.10 (1H, m, H27b), 0.87 (3H, m, H34); 13C NMR (125 
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MHz, CDCl3) δ 174.1, 148.9, 134.3, 130.6, 130.0, 83.1, 82.1, 82.0, 81.5, 79.9, 77.8, 77.4, 
74.1, 36.5, 32.5, 32.4, 31.9, 31.4, 29.7, 29.6, 29.4, 29.3, 29.2, 28.8, 28.6, 28.3, 28.0, 27.4, 
27.2, 26.9, 25.6, 25.5, 25.1, 23.5, 22.6, 19.2, 14.1; HRMS (ES+) Calc for C37H62O6Na 
[M+Na]+ 625.4444, found 625.4420. 
 
 (2R,5S)-2-[(2R’,5R’)-5’-(1R,7E)-1-(hydroxy)-13-[(5R)-3-(5-methyl-2,5-dihydrofuran-
2-one)tridec-7-ene)-tetrahydrofuran-2-yl]-5-[(2S’’,6S’’)-6-hexyltetrahydropyran-2-
yl]tetrahydrofuran (238) 
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To a solution of alkene 236 (8.00 mg, 11.0 µmol) in MeOH (2 mL) with stirring at 0 °C 
was added 3 N HCl (800 µL). After 45 min with warming to RT, the reaction mixture was 
quenched by the addition of saturated aqueous NaHCO3 (3 mL). The organics were 
extracted with CH2Cl2 (3 x 5 mL). The combined organic extracts were dried (Na2SO4), 
filtered and concentrated in vacuo. Purification by flash column chromatography (30% 
EtOAc/Hexane) provided alkene 238 (6.00 mg, 89%), as a colourless oil.   
Rf 0.12 (25% EtOAc/Hexane); 
€ 
[α]D20  -11.1 (c 0.64, CHCl3); IR (NaCl) 3447, 2926, 2855, 
1755 cm-1; 1H NMR (400 MHz, CDCl3) δ 6.98 (1H, app q, J = 1.5 Hz, H35), 5.42-5.32 
(2H, m, H8 + H9), 4.99 (1H, qq, J = 6.7, 1.4 Hz, H36), 3.96-3.88 (2H, m, H19 + H23), 3.86-
3.81 (2H, m, H16 + H20), 3.39-3.35 (1H, m, H15), 3.29 (1H, ddd, J = 11.3, 5.5, 1.6 Hz, H24), 
3.25-3.21 (1H, m, H28), 2.51 (1H, d, J = 3.2 Hz, OH), 2.28-2.24 (2H, ddt, J = 8.9, 7.4, 1.6 
Hz, H3), 2.01-1.91 (6H, m, H7 + H10 + H17a + H18a), 1.87-1.71 (5H, m, H17b + H18b + H22 + 
H26a), 1.68-1.45 (7H, m, H4 + H21 + H25a + H26b + H27a), 1.44-1.23 (23H, m, H5-6 + H11-14 + 
H25b + H29-33), 1.40 (3H, d, J = 6.8 Hz, H37), 1.16-1.09 (1H, m, H27b), 0.87 (3H, t, J = 6.6 
Hz, H34); 13C NMR (125 MHz, CDCl3) δ 173.9, 148.9, 134.2, 130.6, 130.0, 83.1, 82.1 
82.0, 81.5, 79.9, 77.8, 77.4, 74.1, 36.5, 33.4, 32.5, 32.4, 31.9, 31.4, 29.6, 29.4, 29.3, 29.2, 
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28.8, 28.6, 28.3, 28.0, 27.4, 27.2, 26.9, 25.6, 25.5, 25.1, 23.5, 22.6, 19.2, 14.1; HRMS 
(ES+) Calc for C37H66O6N [M+NH4]+ 620.4885, found 620.4881. 
 
(2R,5R)-2-(hydroxymethyl)-5-[(1R)-(hydroxy)-13-(5S)-3-(5-methyl-2,5-dihydrofuran-
2-one)tridecyl] tetrahydrofuran (239)  
 
O
OH
20
HO O
O
1
 
 
A solution of alkene 195 (24.5 mg, 39.0 µmol) and TsNHNH2 (439 mg, 2.36 mmol) in 
DME (4 mL) was heated to reflux. To the reaction solution was added NaOAc (321 mg, 
2.36 mmol) in H2O (4 mL) over 3 h. The reaction mixture was cooled and diluted with 
H2O (3 mL) and EtOAc (5 mL). The organics were extracted with EtOAc (3 x 10 mL) and 
the combined organic extracts were washed with 3 N HCl (3 x 5 mL), NaHCO3 (10 mL) 
and brine (10 mL), dried (Na2SO4), filtered and concentrated in vacuo. The crude alkane 
was redissolved in MeOH (1 mL) and CH2Cl2 (0.5 mL) with stirring at 0 °C and 3 N HCl 
(0.3 mL) was added. After 45 min with warming to RT, the reaction mixture was quenched 
by the addition of saturated aqueous NaHCO3 (3 mL). The organics were extracted with 
CH2Cl2 (3 x 5 mL). The combined organic extracts were dried (Na2SO4), filtered and 
concentrated in vacuo. Purification by flash column chromatography (50→70% 
EtOAc/Hexane) provided diol 239 (6.00 mg, 38%), as a colourless oil.   
Rf 0.16 (70% EtOAc/Hexane); 
€ 
[α]D20  +25.4 (c 0.52, CHCl3); IR (thin film) 3433, 2924, 
2856 cm-1; 1H NMR (300 MHz, CDCl3) δ 6.98 (1H, app q, J = 1.4 Hz, H35), 4.99 (1H, qq, 
J = 6.8, 1.7 Hz, H36), 4.14-4.06 (1H, m, H19), 3.82 (1H, app q, J = 6.8 Hz, H16), 3.68 (1H, 
dd, J = 11.7, 3.1 Hz, H20a), 3.51 (1H, dd, J = 11.7, 6.0 HZ, H20b), 3.44-3.36 (1H, m, H15), 
2.29-2.23 (2H, m, H3), 2.08-1.91 (2H, m, H17a + H18a), 1.88-1.64 (2H, m, H17b + H18b), 
1.61-1.21 (22H, m, H4-14), 1.40 (3H, d, J = 6.8 Hz, H37); 13C NMR (125 MHz, CDCl3) δ 
173.9, 148.9, 134.3, 82.9, 79.6, 77.4, 74.1, 64.8, 33.4, 29.7, 29.6 (4C), 29.5, 29.3, 29.2, 
28.5, 27.8, 27.4, 25.6, 25.1, 19.2; HRMS (ES+) Calc. for C23H44O5N [M+NH4]+ 414.3214, 
found 414.3216.  
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(1S,4S)-4-[(2S’’,6S’’)-6-hexyltetrahydropyran-2-yl]-1-[(2R’,5R’)-5’-(1R)-(hydroxy)-
13-[(5S)-3-(5-methyl-2,5-dihydrofuran-2-one)tridecyl)-tetrahydrofuran-2-yl]-butan-
1,4-diol (240) 
 
20O
34
OH
OH
O
OH
O
O
 
 
To a solution of alcohol 216 (6.20 mg, 7.30 µmol) in MeOH (3 mL) and CH2Cl2 (0.5 mL) 
with stirring at 0 °C was added 3 N HCl (0.3 mL). After 1.5 h with warming to RT, the 
reaction mixture was quenched by the addition of saturated aqueous NaHCO3 (3 mL). The 
organics were extracted with CH2Cl2 (3 x 5 mL). The combined organic extracts were 
dried (Na2SO4), filtered and concentrated in vacuo. Purification by flash column 
chromatography (60% EtOAc/Hexane) provided triol 240 (3.40 mg, 75%), as a colourless 
oil.   
Rf 0.12 (50% EtOAc/Hexane); 
€ 
[α]D20  +6.67 (c 0.18, CHCl3); IR (thin film) 3431, 2923, 
2853, 1757, 1670 cm-1; 1H NMR (400 MHz, CDCl3) δ 6.98 (1H, app q, J = 1.5 Hz, H35), 
4.99 (1H, qq, J = 6.8, 1.8 Hz, H36), 3.87-3.79 (2H, m, H16 + H19), 3.74-3.71 (1H, m, H20), 
3.47-3.43 (1H, m, H23), 3.41-3.36 (1H, m, H15), 3.31-3.25 (1H, m, H28), 3.15 (1H, ddd, J = 
11.3, 7.0, 1.6 Hz, H24), 2.26 (2H, ddt, J = 8.7, 7.5, 1.5 Hz, H3), 2.01-1.83 (4H, m, H17a + 
H18 + H26a), 1.70-1.62 (2H, m, H17b + H22a), 1.60-1.46 (7H, m, H4 + H21 + H22b + H26b + 
H27a), 1.44-1.23 (31H, m, H5-14 + H25a + H29-33), 1.40 (3H, d, J = 6.8 Hz, H37), 1.21-1.11 
(2H, m, H25b + H27b), 0.88 (3H, t, J = 6.6 Hz, H34); 13C NMR (125 MHz, CDCl3) δ 174.0, 
148.9, 134.3, 83.1, 82.2, 80.5, 78.0, 77.4, 77.2, 74.3, 72.3, 36.4, 33.2, 31.8, 31.5, 29.7, 
29.6, 29.5, 29.3, 29.3, 29.3, 29.2, 28.5, 27.4, 27.3, 26.4, 25.6, 25.6, 25.2, 23.2, 22.6, 19.2, 
14.1; HRMS (ES+) Calc. for C37H66O7Na [M+Na]+ 645.4706, found 645.4714.  
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(1R,4S)-4-[(2S’’,6S’’)-6-hexyltetrahydropyran-2-yl]-1-[(2R’,5R’)-5’-(1R)-(hydroxy)-
13-[(5S)-3-(5-methyl-2,5-dihydrofuran-2-one)tridecyl)-tetrahydrofuran-2-yl]-butan-
1,4-diol (241) 
 
20O
34
OH
OH
O
OH
O
O
 
 
To a solution of alcohol 217 (5.80 mg, 6.80 µmol) in MeOH (1 mL) and CH2Cl2 (0.3 mL) 
with stirring at 0 °C was added 3 N HCl (0.3 mL). After 1.5 h with warming to RT, the 
reaction mixture was quenched by the addition of saturated aqueous NaHCO3 (3 mL). The 
organics were extracted with CH2Cl2 (3 x 5 mL). The combined organic extracts were 
dried (Na2SO4), filtered and concentrated in vacuo. Purification by flash column 
chromatography (60% EtOAc/Hexane) provided triol 241 (2.10 mg, 49%), as a colourless 
oil.   
Rf 0.13 (70% EtOAc/Hexane); 
€ 
[α]D20  +7.62 (c 0.21, CHCl3); IR (thin film) 3447, 2929, 
2855, 1757 cm-1; 1H NMR (400 MHz, CDCl3) δ 6.99 (1H, app q, J = 1.5 Hz, H35), 4.99 
(1H, qq, J = 6.8, 1.7 Hz, H36), 3.85-3.78 (2H, m, H16 + H19), 3.46-3.38 (3H, m, H15 + H20 + 
H23), 3.31-3.25 (1H, m, H28), 3.13 (1H, ddd, J = 11.1, 7.0, 1.9 Hz, H24), 2.26 (2H, ddt, J = 
8.9, 7.1, 1.6 Hz, H3), 2.02-1.92 (2H, m, H17a + H18a), 1.87-1.62 (3H, m, H17b + H18b + H26a), 
1.60-1.44 (8H, m, H4 + H14 + H21 + H26b + H27a), 1.43-1.23 (31H, m, H5-13 + H22 + H25a + 
H29-33), 1.41 (3H, d, J = 6.8 Hz, H37), 1.21-1.14 (2H, m, H25b + H27b), 0.87 (3H, t, J = 6.8 
Hz, H34); 13C NMR (125 MHz, CDCl3) δ 173.9, 148.8, 134.3, 82.7, 80.8, 77.9, 77.4, 77.2, 
74.6, 74.2, 74.1, 36.4, 33.4, 31.8, 31.5, 29.7, 29.6, 29.5, 29.3, 29.3, 29.2, 28.9, 28.8, 28.7, 
27.4, 25.6, 25.6, 25.2, 23.2, 22.6, 19.2, 14.1; HRMS (ES+) Calc. for C37H66O7Na [M+Na]+ 
645.4706, found 645.4709. 
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8.7 Experimental details for Chapter 6 
 
General procedure A: Copper catalyzed azide-alkyne cycloaddition reactions 
To a solution of alkyne (1 eq) and azide (1 eq) in t-BuOH (1 mL) and H2O (1 mL) was 
added CuSO4·5H2O (1.2 eq) and sodium ascorbate (2.4 eq) at RT and the mixture left to 
stir for 16 h. The reaction mixture was diluted with H2O (5 mL) and CH2Cl2 (5 mL). The 
organics were extracted with CH2Cl2 (3 × 5 mL), dried (Na2SO4) and concentrated in 
vacuo. Purification by flash column chromatography provided the desired 1,4-triazoles.  
 
General procedure B: Benzyl ether cleavage 
To a solution of benzyl ether (1 eq) in EtOH (4 mL) at RT was added Pd(OH)2 on carbon 
(0.2 eq, 20% wt on carbon). The reaction system was purged with H2 and left under a 
positive pressure of H2. After 1.5 h, the reaction mixture was filtered through Celite with 
EtOH (15 mL). The filtrate was concentrated in vacuo and purification by flash column 
chromatography provided the desired alcohols. 
 
(2S,6S)-[2-azidomethyl-6-hexyl]tetrahydropyran (256) 
 
O
N326
  
 
To a solution of alcohol 153 (52.5 mg, 0.26 mmol) in THF (3 mL) was added PPh3 (82.5 
mg, 0.31 mmol) and iPr2NEt (46.0 µL, 0.26 mmol). The solution was then cooled to 10 °C 
and DIAD (62.0 µL, 0.31 mmol) was added dropwise. After 20 min, DPPA (68.0 µL, 0.31 
mmol) was added dropwise and the solution allowed to warm to RT and left to stir for 16 
h. The reaction mixture was quenched by the addition of H2O (3 mL). The organics were 
extracted with EtOAc (3 × 5 mL), dried over Na2SO4 and concentrated in vacuo. 
Purification by flash column chromatography (5% EtOAc/Hexane) provided azide 256 
(42.2 mg, 71%) as a colourless oil.  
Rf 0.79 (10% EtOAc/Hexane); 
€ 
[α]D20  -33.8 (c 1.62, CHCl3); IR (thin film) 2932, 2859, 
2170, 2095, 1591, 1489 cm-1; 1H NMR (400 MHz, CDCl3) δ 3.53 (1H, dddd, J = 11.4, 7.5, 
3.5, 2.1 Hz, H2), 3.34-3.27 (1H, m, H6), 3.29 (1H, dd, J = 12.8, 7.5 Hz, H1a), 3.07 (1H, dd, 
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J = 12.8, 3.5 Hz, H1b), 1.90-1.82 (1H, m, H4a), 1.61-1.33 (7H, m, H3a + H4b + H5a + H7 + 
H10), 1.32-1.14 (8H, m, H3b + H5b + H8-9 + H11), 0.87 (3H, t, J = 6.8 Hz, H12); 13C NMR 
(100 MHz, CDCl3) δ 78.0, 77.0, 55.4, 36.4, 31.8, 31.3, 29.3, 28.7, 25.5, 23.3, 22.6, 14.1; 
HRMS (CI+) Calc. for C12H24ON3 [M+H]+ 226.1914, found 226.1912. 
 
(2R,6S)-[2-carbaldehyde-6-hexyl]tetrahydropyran (259)65  
 
O
H
O
26
 
 
To a solution of dimethyl sulfoxide (300 µL, 4.23 mmol) in CH2Cl2 (8 mL) at -78 °C was 
added oxalyl chloride (300 µL, 3.47 mmol). The reaction mixture was stirred at this 
temperature for 30 min before the addition of alcohol 154 (350 mg, 1.75 mmol) as a 
solution in CH2Cl2 (2 mL) via cannula. The reaction was stirred for a further 1 h, before 
the dropwise addition of Et3N (1.70 mL, 12.2 mmol) and the reaction mixture was warmed 
to RT over 30 min. After the addition of saturated aqueous NH4Cl (10 mL), the organics 
were extracted with CH2Cl2 (3 x 15 mL) and the combined organic extracts were dried 
(Na2SO4), filtered and concentrated in vacuo. Purification by flash column 
chromatography (5% EtOAc/Hexane) provided aldehyde 259 (305 mg, 88%) as a 
colourless oil, which was used without further characterization. 
Rf 0.35 (5% EtOAc/Hexane); 
€ 
[α]D20  -70.4 (c 1.89, CHCl3), lit 
€ 
[α]D20  -24.5 (c 1.8, CHCl3)65; 
1H NMR (500 MHz, CDCl3) δ 9.84 (1H, br s, H1), 4.18 (1H, dd, J = 6.0, 2.9 Hz, H2), 3.58-
3.54 (1H, m, H6), 2.02-1.98 (1H, m, H3a), 1.73-1.65 (2H, m, H3b + H4a), 1.63-1.57 (2H, m, 
H5a + H7a), 1.49-1.25 (11H, m, H4b + H5b + H7b + H8-11), 0.88 (3H, t, J = 6.7 Hz, H12). 
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(2R,6S)-[2-(2,2-dibromo-ethenyl)-6-(hexyl)]tetrahydropyran (264) 
 
O Br
Br
37
 
 
To a solution of CBr4 (1.19 g, 3.59 mmol) in CH2Cl2 (7 mL) at 0 °C was added PPh3 (1.88 
g, 7.17 mmol) and the reaction mixture cooled to -78 °C. After 5 min, a solution of 
aldehyde 259 (356 mg, 1.79 mmol) in CH2Cl2 (3 mL) was added and the reaction mixture 
was not allowed to exceed -50 °C over 45 min. The reaction mixture was quenched by 
addition of saturated aqueous NH4Cl (10 mL), the organics were extracted with CH2Cl2 (3 
× 15 mL) and the combined organic extracts were dried (NaSO4), filtered and concentrated 
in vacuo. Purification by flash column chromatography (2% EtOAc/Hexane) provided 
dibromo alkene 264 (515 mg, 81%) as a colourless oil.  
Rf 0.77 (5% Acetone/Hexane); 
€ 
[α]D20  -40.3 (c 1.01, CHCl3); IR (thin film) 2937, 2857, 
1732, 1607, 1458 cm-1; 1H NMR (400 MHz, CDCl3) δ 6.76 (1H, d, J = 7.5 Hz, H2), 4.46 
(1H, app dt, J = 7.5, 4.4 Hz, H3), 3.65-3.59 (1H, m, H7), 1.78-1.50 (5H, m, H4-5 + H6a), 
1.43-1.23 (11H, m, H6b + H8-12), 0.88 (3H, t, J = 6.7 Hz, H13); 13C NMR (100 MHz, 
CDCl3) δ 137.9, 91.1, 72.4, 72.0, 34.3, 31.8, 30.1, 29.2, 29.0, 25.5, 22.6, 18.9, 14.1; 
HRMS (CI+) Calc. for C13H23O79Br2 [M+H]+ 353.0110, found 353.0110. 
 
(2R,6S)-[2-ethynyl-6-hexyl]tetrahydropyran (258) 
 
O
37
 
 
To a solution of dibromo alkene 264 (151 mg, 0.43 mmol) in THF (6 mL) at -78 °C was 
added n-BuLi (800 µL, 1.6 M solution in hexane, 1.28 mmol). After 1.5 h, the reaction 
mixture was quenched by addition of saturated aqueous NH4Cl (10 mL). The organics 
were extracted with EtOAc (3 × 15 mL), dried (Na2SO4), filtered and concentrated in 
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vacuo. Purification by flash column chromatography (1% EtOAc/Hexane) provided alkyne 
258 (57.7 mg, 70%) as a colourless oil. 
Rf 0.77 (5% Acetone/Hexane); 
€ 
[α]D20  -11.1 (c 1.09, CHCl3); IR (thin film) 3310, 2932, 
2860, 1466, 1456 cm-1; 1H NMR (300 MHz, CDCl3) δ 4.77-4.73 (1H, m, H3), 3.86-3.78 
(1H, m, H7), 2.45 (1H, d, J = 2.3 Hz, H1), 1.91-1.73 (2H, m, H4a + H5a), 1.71-1.57 (3H, m, 
H4b + H5b + H6a), 1.53-1.14 (11H, m, H6b + H8-12), 0.87 (3H, t, J = 6.9 Hz, H13); 13C NMR 
(100 MHz, CDCl3) δ 82.5, 74.1, 71.7, 64.8, 36.2, 31.8, 31.4, 30.4, 29.3, 25.3, 22.6, 19.3, 
14.1; HRMS (CI+) Calc. for C13H23O [M+H]+ 195.1743, found 195.1745. 
 
(2S,6S)-[2-ethynyl-6-hexyl]tetrahydropyran (261) 
 
O
37
 
 
To a solution of dimethyldiazo-2-oxopropylphosphonate 260 (160 mg, 0.83 mmol) and 
K2CO3 (190 mg, 1.38 mmol) in MeOH (4 mL) at RT was added a solution of aldehyde 157 
(136 mg, 0.69 mmol) in MeOH (1 mL). After 16 h, the reaction mixture was quenched by 
addition of saturated aqueous NaHCO3 (5 mL). The organics were extracted with Et2O (3 × 
10 mL), dried (Na2SO4) and concentrated in vacuo. Purification by flash column 
chromatography (1% EtOAc/Hexane) provided alkyne 261 (96.5 mg, 72%) as a colourless 
oil. 
Rf 0.80 (5% EtOAc/Hexane); 
€ 
[α]D20  -36.5 (c 1.55, CHCl3); IR (thin film) 2924, 2855, 1456, 
1377, 1312 cm-1; 1H NMR (400 MHz, CDCl3) δ 4.08 (1H, dt, J = 11.3, 2.2 Hz, H3), 3.30-
3.24 (1H, m, H7), 2.44 (1H, d, J = 2.2 Hz, H1), 1.86-1.78 (2H, m, H4a + H5a), 1.69-1.35 
(5H, m, H4b + H5b + H6a + H8), 1.34-1.18 (9H, m, H6b + H9-12), 0.87 (3H, t, J = 7.0 Hz, 
H13); 13C NMR (100 MHz, CDCl3) δ 83.6, 78.6, 72.1, 67.8, 36.4, 32.5, 31.8, 30.7, 29.3, 
25.4, 23.4, 22.6, 14.1; HRMS (EI+) Calc. for C13H22O [M]+ 194.1665, found 194.1665. 
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4-[(2S’,6S’)-6’-hexyltetrahydropyran-2-yl]-1-[(2S’’,6S’’)-6’’-(hexyltetrahydropyran-
2-yl)methyl]-1H-1,2,3-triazole (262) 
 
O
N
N
NO
26
1' 5'
 
 
General procedure A was followed with alkyne 261 (16.0 mg, 82.3 µmol) and azide 256 
(19.0 mg, 84.3 µmol) in t-BuOH (0.5 mL) and H2O (0.5 mL) to which was added 
CuSO4·5H2O (25.0 mg, 100 µmol) and sodium ascorbate (40.0 mg, 202 µmol). Standard 
workup and flash column chromatography (10% EtOAc/Hexane) provided triazole 262 
(25.2 mg, 71%) as a colourless oil.  
Rf 0.12 (10% EtOAc/Hexane); 
€ 
[α]D20  -25.6 (c 2.38, CHCl3); IR (thin film) 2934, 2859, 
1456 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.64 (1H, s, HAr), 4.59 (1H, dd, J = 11.1, 2.1 
Hz, H1’), 4.45 (1H, dd, J = 14.0, 3.1 Hz, H1a), 4.18 (1H, dd, J = 14.1, 8.2 Hz, H1b), 3.66-
3.60 (1H, m, H2), 3.49-3.42 (1H, m, H5’), 3.23-3.17 (1H, m, H6), 2.03-1.99 (1H, m, H2a’), 
1.95-1.82 (2H, m, H3a’ + H4a), 1.68-1.50 (6H, m, H2b’ + H3a + H3b’ + H4a’ + H4b + H5a), 
1.49-1.11 (23H, m, H3b + H4b’ + H5b + H6’-10’ + H7-11), 0.89-0.84 (6H, m, H11’ + H12); 13C 
NMR (100 MHz, CDCl3) δ 149.9, 122.2, 78.4, 77.8, 76.1, 73.2, 55.0, 36.5, 36.4, 31.8, 
31.8, 31.8, 31.2, 31.2, 29.4, 29.3, 28.6, 25.6, 25.5, 23.6, 23.0, 22.6, 22.6, 14.1, 14.1; 
HRMS (ES+) Calc. for C25H46O2N3 [M+H]+ 420.3585, found 420.3580. 
 
4-[(2R’,6S’)-6’-hexyltetrahydropyran-2-yl]-1-[(2S’’,6S’’)-6’’-(hexyltetrahydropyran-
2-yl)methyl]-1H-1,2,3-triazole (263) 
 
O
N
N
NO
26
1' 5'
 
 
General procedure A was followed with alkyne 258 (12.3 mg, 63.0 µmol) and azide 256 
(14.3 mg, 63.0 µmol) in t-BuOH (0.5 mL) and H2O (0.5 mL) to which was added 
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CuSO4·5H2O (19.0 mg, 76.0 µmol) and sodium ascorbate (30.0 mg, 150 µmol). Standard 
work-up and purification by flash column chromatography (5→10% EtOAc/Hexane) 
provided triazole 263 (20.0 mg, 75%) as a colourless oil.  
Rf 0.14 (15% EtOAc/Hexane); 
€ 
[α]D20  -31.7 (c 0.53, CHCl3); IR (thin film) 2930, 2857, 
1456, 1438, 1377 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.64 (1H, s, HAr), 5.08 (1H, t, J = 
4.3 Hz, H1’), 4.48 (1H, dd, J = 14.1, 3.1 Hz, H1a), 4.26 (1H, dd, J = 14.1, 7.8 Hz, H1b), 
3.69-3.63 (1H, m, H2), 3.59-3.53 (1H, m, H5’), 3.26-3.20 (1H, m, H6), 2.23-2.16 (1H, m, 
H2a’), 2.02-1.94 (1H, m, H2b’), 1.89-1.83 (1H, m, H4a), 1.77-1.46 (7H, m, H3’ + H4a’ + H4b + 
H5a + H6’), 1.43-1.36 (3H, m, H4b’ + H7), 1.33-1.09 (19H, m, H3 + H5b + H7’-10’ + H8-11), 
0.88 (6H, t, J = 6.6 Hz, H11’ + H12); 13C NMR (125 MHz, CDCl3) δ 148.6, 123.3, 77.9, 
76.1, 71.6, 67.8, 55.1, 36.3, 34.9, 31.8, 31.8, 31.2, 30.7, 29.5, 29.3, 28.5, 28.5, 25.7, 25.5, 
23.0, 22.7, 22.6, 19.2, 14.1; HRMS (ES+) Calc. for C25H46O2N3 [M+H]+ 420.3585, found 
420.3580. 
 
4-[(2R’,6S’)-6’-hexyltetrahydropyran-2-yl]-1-[(2R’’,6S’’)-6’’-(hexyltetrahydropyran-
2-yl)methyl]-1H-1,2,3-triazole (265) 
 
O
N
N
NO
26
1' 5'
 
 
General procedure A was followed with alkyne 258 (16.1 mg, 83.0 µmol) and azide 257 
(18.7 mg, 83.0 µmol) in t-BuOH (1 mL) and H2O (1 mL) to which was added 
CuSO4·5H2O (25.0 mg, 99.0 µmol) and sodium ascorbate (39.0 mg, 199 µmol). Standard 
work-up and purification by flash column chromatography (5→10% EtOAc/Hexane) 
provided triazole 265 (17.8 mg, 51%) as a colourless oil.  
Rf 0.30 (15% EtOAc/Hexane); 
€ 
[α]D20  -41.4 (c 0.73, CHCl3); IR (thin film) 2930, 2857, 
1772, 1734, 1558, 1456 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.58 (1H, s, HAr), 5.07 (1H, t, 
J = 4.4 Hz, H1’), 4.43-4.32 (2H, m, H1), 4.02-3.96 (1H, m, H2), 3.83-3.78 (1H, m, H5’), 
3.61-3.55 (1H, m, H6), 2.19-2.12 (1H, m, H2a’), 2.00-1.92 (1H, m, H2b’), 1.76-1.59 (7H, m, 
H3a + H3’ + H4 + H4a’ + H5a), 1.45-1.34 (5H, m, H5b + H6’ + H7), 1.33-1.15 (18H, m, H3b + 
H4b’ + H7’-10’ + H8-11), 0.88-0.83 (6H, m, H11’ + H12); 13C NMR (125 MHz, CDCl3) δ 148.7, 
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123.1, 72.4, 71.7, 69.0, 67.8, 53.8, 34.6, 31.8, 31.7, 31.6, 30.6, 29.4, 29.2, 28.9, 28.7, 28.0, 
25.7, 25.6, 22.6 (2C), 19.1, 18.1, 14.1, 14.0; HRMS (ES+) Calc. for C25H46O2N3 [M+H]+ 
420.3585, found 420.3581. 
 
1-azidooctane (267)149 
 
N3
1
8  
 
To a solution of alcohol 268 (600 µL, 3.81 mmol) in THF (15 mL) was added PPh3 (1.21 
g, 4.61 mmol) and iPr2NEt (670 µL, 3.85 mmol). The solution was then cooled to 10 °C 
and DIAD (910 µL, 4.59 mmol) was added dropwise. After 20 min, DPPA (990 µL, 4.59 
mmol) was added dropwise and the solution allowed to warm to RT and left to stir for 16 
h. The reaction mixture was quenched by the addition of H2O (10 mL). The organics were 
extracted with EtOAc (3 × 10 mL), dried (Na2SO4) and concentrated in vacuo. Purification 
by flash column chromatography (5% EtOAc/Hexane) provided azide 267 (158 mg, 27%) 
as a colourless oil. 
Rf 0.97 (10% EtOAc/Hexane); 1H NMR (300 MHz, CDCl3) δ 3.25 (2H, t, J = 6.9 Hz, H1), 
1.64-1.55 (2H, m, H2), 1.41-1.23 (10H, m, H3-7), 0.88 (3H, t, J = 7.2 Hz, H8).  
 
(5S)-3-(6-azidohexyl)-5-methyl-2,5-dihydrofuran-2-one (269) 
 
O
N3
O
1
10
 
 
To a solution of alcohol 81 (59.3 mg, 0.30 mmol) in THF (3 mL) was added PPh3 (94.0 
mg, 0.36 mmol) and iPr2NEt (52.0 µL, 0.30 mmol). The solution was then cooled to 10 °C 
and DIAD (71.0 µL, 0.36 mmol) was added dropwise. After 20 min, DPPA (77.0 µL, 0.36 
mmol) was added dropwise and the solution allowed to warm to RT and left to stir for 16 
h. The reaction mixture was quenched by the addition of H2O (3 mL). The organics were 
extracted with EtOAc (3 × 5 mL), dried over Na2SO4 and concentrated in vacuo. 
Purification by flash column chromatography (10% EtOAc/Hexane) provided azide 269 
(49.2 mg, 74%) as a colourless oil.  
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Rf 0.78 (45% EtOAc/Hexane); 
€ 
[α]D20  +30.1 (c 0.84, CHCl3); IR (thin film) 2936, 2860, 
2095, 1751, 1456 cm-1; 1H NMR (300 MHz, CDCl3) δ 6.99 (1H, app q, J = 1.5 Hz, H9), 
5.00 (1H, qq, J = 6.8, 1.8 Hz, H10), 3.26 (2H, t, J = 6.8 Hz, H1), 2.30-2.24 (2H, m, H6), 
1.65-1.52 (4H, m, H2 + H5), 1.45-1.32 (4H, m, H3-4), 1.40 (3H, d, J = 6.8 Hz, H11); 13C 
NMR (100 MHz, CDCl3) δ 173.7, 149.1, 133.8, 77.4, 51.2, 28.6, 28.6, 27.1, 26.3, 24.9, 
19.1; HRMS (ES+) Calc. for C11H18O2N3 [M+H]+ 224.1394, found 224.1395. 
 
4-hexyl-1-[(2S’,6S’)-6’-(hexyltetrahydropyran-2-yl)methyl]-1H-1,2,3-triazole (270) 
 
O
N N
N
26
1'
6'
 
 
General procedure A was followed with 1-octyne (11.1 µL, 75.1 µmol) and azide 256 (16.9 
mg, 75.0 µmol) in t-BuOH (0.5 mL) and H2O (0.5 mL) to which was added CuSO4·5H2O 
(22.0 mg, 88.1 µmol) and sodium ascorbate (36.0 mg, 182 µmol). Standard work-up and 
purification by flash column chromatography (15% EtOAc/Hexane) provided triazole 270 
(17.0 mg, 68%) as a colourless oil.  
Rf 0.15 (20% EtOAc/Hexane); 
€ 
[α]D20  +1.0 (c 1.7, CHCl3); IR (thin film) 2930, 2857, 1458, 
1439, 1377 cm-1; 
1H NMR (400 MHz, CDCl3) δ 7.42 (1H, s, HAr), 4.44 (1H, dd, J = 14.1, 
3.0 Hz, H1a), 4.19 (1H, dd, J = 14.1, 8.0 Hz, H1b), 3.65-3.59 (1H, m, H2), 3.24-3.18 (1H, m, 
H6), 2.70 (2H, t, J = 7.5 Hz, H1’), 1.88-1.82 (1H, m, H4a), 1.69-1.44 (5H, m, H2’ + H3a + 
H4b + H5a), 1.41-1.09 (18H, m, H3’-5’ + H3b + H5b + H7-11), 0.89-0.85 (6H, m, H6’ + H12); 
13C NMR (100 MHz, CDCl3) δ 148.1, 122.1, 77.8, 76.2, 54.9, 36.3, 31.8, 31.6, 31.2, 29.4, 
29.2, 28.9, 28.5, 25.7, 25.5, 23.0, 22.6, 22.6, 14.1, 14.0; HRMS (ES+) Calc. for C20H38ON3 
[M+H]+ 336.3009, found 336.3013. 
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4-[(2S’,6S’)-6’-(hexyltetrahydropyran-2-yl)]-1-octyl-1H-1,2,3-triazole (271) 
 
N N
N
O
1' 5'
1
8
 
 
General procedure A was followed with alkyne 261 (17.7 mg, 91.1 µmol) and 1-
azidooctane 267 (14.1 mg, 90.8 µmol) in t-BuOH (0.5 mL) and H2O (0.5 mL) to which 
was added CuSO4·5H2O (27.0 mg, 108 µmol) and sodium ascorbate (43.3 mg, 219 µmol). 
Standard work-up and purification by flash column chromatography (10% EtOAc/Hexane) 
provided triazole 271 (24.6 mg, 77%) as a colourless oil.  
Rf 0.33 (10% EtOAc/Hexane); 
€ 
[α]D20  -28.5 (c 2.34, CHCl3); IR (thin film) 2930, 2857, 
1466, 1458, 1439, 1377 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.45 (1H, s, HAr), 4.59 (1H, 
dd, J = 11.1, 2.1 Hz, H1’), 4.29 (2H, t, J = 7.3 Hz, H1), 3.49-3.43 (1H, m, H5’), 2.10-2.05 
(1H, m, H2a’), 1.96-1.84 (3H, m, H2 + H3a’), 1.68-1.51 (3H, m, H2b’ + H3b’ + H4a’), 1.47-
1.38 (2H, m, H6’), 1.37-1.18 (19H, m, H3-7 + H4b’ + H7’-10’), 0.88-0.85 (6H, m, H8 + H11’); 
13C NMR (100 MHz, CDCl3) δ 150.3, 120.3, 78.5, 73.4, 50.3, 36.5, 31.8 (2C), 31.7, 31.2, 
30.3, 29.4, 29.0, 28.9, 25.5, 25.5, 23.5, 22.6, 22.6, 14.1, 14.0; HRMS (ES+) Calc. for 
C21H40ON3 [M+H]+ 350.3166, found 350.3167. 
 
4-[(2S’,6S’)-6’-(hexyltetrahydropyran-2-yl)]-1-[6-[(5S)-3-(5-methyl-2,5-dihydrofuran-
2-one)hexyl]-1H-1,2,3-triazole (272) 
 
O
N
NN O
O
1
10
1'5'
 
 
General procedure A was followed with alkyne 261 (15.5 mg, 79.8 µmol) and azide 269 
(17.8 mg, 79.7 µmol) in t-BuOH (0.5 mL) and H2O (0.5 mL) to which was added 
CuSO4·5H2O (24.0 mg, 96.1 µmol) and sodium ascorbate (38.0 mg, 192 µmol). Standard 
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work-up and purification by flash column chromatography (30% EtOAc/Hexane) provided 
triazole 272 (26.2 mg, 79%) as a colourless oil.  
Rf 0.20 (30% EtOAc/Hexane); 
€ 
[α]D20  -6.32 (c 2.09, CHCl3); IR (thin film) 2930, 2859, 
1753, 1456 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.47 (1H, s, HAr), 6.98 (1H, app q, J = 1.4 
Hz, H9), 4.98 (1H, qq, J = 6.8, 1.6 Hz, H10), 4.60-4.57 (1H, m, H1’), 4.30 (2H, t, J = 7.2 Hz, 
H1), 3.49-3.42 (1H, m, H5’), 2.27-2.21 (2H, m, H6), 2.11-2.03 (1H, m, H2a’), 1.93-1.85 (3H, 
m, H2 + H3a’), 1.71-1.49 (7H, m, H2b’ + H3b’ + H4a’ + H5 + H6’), 1.45-1.14 (13H, m, H3-4 + 
H4b’ + H7’-10’), 1.39 (3H, d, J = 6.8 Hz, H11), 0.86 (3H, t, J = 7.0 Hz, H11’); 13C NMR (75 
MHz, CDCl3) δ173.8, 150.3, 149.1, 133.9, 120.4, 78.5, 77.4, 73.3, 50.1, 36.5, 31.8 (2C), 
31.2, 30.1, 29.4, 28.5, 27.1, 26.2, 25.5, 25.0, 23.5, 22.6, 19.2, 14.1; HRMS (ES+) Calc. for 
C24H40O3N3 [M+H]+ 418.3064, found 418.3063. 
 
4-hexyl-1-[6-[(5S)-3-(5-methyl-2,5-dihydrofuran-2-one)hexyl]-1H-1,2,3-triazole (273) 
 
N
O
ONN
1
101'
6'
 
 
General procedure A was followed with 1-octyne (26.0 µL, 0.18 mmol) and azide 269 
(39.8 mg, 0.18 mmol) in t-BuOH (2 mL) and H2O (2 mL) to which was added 
CuSO4·5H2O (53.0 mg, 0.21 mmol) and sodium ascorbate (85.0 mg, 0.43 mmol). Standard 
work-up and purification by flash column chromatography (35→60% EtOAc/Hexane) 
provided triazole 273 (45.6 mg, 77%) as a colourless oil.  
Rf 0.29 (50% EtOAc/Hexane); 
€ 
[α]D20  +23.6 (c 1.34, CHCl3); IR (thin film) 2930, 2859, 
1751, 1458, 1319 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.25 (1H, s, HAr), 6.98-6.97 (1H, m, 
H9), 4.99-4.94 (1H, m, H10), 4.28 (2H, t, J = 7.1 Hz, H1), 2.67 (2H, t, J = 7.6 Hz, H1’), 
2.24-2.20 (2H, m, H6), 1.86 (2H, app quint, J = 7.2 Hz, H2), 1.63 (2H, app quin, J = 7.3 
Hz, H2’), 1.52 (2H, app quin, J = 7.4 Hz, H5), 1.39-1.22 (10H, m, H3-4 + H3’-5’), 1.37 (3H, d, 
J = 6.8 Hz, H11), 0.84 (3H, t, J = 6.8 Hz, H6’); 13C NMR (125 MHz, CDCl3) δ 173.7, 
149.2, 148.2, 133.7, 120.4, 77.4, 50.0, 31.5, 30.0, 29.3, 28.8, 28.4, 27.1, 26.0, 25.5, 24.9, 
22.5, 19.1, 14.0; HRMS (ES+) Calc. for C19H32O2N3 [M+H]+ 334.2489, found 334.2494. 
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4-hexyl-1-[6-(5-methylfuran-3-yl)hexyl]-1H-1,2,3-triazole (275) 
 
N
O
NN
1
101'
6'
 
 
To a solution of triazole 273 (35.2 mg, 0.11 mmol) in CH2Cl2 (10 mL) at -78 °C was added 
DIBAL (1.25 mL, 1.0 M solution in hexane, 1.25 mmol). After 3.5 h, glacial acetic acid 
(1.10 mL) was added and the solution allowed to warm to RT. After 1.5 h, the solution was 
quenched by addition of H2O (10 mL). The organics were extracted with EtOAc (3 × 15 
mL), dried (Na2SO4) and concentrated in vacuo. Purification by flash column 
chromatography (50% EtOAc/Hexane) provided furan 275 (18.2 mg, 54%) as a colourless 
oil. 
Rf 0.76 (60% EtOAc/Hexane); IR (thin film) 2928, 2857, 2371, 2097, 1749, 1559, 1456 
cm-1; 1H NMR (400 MHz, CDCl3) δ 7.26 (1H, s, HAr), 7.03-7.02 (1H, m, H8), 5.84-5.83 
(1H, m, H9), 4.31 (2H, t, J = 7.1 Hz, H1), 2.73 (2H, t, J = 7.6 Hz, H1’), 2.34-2.30 (2H, m, 
H6), 2.24 (3H, d, J = 1 Hz, H11), 1.89 (2H, app quin, J = 7.2 Hz, H2), 1.66 (2H, app quin, J 
= 7.5 Hz, H2’), 1.54-1.47 (2H, m, H5), 1.39-1.25 (10H, m, H3-4 + H3’-5’), 0.88 (3H, t, J = 7.0 
Hz, H6’); 13C NMR (125 MHz, CDCl3) δ 152.1, 148.1, 136.8, 125.8, 120.6, 107.0, 50.3, 
31.5, 30.2, 29.6, 29.4, 28.9, 28.5, 26.3, 25.5, 24.7, 22.5, 14.0, 13.5; HRMS (ES+) Calc. for 
C19H32ON3 [M+H]+ 318.2540, found 318.2543. 
 
6-(benzyloxy)-hex-1-ene (277)150  
 
OBn
1
6
 
 
To a  suspension of NaH (3.22 g, 60% dispersion in mineral oil, 134 mmol) in THF (140 
mL) at 0 °C was added a solution of 5-hexen-1-ol 276 (8.24 mL, 69.9 mmol) in THF (10 
mL) via cannula. After 5 min, benzyl bromide (10.0 mL, 84.1 mmol) was added and the 
reaction mixture allowed to warm to RT. After 16 h, the reaction mixture was quenched by 
slow addition of MeOH (2 mL), followed by addition of saturated aqueous NH4Cl (100 
mL). The organics were extracted with Et2O (3 × 50 mL), washed with H2O (50 mL), brine 
(50 mL), dried (Na2SO4) and concentrated in vacuo. Purification by flash column 
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chromatography (5% EtOAc/Hexane) provided alkene 277 (13.0 g, 98%) as a colourless 
oil.  
Rf 0.74 (10% EtOAc/Hexane); 1H NMR (300 MHz, CDCl3) δ 7.42-7.27 (5H, m, ArH), 
5.81 (1H, app ddt, J = 16.9, 10.2, 6.7 Hz, H5), 5.04-4.92 (2H, m, H6), 4.51 (2H, s, 
OCH2Ar), 3.48 (2H, t, J = 6.4 Hz, H1), 2.11-2.03 (2H, m, H4), 1.69-1.56 (2H, m, H2), 1.53-
1.43 (2H, m, H3). 
 
2-[4-(benzyloxy)butyl] oxirane (278)150 
 
OBn
O 1
6
 
 
To a solution of alkene 277 (13.3 g, 69.9 mmol) in CH2Cl2 (200 mL) at 0 °C was added m-
CPBA (20.5 g, 119 mmol) and the reaction mixture allowed to warm to RT. After 16 h, the 
reaction mixture was quenched by addition of saturated aqueous NaHCO3 (150 mL). The 
organics were extracted with CH2Cl2 (3 × 100 mL), washed with KOH (100 mL), H2O 
(100 mL) and brine (100 mL). The combined organic layers were dried (Na2SO4), filtered 
and concentrated in vacuo. Purification by flash column chromatography (1→10% 
EtOAc/Hexane) provided epoxide 278 (10.8 g, 75%) as a colourless oil.  
Rf 0.3 (10% EtOAc/Hexane); 1H NMR (300 MHz, CDCl3) δ 7.38-7.27 (5H, m, ArH), 4.51 
(2H, s, OCH2Ar), 3.49 (2H, t, J = 6.2 Hz, H1), 2.94-2.88 (1H, m, H5), 2.75 (1H, dd, J = 5.0, 
4.0 Hz, H6a), 2.46 (1H, dd, J = 5.0, 2.7 Hz, H6b), 1.73-1.51 (6H, m, H2-4).  
 
(2S)-2-[4-(benzyloxy)butyl] oxirane (281)150  
 
OBn
O 1
6
 
 
To a suspension of (S, S)-Co-salen catalyst 86 (63.0 mg, 0.11 mmol) in toluene (2 mL) at 
RT was added acetic acid (63.0 µL, 1.10 mmol). After 1 h open to air, the solvent was 
removed under reduced pressure and the brown tar residue was dried under vacuum. To the 
residue was added (±)-epoxide 278 (10.8 g, 52.4 mmol), the reaction mixture was cooled 
to 0 °C and water (520 µL, 28.8 mmol) was slowly added. After 16 h at RT, purification by 
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flash column chromatography (5% EtOAc/Hexane) provided (S)-epoxide 281 (4.56 g, 
42%) as a colourless oil. 
Rf 0.3 (10% EtOAc/Hexane); 
€ 
[α]D20  -5.2 (c 2.0, CHCl3), lit 
€ 
[α]D20  -5.1 (c 2.0, CHCl3)150; 1H 
NMR (300 MHz, CDCl3) δ 7.38-7.27 (5H, m, ArH), 4.51 (2H, s, OCH2Ar), 3.49 (2H, t, J 
= 6.2 Hz, H1), 2.94-2.88 (1H, m, H5), 2.75 (1H, dd, J = 5.0, 4.0 Hz, H6a), 2.46 (1H, dd, J = 
5.0, 2.7 Hz, H6b), 1.73-1.51 (6H, m, H2-4). 
 
(5R)-1-(benzyloxy) dec-9-en-5-ol (282) 
 
OH
OBn
6 2
 
 
To a solution of magnesium turnings (2.15 g, 88.4 mmol) in Et2O (15 mL) was added 
slowly a solution of 4-bromo-1-butene (6.70 mL, 66.3 mmol) in THF (20 mL) and the 
reaction mixture heated to 50 °C.  After 2 h, the reaction mixture was allowed to cool to 
RT. To a stirred solution of (S)-epoxide 281 (4.56 g, 22.1 mmol) and copper(I) iodide (550 
mg, 2.87 mmol) in THF (50 mL) at -40 °C was added the freshly prepared 
homoallylmagnesium bromide solution 151 (35 mL, ~1.89 M solution) via cannula and the 
resulting black solution allowed to warm to RT. After 2 h, the solution was quenched by 
the addition of a saturated aqueous NH4Cl (40 mL). The organics were extracted with Et2O 
(3 x 40 mL) and the combined organic extracts were dried (Na2SO4), filtered and 
concentrated in vacuo. Purification by flash column chromatography (10% EtOAc/Pet. 
Ether) provided alcohol 282 (5.77 g, 99%) as a colourless oil.  
Rf 0.48 (20% EtOAc/Hexane); 
€ 
[α]D20  +0.14 (c 1.46, CHCl3); IR (thin film) 3399, 2934, 
2859, 17.17, 1639, 1454 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.37-7.27 (5H, m, ArH), 
5.81 (1H, app ddt, J = 16.9, 10.2, 6.7 Hz, H2), 5.05-4.93 (2H, m, H1), 4.50 (2H, s, 
OCH2Ar), 3.63-3.56 (1H, m, H6), 3.48 (2H, t, J = 6.4 Hz, H10), 2.10-2.06 (2H, m, H3), 
1.69-1.59 (2H, m, H9), 1.58-1.36 (8H, m, H4-5 + H7-8); 13C NMR (75 MHz, CDCl3) δ 
138.7, 138.5, 128.3, 127.6, 127.5, 114.5, 72.9, 71.6, 70.2, 37.2, 36.8, 33.7, 29.7, 24.9, 22.3; 
HRMS (ES+) Calc. for C17H26O2Na [M+Na]+ 285.1839, found 285.1824. 
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(2S,6S)-6-[(4-benzyloxy)butyl]-2-(hydroxymethyl)tetrahydropyran (279) and (2R,6S)-
6-[(4-benzyloxy) butyl]-2-(hydroxymethyl)tetrahydropyran (280) 
 
O
OH
OBn
O
OH
OBn
6
10
2 6
10
2
 
 
To a solution of hydroxy olefin 282 (5.77 g, 22.0 mmol) in CH2Cl2 (100 mL) at 0 °C was 
added m-CPBA (6.53 g, 37.8 mmol). The reaction mixture was allowed to warm to RT for 
3 h before being re-cooled to 0 oC, and addition of (±)-CSA (1.02 g, 4.40 mmol) in one 
portion. The reaction mixture was stirred at RT for an additional 6 h prior to the addition of 
a saturated aqueous solution of NaHCO3 (100 mL). The organics were extracted with 
CH2Cl2 (3 x 50 mL). The combined organic extracts were dried (Na2SO4), filtered and 
concentrated in vacuo. Purification by flash column chromatography (5→10% 
EtOAc/Hexane) gave a separable mixture of syn-alcohol 279 and anti-alcohol 280 as 
colourless oils, in a combined 77% yield (d.r. 279 : 280 = 55 : 44). 
279: Rf 0.27 (25% EtOAc/Hexane); 
€ 
[α]D20  -2.2 (c 1.12, CHCl3); IR (thin film) 3447, 2936, 
2859, 1454 cm-1; 
1H NMR (400 MHz, CDCl3) δ 7.38-7.27 (5H, m, ArH), 4.50 (2H, s, 
OCH2Ar), 3.58-3.55 (1H, m, H1a), 3.51-3.41 (4H, m, H1b + H2 + H10), 3.34-3.28 (1H, m, 
H6), 1.91 (1H, br s, OH), 1.87-1.82 (2H, m, H4), 1.66-1.37 (8H, m, H3a + H5a + H7-9), 1.24-
1.12 (2H, m, H3b + H5b); 13C NMR (75 MHz, CDCl3) δ 138.5, 128.3, 127.6, 127.4, 77.9, 
77.5, 72.8, 70.2, 66.3, 36.1, 31.5, 29.7, 27.1, 23.1, 22.2; HRMS (ES+) Calc. for C17H27O3 
[M+H]+ 279.1955, found 279.1960. 
280: Rf 0.19 (25% EtOAc/Hexane); 
€ 
[α]D20  -24.3 (c 1.0, CHCl3); IR (thin film) 3447, 2936, 
2862, 1456 cm-1; 
1H NMR (400 MHz, CDCl3) δ 7.36-7.27 (5H, m, ArH), 4.50 (2H, s, 
OCH2Ar), 3.80-3.74 (2H, m, H2 + H6), 3.67 (1H, dd, J = 11.1, 8.4 Hz, H1a), 3.50-3.44 (3H, 
m, H1b + H10), 1.87 (1H, br s, OH), 1.80-1.52 (8H, m, H3a + H4 + H5a + H7 + H9), 1.51-1.32 
(4H, m, H3b + H5b + H8); 13C NMR (75 MHz, CDCl3) δ 138.5, 128.2, 127.5, 127.3, 72.7, 
71.5, 70.7, 70.1, 64.1, 32.0, 29.5, 29.3, 26.3, 22.4, 18.3; HRMS (ES+) Calc. for C17H27O3 
[M+H]+ 279.1955, found 279.1960. 
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(2S,6S)-6-[(4-benzyloxy)butyl]-2-(carbaldehyde)tetrahydropyran (284) 
 
O
H
OBn
O
6
10
2
 
 
To a solution of dimethyl sulfoxide (310 µL, 4.37 mmol) in CH2Cl2 (10 mL) at -78 °C was 
added oxalyl chloride (310 µL, 3.59 mmol). The reaction mixture was stirred at this 
temperature for 30 min before the addition of alcohol 279 (500 mg, 1.80 mmol) as a 
solution in CH2Cl2 (5 mL) via cannula. The reaction was stirred for a further 1 h, before 
the dropwise addition of Et3N (1.75 mL, 12.6 mmol) and the reaction mixture was warmed 
to RT over 30 min. After the addition of saturated aqueous NH4Cl (10 mL), the organics 
were extracted with CH2Cl2 (3 x 15 mL) and the combined organic extracts were dried 
(Na2SO4), filtered and concentrated in vacuo. Purification by flash column 
chromatography (5% EtOAc/Hexane) provided aldehyde 284 (432 mg, 87%) as a 
colourless oil. 
Rf 0.54 (25% EtOAc/Hexane); 
€ 
[α]D20  -38.7 (c 1.6, CHCl3); IR (thin film) 3402, 2938, 2859, 
1738, 1454, 1362 cm-1; 1H NMR (300 MHz, CDCl3) δ 9.62 (1H, s, H1), 7.36-7.26 (5H, m, 
ArH), 4.50 (2H, s, OCH2Ar), 3.78 (1H, ddd, J = 11.9, 2.7, 0.6 Hz, H2), 3.48 (2H, t, J = 6.4 
Hz, H10), 3.41-3.32 (1H, m, H6), 1.98-1.89 (1H, m, H4a), 1.85-1.77 (1H, m, H3a), 1.69-1.43 
(8H, m, H4b + H5a + H7-9), 1.41-1.16 (2H, m, H3b + H5b); 13C NMR (75 MHz, CDCl3) δ 
202.3, 138.6, 128.3, 127.6, 127.4, 81.8, 77.9, 72.9, 70.2, 36.0, 31.0, 29.7, 26.1, 22.9, 22.1; 
HRMS (ES+) Calc. for C17H25O3 [M+H]+ 277.1811, found 277.1796. 
 
(2S,6S)-6-[(4-benzyloxy)butyl]-2-(ethynyl)tetrahydropyran (283) 
 
O
OBn
7
11
3
 
 
To a solution of dimethyldiazo-2-oxopropylphosphonate 260 (360 mg, 1.88 mmol) and 
K2CO3 (430 mg, 3.13 mmol) in MeOH (10 mL) at RT was added as a solution of aldehyde 
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284 (432 mg, 1.56 mmol) in MeOH (5 mL) and left to stir for 16 h. The reaction mixture 
was quenched by addition of saturated aqueous NaHCO3 (15 mL). The organics were 
extracted with Et2O (3 × 15 mL), dried over Na2SO4 and concentrated in vacuo. 
Purification by flash column chromatography (5% EtOAc/Hexane) provided alkyne 283 
(376 mg, 88%) as a colourless oil.  
Rf 0.56 (15% EtOAc/Hexane); 
€ 
[α]D20  -28.5 (c 0.72, CHCl3); IR (thin film) 3289, 2938, 
2859, 1717, 1454 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.36-7.27 (5H, m, ArH), 4.49 (2H, 
s, OCH2Ar), 4.08 (1H, dt, J = 11.3, 2.2 Hz, H3), 3.47 (2H, t, J = 6.7 Hz, H11), 3.31-3.25 
(1H, m, H7), 2.44 (1H, d, J = 2.2 Hz, H1), 1.86-1.79 (2H, m, H4a + H5a), 1.69-1.37 (9H, m, 
H4b + H5b + H6a + H8-10), 1.28-1.19 (1H, m, H6b); 13C NMR (100 MHz, CDCl3) δ 138.6, 
128.3, 127.6, 127.5, 83.6, 78.4, 72.9, 72.2, 70.3, 67.8, 36.1, 32.5, 30.7, 29.7, 23.3, 22.1; 
HRMS (ES+) Calc. for C18H25O2 [M+H]+ 273.1849, found 273.1854. 
 
(2R,6S)-6-[(4-benzyloxy)butyl]-2-(carbaldehyde)tetrahydropyran (286) 
 
O
H
OBn
O
6
10
2
 
 
To a solution of dimethyl sulfoxide (360 µL, 5.08 mmol) in CH2Cl2 (10 mL) at -78 °C was 
added oxalyl chloride (370 µL, 4.28 mmol). The reaction mixture was stirred at this 
temperature for 30 min before the addition of alcohol 280 (590 mg, 2.12 mmol) as a 
solution in CH2Cl2 (5 mL) via cannula. The reaction was stirred for a further 1 h, before 
the dropwise addition of Et3N (2.06 mL, 14.8 mmol) and the reaction mixture was warmed 
to RT over 30 min. After the addition of saturated aqueous NH4Cl (10 mL), the organics 
were extracted with CH2Cl2 (3 x 15 mL) and the combined organic extracts were dried 
(Na2SO4), filtered and concentrated in vacuo. Purification by flash column 
chromatography (10% EtOAc/Hexane) provided aldehyde 286 (486 mg, 83%) as a 
colourless oil. 
Rf 0.5 (25% EtOAc/Hexane); 
€ 
[α]D20  -51.0 (c 1.75, CHCl3); IR (thin film) 2940, 2862, 1732, 
1454, 1362 cm-1; 1H NMR (400 MHz, CDCl3) δ 9.83 (1H, br s, H1), 7.36-7.25 (5H, m, 
ArH), 4.50 (2H, s, OCH2Ar), 4.17 (1H, dd, J = 6.1, 3.0 Hz, H2), 3.60-3.54 (1H, m, H6), 
3.49 (2H, t, J = 6.5 Hz, H10), 2.03-1.97 (1H, m, H3a), 1.73-1.53 (7H, m, H3b + H4a + H5a + 
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H8-9), 1.52-1.36 (3H, m, H4b + H7), 1.34-1.24 (1H, m, H5b); 13C NMR (100 MHz, CDCl3) δ 
205.2, 138.5, 128.3, 127.6, 127.5, 78.8, 74.7, 72.8, 70.2, 35.4, 30.5, 29.7, 23.9, 22.1, 19.8; 
HRMS (ES+) Calc. for C17H24O3Na [M+Na]+ 299.1631, found 299.1616. 
 
(2R,6S)-6-[(4-benzyloxy)butyl]-2-[(2,2-dibromo-ethenyl)]tetrahydropyran (287) 
 
O
OBn
Br
Br
7
11
3
 
 
To a solution of CBr4 (1.15 g, 3.47 mmol) in CH2Cl2 (5 mL) at 0 °C was added PPh3 (1.81 
g, 6.90 mmol) and the reaction mixture cooled to -78 °C. After 5 min, a solution of 
aldehyde 286 (478 mg, 1.73 mmol) in CH2Cl2 (5 mL) was added and the reaction mixture 
was not allowed to exceed -50 °C over 50 min. The reaction mixture was quenched by 
addition of saturated aqueous NH4Cl (10 mL), the organics were extracted with CH2Cl2 (3 
× 15 mL) and the combined organic extracts were dried (NaSO4), filtered and concentrated 
in vacuo. Purification by flash column chromatography (5% EtOAc/Hexane) provided 
dibromo alkene 287 (687 mg, 92%) as a colourless oil.  
Rf 0.65 (15% EtOAc/Hexane); 
€ 
[α]D20  -37.0 (c 0.82, CHCl3); IR (thin film) 2938, 2862, 
1759, 1717, 1607, 1454 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.35-7.27 (5H, m, ArH), 6.76 
(1H, d, J = 7.5 Hz, H2), 4.50 (2H, s, OCH2Ar), 4.45 (1H, app dt, J = 7.5, 4.5 Hz, H3), 3.66-
3.58 (1H, m, H7), 3.48 (2H, t, J = 6.5 Hz, H11), 1.80-1.49 (7H, m, H4-5 + H6a + H10), 1.46-
1.24 (5H, m, H6b + H8-9); 13C NMR (100 MHz, CDCl3) δ 138.6, 137.9, 128.3, 127.6, 127.4, 
91.2, 72.8, 72.5, 71.9, 70.3, 34.2, 30.2, 29.7, 29.0, 22.3, 18.9; HRMS (CI+) Calc. for 
C18H25O279Br2 [M+H]+ 431.0216, found 431.0214. 
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(2R,6S)-6-[(4-benzyloxy)butyl]-2-(ethynyl)tetrahydropyran (285) 
 
O
OBn
7
11
3
 
 
To a solution of 1,1-dibromo alkene 287 (636 mg, 1.47 mmol) in THF (15 mL) at -78 °C 
was added n-BuLi (2.80 mL, 1.6 M solution in hexane, 4.48 mmol). After 45 min, the 
reaction mixture was quenched by addition of saturated aqueous NH4Cl (15 mL). The 
organics were extracted with EtOAc (3 × 15 mL), dried (Na2SO4), filtered and 
concentrated in vacuo. Purification by flash column chromatography (5% EtOAc/Hexane) 
provided alkyne 285 (331 mg, 82%) as a colourless oil. 
Rf 0.73 (20% EtOAc/Hexane); 
€ 
[α]D20  -6.7 (c 1.04, CHCl3); IR (thin film) 3290, 2938, 2862, 
1734, 1624, 1558 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.35-7.25 (5H, m, ArH), 4.75-4.74 
(1H, m, H3), 4.50 (2H, s, OCH2Ar), 3.87-3.81 (1H, m, H7), 3.48 (2H, t, J = 6.6 Hz, H11), 
2.45 (1H, d, J = 2.3 Hz, H1), 1.93-1.74 (2H, m, H4a + H5a), 1.70-1.58 (5H, m, H4b + H5b + 
H6a + H10), 1.53-1.38 (4H, m, H8-9), 1.27-1.17 (1H, m, H6b); 13C NMR (100 MHz, CDCl3) 
δ 138.6, 128.3, 127.5, 127.4, 82.4, 74.1, 72.8, 71.4, 70.3, 64.8, 35.9, 31.3, 30.3, 29.6, 21.9, 
19.2; HRMS (CI+) Calc. for C18H25O2 [M+H]+ 273.1849, found 273.1850. 
 
(2S,6S)-2-(azidomethyl)-6-[4-(benzyloxy)butyl]tetrahydropyran (288)  
 
O
N3
OBn
6
10
2
 
To a solution of alcohol 279 (403 mg, 1.45 mmol) in THF (10 mL) was added PPh3 (456 
mg, 1.74 mmol) and iPr2NEt (250 µL, 1.45 mmol). The solution was then cooled to 10 °C 
and DIAD (340 µL, 1.74 mmol) was added dropwise. After 20 min, DPPA (370 µL, 1.74 
mmol) was added dropwise and the solution allowed to warm to RT and left to stir for 16 
h. The reaction mixture was quenched by the addition of H2O (10 mL). The organics were 
extracted with EtOAc (3 × 10 mL), dried over Na2SO4 and concentrated in vacuo. 
Purification by flash column chromatography (15% EtOAc/Hexane) provided azide 288 
(430 mg, 98%) as a colourless oil.  
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Rf 0.68 (20% EtOAc/Hexane); 
€ 
[α]D20  -31.6 (c 1.04, CHCl3); IR (thin film) 2938, 2859, 
2093, 1717, 1454 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.35-7.24 (5H, m, ArH), 4.49 (2H, 
s, OCH2Ar), 3.54-3.48 (1H, m, H2), 3.47 (2H, t, J = 6.5 Hz, H10), 3.34-3.29 (1H, m, H6), 
3.26 (1H, dd, J = 12.8, 7.5 Hz, H1a), 3.05 (1H, dd, J = 12.8, 3.4 Hz, H1b), 1.89-1.82 (1H, m, 
H4a), 1.68-1.39 (9H, m, H3a + H4b + H5a + H7-9), 1.29-1.13 (2H, m, H3b + H5b); 13C NMR 
(100 MHz, CDCl3) δ 138.5, 128.1, 127.4, 127.2, 77.6, 76.8, 72.6, 70.2, 55.1, 36.0, 31.1, 
29.5, 28.5, 23.0, 21.9; HRMS (ES+) Calc. for C17H26O2N3 [M+H]+ 304.2020, found 
304.2021. 
 
4-[(2S’,6S’)-6’-(4-(benzyloxy)butyl)tetrahydropyran-2-yl]-1-[(2S’’,6S’’)-6’’-
(hexyltetrahydropyran-2-yl)methyl]-1H-1,2,3-triazole (289) 
 
O
OBn
N
N
NO
1'
6
12
2
5'
9'
 
General procedure A was followed with alkyne 283 (59.0 mg, 0.22 mmol) and azide 256 
(48.7 mg, 0.22 mmol) in t-BuOH (1 mL) and H2O (1 mL) to which was added 
CuSO4·5H2O (65.0 mg, 0.26 mmol) and sodium ascorbate (103 mg, 0.52 mmol). Standard 
work-up and purification by flash column chromatography (10→25% EtOAc/Hexane) 
provided triazole 289 (75.1 mg, 70%) as a colourless oil.  
Rf 0.47 (30% EtOAc/Hexane); 
€ 
[α]D20  -24.5 (c 1.06, CHCl3); IR (thin film) 2934, 2857, 
1719, 1454 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.64 (1H, s, HAr), 7.36-7.24 (5H, m, 
ArH), 4.61-4.58 (1H, m, H1’), 4.48 (2H, s, OCH2Ar), 4.48-4.42 (1H, m, H1a), 4.17 (1H, dd, 
J = 14.0, 8.2 Hz, H1b), 3.65-3.59 (1H, m, H2), 3.51-3.43 (1H, m, H5’), 3.46 (2H, t, J = 6.4 
Hz, H9’), 3.22-3.16 (1H, m, H6), 2.03-1.82 (3H, m, H3a’ + H4), 1.66-1.41 (12H, m, H2’ + H3a 
+ H3b’ + H4a’ + H5a + H6’ + H8’ + H10), 1.38-1.11 (13H, m, H3b + H4b’ + H5b + H7-9 + H7’ + 
H11), 0.87 (3H, t, J = 6.4 Hz, H12); 13C NMR (75 MHz, CDCl3) δ 149.9, 138.7, 128.3, 
127.6, 127.4, 122.3, 78.3, 77.8, 76.1, 73.2, 72.9, 70.4, 55.0, 36.4, 36.3, 31.9, 31.8, 31.3, 
31.2, 29.8, 29.3, 28.6, 25.6, 23.6, 23.0, 22.6, 22.2, 14.1; HRMS (ES+) Calc. for 
C30H48O3N3 [M+H]+ 498.3690, found 498.3693. 
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4-[(2R’,6S’)-6’-(4-(benzyloxy)butyl)tetrahydropyran-2-yl]-1-[(2S’’,6S’’)-6’’-
(hexyltetrahydropyran-2-yl)methyl]-1H-1,2,3-triazole (290) 
 
O
OBn
N
N
NO
1'
6
12
2
5'
9'
 
 
General procedure A was followed with alkyne 285 (50.0 mg, 0.18 mmol) and azide 256 
(41.2 mg, 0.18 mmol) in t-BuOH (1 mL) and H2O (1 mL) to which was added 
CuSO4·5H2O (55.0 mg, 0.22 mmol) and sodium ascorbate (87.0 mg, 0.44 mmol). Standard 
work-up and purification by flash column chromatography (10→30% EtOAc/Hexane) 
provided triazole 290 (58.7 mg, 65%) as a colourless oil.  
Rf 0.28 (30% EtOAc/Hexane); 
€ 
[α]D20  -22.8 (c 1.0, CHCl3); IR (thin film) 2932, 2857, 1719, 
1454 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.63 (1H, s, HAr), 7.36-7.23 (5H, m, ArH), 5.09-
5.05 (1H, m, H1’), 4.49 (2H, s, OCH2Ar), 4.49-4.42 (1H, m, H1a), 4.23 (1H, dd, J = 14.0, 
7.9 Hz, H1b), 3.67-3.54 (2H, m, H2 + H5’), 3.46 (2H, t, J = 6.5 Hz, H9’), 3.23-3.17 (1H, m, 
H6), 2.24-2.13 (1H, m, H2a’), 2.04-1.91 (1H, m, H2b’), 1.89-1.80 (1H, m, H4a), 1.77-1.69 
(2H, m, H3’), 1.67-1.34 (10H, m, H4’ + H4b + H5a + H6’ + H7 + H8’), 1.30-1.08 (13H, m, H3 
+ H5b + H7’ + H8-11), 0.87 (3H, t, J = 6.5 Hz, H12); 13C NMR (75 MHz, CDCl3) δ 148.5, 
138.6, 128.3, 127.5, 127.4, 123.3, 77.8, 76.0, 72.8, 71.3, 70.3, 67.8, 55.0, 36.3, 34.6, 31.7, 
31.2, 30.6, 29.8, 29.2, 28.5, 28.4, 25.4, 23.0, 22.6, 22.2, 19.1, 14.0; HRMS (ES+) Calc. for 
C30H48O3N3 [M+H]+ 498.3690, found 498.3692. 
 
4-[(2R’,6S’)-6’-(4-(benzyloxy)butyl)tetrahydropyran-2-yl]-1-[(2R’’,6S’’)-6’’-
(hexyltetrahydropyran-2-yl)methyl]-1H-1,2,3-triazole (291) 
 
O
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N
N
NO
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6
12
2
5'
9'
 
 
General procedure A was followed with alkyne 285 (58.0 mg, 0.21 mmol) and azide 257 
(47.9 mg, 0.21 mmol) in t-BuOH (1 mL) and H2O (1 mL) to which was added 
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CuSO4·5H2O (64.0 mg, 0.26 mmol) and sodium ascorbate (100 mg, 0.51 mmol). Standard 
work-up and purification by flash column chromatography (15→25% EtOAc/Hexane) 
provided triazole 291 (81.2 mg, 77%) as a colourless oil.  
Rf 0.41 (30% EtOAc/Hexane); 
€ 
[α]D20  -34.1 (c 1.03, CHCl3); IR (thin film) 2932, 2859, 
1719, 1454 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.58 (1H, s, HAr), 7.33-7.23 (5H, m, ArH), 
5.07 (1H, t, J = 4.5 Hz, H1’), 4.49 (2H, s, OCH2Ar), 4.43-4.28 (1H, m, H1), 4.02-3.94 (1H, 
m, H2), 3.83-3.75 (1H, m, H5’), 3.62-3.54 (1H, m, H6), 3.46 (2H, t, J = 6.4 Hz, H9’), 2.21-
2.12 (1H, m, H2a’), 2.04-1.91 (1H, m, H2b’), 1.77-1.50 (13H, m, H3a + H3’ + H4a’ + H4 + H5a 
+ H6’ + H7 + H8’), 1.47-1.32 (2H, m, H4b’ + H5b), 1.30-1.03 (11H, m, H3b + H7’ + H8-11), 
0.85 (3H, t, J = 6.7 Hz, H12); 13C NMR (75 MHz, CDCl3) δ 148.6, 138.6, 128.3, 127.5, 
127.4, 123.0, 72.8, 72.3, 71.4, 70.3, 69.0, 67.9, 53.6, 34.5, 31.7, 31.6, 30.6, 29.8, 29.2, 
28.9, 28.6, 27.9, 25.6, 22.6, 22.2, 19.1, 18.1, 14.0; HRMS (ES+) Calc. for C30H48O3N3 
[M+H]+ 498.3690, found 498.3693. 
 
4-[(2S’,6S’)-6’-(4-(benzyloxy)butyl)tetrahydropyran-2-yl]-1-[(2R’’,6S’’)-6’’-
(hexyltetrahydropyran-2-yl)methyl]-1H-1,2,3-triazole (292) 
 
O
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N
N
NO
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6
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2
5'
9'
 
General procedure A was followed with alkyne 283 (57.0 mg, 0.21 mmol) and azide 257 
(46.8 mg, 0.21 mmol) in t-BuOH (1 mL) and H2O (1 mL) to which was added 
CuSO4·5H2O (62.0 mg, 0.25 mmol) and sodium ascorbate (99.0 mg, 0.50 mmol). Standard 
work-up and purification by flash column chromatography (15→30% EtOAc/Hexane) 
provided triazole 292 (78.6 mg, 76%) as a colourless oil.  
Rf 0.22 (30% EtOAc/Hexane); 
€ 
[α]D20  -36.0 (c 1.05, CHCl3); IR (thin film) 2932, 2857, 
1717, 1454 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.57 (1H, s, HAr), 7.33-7.22 (5H, m, 
ArH), 4.59-4.54 (1H, m, H1’), 4.48 (2H, s, OCH2Ar), 4.36-4.34 (2H, m, H1), 4.02-3.95 
(1H, m, H2), 3.81-3.76 (1H, m, H5’), 3.49-3.41 (1H, m, H6), 3.46 (2H, t, J = 6.4 Hz, H9’), 
2.08-2.03 (1H, m, H2a’), 1.95-1.86 (1H, m, H4a), 1.65-1.40 (13H, m, H2b’ + H3a + H3’ + H4a’ 
+ H4b + H5a + H6’ + H7 + H8’), 1.37-1.04 (13H, m, H3b + H4b’ + H5b + H7’ + H8-11), 0.85 
(3H, t, J = 6.6 Hz, H12); 13C NMR (75 MHz, CDCl3) δ 149.9, 138.5, 128.2, 127.5, 127.3, 
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121.6, 78.1, 73.2, 72.8, 72.0, 70.3, 69.1, 53.2, 36.2, 31.9, 31.7, 31.5, 31.1, 29.7, 29.1, 29.0, 
27.8, 25.5, 23.5, 22.5, 22.1, 18.1, 14.0; HRMS (ES+) Calc. for C30H48O3N3 [M+H]+ 
498.3690, found 498.3693. 
 
4-[(2S’,6S’)-6’-(4-(benzyloxy)butyl)tetrahydropyran-2-yl]-1-[(2R’’,6R’’)-6’’-
(hexyltetrahydropyran-2-yl)methyl]-1H-1,2,3-triazole (293) 
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General procedure A was followed with alkyne 283 (58.0 mg, 0.21 mmol) and azide 294 
(47.9 mg, 0.21 mmol) in t-BuOH (1 mL) and H2O (1 mL) to which was added 
CuSO4·5H2O (64.0 mg, 0.26 mmol) and sodium ascorbate (101 mg, 0.51 mmol). Standard 
work-up and purification by flash column chromatography (10→20% EtOAc/Hexane) 
provided triazole 293 (45.6 mg, 43%) as a colourless oil.  
Rf 0.43 (30% EtOAc/Hexane); 
€ 
[α]D20  -19.4 (c 0.66, CHCl3); IR (thin film) 2932, 2857, 
1755, 1732, 1454 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.64 (1H, s, HAr), 7.34-7.27 (5H, m, 
ArH), 4.61-4.57 (1H, m, H1’), 4.49 (2H, s, OCH2Ar), 4.45 (1H, dd, J = 14.0, 3.2 Hz, H1a), 
4.21 (1H, dd, J = 14.1, 8.0 Hz, H1b), 3.68-3.60 (1H, m, H2), 3.51-3.43 (1H, m, H5’), 3.47 
(2H, t, J = 6.5 Hz, H9’), 3.26-3.18 (1H, m, H6), 2.08-2.04 (1H, m, H2a’), 1.98-1.81 (2H, m, 
H3a’ + H4a), 1.69-1.43 (12H, m, H2b’ + H3a + H3b’ + H4a’ + H4b + H5a + H6’ + H7 + H8’), 1.41-
1.10 (13H, m, H3b + H4b’ + H5b + H7’ + H8-11), 0.88 (3H, t, J = 6.6 Hz, H12); 13C NMR (125 
MHz, CDCl3) δ 149.6, 138.6, 128.3, 127.6, 127.4, 122.3, 78.2, 77.7, 76.0, 73.0, 72.8, 70.3, 
55.0, 36.3, 36.2, 31.8, 31.5, 31.1 (2C), 29.8, 29.2, 28.6, 25.4, 23.5, 23.0, 22.6, 22.1, 14.1; 
HRMS (ES+) Calc. for C30H48O3N3 [M+H]+ 498.3690, found 498.3680. 
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1-[(2S’,6S’)-6’-(hexyltetrahydropyran-2-yl)methyl]-4-[(2S’’,6S’’)-6’’-(4-
hydroxybutyl) tetrahydropyran-2-yl]-1H-1,2,3-triazole (295) 
 
O
OH
N
N
NO
1'
6
12
2
5'
9'
 
 
General procedure B was followed with benzyl ether 289 (17.3 mg, 35.0 µmol) in EtOH (2 
mL) to which was added Pd(OH)2 on carbon (4.90 mg, 20% wt on carbon, 6.95 µmol). 
Standard work-up and purification by flash column chromatography (50→70% 
EtOAc/Hexane) provided alcohol 295 (13.1 mg, 92%), as a colourless oil. 
Rf 0.14 (50% EtOAc/Hexane); 
€ 
[α]D20  -25.2 (c 0.5, CHCl3); IR (thin film) 3431, 2934, 2859, 
1751, 1456 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.64 (1H, s, HAr), 4.62-4.58 (1H, m, H1’), 
4.46 (1H, dd, J = 14.0, 3.1 Hz, H1a), 4.18 (1H, dd, J = 14.0, 8.3 Hz, H1b), 3.67-3.59 (3H, m, 
H2 + H9’), 3.51-3.45 (1H, m, H5’), 3.22-3.16 (1H, m, H6), 2.02-1.74 (3H, m, H2a’ + H3a’ + 
H4a), 1.67-1.41 (12H, m, H2b’ + H3a + H3b’ + H4a’ + H4b + H5a + H6’ + H7 + H8’), 1.38-1.14 
(13H, m, H3b + H4b’ + H5b + H7’ + H8-11), 0.87 (3H, t, J = 6.5 Hz, H12); 13C NMR (125 
MHz, CDCl3) δ 149.5, 122.6, 78.3, 77.8, 76.0, 72.8, 62.8, 55.2, 36.3, 36.0, 32.6, 31.9, 31.6, 
31.2, 31.2, 29.3, 28.6, 25.6, 23.5, 23.0, 22.6, 21.7, 14.1; HRMS (ES+) Calc. for 
C23H42O3N3 [M+H]+ 408.3221, found 408.3221. 
 
1-[(2S’,6S’)-6’-(hexyltetrahydropyran-2-yl)methyl]-4-[(2R’’,6S’’)-6’’-(4-
hydroxybutyl) tetrahydropyran-2-yl]-1H-1,2,3-triazole (296) 
 
O
OH
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12
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General procedure B was followed with benzyl ether 290 (27.5 mg, 55.0 µmol) in EtOH (4 
mL) to which was added Pd(OH)2 on carbon (7.70 mg, 20% wt on carbon, 11.0 µmol). 
Standard  work-up and purification by flash column chromatography (50→70% 
EtOAc/Hexane) provided alcohol 296 (21.3 mg, 95%), as a colourless oil. 
  Experimental
   
 228 
Rf 0.59 (50% EtOAc/Hexane); 
€ 
[α]D20  -28.1 (c 1.05, CHCl3); IR (thin film) 3421, 2934, 
2860, 1456, 1441, 1381 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.66 (1H, s, HAr), 5.09-5.05 
(1H, m, H1’), 4.47 (1H, dd, J = 13.9, 2.6 Hz, H1a), 4.25 (1H, dd, J = 14.0, 8.0 Hz, H1b), 
3.68-3.57 (4H, m, H2 + H5’ + H9’), 3.24-3.19 (1H, m, H6), 2.18-2.15 (1H, m, H2a’), 2.01-
1.93 (1H, m, H2b’), 1.87-1.34 (14H, m, H3a + H3’-4’ + H4 + H5a + H6’ + H7 + H8’), 1.30-1.09 
(12H, m, H3b + H5b + H7’ + H8-11), 0.87 (3H, t, J = 6.6 Hz, H12); 13C NMR (125 MHz, 
CDCl3) δ 148.4, 123.3, 77.8, 76.1, 71.3, 67.7, 62.7, 55.0, 36.3, 34.4, 32.7, 31.8, 31.2, 30.7, 
29.2, 28.5, 28.3, 25.5, 23.0, 22.6, 21.8, 19.1, 14.1; HRMS (ES+) Calc. for C23H42O3N3 
[M+H]+ 408.3221, found 408.3221. 
 
1-[(2R’,6S’)-6’-(hexyltetrahydropyran-2-yl)methyl]-4-[(2R’’,6S’’)-6’’-(4-
hydroxybutyl) tetrahydropyran-2-yl]-1H-1,2,3-triazole (297) 
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General procedure B was followed with benzyl ether 291 (10.0 mg, 20.0 µmol) in EtOH (2 
mL) to which was added Pd(OH)2 on carbon (2.80 mg, 20% wt on carbon, 4.02 µmol). 
Standard work-up and purification by flash column chromatography (50→70% 
EtOAc/Hexane) provided alcohol 297 (7.60 mg, 93%), as a colourless oil. 
Rf 0.03 (50% EtOAc/Hexane); 
€ 
[α]D20  -48.3 (c 0.84, CHCl3); IR (thin film) 3422, 2934, 
2860, 1749, 1456 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.61 (1H, s, HAr), 5.08 (1H, t, J = 
4.4 Hz, H1’), 4.42 (1H, dd, J = 14.0, 3.5 Hz, H1a), 4.32 (1H, dd, J = 14.1, 8.6 Hz, H1b), 4.00 
(1H, app tt, J = 8.7, 3.1 Hz, H2), 3.83-3.79 (1H, m, H5’), 3.67-3.58 (1H, m, H9’), 3.58-3.54 
(1H, m, H6), 2.19 (1H, app dq, J = 13.1, 4.3 Hz, H2a’), 1.99-1.92 (1H, m, H2b’), 1.75-1.62 
(8H, m, H3a + H3’ + H5a + H6’ + H7), 1.59-1.28 (9H, m, H3b + H4a’ + H4 + H5b + H7’-8’), 
1.27-1.12 (8H, m, H4b’ + H8a + H9-11), 1.10-1.03 (1H, m, H8b), 0.84 (3H, t, J = 7.1 Hz, H12); 
13C NMR (125 MHz, CDCl3) δ 148.4, 123.2, 72.5, 71.0, 69.1, 68.0, 62.8, 53.7, 34.5, 32.6, 
31.7, 31.4, 30.9, 29.2, 28.9, 28.3, 28.0, 25.6, 22.6, 21.6, 19.2, 18.1, 14.0; HRMS (ES+) 
Calc. for C23H42O3N3 [M+H]+ 408.3221, found 408.3218. 
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1-[(2R’,6S’)-6’-(hexyltetrahydropyran-2-yl)methyl]-4-[(2S’’,6S’’)-6’’-(4-
hydroxybutyl) tetrahydropyran-2-yl]-1H-1,2,3-triazole (298) 
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General procedure B was followed with benzyl ether 292 (17.2 mg, 35.0 µmol) in EtOH (4 
mL) to which was added Pd(OH)2 on carbon (4.80 mg, 20% wt on carbon, 6.91 µmol). 
Standard work-up and purification by flash column chromatography (50→70% 
EtOAc/Hexane) provided alcohol 298 (13.0 mg, 92%), as a colourless oil. 
Rf 0.16 (60% EtOAc/Hexane); 
€ 
[α]D20  -41.7 (c 1.04, CHCl3); IR (thin film) 3424, 2932, 
2859, 1742, 1458 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.61 (1H, s, HAr), 4.59-4.56 (1H, m, 
H1’), 4.38-4.37 (2H, m, H1), 4.03-3.97 (1H, m, H2), 3.82-3.78 (1H, m, H5’), 3.64 (2H, m, 
H9’), 3.50-3.45 (1H, m, H6), 2.07-2.04 (1H, m, H2a’), 1.94-1.92 (1H, m, H3a’), 1.74-1.45 
(11H, m, H2b’ + H3a + H3b’ + H4a’ + H4 + H5a + H7 + H8’), 1.40-1.08 (15H, m, H3b + H4b’ + 
H5b + H6’-7’ + H8-11), 0.86 (3H, t, J = 6.8 Hz, H12); 13C NMR (125 MHz, CDCl3) δ 149.6, 
121.9, 78.3, 73.0, 72.2, 69.1, 62.8, 53.5, 36.0, 32.7, 31.9, 31.8, 31.5, 31.2, 29.1, 29.0, 27.8, 
25.6, 23.5, 22.6, 21.7, 18.2, 14.1; HRMS (ES+) Calc. for C23H42O3N3 [M+H]+ 408.3221, 
found 408.3217. 
 
1-[(2R’,6R’)-6’-(hexyltetrahydropyran-2-yl)methyl]-4-[(2S’’,6S’’)-6’’-(4-
hydroxybutyl) tetrahydropyran-2-yl]-1H-1,2,3-triazole (299) 
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General procedure B was followed with benzyl ether 293 (23.1 mg, 46.0 µmol) in EtOH (4 
mL) to which was added Pd(OH)2 on carbon (6.50 mg, 20% wt on carbon, 9.00 µmol). 
Standard work-up and purification by flash column chromatography (50→70% 
EtOAc/Hexane) provided alcohol 299 (17.1 mg, 90%), as a colourless oil. 
Rf 0.06 (60% EtOAc/Hexane); 
€ 
[α]D20  -20.3 (c 1.71, CHCl3); IR (thin film) 2297, 2932, 
2859, 1792, 1734, 1628, 1559 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.67 (1H, s, HAr), 4.64-
  Experimental
   
 230 
4.60 (1H, m, H1’), 4.47 (1H, dd, J = 14.1, 3.1 Hz, H1a), 4.22 (1H, dd, J = 14.0, 8.1 Hz, H1b), 
3.67-3.63 (3H, m, H2 + H9’), 3.52-3.47 (1H, m, H5’), 3.26-3.20 (1H, m, H6), 2.09-2.05 (1H, 
m, H2a’), 2.01-1.84 (2H, m, H3a’ + H4a), 1.72-1.41 (10H, m, H2b’ + H3a + H3b’ + H4a’ + H4b + 
H5a + H6’ + H8’), 1.40-1.11 (15H, m, H3b + H4b’ + H5b + H7’ + H7-11), 0.88 (3H, t, J = 6.7 
Hz, H12); 13C NMR (125 MHz, CDCl3) δ 149.6, 122.2, 78.3, 77.8, 76.0, 73.0, 62.8, 55.0, 
36.3, 36.1, 32.7, 31.9, 31.4, 31.2, 31.1, 29.3, 28.6, 25.5, 23.5, 23.0, 22.6, 21.7, 14.1; 
HRMS (ES+) Calc. for C23H42O3N3 [M+H]+ 408.3221, found 408.3220. 
 
1-[(2S’,6S’)-6’-(hexyltetrahydropyran-2-yl)methyl]-4-[(2S’’,6S’’)-6’’-(4-(sulfanyl-1-
phenyl-1H-1,2,3,4-tetrazolyl)butyl)tetrahydropyran-2-yl]-1H-1,2,3-triazole (301) 
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To a solution of alcohol 295 (38.2 mg, 94.0 µmol) in THF (2 mL) at 0 °C was added 1-
phenyl-1H-tetrazole-5-thiol (21.7 mg, 120 µmol) and PPh3 (32.0 mg, 120 µmol) followed 
by DIAD (24.0 µL, 120 µmol) dropwise.  The reaction mixture was warmed to RT over 3 
h, then quenched by the addition of saturated aqueous NH4Cl (5 mL) and EtOAc (5 mL). 
The organics were extracted with EtOAc (3 × 5 mL), dried (Na2SO4), filtered and 
concentrated in vacuo. Purification by flash column chromatography (20→50% 
EtOAc/Hexane) provided sulfide 301 (35.8 mg, 67%), as a colourless oil. 
Rf 0.46 (30% Acetone/Hexane); 
€ 
[α]D20  -26.1 (c 1.01, CHCl3); IR (thin film) 2932, 2857, 
1728, 1499, 1385, 1086 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.68 (1H, s, HAr), 7.61-7.51 
(5H, m, ArH), 4.66-4.62 (1H, m, H1’), 4.48 (1H, dd, J = 13.9, 3.0 Hz, H1a), 4.20 (1H, dd, J 
= 14.0, 8.4 Hz, H1b), 3.68-3.60 (1H, m, H2), 3.51-3.44 (1H, m, H5’), 3.38 (2H, t, J = 7.3 Hz, 
H9’), 3.23-3.16 (1H, m, H6), 2.10-2.07 (1H, m, H2a’), 1.97-1.79 (4H, m, H4 + H8’), 1.68-
1.42 (10H, m, H2b’ + H3a + H3’ + H4a’ + H5a + H6’ + H7), 1.37-1.14 (13H, m, H3b + H4b’ + 
H5b + H7’ + H8-11), 0.86 (3H, t, J = 6.4 Hz, H12); 13C NMR (75 MHz, CDCl3) δ 154.4, 
149.5, 133.7, 130.0, 129.7, 123.8, 122.3, 77.9, 77.8, 76.0, 73.1, 55.0, 36.3, 35.7, 33.2, 31.8, 
  Experimental
   
 231 
31.6, 31.2, 31.1, 29.3, 29.1, 28.6, 25.5, 24.6, 23.5, 22.9, 22.6, 14.1; HRMS (ES+) Calc. for 
C30H45O2N7S1Na [M+Na]+ 590.3261, found 590.3245. 
 
1-[(2S’,6S’)-6’-(hexyltetrahydropyran-2-yl)methyl]-4-[(2S’’,6S’’)-6’’-(4-(sulfonyl-1-
phenyl-1H-1,2,3,4-tetrazolyl)butyl)tetrahydropyran-2-yl]-1H-1,2,3-triazole (300) 
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To a solution of sulfide 301 (35.8 mg, 63.0 µmol) in MeOH (1 mL) at 0 °C was added a 
mixture of ammonium molybdate (39.0 mg, 32.0 µmol) and H2O2 (143 µL, 30% v/v 
solution in H2O, 1.26 mmol). After 16 h at RT, the reaction mixture was diluted with 
MeOH (3 mL) and H2O (3 mL). The organics were extracted with CH2Cl2 (3 × 5 mL), 
dried (Na2SO4), filtered and concentrated in vacuo. Purification by flash column 
chromatography (20% Acetone/Hexane) provided sulfone 300 (34.3 mg, 91%), as a 
colourless oil. 
Rf 0.43 (30% Acetone/Hexane); 
€ 
[α]D20  -20.1 (c 1.00, CHCl3); IR (thin film) 2932, 2857, 
1732, 1595, 1499, 1340 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.72-7.55 (6H, m, ArH + 
HAr), 4.60-4.57 (1H, m, H1’), 4.44 (1H, dd, J = 14.0, 3.2 Hz, H1a), 4.18 (1H, dd, J = 14.0, 
8.3 Hz, H1b), 3.72-3.68 (2H, m, H9’), 3.65-3.59 (1H, m, H2), 3.51-3.45 (1H, m, H5’), 3.21-
3.16 (1H, m, H6), 2.01-1.91 (3H, m, H2a’ + H8’), 1.86-1.82 (1H, m, H4a), 1.70-1.42 (11H, 
m, H2b’ + H3a + H3’ + H4a’ + H4b + H5a + H6’ + H10), 1.39-1.10 (13H, m, H3b + H4b’ + H5b + 
H7’ + H7-9 + H11), 0.86 (3H, t, J = 6.7 Hz, H12); 13C NMR (75 MHz, CDCl3) δ 153.4, 149.4, 
133.0, 131.4, 129.6, 125.0, 122.3, 77.8, 77.7, 76.1, 73.1, 55.9, 55.0, 36.3, 35.5, 31.8, 31.6, 
31.2, 31.2, 29.3, 28.6, 25.5, 24.2, 23.5, 23.0, 22.6, 22.0, 14.1; HRMS (ES+) Calc. for 
C30H46O4N7S1 [M+H]+ 600.3340, found 600.3320. 
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1-[(2S’,6S’)-6’-(hexyltetrahydropyran-2-yl)methyl]-4-[(2S’’,6S’’)-6’’-[(4E)-10-[(5S)-3-
(5-methyl-2,5-dihydrofuran-2-one)dec-4-ene)-tetrahydropyran-2-yl]-1H-1,2,3-triazole 
(302) 
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O
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To a solution of sulfone 300 (31.5 mg, 53.0 µmol) in THF (3 mL) at -78 °C was added 
NaHMDS (410 µL, 0.2 M solution in THF, 82.0 µmol). After 10 min, a solution of 
aldehyde 188 (37.0 mg, 190 µmol) in THF (1 mL) was added dropwise via cannula. After 
1.25 h, saturated aqueous NH4Cl (4 mL) was added, and the reaction mixture was warmed 
to RT. The organics were extracted with EtOAc (3 x 5 mL) and the combined organic 
extracts were washed with brine (10 mL), dried (Na2SO4), filtered and concentrated in 
vacuo. Purification by flash column chromatography (3% EtOAc/CH2Cl2) provided alkene 
302 (18.4 mg, 61%) as a colourless oil.   
Rf 0.61 (30% Acetone/Hexane); 
€ 
[α]D20  -9.40 (c 1.84, CHCl3); IR (thin film) 2934, 2856, 
1751, 1456, 1084 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.64 (1H, s, HAr), 6.97 (1H, app q, J 
= 1.5 Hz, H18’), 5.37-5.31 (2H, m, H9’-10’), 4.98 (1H, qq, J = 6.7, 1.7 Hz, H19’), 4.60 (1H, 
dd, J = 11.1, 1.9 Hz, H1’), 4.46 (1H, dd, J = 14.0, 3.0 Hz, H1a), 4.18 (1H, dd, J = 14.1, 8.3 
Hz, H1b), 3.62 (1H, app ddt, J = 11.3, 8.5, 2.5 Hz, H2), 3.49-3.43 (1H, m, H5’), 3.23-3.16 
(1H, m, H6), 2.27-2.22 (2H, m, H15’), 2.02-1.83 (7H, m, H2a’ + H3a’ + H4a + H8’ + H11’), 
1.64-1.43 (10H, m, H2b’ + H3a + H3b’ + H4a’ + H4b + H5a + H10 + H14’), 1.41-1.30 (8H, m, 
H6’-7’ + H7 + H12’), 1.39 (3H, d, J = 6.8 Hz, H20’), 1.29-1.11 (11H, m, H3b + H4b’ + H5b + H8-
9 + H11 + H13’), 0.87 (3H, t, J = 6.7 Hz, H12); 13C NMR (125 MHz, CDCl3) δ 173.9, 149.7, 
148.9, 134.2, 130.3, 130.2, 122.4, 78.3, 77.8, 77.3, 76.1, 73.0, 55.1, 36.3, 36.0, 32.6, 32.3, 
31.8, 31.7, 31.2, 31.1, 29.3, 29.2, 28.6, 28.6, 27.2, 25.6, 25.5, 25.1, 23.5, 23.0, 22.6, 19.2, 
14.1; HRMS (ES+) Calc. for C34H55O4N3Na [M+Na]+ 592.4099, found 592.4079. 
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1-[(2S’,6S’)-6’-(hexyltetrahydropyran-2-yl)methyl]-4-[(2S’’,6S’’)-6’’-[10-[(5S)-3-(5-
methyl-2,5-dihydrofuran-2-one)decyl)-tetrahydropyran-2-yl]-1H-1,2,3-triazole (303) 
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To a solution of alkene 302 (17.1 mg, 30.0 µmol) and TsNHNH2 (340 mg, 1.80 mmol) in 
DME (3 mL) at reflux was added a solution of NaOAc (240 mg, 1.80 mmol) in H2O (3 
mL) over 3 h. The reaction mixture was cooled and diluted with H2O (3 mL) and EtOAc (5 
mL) and the organics were extracted with EtOAc (3 x 10 mL). The combined organic 
extracts were washed with 3 N HCl (3 x 5 mL), NaHCO3 (10 mL), brine (10 mL), dried 
(Na2SO4), filtered and concentrated in vacuo. Purification by flash column 
chromatography (8% EtOAc/CH2Cl2) provided alkane 303 (14.7 mg, 86%) as a colourless 
oil. 
Rf 0.22 (3% EtOAc/CH2Cl2); 
€ 
[α]D20  -8.1 (c 1.47, CHCl3); IR (thin film) 2928, 2855, 1755, 
1456, 1317, 1198 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.64 (1H, s, HAr), 6.98 (1H, app q, J 
= 1.5 Hz, H18’), 4.98 (1H, qq, J = 6.8, 1.8 Hz, H19’), 4.61-4.58 (1H, m, H1’), 4.46 (1H, dd, J 
= 14.1, 3.0 Hz, H1a), 4.18 (1H, dd, J = 14.1, 8.2 Hz, H1b), 3.65-3.60 (1H, m, H2), 3.48-3.43 
(1H, m, H5’), 3.22-3.17 (1H, m, H6), 2.27-2.23 (2H, m, H15’), 2.02-1.83 (3H, m, H2a’ + H3a’ 
+ H4a), 1.66-1.45 (9H, m, H2b’ + H3a + H3b’ + H4a’ + H4b + H10 + H14’), 1.43-1.32 (5H, m, 
H5a + H6’ + H7), 1.39 (3H, d, J = 6.8 Hz, H20’), 1.32-1.11 (23H, m, H3b + H4b’ + H5b + H7’-
13’ + H8-9 + H11), 0.87 (3H, t, J = 6.5 Hz, H12); 13C NMR (125 MHz, CDCl3) δ 173.9, 
149.9, 148.9, 134.3, 122.3, 78.4, 77.8, 77.4, 76.1, 73.1, 55.0, 36.5, 36.4, 31.9, 31.8, 31.2, 
31.2, 29.7, 29.6 (2C), 29.5, 29.3, 29.3, 29.2, 28.6, 27.4, 25.6, 25.5, 25.1, 23.6, 23.0, 22.6, 
19.2, 14.1; HRMS (ES+) Calc. for C34H58O4N3 [M+H]+ 572.4435, found 572.4405. 
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1-[(2S’,6S’)-6’-(hexyltetrahydropyran-2-yl)methyl]-4-[(2S’’,6S’’)-6’’-[10-(5-
methylfuran-3-yl)decyl)-tetrahydropyran-2-yl]-1H-1,2,3-triazole (304) 
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To a solution of alkane 303 (8.00 mg, 14.0 µmol) in CH2Cl2 (1 mL) at -78 °C was added 
DIBAL (170 µL, 1.0 M solution in hexane, 170 µmol). After 3.5 h, glacial acetic acid (240 
µL) was added and the solution allowed to warm to RT. After 1.5 h, the solution was 
quenched by addition of H2O (1 mL). The organics were extracted with EtOAc (3 × 5 mL), 
dried (Na2SO4) and concentrated in vacuo to afford furan 304 (7.80 mg, 100%) as a 
colourless oil without the need for purification.  
Rf 0.55 (30% EtOAc/Hexane); 
€ 
[α]D20  -16.9 (c 0.86, CHCl3); IR (thin film) 2928, 2855, 
1773, 1684, 1558, 1458 cm-1; 
1H NMR (500 MHz, CDCl3) δ 7.65 (1H, s, HAr), 7.04 (1H, s, 
H17’), 5.85 (1H, s, H18’), 4.60 (1H, dd, J = 11.2, 1.8 Hz, H1’), 4.46 (1H, dd, J = 14.0, 3.0 
Hz, H1a), 4.18 (1H, dd, J = 14.1, 8.3 Hz, H1b), 3.63 (1H, app ddt, J = 10.9, 8.5, 2.6 Hz, H2), 
3.48-3.44 (1H, m, H5’), 3.22-3.19 (1H, m, H6), 2.32 (2H, t, J = 7.6 Hz, H15’), 2.24 (3H, s, 
H20’), 2.03-2.01 (1H, m, H2a’), 1.94-1.91 (1H, m, H3a’), 1.87-1.84 (1H, m, H4a), 1.67-1.36 
(12H, m, H2b’ + H3a + H3b’ + H4a’ + H4b + H5a + H6’ + H7 + H14’), 1.33-1.14 (25H, m, H3b + 
H4b’ + H5b + H7’-13’ + H8-11), 0.88 (3H, t, J = 6.9 Hz, H12); 13C NMR (125 MHz, CDCl3) δ 
152.0, 149.9, 136.7, 126.3, 122.3, 107.1, 78.4, 77.8, 76.1, 73.2, 55.0, 36.5, 36.4, 31.9, 31.8, 
31.3, 31.2, 30.0, 29.7, 29.6 (2C), 29.6, 29.5, 29.4, 29.3, 28.6, 25.6, 25.5, 24.9, 23.6, 23.0, 
22.7, 14.1, 13.6; HRMS (ES+) Calc. for C34H57O3N3Na [M+Na]+ 578.4306, found 
578.4285. 
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1-[(2S’,6S’)-6’-(4-(benzyloxy)butyltetrahydropyran-2-yl)methyl]-4-[(2S’’,6S’’)-6’’-
(hexyltetrahydropyran-2-yl)]-1H-1,2,3-triazole (306) 
 
O
N
N
NO
OBn
26
1' 5'
 
 
General procedure A was followed with alkyne 261 (26.0 mg, 0.14 mmol) and azide 288 
(41.0 mg, 0.14 mmol) in t-BuOH (2 mL) and H2O (2 mL) to which was added 
CuSO4·5H2O (40.0 mg, 0.16 mmol) and sodium ascorbate (64.0 mg, 0.32 mmol). Standard 
work-up and purification by flash column chromatography (15% EtOAc/Hexane) provided 
triazole 306 (27.0 mg, 41%) as a colourless oil.  
Rf 0.43 (30% EtOAc/Hexane); 
€ 
[α]D20  -23.5 (c 1.0, CHCl3); IR (thin film) 2934, 2857, 1456 
cm-1; 1H NMR (500 MHz, CDCl3) δ 7.62 (1H, s, HAr), 7.35-7.31 (4H, m, ArH), 7.28-7.27 
(1H, m, ArH), 4.59-4.57 (1H, m, H1’), 4.49 (2H, s, OCH2Ar), 4.44 (1H, dd, J = 14.0, 3.2 
Hz, H1a), 4.20 (1H, dd, J = 14.0, 7.9 Hz, H1b), 3.66-3.62 (1H, m, H2), 3.46-3.41 (3H, m, H5’ 
+ H10), 3.24-3.19 (1H, m, H6), 2.02-2.00 (1H, m, H2a’), 1.91-1.84 (2H, m, H3a’ + H4a), 1.65-
1.37 (14H, m, H2b’ + H3a + H3b’ + H4a’ + H4b + H5a + H6’ + H7 + H9 + H9’), 1.35-1.12 (11H, 
m, H3b + H4b’ + H5b + H7’-8’ + H8 + H10’), 0.86 (3H, t, J = 6.7 Hz, H11’); 13C NMR (125 
MHz, CDCl3) δ 149.9, 138.5, 128.3, 127.5, 127.4, 122.2, 78.4, 77.6, 76.0, 73.1, 72.8, 70.3, 
55.0, 36.5, 36.0, 31.8, 31.7, 31.2, 31.1, 29.6, 29.4, 28.5, 25.5, 23.6, 22.9, 22.6, 22.1, 14.1; 
HRMS (CI+) Calc. for C30H48O3N3 [M+H]+ 498.3690, found 498.3686. 
 
4-[(2S’,6S’)-6’-(hexyltetrahydropyran-2-yl)]-1-[(2S’’,6S’’)-6’’-(4-hydroxybutyl 
tetrahydropyran-2-yl)methyl]-1H-1,2,3-triazole (307) 
 
O
N
N
NO
OH
26
1' 5'
 
General procedure B was followed with benzyl ether 306 (26.2 mg, 53.0 µmol) in EtOH (4 
mL) to which was added Pd(OH)2 on carbon (7.40 mg, 20% wt on carbon, 11.0 µmol). 
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Standard work-up and purification by flash column chromatography (60% EtOAc/Hexane) 
provided alcohol 307 (21.5 mg, 100%), as a colourless oil. 
Rf 0.2 (60% EtOAc/Hexane); 
€ 
[α]D20  -20.3 (c 0.39, CHCl3); IR (thin film) 3395, 2932, 2859, 
1456, 1439 cm-1; 
1H NMR (500 MHz, CDCl3) δ 7.63 (1H s, HAr), 4.60-4.58 (1H, m, H1’), 
4.44 (1H, dd, J = 14.0, 2.8 Hz, H1a), 4.19 (1H, dd, J = 14.0, 8.4 Hz, H1b), 3.67-3.63 (1H, m, 
H2), 3.61-3.56 (2H, m, H10), 3.48-3.44 (1H, m, H5’), 3.24-3.20 (1H, m, H6), 2.05-2.03 (1H, 
m, H2a’), 1.94-1.84 (2H, m, H3a’ + H4a), 1.66-1.40 (14H, m, H2b’ + H3a + H3b’ + H4a’ + H4b + 
H5a + H6’ + H7 + H9 + H9’), 1.35-1.17 (11H, m, H3b + H4b’ + H5b + H7’-8’ + H8 + H10’), 0.86 
(3H, t, J = 6.1 Hz, H11’); 13C NMR (125 MHz, CDCl3) δ 149.8, 122.2, 78.6, 77.6, 76.1, 
73.3, 62.6, 55.0, 36.5, 35.7, 32.5, 31.8, 31.7, 31.2, 31.2, 29.4, 28.6, 25.5, 23.6, 23.0, 22.6, 
21.7, 14.1; HRMS (CI+) Calc. for C23H42O3N3 [M+H]+ 408.3221, found 408.3218. 
 
4-[(2S’,6S’)-6’-(hexyltetrahydropyran-2-yl)]-1-[(2S’’,6S’’)-6’’-(4-(sulfanyl-1-phenyl-
1H-1,2,3,4-tetrazolyl)butyltetrahydropyran-2-yl)methyl ]-1H-1,2,3-triazole (308) 
 
O
N
N
NO
SN
N
N N
Ph
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To a solution of alcohol 307 (21.9 mg, 54.0 µmol) in THF (2 mL) at 0 °C was added 1-
phenyl-1H-tetrazole-5-thiol (12.0 mg, 70.0 µmol) and PPh3 (18.0 mg, 70.0 µmol) followed 
by DIAD (14.0 µL, 70.0 µmol) dropwise.  The reaction mixture was warmed to RT over 3 
h, then quenched by the addition of saturated aqueous NH4Cl (5 mL) and EtOAc (5 mL). 
The organics were extracted with EtOAc (3 × 5 mL), dried (Na2SO4), filtered and 
concentrated in vacuo. Purification by flash column chromatography (15→30% 
EtOAc/Hexane) provided sulfide 308 (23.1 mg, 76%), as a colourless oil. 
Rf 0.57 (30% Acetone/Hexane); 
€ 
[α]D20  -15.4 (c 1.0, CHCl3); IR (thin film) 2932, 2857, 
1499, 1456, 1387 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.60 (1H, s, HAr), 7.58-7.52 (5H, m, 
ArH), 4.59 (1H, dd, J = 11.1, 1.9 Hz, H1’), 4.43 (1H, dd, J = 14.1, 3.3 Hz, H1a), 4.20 (1H, 
dd, J = 14.1, 8.0 Hz, H1b), 3.67-3.62 (1H, m, H2), 3.46-3.42 (1H, m, H5’), 3.41-3.31 (2H, 
m, H10), 3.24-3.20 (1H, m, H6), 2.04-2.02 (1H, m, H2a’), 1.90-1.76 (4H, m, H4 + H9), 1.64-
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1.36 (12H, m, H2b’ + H3a + H3’ + H4a’ + H5a + H6’ + H7-8), 1.31-1.12 (11H, m, H3b + H4b’ + 
H5b + H7’-10’), 0.85 (3H, t, J = 6.6 Hz, H11’); 13C NMR (125 MHz, CDCl3) δ 154.3, 149.8, 
133.6, 130.0, 129.7, 123.7, 122.2, 78.4, 77.3, 76.1, 73.1, 54.9, 36.5, 35.4, 33.1, 31.8, 31.7, 
31.2, 31.1, 29.3, 28.9, 28.5, 25.5, 24.5, 23.5, 22.9, 22.6, 14.1; HRMS (CI+) Calc. for 
C30H46O2N7S [M+H]+ 568.3428, found 568.3425. 
 
4-[(2S’,6S’)-6’-(hexyltetrahydropyran-2-yl)]-1-[(2S’’,6S’’)-6’’-(4-(sulfonyl-1-phenyl-
1H-1,2,3,4-tetrazolyl)butyltetrahydropyran-2-yl)methyl ]-1H-1,2,3-triazole (309) 
 
O
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To a solution of sulfide 308 (22.0 mg, 39.0 µmol) in MeOH (1 mL) at 0 °C was added a 
mixture of ammonium molybdate (24.0 mg, 19.0 µmol) and H2O2 (90.0 µL, 30% v/v 
solution in H2O, 770 µmol). After 16 h at RT, the reaction mixture was diluted with MeOH 
(3 mL) and H2O (3 mL). The organics were extracted with CH2Cl2 (3 × 5 mL), dried 
(Na2SO4), filtered and concentrated in vacuo. Purification by flash column 
chromatography (15% Acetone/Hexane) provided sulfone 309 (21.9 mg, 94%), as a 
colourless oil. 
Rf 0.5 (30% Acetone/Hexane); 
€ 
[α]D20  -15.0 (c 0.98, CHCl3); IR (thin film) 2936, 2859, 
1499, 1456, 1339 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.72-7.68 (2H, m, ArH), 7.64-7.54 
(4H, m, ArH + HAr), 4.60-4.58 (1H, m, H1’), 4.43 (1H, dd, J = 13.9, 3.2 Hz, H1a), 4.22 (1H, 
dd, J = 13.8, 8.0 Hz, H1b), 3.76-3.65 (3H, m, H2 + H10), 3.48-3.43 (1H, m, H5’), 3.25-3.21 
(1H, m, H6), 2.05-2.03 (1H, m, H2a’), 1.94-1.84 (4H, m, H3a’ + H4a + H9), 1.65-1.39 (12H, 
m, H2b’ + H3a + H3b’ + H4a’ + H4b + H5a + H6’ + H7-8), 1.31-1.15 (11H, m, H3b + H4b’ + H5b + 
H7’-10’), 0.85 (3H, t, J = 6.5 Hz, H11’); 13C NMR (125 MHz, CDCl3) δ 153.4, 149.9, 133.0, 
131.4, 129.7, 125.0, 121.2, 78.4, 77.0, 76.1, 73.2, 55.8, 54.9, 36.5, 35.2, 31.8, 31.7, 31.2, 
31.1, 29.3, 28.4, 25.5, 24.1, 23.5, 22.8, 22.6, 21.9, 14.1; HRMS (ES+) Calc. for 
C30H45O4N7SNa [M+Na]+ 622.3160, found 622.3138. 
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4-[(2S’,6S’)-6’-(hexyltetrahydropyran-2-yl)]-1-[(2S’’,6S’’)-6’’-[(4E)-10-[(5S)-3-(5-
methyl-2,5-dihydrofuran-2-one)dec-4-ene-(tetrahydropyran-2-yl)methyl]-1H-1,2,3-
triazole (310) 
 
O
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N
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O
O
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To a solution of sulfone 309 (21.9 mg, 37.0 µmol) in THF (2 mL) at -78 °C was added 
NaHMDS (220 µL, 0.20 M solution in THF, 44.0 µmol). After 10 min, a solution of 
aldehyde 188 (11.0 mg, 55.0 µmol) in THF (1 mL) was added dropwise via cannula. After 
1.5 h, saturated aqueous NH4Cl (5 mL) was added, and the reaction mixture was warmed 
to RT. The organics were extracted with EtOAc (3 x 5 mL) and the combined organic 
extracts were washed with brine (10 mL), dried (Na2SO4), filtered and concentrated in 
vacuo. Purification by flash column chromatography (3% EtOAc/CH2Cl2) provided alkene 
310 (9.20 mg, 44%) as a colourless oil.   
Rf 0.43 (30% EtOAc/Hexane); 
€ 
[α]D20  -5.7 (c 0.92, CHCl3); IR (thin flm) 2932, 2859, 2097, 
1755 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.63 (1H, s, HAr), 7.00-6.97 (1H, m, H19), 5.43-
5.29 (2H, m, H10-11), 5.03-4.95 (1H, m, H20), 4.61-4.58 (1H, m, H1’), 4.45 (1H, dd, J = 
14.1, 3.1 Hz, H1a), 4.20 (1H, dd, J = 14.0, 8.0 Hz, H1b), 3.69-3.60 (1H, m, H2), 3.50-3.42 
(1H, m, H5’), 3.26-3.17 (1H, m, H6), 2.29-2.23 (2H, m, H16), 2.04-1.83 (7H, m, H2a’ + H3a’ 
+ H4a + H9 + H12), 1.71-1.48 (7H, m, H2b’ + H3a + H3b’ + H4a’ + H4b + H15), 1.46-1.32 (9H, 
m, H5a + H6’ + H7-8 + H13), 1.40 (3H, d, J = 6.8 Hz, H21), 1.30-1.11 (13H, m, H3b + H4b’ + 
H5b + H7’-10’ + H14), 0.86 (3H, t, J = 6.9 Hz, H11’); 13C NMR (125 MHz, CDCl3) δ 173.8, 
149.9, 148.9, 134.2, 130.3, 130.2, 122.3, 78.4, 77.7, 77.4, 76.1, 73.1, 55.0, 36.5, 35.8, 32.5, 
32.4, 31.8, 31.7, 31.2 (2C), 29.4, 29.2, 28.7, 28.6, 27.3, 25.5 (2C), 25.1, 23.6, 23.0, 22.6, 
19.2, 14.1; HRMS (ES+) Calc. for C34H56O4N3 [M+H]+ 570.4279, found 570.4262. 
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4-[(2S’,6S’)-6’-(hexyltetrahydropyran-2-yl)]-1-[(2S’’,6S’’)-6’’-[10-[(5S)-3-(5-methyl-
2,5-dihydrofuran-2-one)decyl-(tetrahydropyran-2-yl)methyl]-1H-1,2,3-triazole (305) 
 
O
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N
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O
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To a solution of alkene 310 (9.20 mg, 16.0 µmol) and TsNHNH2 (180 mg, 970 µmol) in 
DME (1 mL) at reflux was added a solution of NaOAc (131 mg, 970 µmol) in H2O (1 mL) 
over 3 h. The reaction mixture was cooled and diluted with H2O (3 mL) and EtOAc (5 mL) 
and the organics were extracted with EtOAc (3 x 5 mL). The combined organic extracts 
were washed with 3 N HCl (3 x 5 mL), NaHCO3 (10 mL), brine (10 mL), dried (Na2SO4), 
filtered and concentrated in vacuo. Purification by flash column chromatography (8% 
EtOAc/CH2Cl2) provided alkane 305 (6.90 mg, 75%) as a colourless oil. 
Rf 0.43 (30% EtOAc/Hexane); 
€ 
[α]D20  -6.4 (c 0.67, CHCl3); IR (thin film) 2930, 2855, 1757, 
1456, 1373, 1317 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.67 (1H, s, HAr), 6.99-6.98 (1H, m, 
H19), 5.03-4.96 (1H, m, H20), 4.68-4.61 (1H, m, H1’), 4.47 (1H, dd, J = 14.0, 3.2 Hz, H1a), 
4.21 (1H, dd, J = 13.9, 8.1 Hz, H1b), 3.37-3.62 (1H, m, H2), 3.49-3.44 (1H, m, H5’), 3.26-
3.18 (1H, m, H6), 2.28-2.24 (2H, m, H16), 2.09-2.04 (1H, m, H2a’), 1.95-1.84 (2H, m, H3a’ + 
H4a), 1.67-1.46 (10H, m, H2b’ + H3a + H3b’ + H4a’ + H4b + H5a + H9’ + H15), 1.43-1.36 (4H, 
m, H6’ + H7), 1.40 (3H, d, J = 6.8 Hz, H21), 1.32-1.12 (23H, m, H3b + H4b’ + H5b + H7’-8’ + 
H8-14 + H10’), 0.87 (3H, t, J = 6.9 Hz, H11’); 13C NMR (125 MHz, CDCl3) δ 173.9, 149.2, 
148.9, 134.3, 122.9, 78.4, 77.9, 77.4, 75.9, 72.7, 55.4, 36.5, 36.3, 31.8 (2C), 31.2, 31.1, 
29.7, 29.6 (2C), 29.5, 29.4, 29.3, 29.2, 28.5, 27.4, 25.6, 25.5, 25.2, 23.5, 22.9, 22.6, 19.2, 
14.1; HRMS (ES+) Calc. for C34H58O4N3 [M+H]+ 572.4435, found 572.4413. 
 
6-(tert-butyldimethylsilyloxy)hexan-1-ol (311)151 
 
TBSO
OH
1
6
 
 
To a solution of 1,6-hexanediol 92 (11.8 g, 100 mmol), Et3N (6.00 mL, 43.1 mmol) and 
DMAP (410 mg, 3.32 mmol) in CH2Cl2 (120 mL) at RT was added a solution of TBSCl 
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(5.00 g, 33.2 mmol) in CH2Cl2 (30 mL). After 16 h, the reaction mixture was quenched by 
the addition of saturated aqueous NH4Cl (100 mL) and the organics were extracted with 
CH2Cl2 (3 x 100 mL). The combined organic extracts were washed with brine (100 mL), 
dried (MgSO4) and concentrated in vacuo. Purification by flash column chromatography 
(5→10% EtOAc/Pet. Ether) provided alcohol 311 (5.81 g, 75 %), as a colourless oil. 
Rf 0.21 (20% EtOAc/Hexane); 1H NMR (300 MHz, CDCl3) δ 3.66-3.58 (4H, m, H1 + H6), 
1.62-1.48 (4H, m, H2 + H5), 1.42-1.31 (4H, m, H3-4), 0.89 (9H, s, SiC(CH3)3), 0.04 (6H, s, 
2 × SiCH3).   
 
6-[(5S)-5-methyl-2-oxo-2,5-dihydrofuran-3-yl)hexanoic acid (313) 
 
O
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To a solution of aldehyde 188 (102 mg, 0.52 mmol) in t-BuOH (2 mL) and H2O (1 mL) at 
0 °C was added 2-methyl-2-butene (1.60 mL, 2.0 M solution in THF, 3.13 mmol). To the 
resultant solution was added dropwise a solution of NaClO2 (120 mg, 1.04 mmol) and 
NaH2PO4•2H2O (325 mg, 2.09 mmol) in H2O (1 mL) and the mixture allowed to warm to 
RT. After 2 h, the reaction mixture was diluted with H2O (3 mL) and acidified with AcOH 
(few drops, pH 6). The organics were extracted with EtOAc (4 × 5 mL), dried (Na2SO4) 
and concentrated in vacuo to provide acid 313 (111 mg, 100%) as a colourless oil. 
Rf 0.4 (80% EtOAc/Hexane); 
€ 
[α]D20  +27.2 (c 1.43, CHCl3); IR (thin film) 3088, 2934, 
2862, 1744, 1456, 1319 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.00-6.99 (1H, m, H9), 4.97 
(1H, qq, J = 6.7, 1.6 Hz, H10), 2.32 (2H, t, J = 7.4 Hz, H2), 2.25-2.22 (2H, m, H6), 1.65-
1.59 (2H, m, H3), 1.57-1.51 (2H, m, H5), 1.39-1.34 (2H, m, H4), 1.36 (3H, d, J = 6.8 Hz, 
H11); 13C NMR (125 MHz, CDCl3) δ 179.5, 173.9, 149.3, 133.7, 77.5, 33.7, 28.3, 26.9, 
24.8, 24.1, 19.0; HRMS (ES+) Calc. for C11H15O4 [M-H]+ 211.0975, found 211.0975. 
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1-[(2S’,6S’)-6’-(hexyltetrahydropyran-2-yl)methyl]-4-[(2S’’,6R’’)-6’’-(4-
oxobutyl)tetrahydropyran-2-yl]-1H-1,2,3-triazole (317) 
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To a solution of alcohol 295 (32.4 mg, 79.0 µmol) in CH2Cl2 (2 mL) at 0 ºC was added 
NaHCO3 (33.0 mg, 400 µmol) followed by Dess-Martin periodinane (100 mg, 240 µmol). 
The reaction mixture was stirred at 0 ºC for 30 min, followed by warming to RT over an 
additional 1 h. The reaction mixture was re-cooled to 0 ºC, prior to the addition of cold 
hexane (5 mL) and cold toluene (5 mL). The resultant white suspension was filtered over 
celite and the filtrate concentrated in vacuo. Purification by flash column chromatography 
(50% EtOAc/Hexane) provided aldehyde 317 (32.2 mg, 100%) as a colourless oil. 
Rf 0.39 (50% EtOAc/Hexane); 
€ 
[α]D20  -23.9 (c 1.91, CHCl3); IR (thin film) 2934, 2859, 
1724, 1456, 1440 cm-1; 1H NMR (300 MHz, CDCl3) δ 9.73 (1H, t, J = 1.7 Hz, H9’), 7.62 
(1H, s, HAr), 4.58 (1H, dd, J = 11.7, 2.7 Hz, H1’), 4.45 (1H, dd, J = 14.0, 3.1 Hz, H1a), 4.18 
(1H, dd, J = 14.0, 8.3 Hz, H1b), 3.62 (1H, app ddt, J = 11.0, 8.4, 2.6 Hz, H2), 3.52-3.44 
(1H, m, H5’), 3.23-3.15 (1H, m, H6), 2.43 (2H, td, J = 7.2, 1.7 Hz, H8’), 2.02-1.70 (4H, m, 
H2a’ + H4a + H7’), 1.68-1.41 (11H, m, H2b’ + H3a + H3’ + H4a’ + H4b + H5a + H6’ + H7), 1.37-
1.08 (11H, m, H3b + H4b’ + H5b + H8-11), 0.86 (3H, t, J = 6.6 Hz, H12); 13C NMR (125 
MHz, CDCl3) δ 202.7, 149.6, 122.3, 77.8 (2C), 76.1, 73.1, 55.0, 43.8, 36.3, 35.7, 31.9, 
31.6, 31.2, 31.2, 29.3, 28.6, 25.6, 23.5, 23.0, 22.6, 18.3, 14.1; HRMS (ES+) Calc. for 
C23H39O3N3Na [M+Na]+ 428.2897, found 428.2878.  
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4-[(2S’,6R’)-6’-(4-carboxybutyl)tetrahydropyran-2-yl]-1-[(2S’’,6S’’)-6’’-
(hexyltetrahydropyran-2-yl)methyl]- 1H-1,2,3-triazole (316) 
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To a solution of aldehyde 317 (32.2 mg, 79.0 µmol) in t-BuOH (2 mL) and H2O (1 mL) at 
0 °C was added 2-methyl-2-butene (240 µL, 2.0 M solution in THF, 480 µmol). To the 
resultant solution was added dropwise a solution of NaClO2 (18.0 mg, 160 µmol) and 
NaH2PO4•2H2O (50.0 mg, 320 µmol) in H2O (1 mL) and the mixture allowed to warm to 
RT. After 2 h, the reaction mixture was diluted with H2O (2 mL) and acidified with AcOH 
(few drops, pH 6). The organics were extracted with EtOAc (4 × 5 mL), dried (Na2SO4) 
and concentrated in vacuo to provide acid 316 (33.5 mg, 100%) as a colourless oil without 
the need for further purification.  
Rf 0.2 (70% EtOAc/Hexane); 1H NMR (500 MHz, CDCl3) δ 7.63 (1H, s, HAr), 4.61 (1H, 
dd, J = 11.2, 2.0 Hz, H1’), 4.46 (1H, dd, J = 14.0, 3.1 Hz, H1a), 4.19 (1H, dd, J = 14.0, 8.3 
Hz, H1b), 3.63 (1H, app ddt, J = 11.1, 8.2, 2.6 Hz, H2), 3.53-3.48 (1H, m, H5’), 3.22-3.18 
(1H, m, H6), 2.38 (2H, td, J = 7.5, 2.0 Hz, H8’), 2.03-1.70 (4H, m, H2a’ + H4a + H7’), 1.69-
1.42 (10H, m, H2b’ + H3a + H3’ + H4a’ + H4b + H5a + H6’ + H7a), 1.39-1.13 (12H, m, H3b + 
H4b’ + H5b + H7b + H8-11), 0.87 (3H, t, J = 7.0 Hz, H12).    
 
(2S,6S)-6-[(4-benzyloxy)butyl]-2-[hydroxyimino]tetrahydropyran (324) 
 
O
OBn
H
N
OH
26
 
 
To a solution of aldehyde 284 (29.3 mg, 0.11 mmol) in EtOH (2 mL) at 0 °C was added a 
solution of hydroxylamineHCl (14.7 mg, 0.21 mmol) in water (1 mL). After 1 h, the 
reaction mixture was quenched by the addition of H2O (5 mL). The organics were 
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extracted with CH2Cl2 (3 × 5 mL), washed with brine (10 mL), dried (NaSO4) and 
concentrated in vacuo to afford oxime 324 (28.9 mg, 94%). The crude oil was used directly 
without the need for further purification.  
Rf 0.32 (20% EtOAc/Hexane); 
€ 
[α]D20  -22.1 (c 1.82, CHCl3); IR (thin film) 3335, 2936, 
2860, 1454 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.40 (1H, br s, H1), 7.36-7.28 (5H, m, 
ArH), 4.50 (2H, s, OCH2Ar), 3.99 (1H, ddd, J = 11.3, 5.8, 2.1 Hz, H2), 3.45 (2H, t, J = 6.6 
Hz, H10), 3.37-3.32 (1H, m, H6), 1.90-1.85 (1H, m, H4a), 1.69-1.39 (10H, m, H3 + H4b + H5a 
+ H7-9), 1.28-1.18 (1H, m, H5b); 13C NMR (125 MHz, CDCl3) δ 152.1, 138.6, 128.3, 127.6, 
127.5, 78.0, 75.1, 72.9, 70.3, 36.1, 30.9, 29.7, 29.4, 23.0, 22.1; HRMS (ES+) Calc. for 
C17H26O3N [M+H]+ 292.1907, found 292.1905. 
 
3-[(2S’,6S’)-6’-(4-(benzyloxy)butyl)tetrahydropyran-2-yl]-5-[(2S’’,6S’’)-6’’-
hexyltetrahydropyran-2-yl)]-1,2-oxazole (325) 
 
O
OBn
O
N
O
15
1' 5'
 
 
To a solution of oxime 324 (18.5 mg, 63.0 µmol) in CH2Cl2 (1 mL) at -78 °C was slowly 
added t-BuOCl (7.30 µL, 67.0 µmol). After 1.25 h, the solution was added via cannula to a 
solution of alkyne 261 (25.0 mg, 130 µmol) and Et3N (13.0 µL, 95.0 µmol) in CH2Cl2 (1 
mL) at -78 °C and left to slowly warm to RT. After 16 h, the reaction mixture was 
quenched by addition of saturated aqueous NH4Cl (5 mL) and extracted with CH2Cl2 (3 × 5 
mL). The organics were washed with brine (10 mL), dried (Na2SO4) and concentrated in 
vacuo. Purification by flash column chromatography (5% EtOAc/Hexane) provided 
isoxazole 325 (5.30 mg, 17%) as a colourless oil.  
Rf 0.67 (20% EtOAc/Hexane); 
€ 
[α]D20  -44.2 (c 0.53, CHCl3); IR (thin film) 2938, 2860, 
1734, 1605, 1454 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.37-7.28 (5H, m, ArH), 6.24 (1H, 
s, HAr), 4.55-4.47 (2H, m, H1 + H1’), 4.49 (2H, s, OCH2Ar), 3.51-3.39 (2H, m, H5 + H5’), 
3.47 (2H, t, J = 6.5 Hz, H9), 1.96-1.86 (4H, m, H2a + H2a’ + H3a + H3a’), 1.68-1.53 (8H, m, 
H2b + H2b’ + H3b + H3b’ + H4a + H4a’ + H8), 1.52-1.38 (4H, m, H6 + H6’), 1.36-1.21 (12H, m, 
H4b + H4b’ + H7 + H7’-10’), 0.88 (3H, t, J = 6.9 Hz, H11’); 13C NMR (125 MHz, CDCl3) δ 
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172.7, 165.3, 138.6, 128.3, 127.6, 127.5, 98.9, 78.7, 78.3, 72.9, 72.8, 72.6, 70.3, 36.4, 36.2, 
31.8, 31.2, 31.0, 30.2, 29.8, 29.3, 25.4, 23.4, 23.2, 22.6, 22.1, 14.1; HRMS (ES+) Calc. for 
C30H46O4N [M+H]+ 484.3421, found 484.3414. 
 
Undec-2-yn-1,5-diol (329) 
 
OH
OH
1
5
 
 
To a solution of alkyne 328 (4.18 g, 27.3 mmol) in THF (120 mL) at -78 °C was added n-
BuLi (18.8 mL, 1.6 M solution in hexane, 30.0 mmol). After 15 mins, epoxide 150 (3.50 g, 
27.3 mmol) in THF (30 mL) was added via canula followed by the addition of BF3•Et2O 
(3.46 mL, 27.3 mmol). After 1.5 h at -78 °C, the reaction mixture was quenched by the 
addition of H2O (50 mL) and 10% HCl (50 mL) and the solution allowed to warm to RT 
over 1 h. The organics were extracted with EtOAc (3 × 100 mL), dried (Na2SO4) and 
concentrated in vacuo.  Purification by flash column chromatography (30→50% 
EtOAc/Hexane) provided diol 329 (3.02 g, 60%) as a yellow oil.  
Rf 0.11 (30% EtOAc/Hexane); 
€ 
[α]D20  +1.9 (c 1.01, CHCl3); IR (thin film) 3354, 2928, 
2857, 1717, 1456 cm-1; 1H NMR (300 MHz, CDCl3) δ 4.27 (2H, t, J = 2.1 Hz, H1), 3.79-
3.71 (1H, m, H5), 2.47 (1H, ddt, J = 16.7, 4.4, 2.1 Hz, H4a), 2.34 (1H, ddt, J = 16.6, 6.8, 2.1 
Hz, H4b), 1.94 (2H, br s, 2 × OH), 1.56-1.47 (2H, m, H6), 1.43-1.26 (8H, m, H7-10), 0.88 
(3H, t, J = 6.8 Hz, H11); 13C NMR (75 MHz, CDCl3) δ 82.7, 80.8, 70.1, 51.0, 36.3, 31.8, 
29.2, 27.5, 25.6, 22.6, 14.0; HRMS (CI+) Calc. for C11H19O2 [M-H]+183.1380, found 
183.1376. 
 
Undecan-1,5-diol (330) 
 
OH
OH
1
5
 
 
A solution of alkyne 329 (1.38 g, 7.50 mmol) in MeOH (50 mL) was subjected to 
hydrogenation conditions using the H-cube system, 10% Pd/C (30 × 4 mm) at 30 bar and 
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RT (2 cycles with flow rate of 0.5 mL/min). The resultant solution was concentrated in 
vacuo which gave diol 330 (1.29 g, 91%) as a yellow oil without the need for purification.  
Rf 0.15 (40% EtOAc/Hexane); 
€ 
[α]D20  +1.7 (c 1.06, CHCl3); IR (thin film) 3327, 2928, 
2859, 1458 cm-1; 1H NMR (400 MHz, CDCl3) δ 3.66 (2H, t, J = 6.3 Hz, H1), 3.63-3.55 
(1H, m, H5), 1.70-1.55 (2H, m, H2), 1.54-1.23 (14H, m, H3-4 + H6-10), 0.88 (3H, t, J = 7.0 
Hz, H11); 13C NMR (100 MHz, CDCl3) δ 71.6, 62.2, 37.5, 36.7, 32.3, 31.8, 29.3, 25.6, 
22.6, 21.7, 14.0; HRMS (CI+) Calc. for C11H25O2 [M+H]+ 189.1849, found 189.1848. 
 
(6S)-hexyltetrahydropyran-2-one (331) 
 
O
O
1
5
 
 
To a solution of diol 330 (1.16 g, 6.18 mmol) in CH2Cl2 (60 mL) at RT was added TEMPO 
(400 mg, 2.47 mmol) followed by iodobenzene diacetate (4.89 g, 14.2 mmol). After 16 h, 
the reaction mixture was quenched by the addition of saturated aqueous Na2S2O3 (20 mL) 
and NaHCO3 (20 mL). The organics were extracted with CH2Cl2 (3 × 50 mL), washed with 
NaHCO3 (20 mL), dried (Na2SO4) and concentrated in vacuo. Purification by flash column 
chromatography (10→35% EtOAc/Hexane) provided lactone 331 (0.76 g, 67%) as a 
yellow oil.  
Rf 0.68 (40% EtOAc/Hexane); 
€ 
[α]D20  -17.6 (c 1.12, CHCl3), lit 
€ 
[α]D20  -44 (c 0.98, 
CHCl3)152; 1H NMR (300 MHz, CDCl3) δ 4.32-4.23 (1H, m, H5), 2.64-2.53 (1H, m, H2a), 
2.49-2.30 (1H, m, H2b), 1.96-1.65 (4H, m, H3 + H4a + H6a), 1.63-1.22 (10H, m, H4b + H6b + 
H7-10), 0.88 (3H, t, J = 6.7 Hz, H11). 
 
(6S)-2-ethynyl-6-hexyldihydro-2H-pyran (326) 
 
O
37
 
To a solution of TMS acetylene (380 µL, 2.67 mmol) in THF (10 mL) at -78 °C was added 
n-BuLi (1.5 mL, 1.6 M solution in hexane, 2.40 mmol). After 15 min, lactone 331 (100 
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mg, 0.54 mmol) in THF (5 mL) was added via canula. After 1 h, the reaction mixture was 
quenched by the addition of saturated aqueous NH4Cl (10 mL). The organics were 
extracted with CH2Cl2 (3 × 10 mL), dried (Na2SO4) and concentrated in vacuo. Purification 
by flash column chromatography (10→15% EtOAc/Hexane) provided 332 (89.7 mg, 79%) 
as a colourless oil and was used without further characterization. 
To a solution of ketone 332 (199 mg, 945 µmol) in benzene (9 mL) was added (±)- CSA 
(11.0 mg, 47.0 µmol) and the reaction mixture heated at reflux under Dean-Stark 
conditions. After 30 min, the reaction mixture was cooled to RT and quenched by addition 
of saturated aqueous NaHCO3 (10 mL) and extracted with Et2O (3 × 15 mL). The organics 
were dried (Na2SO4) and concentrated in vacuo. Purification by flash column 
chromatography (5% EtOAc/Hexane) provided dihydropyran 326 (98.8 mg, 54%) as a 
yellow oil.  
Rf 0.85 (10% EtOAc/Hexane); 
€ 
[α]D20  -65.4 (c 1.02, CHCl3); IR (thin film) 3314, 3289, 
2928, 2859, 2158, 2114, 1714, 1636 cm-1; 1H NMR (300 MHz, CDCl3) δ 5.28-5.25 (1H, 
m, H4), 3.85-3.77 (1H, m, H7), 2.88 (1H, s, H1), 2.18-2.04 (1H, m, H5a), 1.87-1.79 (2H, m, 
H5b + H6a), 1.74-1.64 (2H, m, H8), 1.61-1.23 (9H, m, H6b + H9-12), 0.88 (3H, t, J = 6.7 Hz, 
H13); 13C NMR (100 MHz, CDCl3) δ 136.4, 109.4, 79.6, 76.3, 74.9, 35.0, 31.7, 29.3, 26.6, 
25.1, 22.6, 21.0, 14.1; HRMS (CI+) Calc. for C13H21O [M+H]+ 193.1587, found 193.1585. 
 
3-[(2S’,6S’)-6’-(4-(benzyloxy)butyl)tetrahydropyran-2-yl]-5-[(6S’’)-6’’-hexyldihydro-
2H-pyran-2-yl)]-1,2-oxazole (335) 
 
O
OBn
O
N
O
15
1'
5'
 
 
To a solution of oxime 324 (13.6 mg, 50.0 µmol) in CH2Cl2 (1 mL) at -78 °C was slowly 
added t-BuOCl (5.40 µL, 50.0 µmol). After 40 min, the solution was added via cannula to 
a solution of alkyne 326 (20.5 mg, 110 µmol) and Et3N (9.70 µL, 70.0 µmol) in CH2Cl2 (2 
mL) at -78 °C and left to slowly warm to RT. After 16 h, the reaction mixture was 
quenched by addition of saturated aqueous NH4Cl (5 mL) and extracted with CH2Cl2 (3 × 5 
mL). The organics were washed with brine (10 mL), dried (Na2SO4) and concentrated in 
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vacuo. Purification by flash column chromatography (5% EtOAc/Hexane) provided 
isoxazole 335 (8.60 mg, 38%) as a yellow oil.  
Rf 0.43 (10% EtOAc/Hexane); 
€ 
[α]D20  -57.8 (c 0.69, CHCl3); IR (thin film) 2974, 2862, 
2357, 1744, 1454 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.35-7.27 (5H, m, ArH), 6.28 (1H, 
s, HAr), 5.64-5.62 (1H, m, H2’), 4.55-4.49 (1H, m, H1), 4.49 (2H, s, OCH2Ar), 3.96-3.84 
(1H, m, H5’), 3.49-3.41 (1H, m, H5), 3.45 (2H, t, J = 6.5 Hz, H9), 2.26-2.19 (1H, m, H3a’), 
1.98-1.84 (3H, m, H2a + H3a + H3b’), 1.73-1.41 (11H, m, H2b + H3b + H4a + H4’ + H6 + H6’ + 
H8), 1.39-1.20 (11H, m, H4b + H7 + H7’-10’), 0.92-0.87 (3H, m, H11’); 13C NMR (125 MHz, 
CDCl3) δ 166.1, 165.7, 142.6, 138.6, 128.3, 127.6, 127.4, 102.4, 97.7, 78.4, 76.2, 72.9, 
72.8, 70.3, 36.2, 34.9, 31.8, 31.1, 31.0, 29.7, 29.3, 27.1, 25.3, 23.4, 22.6, 22.1, 20.4, 14.1; 
HRMS (ES+) Calc. for C30H43O4NNa [M+Na]+ 504.3098, found 504.3074. 
 
(2S,6S)-2-[1-(tert-butyldimethylsilyloxy)-4-oxo-tetradec-2-yn-8-ol]-6-
hexyltetrahydropyran (337) 
 
OH
O
OTBS
O
7
14 19
 
 
To a solution of alkyne 84 (248 mg, 0.74 mmol) in THF (8 mL) at -78 °C was added n-
BuLi (430 µL, 1.6 M solution in hexane, 0.69 mmol), After 30 min, a solution of lactone 
331 (90.7 mg, 0.49 mmol) in THF (2 mL) was added via canula and the solution stirred at -
78 °C for 1 h. The reaction mixture was quenched by addition of saturated aqueous NH4Cl 
(10 mL) and extracted with Et2O (3 × 10 mL). The combined organic extracts were dried 
(Na2SO4), filtered and concentrated in vacuo. Purification by flash column 
chromatography (5→10% EtOAc/Hexane) provided alcohol 337 (114 mg, 44%) as a 
colourless oil. 
Rf 0.86 (30% EtOAc/Hexane); 
€ 
[α]D20  -8.7 (c 1.07, CHCl3); IR (thin film) 3447, 2930, 2857, 
2214, 1734, 1682, 1470 cm-1; 1H NMR (500 MHz, CDCl3) δ 4.45 (1H, d, J = 6.3 Hz, H14), 
3.60-3.55 (1H, m, H7), 3.38 (1H, ddd, J = 11.4, 6.5, 2.1 Hz, H15), 3.29-3.24 (1H, m, H19), 
2.59 (2H, t, J = 7.2 Hz, H10), 1.88-1.73 (3H, m, H9 + H17a), 1.57-1.36 (8H, m, H6 + H8 + 
H17b + H18a + H20), 1.35-1.12 (19H, m, H2-5 + H16 + H18b + H21-24), 0.91-0.86 (6H, m, H1 + 
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H25), 0.90 (9H, s, SiC(CH3)3), 0.14 (3H, s, SiCH3), 0.12 (3H, s, SiCH3); 13C NMR (100 
MHz, CDCl3) δ 187.6, 91.4, 84.1, 80.0, 78.0, 71.4, 66.8, 45.3, 37.4, 36.5, 36.3, 31.8, 31.8, 
31.2, 29.4, 29.3, 26.7, 25.7, 25.6, 25.3, 23.1, 22.6, 22.6, 19.9, 18.2, 14.1, 14.0, -4.8, -5.0; 
HRMS (ES+) Calc. for C31H58O4SiNa [M+Na]+ 545.4009, found 545.3995. 
  
7-hexyl-2-(6-hexyltetrahydropyran-2-yl)-1,6-dioxaspiro[4,5]decane (336) 
 
OOO7 14
19
 
 
A solution of alkyne 337 (16.7 mg, 32.0 µmol) in MeOH (2 mL) was subjected to 
hydrogenation conditions using the H-cube system, 5% Pt/C (30 × 4 mm) at 10 bar and RT 
(3 cycles with flow rate of 0.5 mL/min). The resultant solution was concentrated in vacuo. 
To a solution of crude alkane in MeOH (2 mL) and CH2Cl2 (0.5 mL) was added (±)-CSA 
(1.00 mg, 4.30 µmol). After 1.5 h, the reaction mixture was quenched by addition of 
saturated aqueous NaHCO3 (5 mL). The organics were extracted with CH2Cl2 (3 × 5 mL), 
dried (Na2SO4), filtered and concentrated in vacuo. Purification by flash column 
chromatography (5% EtOAc/Hexane) provided spiroketal 336 (6.60 mg, 52%) as a 
colourless oil.  
Rf 0.56 (10% EtOAc/Hexane); 
€ 
[α]D20  -10.5 (c 0.66, CHCl3); IR (thin film) 2930, 2857, 
1730, 1458 cm-1; 1H NMR (300 MHz, CDCl3) δ 3.98-3.89 (1H, m, H14), 3.88-3.78 (1H, m, 
H7), 3.28-3.16 (2H, m, H15 + H19), 1.97-1.73 (8H, m, H9a + H10 + H12-13 + H17a), 1.70-1.44 
(7H, m, H6a + H9b + H16a + H17b + H18a + H20), 1.40-1.22 (18H, m, H2-5 + H6b + H8a + H21-
24), 1.19-1.01 (3H, m, H8b + H16b + H18b), 0.89-0.85 (6H, m, H1 + H25); 13C NMR (75 
MHz, CDCl3) δ 105.7, 82.6, 82.1, 77.6, 70.0, 38.6, 36.6, 36.5, 33.2, 32.0, 32.0, 31.7, 31.2, 
29.6, 29.3, 27.1, 26.3, 26.1, 25.9, 23.6, 22.7 (2C), 20.4, 14.1, 14.1; HRMS (CI+) Calc. for 
C25H47O3 [M+H]+ 395.3520, found 395.3519. 
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(2S,6S)-2-ethynyl-6-(4-hydroxybutyl)tetrahydropyran (341) 
 
O
OH
37
 
 
To a solution of benzyl ether 283 (25.0 mg, 92.0 µmol) in CH2Cl2 (2 mL) at -15 °C was 
added BCl3·DMS (120 µL, 2.0 M solution in CH2Cl2, 240 µmol) dropwise. After 3.5 h the 
reaction was quenched by the addition of saturated aqueous NaHCO3 (5 mL) and the 
organics were extracted with CH2Cl2 (3 × 10 mL). The combined organic extracts were 
dried (Na2SO4), filtered and concentrated in vacuo. Purification by flash column 
chromatography (30→40% EtOAc/Hexane) provided alcohol 341 (13.0 mg, 78%), as a 
colourless oil.  
Rf 0.07 (20% EtOAc/Hexane); 
€ 
[α]D20  -51.2 (c 1.3, CHCl3); IR (thin film) 3385, 2941, 2862, 
1792, 1734, 1624, 1558, 1456 cm-1; 1H NMR (400 MHz, CDCl3) δ 4.08 (1H, app dt, J = 
11.3, 2.2 Hz, H3), 3.63 (2H, t, J = 6.3 Hz, H11), 3.31-3.25 (1H, m, H7), 2.44 (1H, d, J = 2.2 
Hz, H1), 1.87-1.78 (2H, m, H4a + H5a), 1.68-1.35 (9H, m, H4b + H5b + H6a + H8-10), 1.29-
1.18 (1H, m, H6b); 13C NMR (75 MHz, CDCl3) δ 83.4, 78.4, 72.2, 67.8, 62.7, 35.9, 32.6, 
32.4, 30.7, 23.3, 21.6; HRMS (CI+) Calc. for C11H19O2 [M+H]+ 183.1380, found 183.1379. 
 
1-[(2S’,6S’)-6’-(4-(benzyloxy)butyltetrahydropyran-2-yl)methyl]-4-[(2S’’,6S’’)-6’’-(4-
hydroxybutyl tetrahydropyran-2-yl)]-1H-1,2,3-triazole (340) 
 
O
N
N
NO
OBn
OH
26
1' 5'
 
 
General procedure A was followed with alkyne 341 (12.7 mg, 69.0 µmol) and azide 288 
(21.0 mg, 69.0 µmol) in t-BuOH (1 mL) and H2O (1 mL) to which was added 
CuSO4·5H2O (21.0 mg, 84.0 µmol) and sodium ascorbate (33.0 mg, 170 µmol). Standard 
work-up and purification by flash column chromatography (50→70% EtOAc/Hexane) 
provided triazole 340 (11.3 mg, 33%) as a colourless oil.  
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Rf 0.1 (60% EtOAc/Hexane); 
€ 
[α]D20  -18.1 (c 1.15, CHCl3); IR (thin film) 3418, 2938, 2862, 
1717, 1456, 1364 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.66 (1H, s, HAr), 7.35-7.26 (5H, m, 
ArH), 4.61 (1H, app d, J = 11.0 Hz, H1’), 4.49 (2H, s, OCH2Ar), 4.46 (1H, dd, J = 14.1, 3.0 
Hz, H1a), 4.22 (1H, dd, J = 14.0, 8.1 Hz, H1b), 3.66-3.59 (3H, m, H2 + H9’), 3.50-3.46 (1H, 
m, H5’), 3.44 (2H, t, J = 6.7 Hz, H10), 3.24-3.20 (1H, m, H6), 2.29 (1H, br s, OH), 2.06-2.03 
(1H, m, H2a’), 1.93-1.84 (2H, m, H3a’ + H4a), 1.67-1.31 (18H, m, H2b’ + H3a + H3b’ + H4a’ + 
H4b + H5a + H6’-8’ + H7-9), 1.27-1.12 (3H, m, H3b + H4b’ + H5b); 13C NMR (125 MHz, 
CDCl3) δ 149.3, 138.5, 128.3, 127.6, 127.5, 122.7, 78.3, 77.7, 75.9, 72.9, 72.8, 70.2, 62.7, 
55.3, 36.0 (2C), 32.7, 31.5, 31.2, 31.1, 29.6, 28.5, 23.5, 22.9, 22.1, 21.7; HRMS (ES+) 
Calc. for C28H44O4N3 [M+H]+ 486.3340, found 486.3312. 
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